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Abstract  
 
Telemedicine offers an alternative referral strategy for fetal cardiology but is currently 
only used for „high-risk‟ pregnancies.  A case-study of a cost-consequences analysis 
comparing telemedicine to direct referral to a perinatal cardiologist is initially presented, 
which highlights that for high risk women for whom telemedicine was considered no 
cardiac anomalies were missed using either referral method.  In the light of a review of 
the literature on the economics of telemedicine, three of the key methodological issues 
(of selection bias, of patient costs and using quality-adjusted life years (QALYs)) are 
explored to demonstrate how the case study analysis could be improved. 
 
Pregnant women were selected for referral based on their characteristics and risk 
factors; thus the cost and effects for the two groups may have been biased.  Various 
methods identified in the literature are applied to the case study to reduce selection 
bias, but the analysis presented is unable to determine which method is best, given a 
number of limitations including the small sample size.  
 
The analysis is extended to include estimated total patient costs.  However, when 
patient costs are added to the total costs of pregnancy, they did not substantially 
increase the overall cost.  The results presented provide a guideline for future 
researchers and pregnant women of the likely costs during pregnancy.  
 
Given that the majority of missed cardiac anomalies were amongst low risk women, a 
decision analytical model is developed looking at the lifetime costs and QALYs of 
introducing telemedicine screening for pregnant women whose unborn babies are at a 
low risk of congenital heart disease.  The analysis shows that offering telemedicine to 
all low risk women is the dominant strategy.  The thesis demonstrates, within the 
constraints of existing data, that it would be cost-effective to provide telemedicine as 
part of an antenatal screening programme for all low risk women, and this would help 
prevent future „missed anomalies‟.  
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CHAPTER 1: GENERAL INTRODUCTION AND WHAT IS KNOWN ABOUT 
TELEMEDICINE 
 
1.1  Introduction 
The term telemedicine is defined as “the use of electronic information and 
communication technologies to provide and support health care when distance 
separates the participants” [Institute of Medicine, 1996, p16].  The World Health 
Organisation‟s definition for telemedicine is: “the delivery of healthcare services, where 
distance is the critical factor, by all healthcare professionals using information and 
communication technologies for the exchange of valid information for diagnosis, 
treatment and prevention of disease and injuries, research and evaluation, and for the 
continuing education of healthcare providers, all in the interests of advancing health of 
individuals and their communities” [WHO, 1998].  In simple terms, telemedicine means 
„the delivery of medicine at a distance‟.   
 
Telemedicine may be as simple as two health professionals discussing a case over the 
telephone, or as complex as telesurgery, in which a surgeon receives visual and audio 
information to guide robotic instruments to perform surgery at a distance.  In between 
these two types of telemedicine, lies the use of video, audio and data transmission 
technologies such as using videoconferencing to conduct a real-time consultation 
between two medical specialists with the patient present.  Telemedicine can also be 
used for non-clinical applications, for example for medical education, meetings, 
research and administration.   
 
There has always been a strain on National Health Service (NHS) resources and 
finances, not only due to the rapid increase in the costs of medical treatment, but also 
from the growing demand of the ageing population.  Affordability is always an issue.  
Therefore, it is important that the issue of affordability is addressed within a framework 
that allows direct comparison of an intervention with other alternatives in terms of value 
for money.  This has led to increasing pressures on healthcare budgets to show that 
healthcare technologies such as telemedicine, not only demonstrate their safety and 
efficacy, but also show that they are an efficient use of resources.  Economic 
evaluations provide information on whether healthcare technologies are an efficient use 
of resources by comparing the costs and benefits of one healthcare technology, to the 
costs and benefits of another healthcare technology.  So when healthcare budgets are 
limited, resources should be allocated towards those technologies where the ratio of 
incremental costs to incremental benefits is within a given cost-effectiveness threshold.  
That is, a cost-effectiveness ratio that is assumed to represent society‟s willingness to 
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pay for an additional unit of health (e.g. a QALY).  The economics of information and 
communication technologies (ICTs) are important, as financial resources are scarce 
and telemedicine as an ICT can have potentially high costs.  Decisions ultimately have 
to be made by policy makers as where to best allocate these finite resources.   
 
This chapter provides a general introduction to telemedicine, including a background to 
telemedicine and the status of funding for telemedicine services in the UK.  The 
chapter then looks at what information there is on „economic evaluations of 
telemedicine‟; this is followed by the aims and objectives of the thesis; then there will 
be a short summary of the case study which will be used throughout the thesis: the use 
of telemedicine in providing specialist advice in fetal cardiology; and finally, the 
structure for the thesis will be outlined.  
 
1.2 Telemedicine or Telecare? 
Within the NHS it is vital to be able to access the right information required to deliver 
high quality services.  ICTs are enabling technologies for the NHS which aims to 
provide high quality and efficient services.  Telemedicine is one of a number of ICTs, 
which also include picture archiving and communication systems, hospital information 
systems, computerised medical records, computers to support decision making etc. 
 
For clinical applications, telemedicine and telecare are terms that are used 
interchangeably to describe the delivery of healthcare.  The Government in Information 
for Health: an Information Strategy for Modern NHS (1998) defined telemedicine and 
telecare as “Any healthcare related activity (including diagnosis, advice, treatment and 
monitoring) that normally involves a professional and a patient (or one professional and 
another) who are separated in space (and possibly also in time) and is facilitated 
through the use of information and communications technologies.  Telemedicine is 
usually delivered in a hospital clinic or surgery, while telecare is delivered in the 
patient's home” [DoH, 1998, p123].    
 
In other words, telemedicine supports the exchange of information between health care 
professionals and/or patients (such as for diagnosis or referral) usually in a primary or 
secondary care setting, whereas, telecare is a service bringing health and social care 
directly to a patient, usually in their own home.   
 
Telecare is based on the assumption that the elderly, disabled or vulnerable people 
should live independently, in control and with dignity for longer.  Telecare has the 
potential to reduce unnecessary hospital admissions and improve people‟s quality of 
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life and this means that care should be delivered where it is most appropriate; that is, in 
a patient‟s home.  Examples of telecare include: sensors that monitor falls which will 
then trigger a warning to the response centre and systems which can monitor vital 
signs such as blood pressure, and this data is then transmitted to a response centre.   
 
Even though both terms are used interchangeably, they have slightly different 
meanings in terms of where the care is delivered.  The focus of this thesis will be on 
telemedicine and not telecare. 
 
1.3 What is telemedicine? 
The term telemedicine is composed of the Greek word τελε (tele) meaning „far‟, and 
medicine.  Telemedicine services aim to provide access to medical information, 
knowledge and expertise and to support the provision of care processes and the 
services which are delivered.  The classical use of telemedicine in healthcare was to 
support services for distant or isolated populations.  Now, telemedicine can be seen as 
a modern healthcare delivery process.  The factor of distance is becoming less of an 
issue and the focus is now on the boundaries of separation that exists between 
different users i.e. between hospitals and general practices.  Telemedicine has 
diversified into a wide range of applications, for clinical (i.e. patient care) and non-
clinical purposes (i.e. medical education).  For purposes of this thesis, the focus will be 
on the use of telemedicine for clinical applications. 
 
Telemedicine can be conducted in two ways: real-time or store-and forward.  Real-time 
telemedicine requires the presence of both medical specialists and the patient at the 
same time and a communications link between them allows a real-time interaction to 
take place.  Store-and-forward telemedicine involves acquiring the medical data such 
as ultrasound images and then transmitting this to a medical specialist at a convenient 
time for assessment offline.  It does not require both parties of clinicians to be present 
at the same time and offers more flexibility.  Table 1.1 summarises some of the 
advantages and disadvantages of telemedicine.  
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Table 1.1: Advantages and disadvantages of telemedicine 
 Real-time telemedicine Store-and-forward telemedicine 
Advantages Improve a local consultant or general 
practitioners knowledge 
 
Less organisation is required i.e. images 
can be viewed at a convenient time 
 
 Reduced travelling time for specialist 
consultants 
 
Cheaper than real-time telemedicine 
 Reduced travel and hospital time for a 
patient 
 
Possibly shorter consultations 
Disadvantages Higher costs of equipment and 
transmission 
Lack of manipulation capabilities by the 
specialist i.e. they may wish to view the 
image from a different angle 
 
 More time consuming for health 
professionals 
Lack of clinical information which may be 
necessary to make an informed decision 
because the patient is not present 
 
 There may be more complex scheduling 
and organisational factors 
No direct contact with the patient 
 
1.4 Background to telemedicine 
Although, telemedicine in the last 20 to 30 years has become more widely acceptable 
in healthcare, the history of telemedicine goes back much further than that.  According 
to a review by Zundel (1996), the first reference to telemedicine in the medical literature 
appeared in 1950.  Gershon-Cohen and Cooley (1950) described the transmission, 
beginning in 1948, of radiological images such as x-rays over telephone lines between 
West Chester and Philadelphia in Pennsylvania, USA, a distance of 24 miles.  In 1959, 
clinicians at the University of Nebraska medical centre used a two-way, interactive 
television to transmit neurologic examinations and other information across campus for 
medical education, mainly in psychiatry; and the medical centre was also linked to 
remote rural areas to assist with medical treatment [Wittson and Benschoter, 1972].  
Shortly after, many other early telemedicine applications appeared which focused on 
the limited access of remote populations to a variety of health services where medical 
specialists and general practitioners (GP) were not easily reached.  Use of 
telemedicine in urban areas also appeared to assist in emergencies.  For example, in 
1963 the Massachusetts General Hospital established a telecommunications link with a 
medical station staffed by nurse clinicians at Boston‟s Logan Airport [Bird, 1972].  
 
1.5 Examples of telemedicine applications  
Telemedicine has been used for a variety of healthcare applications and many of them 
appear in hospital based services such as radiology and psychiatry.  Other applications 
of telemedicine in healthcare appear in primary care based services, such as virtual 
outpatient clinics for expert opinion and education networks.  An overview of how 
telemedicine works for radiology, dermatology, psychiatry and cardiology are listed 
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below and Chapter 3, looks at the studies which have been conducted in these four 
areas in more detail.   
 
Teleradiology can be defined as “the electronic transmission of radiologic images from 
one location to another, for the purpose of interpretation and/or consultation” [Ferrer-
Roca, 1998].  Teleradiology involves the ability to send radiographic images such as x-
rays, computed tomography scans and magnetic resonance imaging scans from one 
location to another.  These digital images combined with demographic and other 
patient information, can be easily compressed to allow them to be sent more quickly 
and inexpensively.  Whereas, for teledermatology this involves consultations between a 
patient with skin disease (and the primary health care provider) and a dermatologist for 
diagnosis and management advice.  As with teleradiology, the production of digital 
images of skin disease, supplemented with demographic details, can be sent from one 
site to another quickly and cheaply.  Images can be transmitted using either real-time 
or store-and-forward technology.  Both transmission methods require two instruments: 
a microscope and a dermatoscope.  
 
Telepsychiatry is the delivery of healthcare and exchanges information for purposes of 
psychiatric services across distances.  Mental health interactions are more 
straightforward and demand little other than the participants seeing and talking with 
one another and there is no need for sophisticated devices such as an electronic 
stethoscope.  Telecardiology in contrast, is the transmission of images such as 
echocardiograms from the local centre to the specialist centre.  The transmission of 
images can be done in real-time or using store-and-forward techniques.  The images 
are sent for purposes of interpretation for further assessment or clarification.  The use 
of telemedicine in fetal cardiology will be the main focus of the thesis.  The next section 
will provide an overview of the policies and funding opportunities which have been 
introduced for telemedicine in recent years.   
 
1.6 Telemedicine and funding in the UK  
The UK Government‟s strategy to modernising the NHS involves the use of modern 
computer technology in the health service, in the hope of “giving the people of this 
country the best system of healthcare in the world” [DoH, 1998].  This included the 
publication of three key papers which are outlined below.  
 
The first paper, the new NHS Modern and Dependable White Paper [DoH, 1997] set 
out plans to build a modern and dependable health service fit for the 21st century which 
included frontline patient services backed by more investment and better technology.  
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This meant providing: 1) at home: easier and faster advice and information through 
NHS Direct, a new 24 hour telephone advice line; 2) in the community: patients to 
benefit from quicker test results, up-to-date specialist advice in the doctor's surgery and 
on-line booking of out-patient appointments, when every GP surgery and hospitals 
would be connected to the NHSnet, the NHS's own information superhighway; and 3) 
in hospital: prompt access to specialist services so that treatment and care be 
undertaken efficiently and quickly.  This paper marked a turning point for the NHS and 
set out the basis for a ten-year programme to renew and improve the NHS, including 
an extra £1.5 billion.   
 
Secondly, the publication of the Information for Health report [DoH, 1998], included to 
support the drive for quality and efficiency in the NHS by the use of information 
technology (IT).  This strategy was backed with £1 billion of modernisation funding 
during the lifetime of the strategy.  The report stated that “a modern and dependable 
NHS needs accurate and instantly accessible information and the benefits of new high-
speed, high-capacity information and communications networks” [DoH, 1998].  One of 
the key objectives from this paper included: “to eliminate unnecessary travel and delay 
for patients by providing remote on-line access such as telemedicine to services, 
specialists and care, wherever practicable” [DoH, 1998, p19].  The paper emphasised 
the role of telemedicine and telecare: by improving the quality of care, by making 
information faster and more easily available to patients, by making specialist advice 
and support more accessible to health professionals, and by bringing services closer to 
peoples‟ homes.  The key deliverables from this information strategy included: a 
framework to be published to guide and support the development and application of 
telemedicine; the connection of all computerised GP practices to NHSnet; offering NHS 
Direct services to the whole population; a National Electronic Library for Health 
accessible through local intranets in all NHS organisations; and comprehensive 
electronic patient and health records would be available throughout the NHS to support 
the delivery of care.  
 
The third paper: Modernising Government White Paper [DoH, 1999] set out the vision 
for modernising public services to make life better for people and businesses including: 
delivering better public services; developing an IT strategy for Government which 
would establish cross-government co-ordination and frameworks on issues such as 
digital signatures, smart cards, websites and call centres; and to benchmark progress 
against targets for electronic services.   
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Following on from the second White paper, the Department of Health launched an ICT 
research and development programme (ICTRI-1) to support the national information 
strategy and had a budget guideline of £2.5 million over three to four years.  The main 
aim within this initiative was to commission broad based, multidisciplinary health 
service research to evaluate ways in which ICTs can help to provide clinical, 
managerial and patient benefits, and to improve the evidence-base for decisions on 
ICT investments.  Within the ICTRI-1 programme, 14 projects were commissioned - 
five were in the area of telemedicine. 
 
In early 2001, saw the publication of “Building the Information Core: Implementing the 
NHS Plan” [DoH, 2001a] which updated the Information for Health paper [DoH, 1998] 
and provided a clearer focus on what the priorities for successful delivery needed to be 
and also re-emphasised the future of telemedicine in the NHS.  The Government 
announced an extra £700 million investment in IT.  The investment included more 
consultations with hospital specialists being carried out in GP surgeries using video 
and tele-links removing the need for patients to visit hospital and ensuring swift 
diagnosis and treatment; ambulances equipped with video and monitoring equipment 
so that patients would get specialist care while being taken to hospital; and investment 
in electronic patient records, so allowing patients to connect with staff electronically for 
advice, booking appointments and to see their test results.   
 
At the same time, the UK Telemedicine Information Service website funded by the 
Department of Health was launched on 15th January 2001 at the TeleMed 2001 
conference in London [DoH, 2001b].  The aim of the website was to improve the take-
up of telemedicine technology in the UK and to give access to information on all 
aspects of telemedicine by encouraging those working in the field of telemedicine to 
share their information and experience.  The website contained information on the 
latest projects and developments, an email discussion list, and the option of receiving 
updates from the Medline database about current services.   
 
Shortly after, the Department of Health published a report on “Delivering 21st Century 
IT Support for the NHS” [DoH, 2002b] which outlined targets for telecare to be available 
in all homes that require it by December 2010.  Their aims included: 
 The support of patients and the delivery of services designed around the patient, 
quickly and conveniently; and 
 The support of staff, through effective electronic communications, better learning 
and knowledge management; cut the time to find essential information and make 
specialised expertise more accessible i.e. telemedicine. 
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The focus for the Department of Health in providing IT in the NHS since 2002 has 
changed from „telemedicine‟ to „telecare‟.  In July 2004, the Department of Health 
announced a Preventative Technology Grant, which aimed to increase the number of 
people who can benefit from telecare services; for people of all ages including those 
with long-term conditions, learning disabilities, mental health problems, those needing 
end of life care and also to help an additional 160,000 older people remain independent 
at home [DoH, 2005].  In 2006, ICTRI-2 was commissioned and this led to a new 
approach to the delivery of care, based on the premise that people in need of care 
should be able to remain independent for as long as possible and care will be delivered 
where it is most appropriate such as the patient‟s home.  This new care delivery 
mechanism was referred to as „Telecare‟.  Finally, in May 2008, the Whole System 
Programme was launched which aimed to determine whether technology can help 
people manage their own health and maintain their independence; specifically 
supporting home care of people with complex medical and social needs [DoH, 2009]. 
 
Due to the devolved Government in the UK, the funding opportunities available for 
telemedicine in each of the countries are different.  As part of an ongoing collaboration 
between NHS Lothian and the Scottish Government, small scale telemedicine projects 
have been set up which have then been rolled out in the region [Bowes and McColgan, 
2006].  For example, one project consisted of managing chronic obstructive pulmonary 
disease patients care remotely at home using a device designed to ask patients 
questions about their symptoms and depending on their response may prompt patients 
to use a device such as a pulse oximeter. This information is transmitted via an online 
interface, highlighting to clinicians any patients at potential risk.  The project began in 
March 2008 with 30 patients and then in February 2009 was rolled out to 400 patients 
across the Lothian area [Glaser, 2009]. 
 
Clearly, IT had a crucial role to play in the modernisation of the NHS and this section 
has highlighted the importance of telemedicine (and telecare) over the last thirteen 
years.  The section also showed that there has been a shift in the provision of 
healthcare from telemedicine to telecare and over time, policy priorities and ICTs have 
changed.   
 
1.7  Economic evaluations of telemedicine  
Economic evaluation is concerned with estimating opportunity costs (the value of the 
next best alternative foregone as a result of the decision made) so that the best use is 
made of the scarce resources and has been defined as “a comparative analysis of 
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alternative courses of action in terms of both their costs and consequences” 
[Drummond et al, 2005].  The basic tasks of any economic evaluation are to identify, 
measure, value, and compare the costs and consequences of the alternatives under 
consideration [Drummond et al, 2005].  In the case of telemedicine, the alternatives 
would usually be the conventional system of delivering healthcare and telemedicine.  
Costs and benefits of both alternatives would be compared to see which service 
provides the best use of resources.  There are five main types of economic evaluation: 
cost-minimisation analysis; cost-consequences analysis; cost-effectiveness analysis; 
cost-utility analysis; and cost-benefit analysis.  Each of these evaluations have been 
outlined in detail elsewhere and the choice of each evaluation depends mainly on the 
type of outcomes which arise [Drummond et al, 2005].  
 
Many studies evaluating telemedicine have adopted a cost-minimisation approach, 
though the justification of using a cost-minimisation approach for telemedicine has 
never really been explained and it is unclear why one should demand cost savings 
from telemedicine interventions, when most evaluations in healthcare compare the 
additional costs with the additional benefits.  Decision makers in health care (those who 
deliver and fund such health services) require assurance that telemedicine can fulfil its 
promise.  Therefore, cost-effectiveness (also cost-consequences, cost-utility and cost-
benefit) studies of telemedicine interventions are required to provide information to 
decision makers on whether these interventions in the various healthcare areas 
represent good value for money.   
 
A few papers have outlined a framework for the economic evaluation of telemedicine.  
McIntosh and Cairns‟ (1997) described the economic issues associated with the 
introduction of telemedicine systems and the main challenges to their evaluation.  The 
approach they suggested is based on a cost-consequences framework and their paper 
links the costs and consequences more formally within a set of evaluative questions 
which in turn forms the basis for an economic model evaluating telemedicine.  The 
authors listed the main challenges to the economic evaluation of telemedicine which 
included: constantly changing technology; lack of appropriate study design to manage 
the frequently inadequate sample sizes; inappropriateness of the conventional 
techniques of economic evaluation; and the valuation of health and non-health 
outcomes.  However, they did not provide additional detail on these points, whereas, 
the proposed framework for economic evaluation of telemedicine by Sisk and Sanders 
(1998) considers the use of a cost-effectiveness analysis to help to assess whether the 
expected health benefits are worth the investment.  The authors felt that telemedicine 
raises particular challenges for evaluators: a telemedicine system may have multiple 
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uses and joint costs that are difficult to apportion to one service; the existence of a 
system may lead to expanded indications for use; and technological change may 
rapidly make an evaluation outdated.  The authors believed that economic analysis can 
be helpful in addressing these issues; however, they cannot necessarily resolve them.  
Lobley (1997) found that even though there had been a large number of telemedicine 
trials by the mid 1990s, little information had been published on its economic costs and 
benefits.  He believed that a framework was needed to enable decision makers to 
analyse the potential effects of telemedicine applications on the activities, functions and 
roles of the different parties involved, and the different costs and benefits for each of 
these groups.  He found that telemedicine costs are strongly related to patient volumes. 
 
There has also been a lot of discussion around the need for cost-effectiveness studies 
in telemedicine.  For example, Hailey (2005) said that “Telemedicine has the potential 
substantially to improve the delivery of health.  However, cost-effectiveness studies are 
needed to help define the appropriate scope and application of telemedicine in different 
settings”.  The author found that there were a lot of studies on telemedicine which 
looked at the feasibility and technical sides, which are helpful to initial decision making; 
however, in the longer-term, information on the cost-effectiveness of telemedicine 
applications are required.   
 
A small number of literature reviews have been conducted looking at the cost-
effectiveness of telemedicine interventions.  Whitten and colleagues (2002) undertook 
a systematic review of the cost-effectiveness of telemedicine studies and concluded 
that there is no good evidence that telemedicine is a cost-effective means of delivering 
healthcare.  Roine et al (2001) examined evidence on the effectiveness or cost-
effectiveness of telemedicine studies and concluded that the “evidence regarding the 
effectiveness or cost-effectiveness of telemedicine is still limited”.  Hailey and 
colleagues (2002) conducted a systematic review of evidence for the benefits of 
telemedicine and concluded that “although useful clinical and economic outcomes data 
have been obtained for some telemedicine applications, good quality studies are still 
scarce and the generalisability of most assessment findings is rather limited”.  A more 
recent review of economic evaluations of telemedicine conducted by Bergmo (2009) 
found that “the majority of the economic evaluations were not in accordance with 
standard evaluation techniques” 
 
Other systematic reviews of telemedicine also found no conclusive evidence that their 
findings could be generalised to other telemedicine applications.  For example, Mair 
and Whitten (2000) conducted a systematic review of studies on patient satisfaction 
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with telemedicine, and found that “methodological deficiencies of the published 
research limit the generalisability of the findings”.  Likewise, Hersh and colleagues 
(2002) conducted a systematic review of the literature to evaluate the efficacy of 
telemedicine for making diagnostic and management decisions and the authors found 
that “despite the widespread use of telemedicine in most major medical specialties, 
there is strong evidence in only a few of them that diagnostic and management 
decisions provided by telemedicine are comparable to face-to-face care”.  
 
Furthermore, there have been reports and journal articles looking at screening for 
specific diseases.  For example, the Health Technology Assessment report by Karnon 
and colleagues (2007) looked at different screening models for diseases such as 
cancer, diabetes and cardiovascular disease and they also reviewed models evaluating 
antenatal screening programmes.  Whilst some of the methodological challenges 
raised in this report resonate with this thesis, there has only been one mention 
previously of the use of telemedicine in screening and the challenges associated with 
the economic evaluation of such technologies [Norum et al, 2007].  Some of the 
challenges raised by these papers and the challenges identified from the literature 
review will be discussed further in Chapter 3.   
 
1.8  Focus of the thesis 
A framework for economic evaluation is needed to enable decision makers to analyse 
the costs and benefits of telemedicine services.  Many telemedicine initiatives have 
been funded as special projects, rather than from normal healthcare budgets.  The 
continuation of such projects in routine practice means allocating resources towards 
telemedicine services that may not only have to be justified on the resulting health 
benefits which need to be sufficient, but also on the basis that the telemedicine service 
is an efficient use of scarce resources.   
 
The main contribution of this thesis is to look at some of the problematic issues relating 
to the economic evaluations of telemedicine.  Firstly, a cost-consequences analysis will 
be presented comparing two different referral methods: telemedicine versus direct 
referral to specialist hospital for obtaining specialist advice for fetal cardiology.  This 
analysis was undertaken by myself (supervised by Dr Robin Dowie), but the 
methodology for this study was determined prior to my involvement.  The next step is to 
see what the existing literature says about the costs and benefits of telemedicine and 
to discuss some of the economic issues associated with telemedicine which were 
highlighted in the review, particularly those that are relevant to the case study.  All 
earlier reviews are dated now, so I conducted my own literature review.  In light of the 
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literature review, a critique of the case study which is used in this thesis is provided and 
also the limitations are discussed.  
 
This thesis will then focus on three issues which came to light from the literature review 
and to see how the analysis provided in the case study can be improved.  These issues 
are not specific to telemedicine, but are perceived as a problem for the evaluation of 
telemedicine technologies.  Firstly, from the literature review the majority of studies 
identified were non-randomised, and they did not account for selection bias.  Selection 
bias refers to systematic differences in comparison groups.  The case study used for 
the thesis was an observational study, as local clinicians selected the referral mode for 
women to obtain specialist advice according to local protocols (i.e. selection bias).  This 
thesis will apply the methods which were identified in the literature to reduce selection 
bias between the two groups of women and to see what impact this has on the costs 
and effects. 
 
Secondly, the majority of studies identified in the literature review only looked at costs 
from the perspective of the healthcare service.  This neglects costs which fall on the 
patients and their families.  There is a limited understanding of patient costs associated 
with pregnancy.  In this thesis, using various assumptions, costs which pregnant 
women incur when visiting hospital for their antenatal appointments are calculated and 
it then estimates what the overall impact is on the total costs of pregnancy with the 
addition of these extra costs, when comparing a service with telemedicine to a service 
without telemedicine. 
 
Thirdly, the majority of studies identified in the literature review only looked at costs of 
telemedicine and not at the benefits of telemedicine.  Guidance for health technology 
assessment from the National Institute of Health and Clinical Excellence (NICE) prefer 
health benefits to be measured in terms of quality-adjusted life years (QALYs) [NICE, 
2008]; so decisions for value for money can be made across different technologies and 
different disease areas.  This thesis will attempt to calculate QALYs using various 
assumptions for the patient cohort in the case study, by looking at the cost-
effectiveness of a screening strategy with telemedicine versus a screening strategy 
without telemedicine.  The results for the cost-effectiveness analysis will be expressed 
in terms of cost per QALY gained.  
 
Despite a large number of telemedicine trials, little information has been published on 
the costs and benefits of telemedicine services and the few systematic reviews 
published on telemedicine have not provided any conclusive evidence as to whether 
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telemedicine is cost-effective or not.  Various studies have shown whether a 
telemedicine service used in a particular area of health is cost-effective in relation to 
the current service [e.g. Harley, 2006; Kumar et al, 2006; Daucourt et al, 2006; Peng et 
al, 2006].  Therefore, there is a need for an informative approach to consider the issues 
which can arise when conducting an economic evaluation of telemedicine services.  
For this reason, the main aim of this thesis is to determine the costs and cost-
effectiveness of telemedicine compared to conventional care for fetal cardiology; and to 
look at the three economic issues which are important to telemedicine services in 
general and to see how these issues can be addressed in order to undertake a „good‟ 
economic evaluation of telemedicine services. 
 
1.9  Case study:  The use of telemedicine in providing specialist advice in fetal 
cardiology  
Throughout this thesis the application of telemedicine in fetal cardiology is used as a 
case study to examine some of the economic issues which may arise with telemedicine 
services.  Almost all pregnant women in the UK are offered an anomaly scan at 18-22 
weeks gestation to detect major congenital heart problems or other structural 
anomalies.  For the great majority of women, no defects are found.  In the case of a 
suspected abnormality, women would have to travel to specialist centres for 
investigation and management and only a few days may elapse between the local 
decision to refer and the specialist appointment, so travel arrangements have to be 
made quickly.  There are various clinical and resource factors which make perinatal 
cardiology particularly suitable for telemedicine.  Telemedicine offers an alternative 
referral strategy for fetal cardiology.   
 
The population of interest is all pregnant women at Medway Maritime Hospital, in 
Gillingham, Kent who have (or should have) had an anomaly scan at 20-22 weeks 
gestation to detect major congenital heart anomalies.  The dataset for this thesis were 
collected in two parts.  The first set was collected from 1st May 2001 to 31st July 2002, 
and formed part of a wider study which was commissioned by the NHS Information and 
Communication Technology Research Initiative (ICTRI-1).  The project also known as 
the „TelePaed‟ study, examined from the hospital perspective whether the use of 
telemedicine was cost-effective in obtaining specialist advice in paediatric and fetal 
cardiology when compared to conventional methods.  The second dataset has been 
collected since the conclusion of the TelePaed project, and the data were collected 
retrospectively for the time period: 1st May 2005 to 31st July 2006.  
 
The additional data collected for this thesis along with the earlier data will enable a 
31 
 
more appropriate cost-effectiveness analysis of a screening service with telemedicine 
compared to a screening service without telemedicine to be conducted and also to 
address the economic issues associated with telemedicine services highlighted earlier. 
 
1.11 Structure of the thesis 
The thesis is made up of seven further chapters as set out below. 
 
Chapter 2 introduces the original case study that forms the baseline for this thesis: an 
economic evaluation of the use of telemedicine in providing specialist advice in fetal 
cardiology.  The chapter provides information about the case study and details the 
methods used and the results for a cost-consequences analysis comparing two groups 
of women: those who were assessed via telemedicine and those who were referred 
directly to obtain advice from a fetal cardiologist.   
 
Chapter 3 steps back and reviews the literature on the costs (and benefits) of 
telemedicine.  The first part of the chapter contains a literature review on the 
economics of telemedicine and aims to provide a review on the studies which focus on 
the economics of telemedicine and to see what data were collected within these 
studies.  The second part of the chapter discusses the economic issues associated 
with telemedicine which were highlighted in the review, particularly those that are 
relevant to the case study. 
 
In light of the findings from the literature review in Chapter 3, Chapter 4 provides a 
critique of the TelePaed case study which was presented in Chapter 2 and reflects on 
some of the problems with the design of the study.  This Chapter then outlines the next 
steps for this thesis and provides details on the three issues (selection bias, patient 
costs and the measures of benefits) identified in the literature review and how they can 
be addressed in the context of an economic evaluation of telemedicine services.  The 
following chapters will look at each of these issues in turn and to see how the case 
study analysis can be improved. 
 
Chapter 5 examines the first of the three issues: that of selection bias and this chapter 
highlights the methods to minimise selection bias.  Some of the methods identified in 
the literature to control for selection bias are applied to the fetal cardiology dataset to 
assess what the impact is on mean costs and effects for pregnant women in these two 
groups.  
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Chapter 6 extends the economic analysis presented in Chapter 2 by looking at all 
women (including the non-referred women) who were seen at Medway hospital during 
the same time period.  The economic analysis will also look at the impact over time of 
telemedicine on both costs and effects (the more recent data will be examined here).  
The Chapter then addresses the second issue: patient costs, and examines what the 
overall impact is on the total costs of pregnancy when these additional costs are 
considered.   
 
Chapter 7 covers the final issue: measures of benefits such as QALYs.  Decision 
analytical modelling is used to look at lifetime costs and QALYs of the introduction of a 
telemedicine screening service for pregnant women whose unborn babies are at a low 
risk of congenital heart disease compared to a screening service without telemedicine.  
This large group of low-risk women are more likely to have a missed cardiac anomaly 
and the results from the decision model will be expressed in terms of cost per QALY 
gained. 
 
And finally, Chapter 8 contains a general discussion drawing together the conclusions 
of the thesis, focusing upon its contribution to the literature, with particular reference to 
fetal cardiology.  This Chapter will also consider the implications of the findings from 
the thesis in terms of their policy implications and future research priorities.     
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CHAPTER 2: DETAILED ECONOMIC EVALUATION OF THE ‘TELEPAED’ 
PROJECT 
 
2.1 Introduction 
Chapter 1 has provided a background to telemedicine applications in healthcare and 
set out the main focus for this thesis.  The aim of this chapter is to provide information 
on the case study which is used throughout the thesis: an economic evaluation of the 
use of telemedicine in providing specialist advice in fetal cardiology, also known as the 
TelePaed project [Dowie et al, 2007; Dowie et al, 2008].   
 
The wider TelePaed study outlined in Dowie et al (2007) is summarised here (see 
Appendix 9 for published paper).  A telemedicine service was set up between the Royal 
Brompton hospital (RBH) in west London and four district hospitals (DGHs): Basildon, 
Colchester and Southend hospitals in Essex and Medway Maritime hospital, in 
Gillingham, Kent.  Each of the hospitals‟ obstetric departments had annual deliveries of 
over 3,200 and the RBH paediatric cardiologists held outreach clinics at each of the 
hospitals, monthly at the hospital in Gillingham and every three to four months at the 
other three hospitals.  Telemedicine equipment packages installed in each DGH 
consisted of a Tandberg videoconferencing system for use with six integrated services 
digital network (ISDN) lines.  Training in use of the telemedicine equipment was 
provided and the specialists also provided advanced training in heart screening.  The 
obstetricians and paediatricians in each of the district hospitals could choose how they 
utilised the telemedicine service, and their policies differed.  In particular, only one 
hospital used it for obstetric referrals.   
 
The study set out to compare the costs and outcomes of patients referred to specialists 
in London via the telemedicine service or by conventional means (face-to-face 
assessment in London or assessment in outreach clinics).  Three patient groups were 
studied: pregnant women referred for specialist fetal heart assessment after the 
anomaly scan; newborn babies with a suspected heart problem; and older children and 
infants referred for cardiac assessment.  A total of 504 patients were referred to 
cardiologists from the four hospitals over the 15-month period, and 117 were referred 
via the telemedicine service.  Within the patient groups, telemedicine was used for 52 
of the 248 pregnant women, 17 of the 40 newborn babies, and 48 of the 216 infants 
and older children. 
 
Most pregnant women (83.1%) were referred for screening the fetus rather than to 
confirm a suspected anomaly.  With the newborn babies, a third of the London 
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transfers had suspected critical congenital heart disease (CHD); the rate was lower for 
the telemedicine babies.  For the older children, the majority of them (83.7%) were 
assessed for heart murmurs, most of which were normal.  In terms of costs for all 
patient groups, the telemedicine service was generally more expensive than 
conventional referrals; this was part due to the technology and its operating costs.  
After six months, by the time the women had delivered their baby, antenatal care 
incorporating a teleconsultation was again more costly.  This cost differential was 
mainly due to the different policies followed by the four hospitals over the frequency of 
scheduling antenatal visits for women in the later months of pregnancy.  After six 
months for the newborns, telemedicine remained the cheaper option and for the infants 
and older children, there was relatively little difference in the mean costs for the two 
referral strategies, although telemedicine was cheaper. 
 
The second paper [Dowie et al, 2008], which is the basis for this thesis, focused on the 
one hospital which used the telemedicine equipment for fetal cardiology: Medway 
hospital in Gillingham (the study details are outlined in more detail later in this chapter 
and a summary is provided below; see Appendix 10 for published paper).  The paper 
covered all pregnant women over a 15-month period who were referred for detailed 
ultrasound examination of the fetal heart with a perinatal cardiologist who was based at 
the RBH after a routine anomaly ultrasound scan.  Criteria for specialist referral 
included: traditional CHD risk factors such as diabetes and a family history of CHD. 
 
Referred women formed two groups: a telemedicine group where a pre-recorded 
videoed anomaly scan was relayed to the specialist in the absence of the patient and a 
direct referral group where women were seen face-to-face for a detailed assessment in 
London by the specialist.  Women were followed up from time of the anomaly scan until 
they delivered or in a few cases, after termination of pregnancy.   
 
In total, 76 women were referred for a fetal cardiac assessment: 52 women were 
assessed via the telemedicine link and 24 women were sent directly to London.  The 
ultrasound department adopted the `store-and-forward‟ method for using the 
telemedicine service.  Sixty-four women were referred for detailed screening and 47 of 
these were assessed during videoconferencing sessions.  The direct referral group 
were more likely to have had a cardiac abnormality than the telemedicine group.  In 
terms of total costs until delivery, there were no significant differences in the antenatal 
mean costs for the two cohorts.   
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This chapter will provide in more detail the methods used and results for a cost-
consequences analysis comparing two groups: telemedicine and direct referral groups, 
to obtain specialist advice for fetal cardiology.   
 
2.2 Congenital heart disease and fetal cardiology 
Congenital heart disease has been defined as “a heart condition resulting from an 
abnormality in heart structure or function that is present at birth” [Peterson et al, 2003].  
CHD is one of the leading causes of infant mortality in the UK, representing 26% of all 
infant deaths; this represents a rate of 1.3 congenital heart deaths per 1,000 live births 
[ONS, 2005].  In the UK, it is estimated that there are approximately 4,600 babies born 
each year with CHD - one in every 145 births [Peterson et al, 2003].  Of these, the 
incidence of complex CHD with serious outcomes such as hypoplastic left heart 
syndrome in the UK is estimated as 1.5 per 1,000 live births; and for simple heart 
defects such as small ventricular septal defects the incidence in the UK is estimated as 
4.5 per 1,000 live births [Peterson et al, 2003].  However, there are also small 
proportions of complex CHD cases diagnosed prenatally which are terminated. 
 
Fetal cardiology is concerned with the diagnosis and the management of pregnant 
women with a fetal cardiac anomaly.  The development of ultrasound imaging in the 
1980s enabled a programme of screening for CHD in pregnancy to be developed.  In 
England and Wales, almost all women at approximately 18-22 weeks in their 
pregnancy are screened by trained sonographers using an ultrasound anomaly scan to 
detect major congenital heart problems or other structural anomalies [NCCWCH, 
2008].  No up-to-date information for England and Wales was available during the 
study on prenatal detection rates for fetal cardiac anomalies [Dowie et al, 2004].  
Prenatal detection rates across the UK are approximately 23% [Bull, 1999]; however, 
these rates vary across the UK.  For example, the prenatal detection rate rose from 
17% in 1994 to 36% in 1996 in the northern region of England following training [Hunter 
et al, 2000]; at Liverpool Woman‟s Hospital the detection rate was 23% in 1997 [Bricker 
et al, 2000]; whereas, one specialist fetal centre in London reported a higher detection 
rate of 75% between 1997 and 1999 [Carvalho et al, 2002].  This is important because 
many of the so-called “high-risk” pregnancies have only a modest increased risk of 
CHD of around 3% and so do not yield a high number of CHD cases [Carvalho et al, 
2002].  As the majority of babies (85%) are born to mothers with no identifiable risk 
factors [Tiny Tickers Charity, 2008], screening of the low-risk pregnancies is 
recommended at the anomaly scan to achieve a higher prenatal detection rate for CHD 
[Sharland, 2004, Simpson, 2009].  Since the conclusion of the TelePaed project there 
have been changes in screening policies for CHD which now includes nuchal 
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translucency (NT) screening much earlier in the pregnancy (11-14 weeks).  This 
screening technique was introduced to identify fetuses at high risk of Down‟s 
syndrome; however, the NT thickness is correlated with CHD which is independent of 
the fetal karotype [Hyett et al, 1999] and has a stronger relation with CHD than 
established CHD risk factors [Simpson, 2009]. 
 
For the great majority of women, no defects are found.  Detection of a heart defect at 
the anomaly scan allows parents to choose whether to terminate or to continue with the 
pregnancy.  For those parents who wish to continue with the pregnancy they can be 
informatively counselled and following delivery, operative interventions can be carefully 
planned.  Not all CHD defects require treatments or surgery.  Some mild congenital 
heart defects repair themselves.  However, the majority of heart conditions do require 
treatment, and this varies depending on the type and complexity of the congenital heart 
defect.  
 
The long-term prognosis of children born with heart defects depends on the type of 
CHD.  For example, long-term prognosis for patients with two functioning ventricles is 
better than those with one [Kenny and Stuart, 2009]; and over the past 20 years 
advances in treatment and surgical techniques, has meant that surgical mortality has 
decreased from an average of 15% in 1990 to an average of 5% in 2000 [Gibbs et al, 
2004]. 
 
Infants with serious conditions have improved morbidity levels if their treatment has 
been planned prenatally [Personal communication with Specialist A, October 2007].  
However, there are a few cases of CHD which are not detected prenatally at the 
anomaly ultrasound scan: these are known as “missed cases” and only when the baby 
is born is the heart defect found.  For example, rare conditions associated with total 
anomalous pulmonary vein connections can still be missed at the anomaly scan as 
they lie away from the heart.  Subtle, mild or late developing CHD can also be missed 
at 20 weeks [Tiny Tickers Charity, 2008].  A „missed‟ diagnosis delays the opportunity 
for antenatal intervention and planned delivery. 
 
If a routine anomaly scan reveals a complex life-threatening heart abnormality, the 
DGH obstetrician will normally refer the mother to a specialist in fetal cardiology 
(perinatal cardiologist) for further assessment.  Such referrals are believed to have a 
sensitivity of > 80% for a true abnormality [Personal communication with Specialist A, 
October 2007].  Fetal cardiac referrals may also be made in other circumstances: 
where an anomaly is detected but is clinically less severe; where there is a suspicion 
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that an anomaly exists; or where confirmation is needed that the fetal heart is normal, 
usually because the ultrasound heart images during the scan could not be visualised 
properly or the parents have an elevated risk for a fetal cardiac anomaly [Dowie et al, 
2004].   
 
When women are referred for a fetal cardiac opinion, they usually have to attend a fetal 
medicine department.  These fetal medicine departments are mostly found in tertiary 
units (such as an obstetric unit or maternity hospital) providing regional services.  
Unlike paediatric cardiology, there are no networks of fetal cardiology peripheral clinics 
run by specialists in DGHs.  There are 12 paediatric cardiology units in England and 
perinatal cardiologists from these units provide the fetal cardiology service in these 
fetal medicine departments.   
 
As there are so few tertiary centres in the UK, many pregnant women make lengthy 
journeys for specialist assessments.  For example, women in North Wales are referred 
to maternity services in Liverpool, while women in south-east England have to travel to 
London.  Women using public transport face considerable journeys, and for all women 
there are not only travel costs but other costs to consider, such as babysitting.  In most 
instances, only a few days elapse between the local obstetrician decision to refer the 
women and the specialist appointment, so travel arrangements have to be made 
quickly.   
 
2.3 Fetal cardiology and telemedicine 
Telemedicine offers an alternative referral strategy for fetal cardiology.  Telemedicine 
allows digitised images of heart from obstetric ultrasound machines to be transmitted 
electronically [Begg et al, 2001] and the structures of the heart can be visualised with 
clarity after 18 weeks gestation.  The ultrasound images are usually transmitted 
through ISDN telephone lines. 
 
Teleconsultations can be held either „real-time‟ with a sonographer conducting an 
examination on the patient, whilst a remote specialist jointly views the images, or via 
transmission of pre-recorded videotaped ultrasound images (the „store-and-forward‟ 
approach) in the absence of the patient.  The few reported evaluations of telemedicine 
in obstetric services relied on ultrasound images being relayed in real-time [Fisk et al, 
1996; Chan et al 2001; Sharma et al, 2003]. 
 
Telemedicine can lead to a significant decrease in time to diagnosis compared to 
sending a patient to a specialist hospital.  The telemedicine equipment can be used 
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both to confirm, and to exclude the diagnosis of fetal heart disease (used as a 
screening tool for women who are considered to be at risk of having a fetal cardiac 
anomaly).  Lengthy journeys to specialist centres may be avoided.     
 
2.4 Telemedicine case study: TelePaed project  
2.4.1 Objective and setting  
The main aim of this chapter is to look at the impact of the telemedicine service on the 
hospital costs of antenatal and maternal care received by women and also on their 
personal costs.  As mentioned previously in 2001, under the auspices of the NHS 
ICTRI-1 [DoH, 1998], the RBH in London set up a telecardiology service in four DGHs 
for the provision of specialist advice to clinicians in obstetric and paediatric 
departments.  However, only the district hospital in Kent used the telecardiology 
service for fetal referrals alongside the existing arrangements for referring women 
directly to London specialist centres (Kings College Hospital (KCH) and Queen 
Charlotte‟s Hospital (QCH)). The specialist fetal cardiologist (Specialist A) was based 
at both the Royal Brompton and Queen Charlotte‟s Hospitals.    
 
The number of maternal deliveries at Medway Maritime Hospital has been steadily 
increasing over the years, for example from: 3,817 (1st April 2001 to 31st March 2002) 
to 3,982 (1st April 2005 to 31st March 2006) [Department of Health, 2003; Department 
of Health, 2007].  During 2001/2002 the configuration of the antenatal screening 
services at Medway hospital included offering anomaly scans to all women at 20-22 
weeks gestation.  Nuchal translucency screening for Down‟s syndrome was done 
around 12-13 weeks gestation and only offered to selected women (women with 
previous trisomy; multiple pregnancy; or insulin dependent diabetic).  The quadruple 
serum screening test was offered to all women at 15-21 weeks gestation, except those 
offered the nuchal scan and the risk cut-off level (taking account of serum result and 
maternal age) was 1 in 300. 
 
The anomaly ultrasound scan was usually performed by the obstetric sonographers 
who were based in the obstetric units of the DGH.  After the introduction of the 
telemedicine service, pregnant women with isolated cardiac anomalies were referred to 
QCH (majority of women sent for further assessment) and pregnant women with multi-
organ anomalies plus a cardiac anomaly were referred to KCH (only a few women sent 
for further assessment).  The ultrasound department at Medway hospital adopted a 
„store-and-forward‟ approach for using the telemedicine service, as well as continuing 
to refer patients directly to London.  During 10 months, 10 pre-arranged 
videoconferencing sessions were held and sonographers videoed the heart images of 
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the fetuses during the anomaly scans and the videos were transmitted during monthly 
teleconferencing sessions.  On one occasion an urgent teleconsultation was held, and 
on three other occasions, a serious heart abnormality was diagnosed during an 
anomaly scan performed within 48 hours of a videoconference session, so the images 
were transmitted for verification by the specialist [Dowie et al, 2008].  Approximately 
five video recordings were transmitted per session (median 5, range 2 to 8) and each 
woman‟s scan, diagnosis and management plan was discussed for about five minutes 
[Dowie et al, 2008].  If a woman was sent to London for referral, they were given a 45 
minute slot: 20 minutes for the specialist scan and a further 20 minutes for counselling.   
 
2.4.2 Patients 
A prospective audit, covering all newly presenting eligible pregnant women who 
underwent an anomaly scan at 20-22 weeks gestation over a 15-month period was 
conducted and the following women were identified for the TelePaed database: 
a) women with increase risk factors for fetal CHD: 
- family history of CHD (mother, father, sibling or previous pregnancy); 
- pregestational diabetes mellitus; 
- treatment for maternal epilepsy or lithium; 
- current pregnancy with multiple fetuses; or  
- previous pregnancy diagnosed with Down‟s or other chromosomal malformation. 
b) women with an elevated risk for Down‟s syndrome following a serum test or nuchal 
translucency ultrasound scan or chromosomal test: 
- serum test result was above the risk cut-off level adopted by the hospital (1 in 300); 
- women whose nuchal translucency result was above 3.5mm; or 
- an abnormal chromosome test result. 
c) A representative sample of „average risk‟ women whose screening results were 
within normal limits was obtained by matching.  So women in groups a) and b) were 
matched in terms of their year of birth, parity, month of gestation and calendar month of 
anomaly scan with average risk women [Mistry et al, 2007]. 
 
In total, 408 women were identified in the audit; however, this chapter focuses on the 
76 women who were referred to the perinatal specialist.  The referred women formed 
two groups: a telemedicine referrals group (n = 52) and a direct referrals group as a 
comparator (n = 24).  The telemedicine group consisted of women who, at the time of 
their anomaly scan, were identified for referral according to the department‟s protocol 
for high risk women, and women whose fetal heart images during the anomaly scan 
were abnormal or were poorly visualised.  The direct referral group consisted of women 
who were referred for the same reasons during the three months before the 
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telecardiology service entered regular use and those who travelled to London, during 
the weeks between scheduled teleconferencing sessions.  The direct referral group 
also included women whose fetuses were strongly suspected of having a heart defect.  
A consultation with a fetal cardiologist was held according to Medway hospital 
protocols, usually within two working days [Dowie et al, 2008]. 
 
2.5 Methods 
2.5.1 Resource use and unit costs 
The economic analysis was undertaken from the perspective of the hospital1.  Non-
direct medical costs (patient travel costs) and indirect costs (loss of pay) were also 
considered in a separate analysis.  The time horizon for the analysis was from the time 
of the anomaly scan (20-22 weeks gestation) until just after delivery2 or where 
applicable after termination of pregnancy.   
 
A project facilitator in the district hospital entered data onto a laptop computer.  The 
audit database recorded demographic, clinical and resource use information.  
Resource use items for antenatal care from the time of women‟s anomaly scan until 
delivery or in some cases after termination of pregnancy included: specialist 
consultations either face-to-face or through telemedicine, anomaly ultrasound scans 
and any subsequent antenatal and specialist ultrasound scans, counselling, hospital 
antenatal and outpatient clinic attendances, prenatal inpatient admissions, terminations 
of pregnancy, and the status of NHS personnel who were involved in each resource 
use activity and the time taken (in minutes) for each activity.  Resource use items for 
maternal delivery care included the inpatient admission prior to transfer to labour ward 
or obstetric theatre, labour/delivery bed day, mode of delivery and the mother‟s stay on 
the postnatal ward.   
 
Unit costs in pounds (£) sterling in 2001/2002 prices for the antenatal and obstetric 
resource items listed above were obtained from the hospital finance department in 
Medway and the two fetal medicine centres in London.  The unit costs obtained from 
Medway were attributed to resources at the district hospital, and for specialist care in 
London, average unit costs from the two specialist hospitals were used.  The cost for 
the ultrasound examinations incorporated the sonographer‟s time as well as 
consumables, administrative costs, overheads and capital charges.  The unit cost for 
the clinic attendances included nursing supervision and clerical staff time, consumables 
                                                 
1
 The direct costs were from a hospital perspective and GP and community costs were excluded from the 
analysis 
2
 „Just after delivery‟ only included costs of labour delivery and any postnatal stay for the mother, no costs 
were included for the newborns if they required any hospital stay. 
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and equipment, overheads and capital charges.  The cost for the termination of 
pregnancy was inclusive of stay in the labour ward, and finally, the unit costs for bed 
days were inclusive of medical and nursing staff time, administrative and clerical staff 
time, consumables and equipment, overheads and capital charges (see Table 2.1 – 
these costs are in 2005/2006 prices).   
 
The costs for medical staff time were based on NHS salary scales [Department of 
Health, 2002a].  Hourly rates of pay were calculated by the number of hours expected 
to work each year, taking annual leave and bank holidays into account [Netten and 
Curtis, 2002].  These hourly rates were then applied to the time that it took the relevant 
medical staff to carry out the task (e.g. telemedicine consultation).  
 
Table 2.1: Antenatal resource items with unit costs  
Antenatal resource items  Unit cost (£) 
2005/2006 prices* 
Resource use at district hospital 
Antenatal ultrasound scan (anomaly or other) 
 
Antenatal or outpatient clinic attendance (review clinic) 
 
Clinicians consulted in clinic (mean time)** 
 Consultant (15 minutes) 
 Doctor (15 minutes) 
 Midwife (15 minutes) 
 
Termination of pregnancy 
 
Prenatal maternity bed day 
 
Labour/delivery bed day 
 
Mode of obstetric delivery 
 Normal birth 
 Forceps birth 
 Ventouse birth 
 Caesarean birth (without complications) 
 Home birth 
 
Postnatal maternity bed day 
 
36.16 
 
75.83 
 
 
10.92 
6.84 
3.83 
 
856.28 
 
240.32 
 
240.32 
 
 
1567.91 
1256.43 
1256.43 
2253.87 
560.84 
 
240.32 
Resource use at specialist hospital 
Antenatal ultrasound scan plus consultation with the specialist  
 
Counselling at specialist hospital (20 minutes) 
 
64.58 
 
14.58 
*2001/2002 costs were inflated to 2005/2006 prices using inflation indices provided by Curtis (2007) 
**Costs for staff time were based on NHS salary scales [Department of Health, 2002a] and Netten and 
Curtis (2002) and inflated to 2005/2006 prices 
 
In the RBH where the perinatal cardiologist viewed the pre-recorded images, the 
existing telemedicine suite was already equipped with a Tandberg system that was 
frequently used.  Medway hospital was supplied by the RBH with a Tandberg 
videoconferencing system (model 2500) incorporating a 384Kb/s computer (CODEC) 
with camera, ultrasound and video cassette recorder inputs, a pan-tilt zoom camera, 
loudspeaker with volume control, microphone, and peripheral items [Dowie et al, 2008].  
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The system was designed for use with ISDN-6 lines (i.e. three pairs of ISDN lines, each 
line being 64Kb) which were installed in the hospital, and was mounted on a tele-trolley 
for ease of transfer between the antenatal and neonatal departments.  Training was 
provided for using the telemedicine equipment, as well as, advanced training in fetal 
heart scanning [Dowie et al, 2008]. 
 
Setting up costs 
The total cost of the telemedicine equipment including ISDN-6 line installation, 
equipment maintenance contract and 17.5% value added tax (VAT) was obtained from 
the telemedicine co-ordinator at the RBH.  It was assumed that the expected lifetime of 
the equipment was five years in line with assumptions in another UK study of 
telemedicine in outpatient clinics [Jacklin et al, 2003] and an annual discount rate of 
3.5% was applied as recommended by the Treasury [HM Treasury, 2003].  In order to 
calculate a mean cost of the telemedicine equipment per woman, the total cost of the 
telemedicine equipment (over a lifetime of five years and discounted at 3.5%) was 
divided by the total number of women assessed by telemedicine during the five-year 
period (1st July 2001 to 30th June 2006).  The total number of Medway women seen 
during this five-year period was 283 [Personal communication with RBH administrative 
assistant, July 2008].   
 
Operating costs 
Monthly invoices from a commercial telephone company provided details of ISDN-6 
line rental, call charges and VAT.  Telemedicine co-ordinator costs included time spent 
by the co-ordinator from the specialist hospital on briefing, installation and training in 
the district hospital and return travel from the specialist hospital during the initial 
installation and set-up of the telemedicine equipment.  The cost of line rental and call 
charges and the cost of the telemedicine co-ordinator were divided by the number of 
women during the TelePaed study period to derive a telemedicine cost per woman (see 
Table 2.2).   
 
In practice, the per patient costs for the telemedicine equipment will be dependent on 
the degree to which the equipment is adopted and used in multiple disciplines for other 
purposes such as for other patient groups or even for meetings, research or 
administrative uses.  The telecardiology service in the current study was also used 
within the neonatal unit as part of a wider study [Dowie et al, 2007]; however, when 
calculating the cost for each telemedicine women, the number of newborn patients who 
also used the telemedicine equipment was not taken into account.  As such, we may 
over-estimate the true cost per patient.  
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Table 2.2: Mean costs for the telemedicine system in 2005/2006 prices 
Components of the fetal telemedicine system N = 52 women referred* 
Fixed costs 
Telemedicine equipment, ISDN-6 line installation and equipment 
maintenance contract# 
 
Variable costs  
Telemedicine training and service support 
 
ISDN-6 line rental and call charges* 
 
Specialist, obstetric sonographer and co-ordinator (mean time = 5 
mins per woman) 
 
£60.50 
 
 
 
£10.35 
 
£72.32 
 
£8.73 
Total mean cost per referred woman  £151.90 
# The costs for the telemedicine equipment, ISDN-6 line installation and maintenance contract is based on 
the total cost over five years (useful lifetime of the equipment) and discounted at 3.5% and then divided by 
the total number of patients seen over 5 years 
* In total there were 55 telemedicine consultations, 3 women in the telemedicine group had 2 telemedicine 
consultations each. 
 
Finally, the unit costs3 applied to the 2001/2002 financial year, but for purposes of this 
thesis and to be in line with the published paper they have been inflated to 2005/2006 
prices using Pay and Prices indices [Curtis, 2007].   
 
2.5.1.1 Missing resource use information 
Labour delivery mode, length of time in labour ward and length of time in postnatal 
ward were missing due to censoring from the audit database for 14.7% (60/408) 
patients.  Of these 60 women, 1 was from the direct referral group and 11 women were 
from the telemedicine group.  This was because the women had not given birth before 
the fieldwork had finished.  Where information on labour delivery mode and delivery 
place were missing, the values for these items were estimated using matching.  The 
matching was done within each risk group and the matching took into account four 
factors: mother‟s age at anomaly scan; gestation in weeks at anomaly scan; parity and 
the number of fetuses.  An attempt was made to match on all four variables; when this 
was not possible, matching was based on the next three variables.  If there was more 
than one equal match, then the most frequent delivery mode and delivery place was 
used.  Where information on lengths was missing (continuous variables), the values for 
these items were imputed using regression based imputation.  Standard regression 
analyses provide estimates of the missing data conditional on complete variables in the 
analysis [Briggs et al, 2003].  So within each group, the following variables: mother‟s 
                                                 
3
 One point to note is that these unit costs differ slightly from the published paper [Dowie et al, 2008] and 
there are two reasons for this: 1) the telemedicine equipment cost per patient is different because of the 
annual number of patients is different (for the paper the annual equivalent cost was divided by 52, whereas 
for this thesis the total cost for five years was divided by the total number of patients seen over the 5 
years); and 2) the Pay and Prices Index inflator used to inflate prices from 2001/2002 prices to 2005/2006 
prices is slightly different.  For the paper we used an estimate [Curtis and Netten, 2006] and for this thesis, 
the observed figure is used [Curtis, 2007]. 
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age at anomaly scan; gestation in weeks at anomaly scan; parity and the number of 
fetuses were used as predictor variables to predict missing length times [Morris, 2005].   
 
2.5.2 Effectiveness 
The main measure for effectiveness was the detection of cardiac abnormalities before 
birth.  The project facilitator noted the findings on the audit database from the anomaly 
scan: 1) a normal heart or 2) an abnormal heart.  Further diagnosis of the heart was 
confirmed at either the telemedicine consultation or at the face-to-face meeting with the 
fetal cardiologist in London.  If a cardiac anomaly was detected, this gave the women 
the opportunity to be informatively counselled and to make an informed decision on 
whether or not to continue with the pregnancy.   
 
2.5.3 Comparative analyses 
In the comparative analyses for this chapter, all the referred women had an elevated 
risk factor for CHD and/or Down‟s syndrome and were categorised into two groups 
(see Figure 2.1 below): 
1. Women who were referred to a specialist via telemedicine (telemedicine group); 
and 
2. Women who were referred directly to see a specialist face-to-face (direct referral 
group). 
No anomaly
Anomaly
via telemedicine
No anomaly
Anomaly
via direct referral
Referred to perinatal 
cardiologist
Anomaly ultrasound scan
for pregnant women
 
Figure 2.1: Care pathway for pregnant women referred to perinatal cardiologist 
 
A mean cost per women in each of the two groups listed above was estimated for the 
following scenarios: 1) for events from the time of anomaly scan until delivery 
(antenatal care spanned the second and third trimesters until delivery); 2) for events 
during maternal delivery; and 3) for events for total obstetric care – the summation of 
antenatal and delivery costs (scenarios 1 and 2) [Information on scenarios 2 and 3 are 
not in the published paper].  Given the short time frame, costs (and effects) were not 
discounted.  
 
As the cost data were skewed, bootstrapping was used whereby the distribution of 
costs are generated by repeated sampling of the data (to stabilise the mean), with 
replacement and, in the absence of any other data from the population, gives a guide 
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to its distribution [Manly, 1997].  Bootstrapping was performed using Stata version 10 
[StataCorp, 2007] by taking 5,000 iterations of the data. 
 
2.5.4 Sensitivity analysis 
The main focus of the sensitivity analysis was to look at what the impact would be on 
the mean costs of the telemedicine group, if the cost of the telemedicine equipment 
changes.  For the base case analysis, the discount rate used for the telemedicine 
equipment was 3.5% and a lifetime of 5 years was assumed.  One-way parameter 
sensitivity analyses were performed on the unit cost of the telemedicine equipment, by 
changing the discount rate and the length of the telemedicine equipment lifetime.  
Depending on the lifetime of the telemedicine equipment, the number of patients seen 
during the 5-year period was pro-ratad.  So the annual number of patients seen each 
year was 57 (total number of patients/equipment lifetime in years = 283/5).   
 
2.5.5 TelePaed postal questionnaires 
During the study postal questionnaires were sent to pregnant women who were eligible 
for inclusion in the study database between October 2001 and July 2002.  The project 
facilitator posted the questionnaire package at least two weeks after the women had 
undergone the anomaly scan.  The women were asked to return the completed 
questionnaire to the project office at Brunel University, using a pre-paid, pre-addressed 
envelope.  Each questionnaire had a code number entered at the front.  A 
questionnaire pack was sent to the following women: 
 Women who have a higher than average risk of having a baby with a cardiac 
abnormality; 
 Women of normal risk, but who are matched with the women at risk of fetal CHD 
and women with an elevated risk of Down‟s syndrome (see section 2.4.2); and 
 Women of normal risk, but at the anomaly scan are suspected of having a baby 
with a cardiac abnormality. 
These questionnaires included a section on patient costs and also included two health 
status instruments - the EQ-5D health status questions and the visual analogue scale 
[Brooks, 1996], and the Hospital Anxiety and Depression Scale [Zigmond and Snaith, 
1983].  Respondents were sent a follow-up questionnaire after three months.  For both 
the initial and follow-up questionnaires, one reminder questionnaire was posted three 
weeks later where necessary. 
 
2.5.5.1 Patient costs 
The questions for eliciting patient costs included: mode of travel to and from hospital; 
journey distance; travel expenditure; time spent in travelling to and from hospital; time 
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spent at hospital; activities foregone; loss of earnings; and out-of-pocket expenses (e.g. 
childcare).  The women were also asked whether they were accompanied on their 
hospital visit, and what these companions would have been doing if they had not 
visited the hospital. 
 
To calculate travel costs, for women who travelled by train, bus or taxi the actual cost 
supplied by them was used (inflated to 2005/2006 prices) [Curtis, 2008].  For women 
who travelled by car, postcode data [AA website, 2008a] were used to calculate the 
„road‟ distance (in miles) between the home address and the district or specialist 
hospital.  The motoring costs published by the Automobile Association (AA) [AA 
website, 2008b], were applied to the mileage.  The cost per mile of travel (44 pence) 
was built on the assumption that patients had an unleaded petrol fuelled car with an 
engine size of 1101-1400cc and travelled 10,000 miles a year.  This assumption also 
allowed for fixed costs, depreciation and running costs for 2005-2006.  Also, if the 
women incurred car parking charges, this was also included in the travel cost (inflated 
to 2005/2006 prices) [Curtis, 2008].   
 
The additional costs which patients may have also incurred when attending hospital 
were also taken into account.  If women incurred costs for childcare or care of other 
dependents the actual cost stated by them was used (inflated to 2005/2006 prices) 
[Curtis, 2008].  If women were in paid work and lost pay when attending hospital, if they 
stated the amount of pay lost whilst they attended hospital, this figure was used.   If 
not, then the opportunity cost of time lost from work was estimated from the mean 
gross weekly wage rate for women in Great Britain in April 2002, which was £383.40 
[ONS, 2002].  From this figure, an hourly rate of £6.65 was estimated from the gross 
salary, minus 35% tax, pensions and national insurance contributions.  This rate was 
used where women lost pay to attend hospital.  Where the woman took annual leave or 
her appointment was outside work time, her time was valued at 40% of the mean 
female wage rate (£2.66 per hour) [Bricker et al, 2000].  These hourly costs were 
inflated to 2005/2006 prices [Curtis, 2008].  Loss of pay from companions was not 
taken into account, because not enough information was provided.  
 
To calculate the time spent in the hospital by each pregnant woman, the actual time (in 
minutes) supplied by each woman was used.  To calculate the time spent by each 
woman in travelling (regardless of which mode of transport they travelled to the 
hospital) time data supplied by AA [AA website, 2008a] were used to calculate the time 
(in minutes) between the home address and the district or specialist hospital.  The 
travel times and distances published by the AA [AA website, 2008a] are calculated on 
47 
 
the basis of the driver driving at the maximum speed limit for each type of road (e.g. 
residential road at 30 miles per hour and on motorways at 70 miles per hour) [Personal 
communication with AA, December 2008]. 
 
2.5.5.2 Health Status instruments 
The Hospital Anxiety and Depression Scale (HADS) is an easy-to-use measure of a 
person‟s present state of mind [Zigmond and Snaith, 1983].  The questionnaire 
provides separate measures of two dimensions: anxiety and depression.  Each 
dimension has 7 items and the total scores for each dimension can range from 0 to 21.  
For each scale, a score below 8 indicates that the person is within the normal range, 8-
10 indicates a possible disorder of the relevant mood and above 10 indicates a 
probable disorder of the relevant mood.   
 
EuroQol EQ-5D is a standardised instrument for use as a measure of health-related 
utilities and is designed for self-completion by respondents.  It consists of two parts: the 
descriptive part and the visual analogue scale.  The EQ-5D descriptive system 
comprises 5 attributes of health (mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression) [Brooks, 1996].  Each attribute has three levels (no problems, 
some problems and extreme problems), generating a total of 243 possible health 
states, to which „unconscious‟ and „dead‟ have been added for a total of 245.  
Preferences for the scoring function were measured originally with the time trade-off 
technique [Dolan et al, 1996].  The scores lie on a value scale where 0 = dead and 1 = 
full health.  The EQ-5D visual analogue scale (VAS) records the respondents‟ self-
rated health status on a 0-100 scale where 0 is the worst state you can imagine and 
100 is the best state you can imagine. 
 
2.5.6 Statistical analysis and tests  
Statistical analyses were conducted using Stata version 10 [StataCorp, 2007].  If 
distributions were normal, means, standard deviations (SD) and ranges are presented, 
and chi-squared (or Fisher‟s exact) and t tests were conducted (A Fisher‟s Exact test is 
conducted instead of a chi-squared test when expected cells are less than 5 for 2 by 2 
comparisons).  If distributions are not normal, means, SDs, medians and inter-quartile 
ranges (IQRs) are presented and Wilcoxon rank-sum tests conducted.  All statistical 
tests were two-sided unless otherwise stated.  A p-value ≤ 0.05 was considered to be 
statistically significant. 
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2.6 Results 
2.6.1 Patient sample and demographics 
Over the 15 months, 76 women were referred for a fetal cardiac assessment.  Fifty-two 
women were assessed via the telemedicine link and 24 women were sent directly to 
London for face-to-face assessment.  For the direct referral group, 13 women were 
referred before the telecardiology service entered regular use and 11 women over the 
following 10 months. 
 
Table 2.3 shows the demographic characteristics for the referred women.  The mean 
age for women in each group was not statistically different (p = 0.560); there were no 
significant differences between the groups in terms of parity (p = 0.267); one women in 
the direct referral group was expecting a multiple birth; half of the women in each group 
had their anomaly scan at 21 weeks; and over 50% of women gave birth between 38 to 
40 weeks gestation.  There were more diabetic women and women on epilepsy 
treatment in the telemedicine group compared to the direct referral group. 
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Table 2.3: Demographic characteristics and risk factors of pregnant women±  
 Telemedicine group  
(n = 52) 
Direct referral group  
(n = 24) 
Maternal age: Mean (SD) 
Range 
 
Parity 
Primaparous 
Multiparous 
 
Type of pregnancy 
Singleton 
Multiple 
 
Gestation at anomaly scan* 
Mean (SD) 
Range 
 
≤ 19 weeks 
20 weeks 
21 weeks 
22 weeks 
≥ 23 weeks 
 
Gestation at birth 
N
# 
Mean (SD) 
Range 
 
≤ 30 weeks 
31-35 weeks 
36-37 weeks 
38-39 weeks 
40 weeks 
≥ 41 weeks 
 
Does the mother have diabetes? 
Yes 
No 
 
Does the unborn baby have a high risk of Down’s syndrome 
or does the mother have an elevated serum risk? 
Yes 
No 
 
Is the mother on any anti-epilepsy drug therapy?** 
Yes 
No 
 
Does the mother have a family history of CHD or had a 
previous pregnancy with an anomaly? 
Yes 
No 
28.7 (6.1) 
17 to 44 
 
 
19 (36.5%) 
33 (63.5%) 
 
 
52 (100.0%) 
0 (0.0%) 
 
 
20.8 (0.9) 
18 to 23 
 
4 (7.7%) 
12 (23.1%) 
28 (53.8%) 
7 (13.5%) 
1 (1.9%) 
 
 
50 
38.1 (2.8) 
29 to 42 
 
2 (4.0%) 
5 (10.0%) 
6 (12.0%) 
16 (32.0%) 
16 (32.0%) 
5 (10.0%) 
 
 
10 (19.2%) 
42 (80.8%) 
 
 
 
3 (5.8%) 
49 (94.2%) 
 
 
11 (21.2%) 
41 (78.8%) 
 
 
 
19 (36.5%) 
33 (63.5%) 
29.6 (6.8) 
20 to 44 
 
 
12 (50.0%) 
12 (50.0%) 
 
 
23 (95.8%) 
1 (4.2%) 
 
 
21.8 (3.0) 
19 to 33 
 
1 (4.2%) 
4 (16.7%) 
12 (50.0%) 
5 (20.8%) 
2 (8.3%) 
 
 
20 
37.6 (2.2) 
33 to 41 
 
0 (0.0%) 
3 (15.0%) 
6 (30.0%) 
7 (35.0%) 
2 (10.0%) 
2 (10.0%) 
 
 
3 (12.5%) 
21 (87.5%) 
 
 
 
5 (20.8%) 
19 (79.2%) 
 
 
1 (4.2%) 
23 (95.8%) 
 
 
 
8 (33.3%) 
16 (66.7%) 
± 
Statistical tests conducted: t tests for age, gestation at anomaly scan and birth; chi-squared tests for 
parity, previous pregnancy with anomaly; Fisher‟s Exact tests for type of pregnancy, diabetes, Down‟s 
syndrome risk, and anti-epilepsy drug therapy;  
#
 Not including women who had a termination of pregnancy; * p < 0.05; ** p < 0.1 
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2.6.2 Effectiveness and clinical results  
Table 2.4 shows the clinical circumstances for using telemedicine: for screening 
women who met the department‟s protocol for identifying cardiac risk and for 
establishing the severity of a diagnosed abnormality.  Of the 64 women referred for 
screening, 47 (73.4%) were assessed via telemedicine.  The direct referral group were 
more likely to have had a cardiac abnormality (7/24 versus 5/52, Fisher‟s exact test, p 
= 0.043) due to the higher prevalence.  There were no missed diagnoses amongst the 
two groups of women. 
 
Table 2.4: Clinical circumstances in which the telemedicine service was used 
Clinical circumstances Telemedicine 
group (n = 52) 
Direct referral 
group (n = 24) 
All referrals 
Screening - fetus presumed to be 
normal 
47 (73.4%) 17 (26.6%) 64 (100.0%) 
Confirmation of a cardiac abnormality    
N 5 (41.7%) 7 (58.3%) 12 (100.0%) 
Mean 0.0962 0.2917 n/a 
Total per referral mode 52 (68.4%) 24 (31.6%) 76 (100.0%) 
 
2.6.3 Resource use analysis and hospital utilisation patterns for a sample 
population 
Table 2.5 shows the resources used by each of the two referral groups.  One point to 
note is that for the following items of resource use: prenatal maternity bed day (prior to 
transfer to labour ward); mode of obstetric delivery; and postnatal bed day include 
missing values which have been imputed (see section 2.5.1.1).   
 
All patients had at least one ultrasound scan, usually this was the anomaly ultrasound 
scan, and the mean number of scans for both groups was 2.8.  Almost all patients had 
an outpatient or antenatal clinic visit; the few patients who did not have a clinic visit 
during the second or third trimester were patients who had their pregnancies 
terminated.  The telemedicine women had slightly more clinic visits than the direct 
referral women, a difference which was not significant (11.4 vs. 10.5, p = 0.564).  About 
a third of patients in the telemedicine group had a prenatal admission during the 
antenatal period; this rate was much lower for the direct referral group.  Over half of the 
women in each group had a normal birth; the next most common form of labour 
delivery was a caesarean birth.  Over two-thirds of women in each group had a 
postnatal stay and the mean range of postnatal stay was from 3.9 days (direct referral 
women) to 4.5 days (telemedicine women).  All women in the direct referral group and 
6 of the 52 telemedicine women had a specialist ultrasound scan, and only a proportion 
of women who had a specialist scan received counselling.  This was mainly for 
pregnant women whose scans indicated abnormal findings.  
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Table 2.5: Resource components and the number of women who used the 
resource items±  
Mean per patient Telemedicine group  
(n = 52) 
Direct referral group  
(n = 24) 
At district hospital 
1. Antenatal ultrasound scans 
Mean number of scans (SD) 
Range 
 
2. Antenatal or outpatient clinics 
Mean number of clinics (SD) 
Range 
 
3. Termination of pregnancy** 
 
4. Prenatal maternity bed day 
a) During antenatal period 
Mean number of days (SD) 
Median  
Inter-quartile range 
 
b) Prior to transfer to labour ward** 
Mean number of days (SD) 
Median  
Inter-quartile range 
 
5) Mode of obstetric delivery 
Normal birth 
Forceps birth 
Ventouse birth 
Caesarean birth
#
  
Home birth 
 
6) Postnatal maternity bed day 
Mean number of days (SD) 
Median  
Inter-quartile range 
 
At specialist hospital 
1. Specialist ultrasound scans* 
Mean number of scans (SD) 
Median  
Inter-quartile range 
2. Counselling 
 
52 (100%) 
2.8 (1.5) 
1 to 6 
 
50 (96.2%) 
11.4 (6.7) 
1 to 35 
 
2 (3.9%) 
 
 
19 (36.5%) 
3.3 (2.5) 
2.0 
1.0 to 5.0 
 
17 (34.0%) 
0.9 (0.8) 
0.4 
0.3 to 1.0 
 
 
32 (64.0%) 
0 (0.0%) 
1 (2.0%) 
16 (32.0%) 
1 (2.0%) 
 
39 (78.0%) 
4.5 (3.9) 
4.0 
2.0 to 5.4 
 
 
6 (11.5%) 
1.2 (0.4) 
1 
1 to 1 
5 (9.6%) 
 
24 (100.0%) 
2.8 (1.3) 
1 to 5 
 
20 (83.3%) 
10.5 (5.6) 
1 to 24 
 
4 (16.7%) 
 
 
4 (16.7%) 
2.5 (1.3) 
2.5 
1.5 to 3.5 
 
4 (16.7%) 
2.4 (1.9) 
2.5 
0.8 to 4.0 
 
 
11 (55.0%) 
0 (0.0%) 
1 (5.0%) 
8 (40.0%) 
0 (0.0%) 
 
18 (90.0%) 
3.9 (2.5) 
3.0  
2.0 to 6.0 
 
 
24 (100.0%) 
1.1 (0.3) 
1 
1 to 1 
9 (37.5%) 
± 
Statistical tests conducted: Wilcoxon rank sum tests for scans and bed days; t tests for clinics; Fisher‟s 
Exact tests for termination of pregnancy and mode of delivery; 
#
 Caesarean birth without complications; * p < 0.05; ** p < 0.1 
 
2.6.4 Bootstrapped cost results in 2005/2006 prices 
The bootstrapped cost results presented below in Table 2.6 are shown for the three 
time periods (see section 2.5.3).  The mean costs per women for events from the time 
of anomaly scan until delivery show that the mean costs for the telemedicine group 
were higher than the direct referral group (£1,485 vs. £1,120), and this difference in 
costs between the two groups was approaching the level of statistical significance (p = 
0.060).  This was because these costs not only incorporated the cost of the 
telemedicine service (the marginal extra cost to the hospital of a teleconsultation over a 
specialist consultation was £87.32), but also each telemedicine woman had on average 
more antenatal attendances.  This was primarily due to two reasons: firstly, because 
some women in the telemedicine group were scanned earlier in the second trimester of 
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pregnancy compared to women in the direct referral group; and secondly, due to the 
underlying medical conditions of the women in each group.  There were significantly 
more diabetic women and women on treatment for epilepsy in the telemedicine group 
than the direct referral group: 21 (40.4%) in the telemedicine group and 4 (16.7%) in 
direct referral group (chi-square test: 2
1
4.18, p = 0.041).   
 
Table 2.6: Bootstrapped hospital costs per group in 2005/2006 prices± 
 Telemedicine group  
(n = 52) 
Direct referral group  
(n = 24) 
From time of anomaly scan up until delivery (Total antenatal costs) 
N** 
Mean (SD) 
95% CI 
52 
£1,485 (£118) 
£1,253 to £1,717 
24  
£1,120 (£109) 
£906 to £1,334 
During maternal delivery 
N 
Mean (SD) 
95% CI 
50 
£2,993 (£150) 
£2,699 to £3,287 
20 
£3,246 (£185) 
£2,884 to £3,607 
Total costs of pregnancy 
N 
Mean (SD) 
95% CI 
52 
£4,363 (£238) 
£3,896 to £4,830 
24  
£3,825 (£311) 
£3,215 to £4,435 
± 
Statistical tests conducted: t tests for all costs; ** p < 0.1 
CI = confidence interval 
 
Table 2.6 also shows the mean costs per group during delivery.  The cost for the 
telemedicine group was slightly lower than the direct referral group, although not 
significantly so (p = 0.351).  The majority of births were delivery by „normal means‟, 
however, 40% of women in the direct referral group had caesarean sections compared 
to only 32% in the telemedicine group.  This higher percentage maybe due to the 
higher number of abnormal hearts in the direct referral group and as caesarean section 
was the most costly mode of delivery this accounted for the slightly higher mean 
delivery cost for the direct referral group compared to the telemedicine group.  Finally, 
the table also shows the total bootstrapped mean costs per group of pregnancy from 
the second trimester to just after delivery (or in some cases after termination of 
pregnancy).  The overall costs for the telemedicine group were approximately £540 
greater than direct referral group, a difference which was not significant (p = 0.202).   
 
2.6.5 Sensitivity analyses results 
Table 2.7 shows the impact on costs when changing the discount rate and lifetime of 
the telemedicine equipment.  For this sensitivity analysis, it was assumed that these 
changes would not have an effect on the detection of cardiac anomalies.  Costs are 
shown for the telemedicine group.  Depending on the lifetime of the equipment, and 
assuming a 3.5% discount rate the total antenatal costs ranged from £1,531 (3 years 
lifetime) to £1,451 (10 years lifetime) for the telemedicine group.  These one-way 
sensitivity analyses confirmed the robustness of the results from the main analyses.  
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Even if the discount rate and the lifetime of the equipment were to change and this 
changed the costs for the telemedicine group, this would not change the overall 
conclusion.    
 
Table 2.7: Impact on mean costs when changing discount rate and lifetime of 
telemedicine equipment  
Discount rate & lifetime of 
equipment 
Telemedicine group (n = 52) 
Total antenatal costs Total costs of pregnancy 
Base case  
3.5% & 5 years £1,485  £4,363  
Sensitivity analyses 
0% & 5 years £1,489  £4,368  
6% & 5 years £1,482  £4,360  
3.5% & 3 years £1,531 £4,410  
3.5% & 4 years £1,503  £4,381  
3.5% & 6 years £1,474  £4,352  
3.5% & 7 years £1,465  £4,344 
3.5% & 8 years £1,459  £4,337  
3.5% & 9 years £1,455  £4,333  
3.5% & 10 years £1,451  £4,329  
 
2.6.6 TelePaed postal questionnaires results  
Questionnaires were sent to 235 out of the 408 women in the audit.  Information on 
travel arrangements and expenditure when visiting the hospital for an antenatal 
appointment were received from 125 women, giving a response rate of 53.2%.  This 
information was used to calculate travel costs and any other additional costs.  All but 6 
journeys were made to Medway district hospital: 23 questionnaires where from women 
whose anomaly scans were videoed for a telemedicine assessment and 96 
questionnaires where from women who were managed locally in the district hospital 
(there were no statistical differences in demographic characteristics: age, parity, 
gestation at start, between the telemedicine women and the women who were 
managed locally).   
 
Table 2.8 shows the representativeness of the responders was established by 
comparing their demographic characteristics with the characteristics of the other 
women who were referred for a specialist assessment.  There were no significant 
differences between the respondents and the other eligible women in terms of 
demographic characteristics and risk factors as shown in Table 2.8 (apart from 
gestation at the anomaly scan; this difference between the two groups was 
approaching a level of statistical significance).   
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a) Demographic characteristics of responders 
Table 2.8: Survey respondents compared with the rest of the observed sample± 
Demographic characteristics & risk factors Respondents 
(n = 29) 
Other eligible 
women (n = 47) 
Age 
Mean (SD) 
Range 
 
27.1 (5.4) 
16 to 38 
 
28.5 (6.7) 
17 to 43 
Parity 
Primaparous 
Multiparous 
 
10 (34.5%) 
19 (65.5%) 
 
21 (44.7%) 
26 (55.3%) 
Number of fetus 
Single 
Multiple 
 
29 (100.0%) 
0 (0.0%) 
 
46 (97.9%) 
1 (2.1%) 
Gestation at anomaly scan** 
Mean (SD) 
Range 
 
20.6 (1.1) 
18 to 22 
 
21.4 (2.2) 
19 to 33 
Gestation at birth 
#
 
Mean (SD) 
Range 
 
37.8 (2.5) 
32 to 42 
 
38.0 (2.7) 
29 to 41 
Does the patient have diabetes? 
Yes  
No 
 
7 (24.1%) 
22 (75.9%) 
 
6 (12.8%) 
41 (87.2%) 
Does the unborn baby have a high risk of Down’s syndrome? 
Yes 
No 
 
1 (3.4%) 
28 (96.6%) 
 
2 (4.3%) 
45 (95.7%) 
Does the patient have an elevated serum result? 
Yes 
No 
 
0 (0.0%) 
29 (100.0%) 
 
5 (10.6%) 
42 (89.4%) 
Does the patient have a family history of CHD? 
Yes  
No 
 
11 (37.9%) 
18 (62.1%) 
 
14 (29.8%) 
33 (70.2%) 
Has the patient had a previous pregnancy with an anomaly? 
Yes  
No 
 
1 (3.4%) 
28 (96.6%) 
 
1 (2.1%) 
46 (97.9%) 
± 
Statistical tests conducted: t tests for age, gestation at anomaly scan and birth; chi-squared tests for 
parity, diabetes and family history of CHD; Fisher‟s Exact tests for number of fetuses, Down‟s syndrome 
risk, elevated serum result and previous pregnancy with anomaly. 
#
 Not including women who had a termination of pregnancy; ** p < 0.1 
 
For this section of the thesis, the results of the 6 women in the direct referral group, 
and the 23 women who were in the telemedicine group for whom a completed initial 
questionnaire was received will be compared.  A follow-up questionnaire (sent after 3 
months) was returned by 18 women in the telemedicine group and 3 women in the 
direct referral group. 
 
Table 2.9 shows the demographic attributes of the responders, depending on which 
hospital they travelled to for that appointment (London or Medway hospital).  There 
were no significant differences between the two groups of respondents in terms of 
marital status, United Kingdom as country of birth, educational experience and whether 
they had ever smoked.  However, the direct referral group were significantly older (p = 
0.010). 
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Table 2.9: Characteristics of responders± 
Characteristics  Telemedicine group 
(n = 23) 
Direct referral group  
(n = 6) 
Age* 
Mean (SD) 
range 
 
25.8 (4.6) 
16 to 34 
 
32.0 (6.1) 
21 to 38 
Marital status 
Married or living as married 
Widowed 
Divorced 
Single 
 
19 (82.6%) 
0 (0.0%) 
0 (0.0%) 
4 (17.4%) 
 
6 (100.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
Were you born in the UK? 
Yes 
No 
 
21 (91.3%) 
2 (8.7%) 
 
6 (100.0%) 
0 (0.0%) 
Did you continue education after the 
minimum school leaving age (16)? 
Yes 
No 
 
 
15 (65.2%) 
8 (34.8%) 
 
 
5 (83.3%) 
1 (16.7%) 
Have you ever smoked? 
Yes 
No 
 
9 (39.1%) 
14 (60.9%) 
 
3 (50.0%) 
3 (50.0%) 
± 
Statistical tests conducted: t tests for age; chi-squared tests for smoking; Fisher‟s Exact tests for marital 
status, UK birth and continuing education; ** p < 0.1 
 
b)  Mode of transport 
The majority of women attending an antenatal appointment at Medway hospital 
(87.0%) travelled by car; 4.3% travelled by bus or train; and 8.7% went by taxi or 
walked.  For those six patients who travelled to London for an antenatal appointment, 
three travelled by car and the other three travelled by bus or train.   
 
c) Journey distance 
The length of each return journey was calculated using postcode data to establish the 
„true‟ distance from the woman‟s home to the hospital.  Table 2.10 shows the return 
journey length to and from hospital.  Patients who travelled to London had significantly 
longer journeys than those women attending the local hospital (p < 0.001).  
 
Table 2.10: Length of return journey (in miles) to and from and hospital for one 
hospital visit± 
 Telemedicine group (n = 23) Direct referral group (n = 6) 
Mean (SD)* 
Median 
IQR 
8.2 (7.7) 
7.0 
3.8 to 8.6 
88.5 (8.8) 
89.6 
83.2 to 90.8 
± 
Statistical test conducted: Wilcoxon rank-sum; * p < 0.05 
 
d) Duration of time 
Table 2.11 shows the duration of time spent on the different activities associated with 
the antenatal appointment.  Women who had to travel to London naturally had a 
significantly longer journey time than those attending the local hospital (p < 0.001).  
The great majority of antenatal attendances lasted between 50 and 90 minutes for 
women who were seen in the local hospital and the median time was about an hour.  
For those women in London, they spent an average of 90 minutes in the hospital.  This 
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time difference between the two groups, was not statistically significant (p = 0.291).  
The average time spent on antenatal visits for those who travelled to the local hospital 
was just over 90 minutes, whereas for women who had to travel to London for an 
antenatal appointment, the time spent on antenatal visits was substantially longer, at 
just over 4½ hours (p < 0.001). 
 
Table 2.11: Duration of times (in minutes) for one hospital visit± 
 Telemedicine group (n = 23) Direct referral group (n = 6) 
Duration of return journey (in minutes) 
Mean (SD)* 
Median 
IQR 
21 (15) 
18 
12 to 26 
184 (7) 
185 
182 to 190 
Duration of time in hospital (in minutes) 
Mean (SD) 
Median 
IQR 
75 (43) 
60 
50 to 90 
99 (55) 
90 
60 to 145 
Total time spent on visit (in minutes) 
Mean (SD)* 
Median 
IQR 
96 (50) 
87 
56 to 112 
283 (57) 
274 
232 to 335 
± 
Statistical tests conducted: Wilcoxon rank-sum; * p < 0.05 
 
e) Total travel costs of hospital visits 
Costs associated with journeys were estimated from the mileage rates calculated for 
the return car journeys and car parking fees, and from actual fares reported in the 
questionnaires for other modes of transport (e.g. rail and bus fares).  Table 2.12 shows 
that the cost of travel for pregnant women who had to travel to London was 
approximately £35 - nearly seven times that of women who travelled to the local 
hospital for their antenatal appointment, this difference was statistically significant (p < 
0.001).   
 
Table 2.12: Bootstrapped costs of one hospital visit (in 2005/2006 prices)± 
  Telemedicine group (n = 23) Direct referral group (n = 6) 
Total travel costs  
Mean (SD)* 
95% CI 
£5.01 (£0.81) 
£3.42 to £6.59 
£35.16 (£4.64) 
£26.08 to £44.25 
Additional costs 
N 
Mean (SD) 
95% CI 
6 
£38.87 (£13.52) 
£12.37 to £65.37 
2 
£34.85 (£16.73) 
£2.06 to £67.65 
Total costs (travel plus additional costs) 
Mean (SD)* 
95% CI 
£15.15 (£5.12) 
£5.12 to £25.18 
£46.78 (£10.79) 
£25.63 to £67.93 
± 
Statistical tests conducted: Wilcoxon rank-sum for all costs; * p < 0.05 
 
f) Additional costs of hospital visits 
Two-thirds of respondents (65.5%) were accompanied by another adult on their 
hospital visit.  The questionnaire asked both the patient and companion what they 
would have been doing if they were not attending hospital; for those who reported paid 
employment, what arrangements had been made to be absent from work and what 
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arrangements had been made if they had children or other dependents who needed 
looking after whilst they attended the hospital.  
 
If they had not been attending hospital, 41.4% of the respondents would have been in 
paid employment; just under half the respondents (48.3%) reported they would have 
been undertaking household duties; and 10.3% of patients had children or adults to 
look after.  Of those, 12 pregnant women who were in paid employment, 8 (66.7%) of 
them received time off with pay for their antenatal appointment (this cost being borne 
by the employer); 2 (16.7%) patients took annual leave; 1 (8.3%) woman had to make 
time up; and the other woman took time off work with loss of pay. 
 
Of the 19 companions who accompanied women on their hospital visit, 18 of them 
(94.7%) would have been in paid employment; and the remaining companion would 
have been undertaking household duties.  Of the 18 companions who were in paid 
employment, only 14 of them responded to the question what arrangements had been 
made to be absent from work.  Five (35.7%) companions took annual leave, three 
(21.4%) companions had to make the time up, a further two (14.3%) companions had 
time of work without loss of pay, three (21.4%) companions had time off work with loss 
of pay and finally, one companion (7.1%) went outside work hours. 
 
In total, 55.2% (16 respondents) had children or other dependents that needed looking 
after.  Of these 16 respondents, four (25.0%) of them said that someone else had to 
take time off work to look after them and two of these four respondents paid someone 
else to look after them. 
 
Table 2.12 also shows the total amount of additional costs for each patient, which 
included the loss of pay for the patient and any incidental expenses (e.g. child care), 
these costs have been inflated to 2005/2006 prices.  Only eight (27.6%) women 
reported additional costs incurred during their hospital visit (two women in the direct 
referral group), however, there was no statistical difference in additional costs between 
the two groups of women (p = 1.000).  If these costs were averaged out across all 
women who responded to the questionnaires in each group, for the direct referral group 
this additional cost was £11.62 for the 6 women and for the telemedicine group this 
additional cost was £10.14 for the 23 women.    
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g) Total costs of hospital visits 
After accounting for the travel costs and any additional costs by the women, the mean 
total costs for women who had to travel to London were significantly greater than 
women who were assessed via telemedicine (£46.78 vs. £15.15, p = 0.006). 
 
h) Health status instruments results 
Table 2.13 shows the differences in the results from the HADS questionnaire between 
the two groups, where women were asked about their level of anxiety and depression 
in the past week.   
 
Table 2.13: Anxiety and depression in the past week ± 
 Telemedicine group  Direct referral group  
Initial questionnaire n = 23 n = 6 
Anxiety scores  
Mean (SD) 
Median 
IQR 
8 (3) 
9 
5 to 10 
7 (3) 
8 
5 to 9 
Anxiety categories  
No anxiety (0-7) 
Possible anxiety (8-10) 
Probable anxiety (11-21) 
8 (34.8%) 
10 (43.5%) 
5 (21.7%) 
2 (33.3%) 
4 (66.7%) 
0 (0.0%) 
Depression scores  
Mean (SD) 
Median 
IQR 
5 (3) 
5 
1 to 7 
2 (2) 
3 
1 to 3 
Depression categories  
No depression (0-7) 
Possible depression (8-10) 
Probable depression (11-21) 
19 (82.6%) 
3 (13.0%) 
1 (4.4%) 
6 (100.0%) 
0 (0.0%) 
0 (0.0%) 
Follow-up questionnaire n = 18 n = 3 
Anxiety scores  
Mean (SD) 
Median 
IQR 
7 (3) 
7 
5 to 9 
5 (3) 
7 
2 to 7 
Anxiety categories  
No anxiety (0-7) 
Possible anxiety (8-10) 
Probable anxiety (11-21) 
11 (61.1%) 
4 (22.2%) 
3 (16.7%) 
3 (100.0%) 
0 (0.0%) 
0 (0.0%)  
Depression scores  
Mean (SD) 
Median 
IQR 
6 (4) 
5 
2 to 8 
2 (2) 
3 
0 to 4 
Depression categories  
No depression (0-7) 
Possible depression (8-10) 
Probable depression (11-21) 
11 (61.1%) 
4 (22.2%) 
3 (16.7%) 
3 (100.0%) 
0 (0.0%) 
0 (0.0%) 
± 
Statistical tests conducted: Wilcoxon rank-sum for all anxiety and depression scores; Fisher‟s Exact tests 
for all anxiety and depression categories 
 
In the initial survey, the telemedicine women recorded slightly higher levels of anxiety 
than the direct referral women, although this finding was not statistically significant.  
These findings applied to both the mean anxiety scores and the anxiety categories.  
After three months, although the telemedicine women were still comparatively more 
anxious than the direct referral women, the anxiety levels for both groups had eased 
59 
 
(differences were not statistically significant over time).  In both, the initial and follow-up 
questionnaires, the telemedicine women were slightly more depressed than the direct 
referral women, although not significantly so.   
 
Soon after having their anomaly scan, the telemedicine women in general gave their 
health a lower rating on the EQ-5D VAS than the direct referral women, although this 
difference was not statistically significant (p = 0.302) (see Table 2.14).  This may have 
been because there were more diabetic women in the telemedicine group compared to 
the direct referral group.  Three months later, even though the telemedicine women still 
gave a lower rating for the health (EQ-5D VAS) compared to the direct referral group, 
this value was higher than the initial survey. 
 
In the initial survey, when the women rated the statements on mobility, self-care, usual 
activities, pain or discomfort, and anxiety or depression, the telemedicine group had a 
higher overall mean tariff score than the direct referral group.  Although, this difference 
between the two groups was not statistically significant (p = 0.582), this may have been 
because the telemedicine women were younger.  Three months later, the EQ-5D tariff 
score for the telemedicine women had fallen over time, whereas for the direct referral 
women, this score had increased (see Table 2.14) and over time these differences 
were not statistically significant.  
 
Table 2.14: EQ-5D visual analogue assessment and EQ-5D tariff of own health 
today±  
 Telemedicine group  
(n = 23) 
Direct referral group  
(n = 6) 
EQ-5D visual analogue scale (initial survey) 
Mean (SD) 
Median 
IQR 
77 (13) 
80 
70 to 86 
84 (13) 
85 
70 to 98 
EQ-5D tariff based on 5 dimensions (initial survey) 
Mean (SD) 
Median 
IQR 
0.846 (0.146) 
0.812 
0.760 to 1.000 
0.820 (0.159) 
0.804 
0.691 to 1.000 
EQ-5D visual analogue scale (follow-up survey) 
Mean (SD) 
Median 
IQR 
80 (12) 
85 
70 to 90 
83 (6) 
80 
80 to 90 
EQ-5D tariff based on 5 dimensions (follow-up survey) 
Mean (SD) 
Median 
IQR 
0.831 (0.131) 
0.796 
0.727 to 1.000 
0.932 (0.118) 
1.000 
0.796 to 1.000 
± 
Statistical tests conducted: Wilcoxon rank-sum for all EQ-5D scores 
 
2.7 Discussion 
2.7.1 Summary of findings 
This chapter has focused primarily on comparing two groups of women who were 
referred for a specialist fetal cardiac opinion in two different ways: by direct referral to 
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specialist hospital for face-to-face assessment or via telemedicine assessment where 
pre-recorded videoed ultrasound images were relayed to the specialist in the absence 
of patients‟.   
 
Over the 15-month study period, 76 women were referred for specialist opinion: 24 
women were sent for a face-to-face assessment in London hospitals and 52 women‟s 
anomaly scans were pre-recorded by video and transmitted to the specialist hospital.  
There were no statistical significant differences in age, parity, type of pregnancy (single 
or multiple births) or gestation in weeks at birth between the two groups of women.   
 
The perspective adopted for the cost analysis was that of the hospital and costs were 
presented in pounds sterling (£) in 2005/2006 prices.  There were no significant 
differences in terms of resources used between the two groups, although the 
telemedicine women had more antenatal clinic attendances.  The observed cost 
differences between the telemedicine group and the direct referral group may have 
been partly due to the additional cost of a teleconsultation (the cost difference between 
a specialist scan in London and a teleconsultation was £87).  In addition, some of the 
women in the telemedicine group were scanned earlier in the second trimester and 
their antenatal care over the remaining months would include one or two extra 
antenatal visits; and also the telemedicine group contained more diabetic women.  
Finally, four women (16.7%) in the direct referral group had terminations compared to 
only two women (3.8%) in the telemedicine group, and for these women their total 
costs of pregnancy would have been lower.  Overall, telemedicine was shown to be 
more costly, than direct referral.  The effectiveness measure was the detection of 
cardiac anomalies before birth and the direct referral group had a higher prevalence of 
women with cardiac abnormalities in their fetus, than the telemedicine group.  In terms 
of the quality of life data, telemedicine women gave a lower rating on the EQ-5D VAS 
and this may be because there were more diabetic women in this group compared to 
the direct referral group.  
   
2.7.2 The use of telemedicine and why it may not have been cost-saving?  
The results from this study were reported in terms of a cost-consequence analysis, as 
a cost-effectiveness analysis was deemed to be inappropriate. The results from a cost-
effectiveness analysis are typically presented in the form of an incremental ratio e.g. 
cost per cardiac case detected.  Whilst such an outcome may resonate with clinical 
decision makers, it is unlikely to be particularly meaningful to health service 
administrators.  Unlike the cost per QALY ratio, such an outcome does not allow for 
comparisons across different diseases, treatments or patient groups.  Furthermore, in 
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the absence of a net benefit calculation, it is difficult to infer whether an incremental 
cost effectiveness ratio, based on a clinical outcome such as a cardiac case avoided, 
will result in net costs or savings to the health service.  
 
There are a number of reasons why telemedicine may appear to be not as cost-saving 
as direct referral.  Firstly, the study was not randomised.  The sonographers (or in 
some instances, the district obstetricians) at Medway hospital identified women „at risk‟ 
and then chose the method of referral for these pregnant women who required further 
assessment and they also decided on the use of telemedicine.  The two groups of 
women at the time of their anomaly scan were identified for echocardiographic referral 
according to the obstetric department‟s existing protocol for high risk women and they 
also included women whose fetal heart images during the anomaly scan were 
abnormal in some way or were poorly visualised.  So if there was anything abnormal in 
the anomaly ultrasound scan, the woman was sent straight away to London for a 
detailed anomaly scan, unless the telemedicine clinic was scheduled to take place in 
the next few days.  Women with apparently normal fetuses were checked by the fetal 
cardiologist over the telemedicine link.  Hence, the higher underlying prevalence rate of 
cardiac anomalies in the direct referral group compared to the telemedicine group.   
 
The use of telemedicine at Medway hospital became part of routine practice fairly 
quickly and this enabled monthly telemedicine clinics to be scheduled and only the 
occasional „adhoc urgent‟ case(s) had to be sent to London.  Telemedicine at Medway 
hospital was (and still is) being used primarily for reassurance and for detailed 
echocardiography.  In practice, women with abnormal scans were sent to London, 
whereas women with „normal‟ fetuses are assessed over the telemedicine link.  This is 
important as the telemedicine link reduces the time taken to assess a woman and to 
screen the fetal heart (mean time: 5 vs. 45 minutes), which in most cases is usually 
thought to be normal by the screening sonographers (but is not always so).  In most 
instances, fetal clinics in DGHs are overloaded with normal cases and this leaves little 
time and space to evaluate and counsel mothers with abnormal foetuses [Personal 
communication with Sonographer B, October 2007].  Practice over the years has 
meant that women have been selected (based on clinical factors) for further 
assessment who were thought to have an increased risk of CHD in their fetus.   
 
Secondly, the antenatal costs for the telemedicine group were approximately £360 
higher than the direct referral group.  On average the telemedicine group, had more 
antenatal clinic attendances compared to the direct referral group.  This was primarily 
due to the underlying medical conditions of the women in each group.  These results 
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are confirmed by a separate analysis of the study‟s pregnancy dataset in which the 
NHS costs of multiple pregnancies were compared with those of low-risk and high-risk 
singleton pregnancy [Mistry et al, 2007].  Pre-gestational diabetes was the most 
influential factor driving singleton costs, where women with diabetes (£4,877) had 
similar total costs to women with multiple pregnancies (£4,442) and this total cost was 
approximately a £1,000 greater than women who had cardiac risk factors for a 
singleton pregnancy (£3,625) [Mistry et al, 2007].   
 
Thirdly, given that this analysis for this section is based on a small number of referred 
women (n = 76) this might increase the level of uncertainty in the cost and effect 
calculations and limits the generalisation to other women who may need a specialist 
opinion.  Fourthly, there was only a small number of referred women (23 (44.2%) in 
telemedicine group and 6 (25.0%) in the direct referral group) who completed a 
questionnaire with regards to their health status and these results need to be 
interpreted with caution.  The underlying risk factors as mentioned earlier may also 
partly explain why the telemedicine group were slightly more anxious and depressed 
compared to the direct referral group (see Table 2.13).  In terms of checking whether 
the respondents were representative of the observed patient sample (i.e. other women 
who were referred for specialist assessment), both groups were compared and no 
significant differences were found in terms of demographic characteristics or cardiac 
risk factors which were measured in the study.  However, extrapolating to other women 
in the study isn‟t quite as straightforward as a woman‟s anxiety and depression levels 
changes throughout pregnancy [Heron et al, 2004].  
 
2.7.3 Next steps 
This chapter has provided important information on the two different referral strategies 
which were used to obtain specialist advice for fetal cardiology.  The results highlighted 
that telemedicine was more costly than direct referral and also that telemedicine had a 
lower prevalence rate for cardiac anomalies than direct referral.  In the next chapter, a 
literature review will be conducted in which existing evidence on the costs and benefits 
of telemedicine is presented and discussed.  The chapter will then go onto discuss 
some of the economic issues associated with telemedicine which were highlighted in 
the review, and how important some of these issues are for the studies which are 
presented in the review; and finally, the issues which are relevant to the case study will 
be considered.  Following on from the findings from the literature review, in Chapter 4, 
a critique of the TelePaed case study will be provided and also to reflect on some of 
the problems with the design of the study. 
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CHAPTER 3: A LITERATURE REVIEW OF STUDIES INVESTIGATING THE 
ECONOMICS OF TELEMEDICINE 
 
3.1 Introduction 
Chapter 2 provided an introduction to the case study which is used throughout this 
thesis.  The objectives for this chapter are: firstly, to examine what evidence there is to 
support whether telemedicine interventions are cost-effective; secondly, to see what 
this new review adds over previous reviews on telemedicine; and thirdly, to discuss 
some of the economic issues that were identified in the literature review that face 
telemedicine technologies and how best to solve these difficulties in the context of an 
economic evaluation.  The literature review will aim to identify methodologies that have 
been used and enable a comparison of these methodologies with that of the case study 
and explore further the economic issues which have been identified with regards to the 
case study.  
 
3.2 Methods 
3.2.1 Literature Search 
A small number of literature reviews have been conducted looking at the cost-
effectiveness of telemedicine interventions.  Whitten and colleagues (2002) undertook 
a systematic review of the cost-effectiveness of telemedicine studies which were 
published until June 2000.  They searched the following databases: Medline, Embase, 
ISI Web of Knowledge and Telemedicine Information Exchange using the following 
search terms: 'telemedicine or telehealth or telemonitoring or telecommunications' AND 
'cost or cost-effectiveness or economic or cost analysis or budget or financial or health 
care costs'.  Their inclusion criteria included: original research on telemedicine 
examining cost-effectiveness of healthcare delivery; and their exclusion criteria were: 
papers reporting cost benefits of telemedicine used mainly for educational or 
administrative purposes; papers reporting hypothetical cost analyses or modelling 
exercises without any associated formal clinical trial; and papers reporting economic 
analyses without any means of substantiating claimed resource use.   
 
Two further reviews on telemedicine not only looked at the cost-effectiveness, but they 
also made conclusions with regards to the clinical outcomes of telemedicine 
interventions.  Roine et al (2001) examined evidence on the effectiveness or cost-
effectiveness of telemedicine studies and Hailey and colleagues (2002) in another 
review conducted a systematic review of evidence for the benefits of telemedicine, 
which included providing evidence on the effectiveness and economics of telemedicine 
applications.  Further details about these three studies and other systematic reviews of 
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telemedicine applications (including the conclusions by the authors) are provided in 
more detail in the discussion section (section 3.4.2 and Appendix 5).   
 
Instead of updating the literature search from June 2000 which was carried out by 
Whitten and colleagues (2002), a new search has been conducted on the costs and 
cost-effectiveness of telemedicine interventions, to make sure that no important papers 
were omitted.  The search strategy aimed to identify all published studies of the costs 
and cost-effectiveness associated with telemedicine interventions.   
 
As there has been an increasing amount of literature in the area of health economics 
and in order to widen the literature search to make sure that all articles relating to the 
costs and cost-effectiveness of telemedicine are retrieved, health economics 
databases have also been included.  The following databases (with the relevant time 
periods) outlined below were searched and details of the search strategies including 
any search terms used can be found in the Appendix 1.    
 MEDLINE (1950 to 12th October 2007) - articles were limited to English Language, 
to humans and any duplicates within Medline were deleted.  The search retrieved 
a total of 2,252 abstracts; 
 CINAHL (Cumulative Index to Nursing and Allied Health Literature) (1982 to 12th 
October 2007) – articles were limited to English Language, to humans and any 
duplicates within Cinahl were deleted.  The search retrieved 838 abstracts; 
 EMBASE (1974 to 12th October 2007) – articles were limited to English Language, 
to humans, to articles within the Embase database and any duplicates within 
Embase were deleted.  The search retrieved 2,464 abstracts; 
 ISI Science Citation Index (1970 to 12th October 2007), ISI Social Science Citation 
Index (1970 to 12th October 2007) and ISI Arts and Humanities Citation Index 
(1975 to 12th October 2007) – searches were restricted to English Language and 
document type was restricted to articles or abstracts of published items.  Within 
this ISI search any duplicates which were identified were removed.  Two searches 
were run, firstly using the keyword search term topic (TS), this identified 5,694 
abstracts, and secondly, restricting the search terms to within the title (TI), this 
retrieved 180 abstracts.  All articles regarding the costs and cost-effectiveness of 
telemedicine found in the topic search were also identified in the title search.  
Hence, the decision to use the search strategy which was restricted to title search 
was justified, as nothing important seemed to be omitted and the other articles 
which were identified in the TS search were not relevant. 
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In addition, the following databases outlined below were searched on 12th October 
2007 using the search term “telemedicine” and limiting where possible to English 
Language abstracts.  The number of abstracts retrieved for each database is also 
noted: 
 Database of Abstracts of Reviews of Effectiveness (DARE) - 27 abstracts;  
 NHS Economic Evaluation Database (NHS EED) -163 abstracts; 
 Health Technology Assessment database (HTA) - 34 abstracts; 
 European Network of Health Economic Evaluation Databases (EURONHEED) - 
54 abstracts;  
 Office of Health Economics: Health Economic Evaluations Database (OHE 
HEED) - 93 abstracts;  
 Cochrane Database of Systematic Reviews - 14 abstracts;  
 Cochrane Central Register of Controlled Trials - 274 abstracts; and  
 Cochrane Methodology Register - 3 abstracts. 
 
The database of Telemedicine Information Exchange which was used by Whitten and 
Colleagues (2002) was searched using only the economic evaluation and quality of life 
terms, as all the citations relate to telemedicine and the searches were restricted to 
English Language and journal articles only.  However, this search was not included: 
firstly, it retrieved over 18,754 abstracts and the search truncates the results to the first 
two hundred citations found (even if the word „cost‟ was entered as a search term on its 
own, this search retrieved 1,207 articles and also truncated to the first 200 articles); 
and secondly, the 24 articles mentioned in the paper by Whitten et al (2002) were also 
retrieved from the other databases in the literature search, implying that any relevant 
articles were not missed. 
 
Once all abstracts were retrieved they were exported into the citation software 
package, Endnote [Endnote, 2002] and any duplicates identified from the different 
databases were deleted.  All titles, bibliographic data and abstracts of the results from 
these searches were then read and scanned for relevance based on the inclusion and 
exclusion criteria.  Many of the abstracts identified in the search were due to the word 
„cost‟ or „economics‟ being included in the abstract.  A lot of these abstracts did not 
actually report any economic analyses; however, they simply stated that it was 
important for economic aspects to be taken into account.  The inclusion criteria was 
articles relating to research which examined the costs and cost-effectiveness of 
telemedicine applications.  The exclusion criterion for the abstracts included: no original 
economic evaluation or related type of study; studies with no cost data; effectiveness 
studies with no cost data; telecare or telehealth devices used specifically for use in the 
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home; language other than English; and articles where one project led to multiple 
reporting of the same results. 
 
3.2.2 Data Extraction 
Relevant full-text articles were then obtained and evaluated.  A data extraction form 
was set up to retrieve information from the articles obtained.  In addition to the 
author(s), title, year, volume, issue and page numbers, the fields in the data extraction 
form included: the aim of paper; the method of economic evaluation undertaken for the 
analysis; country in which the study took place; viewpoint of study; study time frame 
(how long the telemedicine intervention was evaluated for); what the telemedicine 
intervention and the comparators were; clinical application or area; study design 
(randomised or not–randomised); sample size of the patients in the study; the type of 
costs included in the study which would fall into one of the following categories: fixed, 
variable and other costs; costs excluded from the study; total costs for the telemedicine 
intervention and for the conventional comparator(s); currency in which the total costs 
were presented; any benefits/outcomes associated with the telemedicine intervention 
or the comparator; whether discounting was undertaken (not including the depreciation 
of the telemedicine intervention); whether any sensitivity analyses were undertaken 
after the base-case results were presented; number of telemedicine conferences or 
sessions held during study period; transmission mode for the telemedicine images; the 
average duration for the telemedicine consultations; strengths or limitations mentioned 
by the authors in their study; and the conclusion which the authors finally came to. 
 
3.2.3 Meta-analysis 
Meta-analysis is a statistical analysis of the summary of findings of quantitative studies.  
By pooling results together from various studies, including individual studies with small 
sample sizes, it is possible to increase power and precision of estimates of treatment 
effects and exposure risks [Mulrow, 1994].  For a fixed effect meta-analysis, it is 
assumed that all studies come from a common population, and that the effect size is 
not significantly different among the different studies.  For a random effects meta-
analysis, the random variation within the studies and the variation between the different 
studies are incorporated.  Random effects meta-analysis can lead to wider confidence 
intervals than fixed effects models [Egger et al, 1993].  From the literature review, 
relevant data was abstracted in order to conduct a meta-analysis for the cost studies 
using a random effects procedure (the data obtained from the articles in the literature 
review did not have enough information to conduct a cost-effectiveness meta-analysis).  
This abstracted data for both the telemedicine and conventional arms included: sample 
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sizes; total costs; mean costs; standard deviations; 95% confidence intervals; and p 
values (from statistical tests) which where reported in the studies. 
 
Once information was abstracted from the studies, using the World Bank gross 
domestic product (GDP) deflators [World Bank, 2006], costs in local currency units in 
the study year were converted to local currency units in 2007 prices.  The GDP price 
deflators measure the change in price level of GDP relative to real output and has an 
advantage over consumer price indices, as it is not based on a fixed basket of goods 
and services.  Once all local currencies were in 2007 prices, using purchasing power 
parity (PPP) measures [OECD, 2008] local costs were converted in UK pounds sterling 
in 2007 prices.  “PPP are rates of currency conversion that equalise purchasing power 
of different currencies.  That is, they attempt to eliminate the differences in price levels 
for the same goods between countries” [Mulligan and Fox-Rushby, 2005].  The random 
effects meta-analysis was computed using the comprehensive meta-analysis version 2 
programme [Borenstein, 2005]. 
 
3.3 Results 
3.3.1 General Findings 
In total, 4,721 abstracts were retrieved after removing duplicates.  After application of 
the exclusion criteria, 141 of these articles were obtained and were subject to a full 
review.  After a more detailed evaluation, only 109 studies were included in the 
literature review results (see Figure 3.1 below).  Thirty-two studies were excluded after 
a more detailed evaluation: one of which forms part of the case study used throughout 
the thesis [Dowie et al, 2007]; two studies did not provide any cost information; one 
study only provided time costs and not monetary costs; and the remaining studies (n = 
28) used telemedicine in a home setting („telecare‟).  The results from the data 
extraction form of these 109 studies are summarised in Appendix 2. 
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Figure 3.1: Studies eliminated from or selected for the review after applying inclusion 
and exclusion criteria 
 
3.3.2 What was studied?  
The greater number of studies (n = 106, 97.2%) used telemedicine for clinical 
applications; and three studies [46, 75, 86]4 specifically used telemedicine for clinical 
administration and educational purposes only.  Further selection of these 109 studies 
highlighted the various areas of health in which telemedicine were used: ranging from 
specialist care for patients i.e. paediatrics, pregnant women and the elderly; through to 
specific health advice such as for skin disease (dermatology), through to the use of 
telemedicine for a range of specialties.  The majority of studies which were conducted 
in the one health area (not including studies with multiple specialties) were in 
dermatology (n = 10); psychiatry (n = 9); radiology and cardiology, both of which had 8 
studies each; and cancer (n = 6).   
 
Telemedicine was compared to the conventional method of referral in 78.0% (n = 85) 
studies; in 18 (16.5%) studies telemedicine was compared to two methods of referral.  
The other methods of referral usually involved the patient travelling to specialist 
hospital for face-to-face assessment or a specialist visiting the local hospital to see 
patients in outreach clinics; in four studies [15, 18-19, 79] telemedicine was compared 
to what happened before telemedicine was introduced (before and after comparison); 
                                                 
4
 Formatting of references for this section of the thesis has changed to make it easier for the reader to 
refer to the table in Appendix 2. 
Studies identified for more 
detailed evaluation  
n = 141 
Studies based on abstract 
search, which did not meet the 
inclusion criteria 
n = 4,583 
Potential studies identified 
from electronic searches 
n = 4,721 
Studies excluded after more 
detailed evaluation 
n = 31 
 
Studies included in this review 
n = 109 
Dowie et al (2007) study 
excluded (n = 1) 
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in one study [51] telemedicine across two countries was compared; and in the final 
study [75], telemedicine was used for different activities.   
 
Of those 109 studies, only 37 stated the mode of transmission used for the 
telemedicine service.  Twenty studies [2, 9-10, 12, 14, 24, 27, 29, 39, 47, 49, 55, 59, 
61-62, 77, 80, 95, 106, 108] used real-time telemedicine; 9 studies [1, 3, 20, 42, 48, 56-
57, 74, 103] used store-and-forward methods; and a further 8 studies [7, 15, 38, 60, 63, 
72, 100, 102] used both real-time and store-and-forward methods as a means of 
transmission.   
 
3.3.3 Where, when and for how long? 
Figure 3.2 below shows that the half of the studies (n = 57) were conducted in North 
America and 26 studies were from Europe (not including the UK or Ireland). 
 
 
Figure 3.2:  Country in which telemedicine study was conducted 
 
The journals from which the studies were retrieved were grouped into three areas: 
telemedicine journals; clinical journals; or health service research or health policy 
journals.  The majority of articles were in telemedicine journals (n = 73) (see Figure 3.3. 
below).  
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Figure 3.3: Type of journal 
 
From 1995 to 1999, 30 (27.5%) articles were published; between 2000 and 2004, 59 
(54.1%) articles were published; and between 2005 and 2007, 20 (18.3%) articles were 
published.  The year 2004 had the most articles published on the costs and cost-
effectiveness of telemedicine, 16 (14.7%).  
 
 
Figure 3.4: Time frame 
 
The literature review highlighted that the majority of studies evaluating telemedicine 
interventions were conducted over a two-year time frame or less: 77 studies (70.6%) 
and 21 studies (19.3%) did not report how long the telemedicine intervention was 
evaluated for (see Figure 3.4).  
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3.3.4 Overall methods of cost-effectiveness 
The articles included 71 cost analyses; 16 cost-minimisation analyses; six cost-
consequence analyses; one cost-benefit analysis; 11 cost-effectiveness analyses; one 
joint cost analysis and cost-effectiveness analysis; and three studies used costing 
models.  However, only 45 of the studies informed the reader of the viewpoint of the 
analyses: 22 studies [2, 5, 9, 12, 30, 40, 49, 60-62, 69, 73-74, 78, 83, 86-87, 89, 93, 
95, 106, 108] were from a societal perspective; 21 studies [1, 3-4, 7-8, 10, 17, 21, 27, 
54, 57-58, 66, 75, 81, 84, 91-92, 103-104, 109] were from the perspective of the 
healthcare system or prison; and only two studies [19, 90] were from the patients‟ 
viewpoint.  
 
Eighty-five studies (78.0%) did not report about benefits/outcomes in their articles.  
Twenty-four studies, however, reported some outcome measure (see Appendix 2 for 
further details).  Only two studies [3, 21] used QALYs, a further study [51] used 
disability-adjusted life years (DALYs), two more studies [5, 54] used life years gained 
and one study [49] used health state utility values as an outcome measure.  Eight 
further studies used a different measure for effectiveness: one study [73] used safety 
and clinical effectiveness at 7 days after presentation; another study [103] used days to 
the intervention; three papers [15, 81, 105] used a range of outcomes as measures, 
one of them being mortality; for the other study [2] effectiveness was defined as health 
care access for patients who received outpatient consultations; one study [85] used 
differences in healing rate as an effectiveness measure and the final article [104], used 
three effectiveness measures including the number of cases of severe vision loss 
averted.  Three studies [70, 80, 90] used patient satisfaction as an outcome measure; 
one study [84] used scales for depression, anxiety, functioning and also a generic 
measure short-form 12 (SF-12) for outcome measures; and the final six studies [16, 27, 
31, 83, 89, 92] looked at benefits in terms of transfers or travel avoided and some of 
these studies also included the number of hospitalisations or consultations avoided.  
However, in economic terms, outcomes measures such as the number of transfers or 
hospitalisations avoided are not regarded as benefits, instead these should be classed 
as „costs averted‟.  
 
Only seven out of 109 studies [1-3, 5, 21, 54, 75] used discounting for costs (not 
including the discount methods which were used to estimate the depreciation costs for 
the telemedicine equipment).  This is reasonable as half of the studies (n = 58) 
reported a time frame of less than or equal to a year in which the telemedicine service 
was evaluated for.  However, for a further 26 studies, telemedicine was evaluated for 
more than 12 months and costs in these studies should have been discounted.  Thirty-
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seven studies used some sort of sensitivity analysis for the cost components and 
break-even thresholds.   
 
Table 3.1 below shows a summary of the overall conclusions provided by the authors 
for each study and as the table shows there was no general agreement whether 
telemedicine was cost-saving (or cost-effective) compared to conventional means.  
 
Table 3.1: Overall conclusions 
Conclusion Number (%) Study identifier 
Telemedicine was cost-saving compared to 
the comparator(s) 
39 (35.8%) 4, 6, 8, 10, 13, 16, 18, 20, 22-23, 26, 
28, 31, 33, 37, 39, 41, 43-44, 47, 52, 
55-57, 62, 65-66, 69, 72, 77, 80, 88, 
90, 92-94, 97-98, 102 
Telemedicine was cost-effective compared to 
the comparator(s) 
8 (7.3%) 2-3, 11, 14-15, 50, 85, 101 
Telemedicine was only cost-saving either 
above a certain number of teleconsultations or 
patient throughput 
12 (11.0%) 9, 17, 34, 45, 59, 67, 76, 91, 95, 99, 
108-109 
Telemedicine had the potential to be cost-
saving 
14 (12.8%) 25, 27, 35-36, 42, 51, 53, 60, 63-64, 
71, 79, 82, 86 
Telemedicine had similar cost results to 
conventional methods 
5 (4.6%) 29, 48, 58, 100, 105 
Telemedicine had reduced patients‟ costs 3 (2.8%) 19, 46, 107 
Inconclusive as to whether telemedicine was 
cost-effective or not (i.e. when telemedicine 
was compared to two alternatives) 
4 (3.7%) 1, 32, 87, 96 
Telemedicine was not cost-effective compared 
to the comparator(s) 
12 (11.0%) 5, 7, 21, 49, 54, 73, 75, 84, 89, 103-
104, 106 
Telemedicine was not cost-saving compared 
to the comparator(s) 
12 (11.0%) 12, 24, 30, 38, 40, 61, 68, 70, 74, 78, 
81, 83 
 
Finally, of the 109 studies, 100 studies (91.7%) had insufficient statistical information in 
order for a meta-analysis to be conducted.  Results from the meta-analysis are not 
really informative and for illustration purposes they are presented in Appendix 3.  
 
3.3.5 Use of telemedicine in specific health areas 
The cited systematic reviews (see section 3.4.2 for more detail) deal with telemedicine 
literature in general, without focusing on a particular medical specialty.  Because of the 
significantly different ways telemedicine is performed in specific medical areas, this can 
lead to important details being omitted in favour of general considerations.  Therefore, 
there is a need to perform an analytical review of articles relating to the application of 
telemedicine in a specific medical field.   
 
As a meta-analysis for each clinical area could not be conducted, in Appendix 4, there 
is a brief description of the studies within a particular clinical area (dermatology; 
radiology; psychiatry; cardiology), followed by an overall conclusion for the use of 
telemedicine in each clinical area.   
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3.4 Discussion 
Cost-effectiveness studies are needed to help define the appropriate scope and 
application of telemedicine interventions or services in different settings and to provide 
information to the reader and the decision maker on whether the use of these 
interventions/services in various health areas represent good value for money.  One of 
the aims of this literature review was to present the results of the literature search and 
to see whether there is evidence to support whether telemedicine interventions are 
cost-effective.  The search strategy including search terms and the databases which 
have been searched are highlighted in the methods section and in Appendix 1.  In total, 
109 articles identified in the literature search were subject to a full review in which 
economic data was presented for telemedicine interventions (an overview of the results 
are provided in Appendix 2).   
 
The literature search also identified all 24 studies that Whitten et al (2002) had found in 
their search.  However, 3 of these studies were not included as they did not meet the 
inclusion criterion [Friedman et al (1996) and Wu et al (1995) were excluded as they 
were for telemedicine applications in the home (i.e. telecare applications); and Loane et 
al (1999) looked at time and not monetary costs].  This finding is important as it helps 
to understand and validate the search criteria and to highlight that the methods used 
for the literature search are correct. 
 
Since the beginning of 2002 until October 2007, the search identified 55 studies that 
have been published on the costs and cost-effectiveness of telemedicine interventions.  
Ten of the 11 studies which conducted cost-effectiveness analyses; 21 of the 24 
studies which reported benefit measures; six of the seven studies which used 
discounting; and 24 of the 37 studies that undertook some sensitivity analyses have 
been published during this time period.  This has shown that economic tools are 
increasingly being used for evaluations to ensure that treatment choices reflect 
evidence not only on the clinical effectiveness, but also the cost-effectiveness.   
 
The analysis of the results from the literature search of the use of telemedicine in 
specific health areas also gave mixed feedback (see Appendix 4) and one of the big 
limitations was that a meta-analysis could not be conducted for each health area 
separately as there was not enough statistical information.  Therefore, it was not 
possible to summarise the results further from each health area in which telemedicine 
was used.  This was because there were variations in the patient populations, study 
designs and the intervention and the comparator groups.  Instead, the results for each 
health area were reviewed and summarised.  These findings are confirmed by a cost 
74 
 
review conducted by Hyler and Gangure (2003) in psychiatry.  They identified over 380 
articles relating to telepsychiatry, but only 12 articles focused on the cost of 
telepsychiatry [not all cost studies identified by Hyler and Gangure (2003) were 
identified in my literature review: 1) they also searched the PsycINFO database for 
additional articles relating to costs of telepsychiatry (this database is an abstract 
database of psychological literature); and 2) some of the studies included in their 
literature review were cost feasibility studies, where costs were calculated with no 
actual service being delivered and two studies were based on surveys as a way to 
subjectively probe cost without determining it objectively].  In seven studies, 
telepsychiatry was worth the cost, and a further three studies telepsychiatry 
consultations had to be over a certain number to be financially viable.  Of the remaining 
two studies, in one study telepsychiatry was not financially viable and in the other study 
a lack of clear business plan contributed to its inability to determine its cost-
effectiveness.  The authors concluded that “telepsychiatry can be cost-effective in 
selected settings and can be financially viable if used beyond the break-even point in 
relation to the cost of providing in-person psychiatric services.” 
 
The term telemedicine groups together all services which comprise a tele-link and can 
include any medical service or act which is performed from a distance.  Whilst there are 
some benefits to grouping such interventions under a common definition the 
interventions included may actually differ quite significantly.  For example, telemedicine 
may be classed as two doctors talking on the telephone about a complex issue and 
determining the best course of action for a patient or telemedicine could be a complex 
as telesurgery, in which a surgeon receives visual and audio information to guide 
robotic instruments to perform surgery at a distance.  Even though the concept of 
telemedicine is simple (i.e. an exchange of information), arguably it doesn‟t make 
sense putting all tele-services together for the purposes of evaluation.  Just as different 
approaches to evaluation may be required for different disciplines of medicine together 
such as paediatrics, obstetrics, and the elderly, then this too applies to telemedicine.  
Telemedicine is actually a broad term, and as we have seen in this Chapter when 
comparisons such as literature reviews (of the cost-effectiveness of telemedicine 
studies) or analyses need to be undertaken then the medical specialties within 
telemedicine need to be categorised such as real-time versus store-and-forward 
telemedicine, or home versus hospital based telemedicine, or telecardiology versus 
telepsychiatry to get meaningful conclusions.  For this reason, it would be inappropriate 
to attempt to apply a „one size fits all‟ approach to evaluation and it would be 
inappropriate to attempt to make broad, sweeping generalisations about the 
effectiveness or cost-effectiveness of telemedicine.  
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Finally, the results from the literature review may also be due to publication bias, that 
is, studies with positive results have a better chance of being published, and therefore 
conclusions based exclusively on published studies may be misleading.  For example, 
the results from the meta-analysis (see Appendix 3) highlighted that there was 
significant heterogeneity and that there was also evidence of funnel plot asymmetry 
(graph has not been presented in the Appendix); that is, the smaller studies were more 
widely spread around the mean effect due to the large random error, highlighting 
publication bias amongst the studies.  Furthermore, there are few published studies 
which suggest that telemedicine might be cost additive and/or lead to inferior outcomes 
to current practice.  
 
The next section (section 3.4.1) sets out some of the economic issues which arose 
from the literature review.  In section 3.4.2, the findings from the literature review will be 
compared to previous reviews; and in the final section (section 3.4.3), some of the 
challenges to economic evaluations of telemedicine interventions/services which will be 
addressed in this thesis will be discussed. 
 
3.4.1 Economic issues arising from the literature review  
The economic issues which emerged from the literature review are outlined below; 
these are not only relevant to most health technologies, but also to telemedicine.  The 
Drummond et al (2005) checklist for assessing economic evaluations has been 
followed (but not in a strict manner), as there were some other issues which were of 
importance that had arisen in the literature review.   
 
a) Inadequate details about study design and methodologies 
The literature review highlighted three main issues with regards to study design: 1) 
whether the study was randomised or not; 2) how long the telemedicine intervention 
was evaluated for; and 3) reporting of methodologies. 
 
Firstly, in primary research, the normal gold standard study design is a randomised 
controlled trial (RCT).  In secondary research, the gold standard study is a systematic 
review, followed by a meta-analysis of the findings, and if appropriate modelling.  The 
literature review indicated RCTs of telemedicine services were limited.  In total, 12 of 
the 109 (11.0%) studies identified were RCTs [24, 40, 49, 61-62, 73, 76, 84-85, 103, 
105-106] (see Appendix 2) and the rest of the studies were all of observational nature.  
Of those 12 studies which were randomised, for 11, the unit of randomisation was the 
individual patient/subject and in the remaining study [85] the unit of randomisation was 
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the clinical site.  For example, Wootton and colleagues (2000) conducted a multicentre 
RCT which aimed to evaluate the health outcomes and cost-effectiveness of real-time 
teledermatology compared with conventional outpatient dermatological care from a 
societal viewpoint.  Patients were randomised to either teledermatology consultation 
(n=102) or to conventional care (n=102).  The authors found no major differences in 
outcomes, and real-time teledermatology was not cost-effective compared to 
conventional consultation.    
 
Secondly, the majority of telemedicine studies were undertaken as pilot or short-term 
studies.  Of these, 77 studies were undertaken for a time period of less than two years, 
thereby not allowing what would be the longer-term impact on patients, on costs or 
even outcomes (21 studies did not report a time frame).  One of the main reasons why 
some of these telemedicine studies may only be of a short-term duration, is due to the 
limited funding or one-off special budgets which have been given to these applications 
and for these studies to continue, it may be difficult if the funding is not in place or if no 
further funding can be found.  As some of the telemedicine studies are pilot services, 
the costs and benefits which have arisen in the pilot stage may not reflect the costs and 
benefits when the telemedicine service is in routine use.  Therefore, generalising these 
study findings from pilot studies to other settings may not always be possible.   
 
Thirdly, most of the studies identified in the literature search did not give enough 
adequate details about their study design or they had weak methodologies i.e. there 
was no consistency in the analyses conducted between the studies.  For example, 
there may not be enough information on how costs (and/or outcomes) are collected, 
calculated and reported.  If studies report the appropriate methodology, it would then 
be easier for the reader to understand how the author(s) came to their results and 
conclusions.   
 
In the example, by Tsitlakidis et al (2005) they conducted a cost-minimisation analysis 
of patients assessed via telemedicine compared to the alternative option of referring 
patients to hospital.  The telemedicine service at the Airforce health centre was linked 
to two remote Greek Islands.  The mean duration of a telemedicine consultation was 
approximately 15 minutes compared with 40 minutes for a direct referral consultation.  
The authors did not explain whether it was the telemedicine intervention itself that 
allowed for this substitution of time saving.  In another study by Crowe et al (1996), 
there was insufficient background information on the nature of the journeys or mode of 
transfer to enable adjustments to be made by the reader for alternative distances and 
conditions. 
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b) Study perspective 
The perspective for the analysis should be clearly stated and justified, as it allows the 
reader to make an informed choice as to whether the information provided in the article 
is sufficient to answer the study question and that of the policymakers and/or funders.  
For example, a full economic evaluation of a telemedicine service would consider all 
costs and benefits to all groups of the society who would use the telemedicine service 
i.e. a health service and patient perspective.  If a narrow perspective is adopted, one 
such as the health service, then the benefits to patients would be omitted.  From the 
literature review, over half of the articles (58.7%) did not explicitly report the viewpoint 
of the analysis, thus it is hard to make judgements as to whether the conclusions 
reached by the authors are appropriate. 
 
c) Small sample sizes 
Most telemedicine studies identified in the literature review have small sample sizes.  
Only 78 studies (71.6%) reported patient numbers, whereas some studies did not state 
the sample size, but stated the number of telemedicine consultations which took place 
or the number of images which were transmitted.  Of the 78 studies that reported a 
sample size, 28 studies (35.9%) had a sample size of 100 patients or less.  The 
smallest sample size for a study was eight patients who had chronic pain and 
telemedicine was shown to be cost-saving when compared to conventional care [Peng 
et al, 2006].  These studies with small sample sizes will have low statistical power to 
detect differences in health outcomes and the difference between the two groups may 
not always be due to the telemedicine intervention.   
 
d) Choice of alternatives 
In most cases, the comparator for the telemedicine intervention is usually the most 
widely used current alternative method for accessing specialist care.  The comparator 
must be able to be justified to be used in such an analysis and be reasonably accepted 
by all parties using the services.   
 
Most of the time, the telemedicine intervention in literature is described quite carefully, 
but costs and consequences in relation to the comparator are not reported in sufficient 
detail to make proper comparisons and therefore assessing the costs and cost-
effectiveness of the telemedicine intervention and the alternative is of limited value.  
For example, in the article by Bracale and colleagues (2002) they evaluated whether 
telemedicine services might have a role in the provision of healthcare for two remote 
islands.  The alternative was patient transfer by boat or by helicopter ambulance.  The 
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paper considers in length how the telemedicine services were established and how 
they worked, but no further details were given about the comparator.  
 
e) Economic importance of question 
The economic importance of the research question should be outlined and be phrased 
in a way which would consider both costs and outcomes.  The literature review findings 
indicated that most telemedicine studies did not state a clear research question.  For 
example, “a cost analysis of teledermatology system” would most likely look at the 
costs of the teledermatology service and maybe the alternative, but not the outcomes, 
whereas in “a cost-effectiveness analysis of a teledermatology service”, one would 
hope that the study would compare both the costs and outcomes of the two alternative 
methods.  A more limited research question such as “Is a teledermatology service 
undertaken in a hospital in Maidstone cost-effective compared with the alternative of 
transporting patients to London?” places cost-effectiveness in a local context and 
provides a relevant comparator. 
 
f) Type of economic evaluation adopted for the telemedicine study 
The majority of studies (79.8%) identified in the literature review stated that the 
economic evaluation was a simple cost analysis or a cost-minimisation analysis.  Thus, 
these studies compared the total (or mean) costs of the telemedicine intervention to the 
total (or mean) costs of the comparator.  The studies also assumed that the outcomes 
are equivalent or assumed to be established without any proper scientific evidence.  
Studies otherwise can simply be cost studies with no claim to being an economic 
evaluation.  Unless outcomes can be proved to be identical, then the economic 
evaluations should take place in the form of a cost-consequence(s), a cost-
effectiveness, a cost-utility or even a cost-benefit analysis.   
 
Depending on which of the five economic evaluations would be undertaken depends on 
the context of the study, the alternative and the outcome measure.  None of the studies 
stated that they used a cost-utility analysis to compare costs and outcomes 
simultaneously of the telemedicine intervention and the alternative(s).  In a cost-utility 
analysis (which is a special form of a cost-effectiveness analysis), outcomes are 
measured as health related preferences, which are most often expressed as QALYs 
and the results are expressed as cost per QALY gained.  Cost-utility analysis is useful 
when an intervention can be expected to have an effect on the health-related quality of 
life and on the length of life.  A cost-utility analysis uses a generic outcome measure 
that permits broad comparisons across different conditions and interventions.  For 
example, in the study by Armstrong et al (2007) who conducted a cost-minimisation 
79 
 
analysis of interactive teledermatology with conventional care (outpatient face-to-face 
dermatology clinic) in the USA, the authors stated that “a cost-minimisation analysis 
compares the costs of multiple interventions that provide the same outcome for the 
purposes of identifying the lowest-cost intervention”.  However, they did not provide 
any evidence to assume that outcomes were identical and whether this justified the use 
of cost-minimisation analysis for choosing between the two alternatives.  
 
g) Costs 
The information provided in the articles varied from detailed cost analyses to simply 
mentioning some of the costs and that a telemedicine service was cost-saving or cost-
effective.  For any economic evaluation the concept of opportunity cost is essential.  
For example, an opportunity cost to a specialist applies if they have to travel to treat 
patient(s) in another location, it is the missed opportunity to treat patient(s) in their own 
hospital.  The viewpoint of the analysis is important so that the appropriate resource 
use and costs are identified for the telemedicine service and the comparator for 
measurement and valuation purposes.  Most articles provided examples of the types of 
costs which were included in their analyses; however, some of the cost components 
were not given (i.e. the cost analyses were not exhaustive).  Some studies did not 
include the telemedicine equipment costs, only the telephone charges and line rental; 
whereas some studies ignored patient costs and/or productivity costs.  Therefore 
caution should be taken when using cost estimates from previous analyses as the 
studies are not explicitly clear in reporting their methodology and results, and allocation 
of costs may not be accurate.  An outline of some of the telemedicine costs which 
should be included in an economic evaluation are listed below.  The two boxes are list 
of costs which have been compiled from the literature review. 
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Box 1: Summary of the types of costs collected and reported in the articles 
Direct Medical Costs 
a) Equipment costs 
 Videoconferencing equipment including monitors, computers, video camera, digital camera, document 
camera, scanner, fax machine, modem, internet connections and software. 
 Equipment depreciation 
 Equipment maintenance 
 Installation of transmission lines – Integrated Services Digital Network or connection via Internet protocol 
 Other equipment (if appropriate) such as microscope, phototherapy machine, laser equipment, 
endoscope, dermatoscope and electronic stethoscope. 
 
b) Communication costs 
 Line rental 
 Call charges 
 
c) Staffing costs 
 Salaries and overheads 
 Training costs 
 Cost of travel for consultants and other staff 
 
d) Administration and overhead costs  
 Overheads i.e. cost of buildings, clinic space or telemedicine room and utilities 
 Other administrative costs such as paperwork 
 
e) Hospital and associated costs 
 Inpatient stays, outpatient or GP visits, accident and emergency visits, and other hospital visits 
 Tests and procedures 
 Treatments and medications 
 
f) Miscellaneous costs 
 Patient transfer or transportation 
 Transfer by courier 
 Fuel and driver costs 
 Escort costs 
 
Direct non-medical costs 
 Patient and family travel expenses 
 Accommodation expenses 
 Subsistence costs i.e. food and drink 
 
Indirect costs 
 Travel time costs 
 Time costs 
 Missed days at work 
 Lost income 
 Lost productivity 
 
Box 1 above provides an overview on the different types of costs collected.  Direct 
medical costs are the costs related to the use of resources due to either the disease or 
treatment and these are the costs that usually fall on the health service; direct non-
medical costs are costs incurred by patients and family members, which contribute to 
the treatment process; and finally, indirect costs are resources lost due to treating a 
disease and can reflect two different costs depending on the perspective.  First, if a 
patient perspective is adopted, this may reflect the loss of time (whether this is work or 
non-work time) to the individual in attending for treatment.  Second, if a societal 
perspective is adopted, time costs incurred by individuals in receiving treatments reflect 
the loss of production to society, whether paid or unpaid.  Some studies also explicitly 
noted that some costs were excluded from their cost analysis as they were common to 
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both arms, these are shown in Box 2.  Not all costs reported in the articles appear in 
the two boxes. 
 
Box 2: Summary of the types of costs excluded in some articles 
Excluded costs 
 Hospitalisation costs 
 Treatments, medications and laboratory test costs 
 Administration costs 
 Electricity and overheads 
 Family travel and subsistence costs 
 Loss of income 
 
Nearly all of the 109 studies reported information on direct medical costs apart from 
two studies [82, 102] which simply reported potential savings and 4 studies [19, 68, 77, 
90] which reported direct non-medical costs and/or indirect costs.  Of those 22 studies 
that were from a societal perspective, all studies reported direct medical costs; in 
addition 20 of the 22 studies also collected information on direct non-medical costs, 
and of those 20 studies, 13 studies also provided information on indirect costs.  Of 
those 64 studies that did not report a perspective, four studies collected information on 
indirect costs, in addition to direct non-medical costs and a further 18 studies collected 
information only on direct medical and direct non-medical costs.  The inconsistency 
about the costs which were collected and reported in these studies and the study 
perspective which has not been stated in all articles, makes it hard to make substantial 
conclusions about the cost-effectiveness of these telemedicine applications and to 
conduct a meta-analysis.  These findings are confirmed by Hailey and colleagues 
(2002) who said “the costs included varied significantly between studies, so that the 
comparison of the cost estimates was not feasible in many cases”. 
 
The telemedicine studies have had to make assumptions in the calculation of 
telemedicine equipment costs.  For example, for the expected lifetime of the equipment 
in the majority of cases this was five years; the choice of discount rate (depreciation 
rate) varied from country to country; and maintenance charges differed depending on 
length of contracts.  Some of the cost assumptions made in these studies may not 
reflect how the telemedicine service is used in practice.  
 
Most telemedicine applications have a large initial capital outlay.  For economic 
evaluations this capital outlay is converted into an annual cost over the expected 
lifetime of the equipment, to allow a comparison of the annual cost of the systems 
without being biased against a system which has a larger capital outlay, but a longer 
life [McIntosh and Cairns, 1997].  When the annual equipment costs have been 
calculated, the estimated annual maintenance costs and annual running costs must 
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also be added.  Telemedicine costs are largely determined by the scale and utilisation 
of the service.  For example, as more patients use a telemedicine service, then the 
costs for the service should be lower.  Also, the number and level of staff at each end 
of the telemedicine link can increase or decrease and have an impact on costs.  Thus, 
the level of skill mix may change and the workload may vary depending on the patient 
throughput. 
 
h) Are outcomes or benefits reported? 
Many telemedicine studies do not report information on patient outcomes or benefits in 
such a way that would enable a cost-effectiveness analysis to be performed.  Indeed, 
telemedicine studies which were identified in the literature review were classed as cost-
minimisation analyses and assumed that the clinical outcomes for both the 
telemedicine and the comparator arms were identical.  Where cost differences are 
reported, rather than assume equivalent outcomes, it maybe more useful to show the 
degree of improvement in outcomes that would be necessary in order to justify those 
cost differences with a given cost-effectiveness criterion.  If there are any differences 
between the two arms of the studies, these may be constrained by the size and 
duration of the study, so that these studies will have low statistical power to detect 
differences in health outcomes.   
 
The benefits of telemedicine may take a while to appear and may also be difficult to 
quantify.  Thus, the few studies that did report outcomes used surrogate measures in 
the short-term such as time-related measures i.e. avoidance of time lost through travel 
or indicators of hospital performance such as the length of stay avoided, rather than 
clinical improvement.  However, these surrogate outcomes may be poor measures for 
final outcomes.  Some studies looked at benefits in terms of travel or hospitalisations 
avoided.  In economic terms, these outcome measures are not regarded as benefits, 
instead these should be classed as „costs averted‟.  
 
Also, many telemedicine studies use non-health benefits such as improvement in 
quality of care through improved treatment, faster and more accurate diagnosis, 
transfer of skills and knowledge, speed of service, improved training and education, 
and reassurance.  The question is how do you identify, measure and most importantly 
value these non-health benefits and should they be included in the evaluation?  
McIntosh and Cairns (1997) commented “this would require a valid and reliable 
instrument which is sensitive enough to detect beneficial changes in the process of 
care of value to the patient”.  
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Various benefits of telemedicine services/interventions were identified in the literature 
and they are summarised below:   
a) Improved access to healthcare  
Telemedicine can increase access to healthcare, especially for those who live in 
remote or underserved areas.  Improved or increased access to healthcare through 
telemedicine also means that diagnoses can be made more quickly and more 
accurately and this may translate not only into better overall health for the patient, but 
also in the reduced need for transfer to hospital and reduced length of hospital stays.  
In the case provided by Sicotte and colleagues (2004) they conducted a cost-
effectiveness analysis of interactive paediatric telecardiology compared with 
conventional care (mainly patient travel to the specialist centre and the occasional 
outreach clinic).  The main aim of the use of the telemedicine system was to ”improve 
accessibility in a remote area by accelerating medical decision making in terms of 
diagnosis and treatment, and to decrease the rate of patient transfers and visits to the 
tertiary centre” [Sicotte and colleagues, 2004].  In this example, access to telemedicine 
provided correct and earlier diagnosis of cases and the consequent confirmation of true 
negatives, which in turn eliminated the unnecessary patient journeys („averted costs‟), 
and also provided reassurance for both the patient and doctor.  
 
b) Patient satisfaction (including acceptability) 
Aspects or indicators of patient satisfaction that are typically evaluated include: 
convenience, comfort during a consultation, acceptability, concerns over privacy and 
confidentiality, and willingness to use telemedicine in the future.  Patient satisfaction 
with telemedicine (including patient perceptions and future needs) enables people to 
understand more about patients‟ experience of using telemedicine, increases 
compliance with treatment and may also be important for the future acceptance and 
adoption of telemedicine.  Overall, patients have documented great satisfaction with 
telemedicine.  Television, audio and computer applications are more common now, 
which means that patients are more at ease and accepting of the use of telemedicine. 
 
Simpson and colleagues (2001a) gathered information on patient perspectives on 
telepsychiatry through self-report questionnaires and telephone interviews and found 
that 89% of patients were satisfied with the telepsychiatry session.  Patients felt 
comfortable in their interaction with the consultant and with their ability to provide the 
same information as they would in a face-to-face interview.  Eighty-one percent of 
patients generally felt that telemedicine was acceptable and would recommend using 
telepsychiatry again.  The acceptance of the telemedicine equipment was high in 
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relation to sound, picture, ease of use and room environment, despite the occurrence 
of occasional technical problems.    
 
Acceptance of telemedicine by health care professionals is also important in any 
telemedicine evaluation.  If clinicians are not comfortable with the technology or judge 
that the technology decreases their control over patient care, they may avoid using it, 
thereby precluding other benefits of telemedicine.  Clinical acceptance of a 
telemedicine application may depend on the degree of confidence the clinician has in 
their own clinical findings (e.g. diagnosis) from using the application, as well as their 
satisfaction with the technology in the absence of a face-to-face interaction with the 
patient.  Simpson and colleagues (2001b) undertook an assessment of a routine 
telepsychiatry service compared with providing consultations by a visiting psychiatrist.  
Twenty health professionals responded to the survey and overall they expressed a high 
satisfaction with the telepsychiatry service with respect to the referral and scheduling 
process, consultation report and follow-up recommendations.  All psychiatric 
consultants agreed that telepsychiatry was an acceptable way of delivering psychiatric 
consultations.  
 
c) Effectiveness (including quality of life and outcome measures)  
Telemedicine has a range of possible outcome measures.  They include clinical 
outcomes which are the results of the interventions or services used to diagnose and 
manage patients.  For diagnosis, this includes screening, triaging and specialist 
consultations.  For clinical management, this includes deciding on an appropriate 
management plan for treatment and follow-up specialist consultations for patients.  For 
example, Whited et al (2005) conducted a cost-effectiveness analysis of a digital 
ophthalmology system versus traditional clinic-based ophthalmology examinations to 
detect diabetic retinopathy.  They modelled the entire population of patients with type 2 
diabetes mellitus for three federal agencies.  They had three effectiveness measures: i) 
the number of true positive cases of diabetic retinopathy detected, ii) the number of 
patients identified who required treatment with panretinal laser photocoagulation, and 
iii) the number of cases of severe vision loss averted. 
 
To measure quality of life, various instruments are used such as: generic measures, 
which use instruments to measure overall health-related quality of life such as the short 
form 36; utility measures, which are a special kind of generic measure but give an 
indication of value placed upon health-related quality of life, for example the EQ-5D; 
and monetary measures, which values benefits in terms of currency using „willingness 
to pay techniques‟.  For example, Jacklin and colleagues (2003) conducted an 
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economic evaluation that compared conventional outpatient consultations with 
teleconsultations (virtual outreach) and they used a generic measure, the SF-12 to 
measure overall health-related quality of life.  The authors found that there were no 
differences in health outcomes in the two groups at six months according the physical 
and psychological scores of the SF-12.  Castillo-Riquelme et al (2004) used a utility 
measure, QALYs‟ to measure health outcomes when comparing the cost-effectiveness 
of alternative methods of screening for retinopathy of prematurity in the UK, which 
included the existing method of indirect ophthalmoscopy by ophthalmologists and 
digital photographic screening by nurses.  The authors used utility estimates from a 
study on cataracts and converted these utility values into QALY estimates over the 
whole expected lifetime of the babies.  This latter study was one of the two studies 
identified in the literature review which measured health benefits in terms of QALYs for 
telemedicine applications and both were in the area of ophthalmology [Aoki et al, 2004; 
Castillo-Riquelme, 2004].   
 
i) Was an incremental approach appropriate? 
Results of the economic analysis can be used to inform decisions on a telemedicine 
application.  For example, to determine whether it should continue; how it may be used 
in other situations; or to what extent any improvements are needed either to its costs or 
performance.  The benefit of using an incremental approach is that it allows the 
decision maker to see the additional cost and/or benefit of the intervention compared to 
the alternative.  Most studies did not provide an incremental analysis of the costs and 
outcomes.  Only eleven (twelve) studies conducted a cost-effectiveness analysis (cost 
analysis and cost-effectiveness analysis) and of these, only six studies [2-3, 51, 54, 89, 
103] provided an incremental ratio.   
 
For example, in the study by Sicotte and colleagues (2004) which looked at the cost-
effectiveness of interactive paediatric telecardiology in comparison with the 
conventional alternative (which included patient travel and outpatient clinics), they 
found that the total cost of telecardiology was C$272,327 and the total cost of 
conventional care would have been C$157,212.  They stated that telemedicine, 
represented a supplementary cost of C$1,500 per patient.  The incremental cost-
effectiveness ratio of teleconsultation was estimated C$3,488 per patient journey 
avoided.  The effectiveness measure used here (patient journey avoided) is technically 
not a benefit measure, but a cost which has been avoided.  So in this situation, the 
incremental cost-effectiveness ratio was used but inappropriately, and should not be 
used to inform healthcare policy decisions. 
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Marginal costs capture the change resulting from the healthcare provision and 
telemedicine costs will largely be determined by the scale and utilisation of the service.  
In some instances, once the infrastructure of the telemedicine service is established, 
the cost of providing an additional telemedicine consultation may be insignificant.  It is 
important to note that marginal costs will differ between different patient groups and 
different geographical locations.  Most studies hypothesised about the relationship 
between utilisation and costs, some studies even reported patient numbers in order for 
it to be cost-saving, but more evidence is needed before a cost function for a 
telemedicine service can be properly identified. 
 
Some telemedicine studies used break-even analysis to indicate the volume of output 
necessary for telemedicine applications to become cost-saving.  Break-even analysis is 
calculated as the difference in fixed costs, divided by the variable cost-saving produced 
by telemedicine.  So activity levels beyond break-even will lead to cost savings, as the 
aggregate variable cost savings will outweigh any additional fixed costs of the 
telemedicine service.  This type of analysis can be useful for decision makers when 
faced with the question of whether to introduce a new telemedicine service or to 
continue with the existing service. 
 
Furthermore, the majority of studies stated whether a telemedicine intervention or 
service was cost-effective or not cost-effective compared to an alternative.  However, 
the authors generally did not define what they meant by cost-effective.  For example, 
they did not provide a cost-effective threshold, that is, a level in which the cost-effective 
ratio should meet in order for the intervention to be regarded as cost-effective.  
 
j) Discounting  
Telemedicine may impose costs and benefits on the health service which may reach 
into the future.  Therefore, the future stream of health benefits and costs should be 
discounted to their present value.  Discounting reflects the fact that people place a 
higher value on events in the present than the future and the funds invested in the 
present can reap interest over time.  Only seven studies undertook discounting, not 
including the discounting methods which were used to estimate the depreciation for the 
telemedicine equipment, because the majority of studies were short-term.   
 
For the telemedicine equipment, discounting is needed as it represents an investment 
in the future provision of the healthcare and therefore, the equipment needs to be 
annuitized over the useful life of the asset, usually this being five years for most 
telemedicine studies identified in the literature review.  However, there is no general 
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agreement about the expected life span of telemedicine equipment or what discount 
rate to use.  Also, due to the rapid development of the telemedicine technologies, the 
likelihood of the technology becoming obsolete is high. 
 
k) Sensitivity analyses 
Sensitivity analyses are conducted to assess the robustness of the study results and 
are considered essential in demonstrating the validity of results.  Any economic 
analysis of telemedicine interventions should undertake sensitivity analyses to deal 
with the uncertainty around key parameters (or assumptions) such as resource use, 
costs and outcomes.  Depending on the circumstances, sensitivity analyses may be a 
simple one-way or multi-way sensitivity analyses, a threshold analysis or a probabilistic 
sensitivity analysis [Drummond et al, 2005].  The findings from sensitivity analyses will 
indicate how sensitive the results are to these uncertainties.   
 
Some of the uncertainties surrounding telemedicine studies include for example: the 
choice of discount rate used in calculation of the equipment costs; expected lifetime of 
the equipment; and any anticipated future changes in equipment and transmission 
costs.  Only 33.9% studies identified in the literature search undertook some sort of 
sensitivity analyses.   
 
3.4.2 General discussion and comparison with other systematic reviews of 
telemedicine 
The results from the literature search make it difficult to generalise these findings to 
other telemedicine interventions or to other ICTs.  For example, an economic 
evaluation which has been conducted for a telemedicine intervention in a rural area is 
unlikely to generate the same cost-effectiveness evidence in an urban area (see study 
by Loane et al (2001a) as an example).  It is important to note that telemedicine 
interventions may be cost-effective in one area, but when transferred to other areas in 
which local services, access, quality of care, and unit costs differ between settings 
and/or countries, the telemedicine intervention may not be cost-effective.  This is 
reiterated by Håkansson and Gavelin (2000) who mentioned that “there are country-
specific variations in the health systems that make it difficult to generalise the results 
from one country to another”.  
 
Another limitation of these studies identified in the literature review was that most were 
conducted in the late 1990s or in early 2000s (63 studies were published before 2003) 
and these older studies may not reflect current telemedicine price structures.  It is 
possible given the likely decrease in technology costs, that telemedicine costs for these 
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studies were higher than telemedicine costs in more recent studies, so that the cost 
calculation may be confounded by the study‟s year of operation or publication (this 
search having been undertaken in October 2007).  There can also be a delay of 2 to 3 
years before the publication of the study article or results.  For example, the study by 
Bynum and colleagues (2003) was conducted during 1998 to 2002 and the results 
were published in 2003.  The literature search shows what was happening some years 
ago and not what is happening today.  It is also very difficult to evaluate telemedicine, 
as it is a constantly changing technology, and technological advances in telemedicine 
over the years have made the equipment less expensive and easier to use [Norris, 
2001] and those studies which may not have been cost-effective or cost-saving then, 
may now be cost-effective or cost-saving, due to the lower prices of the telemedicine 
equipment or communication links (e.g. ISDN calls).   
 
A further major limitation is that there was not enough consistency in the cost (and 
effectiveness) data that were collected; hence, the majority of studies could not be 
included in the meta-analysis.  Most meta-analyses usually only summarise the clinical 
effects and not the costs because of the heterogeneity of the data.  The thesis set out 
to conduct a meta-analysis of the costs of telemedicine.  For example, if the same 
question was being asked, could the studies be pooled together?  Due to the 
heterogeneity of the data, the majority of the studies could not be included in the meta-
analysis (presented in Appendix 3 for illustration purposes only).  The Cochrane 
Collaboration state that the decision to pool any cost-effectiveness estimates using a 
meta-analysis should be interpreted with caution because the metric in question may 
not have the same meaning across studies.  That is, the resource use and costs may 
vary both within a country and between countries.  Therefore, this limits the 
generalisability and transferability of resource use and cost estimates across settings 
[Higgins and Green, 2009].  This may be particularly pertinent to telemedicine where, 
as we have previously highlighted, there is a significant degree of heterogeneity in 
study methods and findings. 
 
Whitten et al (2000) attempted a meta-analysis of telemedicine research studies of the 
costs associated with telemedicine.  They searched six electronic databases and 
identified 551 articles for analysis, of which only 38 studies had quantitative cost data.  
The authors found that most of the 38 studies were inadequately designed or 
conducted, so they were unable to perform a traditional meta-analysis.  The authors 
concluded “that it is premature for any statements to be made, either positive or 
negative, regarding the cost-effectiveness of telemedicine in general”.   
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A few systematic reviews have assessed the cost-effectiveness of telemedicine studies 
and inconsistencies can be found in the studies with respect to their methods, results 
and conclusions about telemedicine see Table 3.2 below and Appendix 5 for more 
details.  However, they all generally come to the same conclusion that evidence on the 
cost-effectiveness of telemedicine studies is still limited and that most cost-
effectiveness studies of telemedicine were not generally carried out in accordance with 
standard economic evaluation guidelines.   
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Table 3.2: Summary of other systematic reviews of telemedicine  
Authors Publication 
year 
Type of telemedicine 
studies considered in 
the review 
Number of 
databases 
searched* 
Number of 
abstracts 
retrieved 
Number of 
articles that met 
inclusion criteria 
General conclusion provided by the author(s) 
Whitten et al  2002 Cost-effectiveness of 
telemedicine 
4 612 24 “There was no good evidence that telemedicine is a 
cost-effective means of delivering healthcare 
compared to standard healthcare delivery”.   
Roine et al  2001 Effectiveness and cost-
effectiveness of 
telemedicine 
8 1,124 50 (16 were 
economic 
analyses) 
“Evidence regarding the effectiveness or cost-
effectiveness of telemedicine is still limited.  Based on 
the current scientific evidence, only a few 
telemedicine applications can be recommended for 
broader use”.   
Hailey et al 2002 Benefits of 
telemedicine 
8 1,323 66 “Although useful clinical and economic outcomes data 
have been obtained for some telemedicine 
applications, good quality studies are still scarce and 
the generalisability of most assessment findings is 
rather limited”.  
Hailey et al  2004 Benefits of 
telemedicine 
6 605 48 The authors felt the results confirmed previous 
findings and that good quality studies are still scarce. 
Mair and Whitten 2000 Patient satisfaction with 
telemedicine 
4 ? 32 “Methodological deficiencies (low sample sizes, 
context, and study designs) of the published research 
limit the generalisability of the findings”.   
Williams et al 2001 Patient satisfaction with 
telemedicine 
4 125 93 “The current evidence concerning patient satisfaction 
with telemedicine is rather limited.” 
Hersh et al 2002 Efficacy of telemedicine 
for making diagnostic 
and management 
decisions  
4 4,709 58 “Despite the widespread use of telemedicine in most 
major medical specialties, there is strong evidence in 
only a few of them that diagnostic and management 
decisions provided by telemedicine are comparable to 
face-to-face care”.   
Hersh et al  2006 Effect of telemedicine 
on diagnosis and 
management decisions, 
patient outcomes and 
access to care 
1 4,083 106 “There are still significant gaps in the evidence base 
between where telemedicine is used and where its 
use is supported by high-quality evidence”.  
Whitten et al  2007 Research methodology 
in telemedicine studies 
15 1,615 85 “Until the telemedicine field adheres to agreed 
standards of reporting methodological details it will be 
difficult to draw firm conclusions from review studies”.   
Bergmo et al  2009 Cost-effectiveness of 
telemedicine 
10 779 33 “The majority of the economic evaluations were not in 
accordance with standard evaluation techniques”.   
*ISI Web of Knowledge counted as one database, but consists of ISI Science Citation Index, ISI Social Science Citation Index and ISI Arts and Humanities Citation Index 
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The results from the literature review do not attempt to make the case for cost-
effectiveness of telemedicine and, as previously discussed, it would be inappropriate to 
attempt to do so.  They do however, highlight some of the limitations in previous 
literature reviews on costs and cost-effectiveness of telemedicine interventions.  Cost-
effectiveness of telemedicine interventions depends not only on the service being 
evaluated, its comparator, the perspective of the analysis, patient group and sample 
size, type of economic analysis and how the costs and outcomes were measured and 
valued, but also on the take-up rate and the usage of the service.  Decision makers 
and readers must be cautious as to the degree to which they can apply the results of 
such assessments to their own circumstances.  Further research needs to be done in 
which telemedicine interventions and their comparators are conducted in accordance 
with general standards for health economic evaluations.  Other issues which need to 
be considered include the sustainability of a telemedicine service, decisions about the 
equipment and telecommunications, and impact on the overall use of health resources 
and the measurement of outcomes.   
 
3.4.3 Three important challenges for the TelePaed study and for economic 
evaluations in general  
Section 3.4.1 highlighted some of the economic issues which arose from the literature 
review.  In this section, three of the challenges to economic evaluations of telemedicine 
which emerged from the literature review will be discussed: non-randomised studies 
and the issue of selection bias; calculation of patient costs; and measures of benefits 
such as QALYs.  These three issues will be addressed in this thesis, in terms of how 
the original analysis for the TelePaed study can be improved. 
 
1) Non-randomised studies and selection bias 
Due to the dominance of pilot studies or short-term studies of telemedicine 
interventions or services, very few evaluations have been conducted as part of an 
adequately powered RCT.  The literature review found that only 12 studies (11.0%) 
were RCTs of telemedicine.  In a RCT, the intervention or treatment is randomly 
allocated, so bias is distributed between the groups by chance.  The randomisation 
process enables researchers to attribute the outcome to the intervention.  As a result, 
there will be high internal validity, control of potential confounders and minimisation of 
random variation on costs and effects.  However, practice within a RCT might be 
atypical (e.g. the patients, setting, protocol), with inadequate follow-up time, inadequate 
sample size for economic evaluations, inappropriate endpoints and there will also be 
limited external validity.  The RCT is an essential tool in assessing the likelihood of a 
causal effect between an intervention and an outcome and as such, is useful in 
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showing a proof of concept.  However, additional evidence may be required beyond 
this to examine the effect of an intervention in practice.  An ideal clinical trial would be 
one which takes a pragmatic approach and the aim would be to evaluate the cost-
effectiveness of the intervention under real life conditions that would prevail once the 
intervention was in routine use.  For the pragmatic trial there would be some 
compromise between the goals of internal and external validity, there would still be 
random allocation to interventions to minimise bias, but would offer fewer restrictions in 
how patients are recruited and followed and thereby increasing the external validity or 
generalisability.  In practice, further evidence from both RCTs and pragmatic studies 
are required to support the more widespread adoption of telemedicine. 
 
As the majority of telemedicine studies were non-randomised, there is a potential for 
bias.  Bias or systematic errors weaken the internal validity of studies and this can 
result in an incorrect estimate of the association between treatment and effect.  The 
greatest difference between randomised and non-randomised studies is the risk of 
selection bias.  Selection bias refers to an absence of comparability between the 
groups being studied.  That is, the selection of patients for the telemedicine group have 
different characteristics from those allocated to the conventional group.  
 
When designing the telemedicine study, if a RCT cannot be undertaken, then steps 
should be taken to ensure that the study is designed in such a way that the various 
biases which can arise are minimised.  For example, in some instances it may not be 
ethical to randomise individual patients, so in this case, randomisation should take 
place at the hospital or centre level.  The literature review identified only one non-
randomised study which looked at whether the two comparator groups were different.  
Rendina and colleagues (1998) looked at whether the utilization of a telemedicine 
system for the interpretation of neonatal echocardiograms reduces the neonatal 
intensive care unit length of stay of low birthweight infants, and they estimated whether 
the two comparison groups were significantly different.  They used a multiple 
regression model to distinguish the effects of telemedicine from those of other risk 
indicators, which might have differed in the two groups.  They found a statistically non-
significant reduction of 5.4 days in the length of stay of low birthweight infants (p = 
0.37); however, they did not say whether or not selection bias was reduced after 
adjusting the length of stay in the regression model.   
 
The case study introduced in Chapter 2 was not randomised (further details are 
provided in Chapter 4 about the study design), as it was deemed unethical to 
randomise individual patients.  There are various methods to reduce selection bias in 
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non-randomised studies and Chapter 5 will focus on the issue of minimising selection 
bias for this case study and see what impact this has on the costs and effects.   
 
2) Calculation of patient costs 
A few of the studies identified in the literature review looked at the distance travelled by 
patients as a measure of access [Loane et al, 1999; Bynum et al, 2003; Doolittle, 
2000].  From the telemedicine literature, access can be defined in various ways: the 
ease with which health services are available and/or sustained; the length of time (or 
travel distance) it takes to access those health services; how easily the patient can 
obtain information regarding health services; and equity of access.  For any 
telemedicine study you would need to take into account: the changes to the number of 
patients using the service who previously wouldn‟t have been seen; changes in patient 
and/or health care professional travel plans; changes in the proportions of patients that 
„did not attend‟; and the changes in treatment centre‟s catchment area.  Patients who 
experience reduced travel or reduced distances to services would imply they are 
experiencing better access to services.   
 
For example, Bynum and colleagues (2003) in the USA evaluated patients‟ cost 
savings in a telemedicine project during 1998-2002.  They assessed patients‟ cost 
savings with telemedicine regarding travel, and travel distance was measured.  Their 
findings indicated that without telemedicine, 94% of the patients would have to travel 
greater than 70 miles for medical care, whereas with telemedicine, 98% of the patients 
travelled less than 30 miles to receive medical care; and 92% of the patients saved at 
least 40 miles in travel distance.  This study highlighted the importance of distance 
when accessing a telemedicine service and the important implications on patients‟ cost 
savings.  
 
With the introduction of telemedicine, the patient and the health care provider would 
want to know the distance they have to travel to receive or provide healthcare at the 
telemedicine site; how long this would take; the frequency of visits, and whether this 
would lead to an increase or decrease in their own expenditure.  Patient costs are a 
subset of direct non-medical costs, and it is important to look at the costs that would fall 
on a patient, as patients can influence the uptake and usage rates of healthcare 
services.  Fifty-four of the 109 studies (49.5%) identified in the literature review 
included some information on patient costs.  However, the majority of these studies did 
not provide enough detail on how the costs were obtained and calculated.  For 
example, Bergmo (1997) in Norway conducted a cost comparison of three different 
methods of providing consultations for ear, nose and throat problems.  Patient travel 
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costs consisted of air tickets, subsistence, and the cost of a guardian who had to take a 
full day‟s absence from work to attend the consultation, because 50% of the patients 
were children or older persons‟.  However, the author did not provide any further 
information on the calculation of these costs. 
 
To capture these results in an economic evaluation, a questionnaire can be given to 
patients and to health care professionals to find out how far they had to travel and what 
the time and costs implications were.  The results from the questionnaire could inform 
future providers or other users of telemedicine of what the time and cost implications 
might be of setting up and using a telemedicine service.  Using various data sources 
and assumptions, Chapter 6 focuses on the calculation of patient costs for the cohort of 
patients in the case study.   
 
3) Measures of benefits such as QALYs 
a) What are QALYs? 
In a cost-utility analysis, outcomes are usually measured as health related preferences, 
which are most often expressed as QALYs gained and the results are expressed as 
cost per QALY gained.  QALYs combine quality of life and length of life into a single 
index value.  So for a QALY, the quality gains are from reduced morbidity and the 
quantity gains are from reduced mortality.  The survival benefit is expressed as life 
years gained and the health-related quality of life benefit is described in terms of health 
states and a score is placed upon the health state indicating how respondents value 
each health state.  The values are on a scale where 0 = dead and 1 = full health.  The 
QALY represents the equivalence of being alive for a year in full health.   
 
The quality component usually comes from individuals‟ preferences on health states 
and in turn, a utility value is obtained for each health state.  Utility values can be 
obtained in two ways: direct or indirect measurement.  Direct measurement is where 
individuals‟ value their own health directly.  There are two main approaches to direct 
measurement these include: the standard gamble approach which is based on the 
axioms of expected utility theory and asks respondents to make choices that weigh 
improvements in health against mortality risks [Torrance, 1986]; and the time-trade off 
approach which is a method for valuing health states that asks respondents to make 
hypothetical choices that weigh improvements in health against reduced longevity 
[Torrance, 1986].   
 
Indirect measurement is where individuals‟ value their own health using instruments 
such as the EQ-5D or the Health Utilities Index (HUI).  For example, the EQ-5D is a 
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simple classification system which has five attributes and each attribute has three 
levels (as reported in Chapter 2, section 2.5.5.2).  The five attributes and three levels 
result in 243 possible health states, to which unconscious and dead have been added 
for a total of 245 health states.  This is then converted to a single-index utility score 
which falls on the 0 (dead) to 1 (full health) value scale, using a set or „tariff‟ of values 
[Dolan, 1997].  Another example is the HUI and there are three versions of HUI, each 
includes a health status classification and a utility scoring formula.  The HUI mark 1 has 
4 dimensions, between 4 and 8 levels on each dimension, which results in 960 health 
states; HUI mark 2 has 7 dimensions (sensation, mobility, emotion, cognition, self-care, 
pain and fertility), between 3 and 5 levels on each dimension, which results in 24,000 
health states; HUI mark 3 has 8 dimensions (vision, hearing, speech, ambulation, 
dexterity, emotion, cognition and pain), between 5 and 6 levels on each dimension, 
which results in 972,000 health states [Horsman et al, 2003]. 
 
b) Are QALYs appropriate for telemedicine? 
For cost-utility analyses, costs are measured in monetary units and the outcomes are 
usually units that relate to a person's health-related quality of life or proxies for 
measures of utility, such as QALYs.  Results for cost-utility analyses are expressed in 
terms of cost per QALY gained and QALYs can provide a „common currency‟ for 
comparison.  QALYs are the preferred outcome measure for NICE [NICE, 2008].  NICE 
states that “given its widespread use, the QALY is considered to be the most 
appropriate generic measure of health benefit that reflects both mortality and health-
related quality of life effects.  It is recognised that alternative measures exist (for 
example, the healthy-year equivalent), but few economic evaluations have used these 
methods and their strengths and weaknesses are not fully understood” [NICE, 2008].  
NICE believes that the EQ-5D is appropriate when calculating QALYs, because it is a 
generic-preference based measure which has been validated on a UK population.  
Also, given the comparative nature of their work at NICE and the consistency across 
appraisals, calculating QALYs for any technology or intervention, allows comparisons 
across technologies or interventions. 
 
Thus, calculating QALYs for telemedicine services would be in line with mainstream 
health economics, but there is still some debate concerning whether meaningful 
differences in QALYS can actually be measured in the case of telemedicine.  McIntosh 
and Cairns (1997) in their paper which looked at a framework for telemedicine 
applications thought that it would be difficult to estimate QALYs for telemedicine 
applications: “In many evaluations it will be difficult to attribute health benefits or 
changes in health outcomes to telemedicine itself.  That is, even if changes in health 
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outcomes are due to telemedicine it will be difficult to quantify this” [McIntosh and 
Cairns, 1997].  Aoki et al (2004) believed that “telemedicine itself may not directly alter 
quantitative clinical outcomes such as mortality and morbidity, because it is not a direct 
therapeutic or diagnostic instrument”.  However, the authors felt that telemedicine was 
a useful tool for improving communication, accessibility and management and suggests 
that telemedicine may have an indirect impact on qualitative clinical outcomes, such as 
patient satisfaction. 
 
For many economic evaluations of telemedicine interventions, QALYs may not be the 
preferred outcome measure as they may not capture all the appropriate health or non-
health benefits of using telemedicine such as improved treatment, faster and more 
accurate diagnosis, transfer of skills and knowledge, speed of service, improved 
training and education, and reassurance.  Non-health benefits of telemedicine require 
an instrument which is sensitive enough to distinguish between process care changes 
which are expected to improve health outcomes such as earlier diagnosis and process 
care changes that are simply about improved service delivery or reduction in costs. 
 
One of the further difficulties with any economic evaluation of telemedicine is how to 
capture the changes in effectiveness.  For example, due to the diversity of the use of 
telemedicine (telemedicine can be used for clinical purposes i.e. for checking skin 
diseases or for administrative purposes i.e. for meetings), it may be difficult to know 
which effectiveness measure to use, that will be appropriate and comparable across all 
telemedicine services and interventions.  There may also be problems measuring and 
valuing this information.  Such as attributing changes in effectiveness, to changes in 
the process of care, rather than to the nature of care itself can be problematic.  Hence, 
QALYs may not be appropriate for telemedicine services.   
 
QALYs may capture some of the health benefits of telemedicine such as anxiety and 
depression.  For example, the EQ-5D questionnaire includes an „anxiety/depression‟ 
domain; the HUI mark 3 instrument has an attribute called „emotion‟; and the SF-6D 
includes a „mental health‟ component.  However, none of the instruments which are 
used to estimate QALYs include non-health benefit components such as patient 
satisfaction, education or speed of service.   
 
To fully capture these health (and non-health) benefits from telemedicine, for any 
economic evaluation of telemedicine you would need to include one of those 
instruments (for example, EQ-5D, SF-6D or HUI mark 3) for eliciting QALYs; but also to 
supplement this with questionnaires that will capture the other health and non-health 
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benefits of telemedicine.  For example, within any economic study a questionnaire or 
survey could be given to patients to find out their perceptions about the telemedicine 
service, such as whether they were satisfied with the service they received.  This 
survey could also incorporate questions on time and money costs.  However, this may 
not always be practical due to time or resource constraints and in most cases decision 
analytical modelling is used instead.  Using a decision analytical framework and 
various assumptions, expert opinion and literature, one can look at the longer-term 
benefits such as QALYs of telemedicine services. 
 
The literature review identified two studies which used QALYs for measuring health 
outcomes for telemedicine – both used telemedicine for eye disease.  In the first study 
by Castillo-Riquelme and colleagues (2004), the authors used a decision analytical 
model to compare the cost-effectiveness of alternative methods for screening for eye 
disease in newborns.  The authors used utility estimates from a study on cataracts and 
converted these utility values into QALY estimates over the whole expected lifetime of 
the babies.  The second study by Aoki et al (2004) looked at a cost-effectiveness 
analysis of telemedicine to evaluate diabetic retinopathy in a prison population.  The 
authors used a Markov decision model and probabilities and utility values were 
obtained from the literature which enabled the calculation of QALYs.   
 
QALYs are thought to be difficult to calculate for telemedicine interventions, because 
the benefits of reduced mortality and morbidity associated with telemedicine are not 
easily quantifiable.  That is, QALYs may not be sensitive enough to detect small 
changes in health outcomes which telemedicine services are most likely to produce.  
Telemedicine doesn‟t actually kill anyone (mortality), unless they are misdiagnosed or 
help prolong life, but indirectly we can say that it can help to prolong life with (faster) 
diagnosis and treatment.  Telemedicine has mainly been used as a method of 
screening or confirmation for diagnosis.  In this thesis, using various sources, such as 
data from patients‟, data from literature, expert opinion and assumptions, QALYs will be 
estimated for this patient cohort (see Chapter 7 for more detail).   
 
3.5 Summary and next steps 
The results from the literature review are consistent with previous findings and there is 
still no further conclusive evidence that telemedicine interventions are cost-effective (or 
not cost-effective as maybe the case) compared with the conventional/standard/usual 
delivery of healthcare.  Even though more studies have been added, the conclusions 
have remained the same.  
 
98 
 
For telemedicine interventions to be demonstrated as being cost-effective depends on 
the service being evaluated, the take-up and usage rate of the intervention, and its 
comparator, plus the research viewpoint, type of economic analysis, and the costs and 
outcomes which were collected.  Most telemedicine studies had the potential to be 
cost-saving or cost-effective, but this depended on the number of patients that used the 
service or if the high start-up costs of the telemedicine equipment were eliminated.  
One of the main limitations of the independent review was that there was not enough 
appropriate information presented in the papers for meta-analysis of the cost-
effectiveness of telemedicine studies to be conducted. 
 
Decision makers in health care (those who fund and deliver such services) require 
assurance that telemedicine can fulfil its promise, not only that it is effective, but that it 
also represents good value for money.  Telemedicine services that move on from pilot 
studies or short-term studies to those which are used in routine or longer-term use 
need to be assessed more routinely, so that the longer-term impact on costs, outcomes 
and the health service organisation can be quantified.  As telemedicine services move 
into routine use other factors may need to be considered in the economic evaluation 
such as: sustainability of the level of telemedicine activity and the organisation of health 
services.  Also, if the study is non-randomised then biases which arise within the study 
such as selection bias need to be minimised.  
 
Finally, and most importantly, how investigators conduct and report their findings on 
telemedicine interventions needs to be improved.  Whitten et al (2007) showed that 
their meta-analysis of research methodology proved difficult, because they could not 
ascertain all the necessary information from the published articles.  The importance of 
missing such methodological details should not be underestimated.  For example, not 
reporting start and end dates could potentially have an impact as we know that 
technology changes over time; and also not explicitly stating the research question 
means that readers may not know whether the study design was appropriate.  Authors 
need to provide more transparent accounts of their study, describing in detail lengths 
the approaches undertaken, perspective of the analysis, sources of data, unit costs 
(and its components) and outcomes collected and reported, assumptions made, the 
reliability of their results and how generalisable their findings are to other settings.   
 
When conducting economic evaluations of telemedicine studies, researchers should 
ensure that they follow guidelines such as the Drummond checklist [Drummond et al, 
2005], therefore to ensure transparency in reporting of methodologies and results.  This 
will enable readers to make comparisons to their own settings and to see whether 
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results can then be transferable and generalisable.  Economic evaluations of 
telemedicine studies should contain the basics from the checklist such as:  
 What is the research question? 
 Who is the study for? 
 The type of economic evaluation conducted 
 How are costs and outcomes going to be measured and valued? 
 Does discounting have to be performed? 
 Are results presented in terms of an incremental analysis? and 
 Was uncertainty in assumptions and results accounted for? 
This applies not only to telemedicine, but for all economic evaluations of clinical 
services.  As mentioned earlier in Chapter 1, there have been a few papers building on 
the Drummond checklist, looking at a framework for the economic evaluation of 
telemedicine (e.g. McIntosh and Cairns, 1997; Sisk and Sanders, 1998).  These 
frameworks have looked at some of the other problems faced when conducting an 
economic evaluation of telemedicine such as: constantly changing technology and 
small sample sizes (some of these points have been discussed further in this Chapter).  
One important final point is that maybe telemedicine intervention and the alternative(s) 
are not the problem, but how the costs and outcomes are collected and reported, leads 
to different conclusions.  
 
The next Chapter will look at the design of the TelePaed study, a critique of the case 
study will be provided and this will be followed by a discussion of the three economic 
issues identified in the literature review in more detail: selection bias, patient costs and 
the measures of benefits such as QALYs in the context of telemedicine services.  The 
following Chapters (5 to 7) will look at how each of these three issues can be 
addressed in the context of the TelePaed case study in order to improve the analysis. 
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CHAPTER 4: DESIGN AND CRITIQUE OF TELEPAED CASE STUDY AND 
ECONOMIC ISSUES ASSOCIATED WITH TELEMEDICINE 
 
4.1 Introduction 
In the previous chapter, a literature review was conducted which looked at the costs 
and cost-effectiveness of telemedicine.  The findings from the literature review 
identified some economic issues which may be of concern when conducting economic 
evaluations of telemedicine; especially in relation to the case study presented in 
Chapter 2.  The aim of this chapter is to look at the design of the case study (including 
the wider TelePaed study) in more detail and to reflect on some of the problems with 
the design of the study.  This chapter will then outline the next steps for this thesis i.e. 
how best to solve the three issues identified in the literature review in the context of an 
economic evaluation of telemedicine.   
 
4.2 Design of TelePaed study and configuration of antenatal screening services 
4.2.1 Brief overview 
In 2001, under the guidance of the NHS ICTRI-1 [DoH, 1998], the RBH in west London, 
introduced a telemedicine service for district hospitals in southeast England that was 
designed for use in paediatric departments, neonatal units, and obstetric departments.  
The RBH already had established paediatric telecardiology links with hospitals in 
Greece and Portugal [Neophytou, 2000].  The four hospitals were Basildon, Colchester 
and Southend in Essex and Medway in Kent and each hospital was between 35 to 65 
miles from central London.  The paediatricians and obstetricians decided on the 
precise role for the telemedicine service within their hospital and they could determine 
how the new service could complement their existing arrangements for obtaining 
specialist advice.  The telemedicine service could be used for face-to-face 
consultations with the patient present and live ultrasound images and heart sounds 
would be transmitted via an electronic stethoscope; or a „store-and-forward‟ approach 
could be adopted, whereby the district clinicians would transmit pre-recorded videoed 
ultrasound images in the absence of patients.  The main fieldwork for the TelePaed 
project was conducted over a 15-month period (1st May 2001 to 31st July 2002). 
 
The project was not set out as a „true experiment‟, but as an evaluation of a service 
delivery organisation.  The project was designed to evaluate the role of telemedicine in 
facilitating the diagnosis and advice on the management of three patient groups: 
1. Newborn babies with suspected heart abnormalities; 
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2. Older infants and children for whom a cardiac opinion is required.  These patients 
would normally be seen by specialists in scheduled outreach clinics, unless the 
case was urgent; and 
3. Pregnant women suspected of a fetal cardiac anomaly. 
 
Ethical approval for the project was obtained from a multi-centre research ethics 
committee and the relevant local research ethics committees for each of the district 
hospitals and the specialist centre [Dowie et al, 2007]. 
 
4.2.2 Selection and randomisation of district hospitals 
Two paediatric cardiologists from the RBH (who were also part of the TelePaed project 
team) routinely held paediatric outreach clinics in 19 DGHs and these hospitals formed 
the sample frame for the selection of the project hospitals [Dowie et al, 2003].  Four of 
these 19 hospitals were chosen for the TelePaed project and the criteria for selection 
focused mainly on the relatively large obstetric caseloads (over 3,500 deliveries 
annually) to ensure that the analyses were based on adequate numbers; their distance 
from the specialist hospital in London; and the presence of a district hospital consultant 
paediatrician with an interest in paediatric echocardiology [Dowie et al, 2003].  Of the 
hospitals which were chosen, Basildon and Southend only had paediatric links with the 
RBH; whereas, Colchester and Medway had both fetal and paediatric links with the 
RBH. 
 
A pragmatic research design was adopted with the hospitals as the unit of 
randomisation (a cluster randomised trial) [Dowie et al, 2003].  Because of the 
uncertainty about how the district hospital clinicians would adopt the telemedicine 
service, the hospitals were randomised rather than individual patients.  Also, it was 
deemed unethical to randomise individual patients due to the nature of the presenting 
conditions and for these patients any delay in the consultation was not appropriate.   
 
The initial research protocol proposed that two of the hospitals would act as 
intervention sites and receive the telemedicine equipment.  The other two hospitals 
would act as control sites and when the fieldwork finished they would also be offered 
the telemedicine equipment.  The telemedicine equipment for each of the district 
hospitals would be supplied by the project, but the hospitals would incur any non-
research costs such as the call charges for the teleconsultations.  However, when 
purchasing the telemedicine equipment for the two intervention sites, it was cost-saving 
to purchase all four telemedicine packages in a single order.  The control hospitals 
were also provided with their telemedicine equipment at the same time as the 
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intervention hospitals on the condition that it could be used for other purposes, but not 
for patients involved in this project [Dowie et al, 2003].  Before the introduction of the 
telemedicine equipment in each hospital, staff in all four hospitals underwent additional 
training in fetal ultrasonography and paediatric echocardiography. 
 
Using a random number generator, a statistician in Brunel University who was 
independent of the project team and unaware of any preferences within the project, 
allocated the hospitals as: 
 Intervention hospitals: Basildon and Medway 
 Control hospitals: Southend and Colchester [Dowie et al, 2003]. 
 
4.2.3 Configuration of the antenatal screening services 
Even though the four hospitals were similar in terms of the number of maternal 
deliveries each year, they were different in terms of the configuration of their antenatal 
screening services.  For example, anomaly ultrasound scans were offered in all four 
hospitals, although each hospital was different at which gestational age the scan was 
offered.  Eighteen to 20 weeks was the norm for Colchester and Southend hospitals; 
Medway hospital conducted anomaly scans at 20-22 weeks gestation; and for Basildon 
hospital anomaly scans were delayed until 23 weeks, as nuchal translucency screening 
for Down‟s syndrome was universally offered to all women (nuchal screening was 
selectively offered in the other 3 hospitals) [Dowie et al, 2004].  Serum screening tests 
were offered in all four hospitals, from about 15 weeks gestation.  However, if women 
in Medway hospital had undergone nuchal screening they were not offered this test.  In 
terms of serum screening programmes, the hospitals were different in terms of the 
choice of tests which were undertaken and the risk cut-off levels.  Basildon and 
Southend hospitals conducted double tests (1 in 250 cut-off); Colchester hospital 
conducted a triple test (1 in 250 cut-off) and Medway hospital conducted a quadruple 
test (1 in 300 cut-off) [Dowie et al, 2004]. 
 
It was important to take into account the different screening policies across the four 
hospitals, as this helped determine the eligibility criteria for entering pregnant women 
into the TelePaed database and in turn these policies influenced the final numbers of 
pregnant women for the hospitals in the database. 
 
4.2.4 Postal surveys 
Postal surveys were sent out two to three weeks after the initial consultation to the 
pregnant women who were eligible for entry in the audit databases in the two hospitals 
that had links with the fetal cardiology service at the RBH (Colchester and Medway 
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hospitals) and to the mothers or guardians of infants and children who were seen as 
outreach outpatients in the four DGHs.  For infants and children, the questionnaires 
were divided into five age groups according to the relevant health status instruments: 
Qualin [Manificat et al, 2000] for babies aged 1 to 3 months; 4 to 12 months; and 13 to 
24 months; and Pediatric Quality of Life Inventory (PedsQL) [Varni et al, 2001]) for 
children aged 25 to 59 months; and 60 months (5 years) and older. 
 
These questionnaires were used to gather information on the expenditure incurred by 
patients (and their families) and also information on their health-related quality of life 
during their first visit to the specialist.  Detailed information on the health status 
instruments used for pregnant women and the calculation of patient costs was set out 
in Chapter 2 (sections 2.5.5.1 and 2.5.5.2).  Follow-up questionnaires were sent three 
months after the initial questionnaire; however, these questionnaires only included the 
health status instruments. 
 
4.2.5 Economic evaluation approach 
A cost-consequences approach was adopted for the economic analysis from the 
viewpoint of the hospital.  The aim of the economic evaluation was to identify any 
differences in the relevant costs and consequences for the patient groups that used 
telemedicine and those that did not use telemedicine.   
 
4.3 Critique of the TelePaed study - what actually happened in practice? 
4.3.1 Uptake and usage of telemedicine services 
From August 2001, the consultant obstetricians and paediatricians in the two 
intervention hospitals were permitted to utilise the telemedicine service.  Uptake of the 
telemedicine service in the intervention sites was slower than anticipated and not 
consistently used for the three patient groups.  To compensate for the delay in the 
uptake of the technology, from February 2002 onwards the two control hospitals were 
invited to use the telemedicine service.  The project was therefore extended by three 
months to allow the control hospitals to introduce the telemedicine service, notably to 
provide sufficient evidence on the use of new services for the research evaluation.  
Hence, the project was no longer a randomised trial and was classed as an 
observational study.  However, there was always the question as to whether the 
TelePaed study was a randomised trial.  In most instances, patients should be 
randomised but in some situations this may not be practical, therefore the use of 
cluster RCTs is recommended; however there may not be enough clusters in each arm 
of the study.  Even by the study design for the TelePaed study, two clusters in each 
arm is questionable; especially when you look at it in terms of statistical power which 
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are required to detect statistical differences in RCTs.  (It is worth noting that the original 
protocol proposed recruiting eight hospitals, but research finance for such a large-scale 
evaluation was not available).  Table 4.1 below summarises the use of telemedicine for 
the four district hospitals. 
 
Table 4.1: Use of telemedicine and specialist referrals from the DGHs 
 Basildon Colchester Medway Southend Total 
referrals 
Duration of TM access: 
 
TM service used for: 
Newborn babies 
Older infants 
Pregnant women 
 
All TM referrals 
12 months 
 
 
  
  
X 
 
38 
6 months 
 
 
X 
  
X 
 
11 
12 months 
 
 
X 
  
    
 
61 
6 months 
 
 
  
  
X 
 
7 
 
 
 
17 
48 
52 
 
117 
Key: TM = telemedicine;   = TM service used; X = TM service not used 
 
For fetal cardiac advice, this slow uptake may have been because Basildon and 
Southend hospitals did not have fetal cardiology links with the RBH, instead they had 
historical links with specialists based in another fetal cardiology unit in London; and 
Colchester hospital had an internal referral service provided by a consultant 
obstetrician with advanced fetal heart diagnostic expertise [Dowie et al, 2004].  Only 
Medway hospital used the telemedicine equipment for fetal cardiology assessments on 
a regular basis, and also the telemedicine equipment was only suitable for screening 
fetal hearts once the women reached 18 weeks gestation.  Thus, as the study was no 
longer randomised, an observational design was adopted, to compare the costs and 
outcomes of patients referred to specialists from all four hospitals by means of the 
telemedicine service or by conventional methods (face-to-face consultations).  The 
cohort of pregnant women who received specialist advice via telemedicine in Medway 
hospital were compared with the cohort of pregnant women in all four hospitals who 
received specialist advice via face-to-face consultations [Dowie et al, 2007].  However, 
for this thesis, methods and results for only Medway hospital are presented. 
 
The selection of patients for the telemedicine service in Medway hospital was based on 
TelePaed eligibility criteria (see Chapter 2, section 2.4.2 for more detail); and as noted 
earlier it was unethical to randomise individual patients (however, this was never tested 
by an ethics committee).  Thus, the pregnant women‟s risk factors played an important 
part in the district clinician‟s choice of referral mode.  For example, women who were 
classed as „high risk‟ were more likely to be seen in London for a face-to-face 
consultation, unless a telemedicine clinic was scheduled to take place within the next 
few days.  Hence, pregnant women who were referred to see a perinatal cardiologist 
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for face-to-face assessments were not „directly comparable‟ to the telemedicine 
women.  As these women were not selected on a random basis for the two referral 
modes, they are most likely to be „biased‟ i.e. that selection bias played an important 
part in choosing which referral mode the pregnant women were allocated to.  
 
4.3.2 Outcome of postal surveys 
With respect to fetal cardiology, postal questionnaires were sent to eligible women in 
Colchester and Medway hospitals.  The number of questionnaires received from 
women in each hospital was: 125 out of 235 (53.2%) - Medway hospital and 115 out of 
201 (57.2%) - Colchester hospital [Dowie et al, 2004].  The majority of questionnaire 
responses were from women who were screened locally in the district hospitals.  Of the 
women respondents who were referred to a specialist fetal cardiologist, 29 women from 
Medway hospital (23 whose scans were videoed for further assessment and 6 women 
who went to London – these results were presented in Chapter 2) and 4 women from 
Colchester hospital.   
 
In terms of patient costs calculation, information on the expenditure incurred by 
patients was only collected at one time point.  This is important as over the course of 
their pregnancy, a woman has to travel often to the district hospital (in some instances, 
to the specialist hospital) for prenatal clinical attendances and ultrasound scans and 
these additional expenses can add up. 
 
4.3.3 Measures of benefits  
As the project set out to establish the cost-consequences of using telemedicine for 
specialist advice, in terms of the benefits which were recorded in the audit database for 
fetal cardiology, these mainly concentrated on clinical outcomes.  The project aimed to 
collect and present the demographic characteristics, the clinical findings and specialist 
referral patterns according to the four DGHs [Dowie et al, 2004].   
 
In terms of the clinical findings, the study identified the number of pregnant women with 
fetal cardiac anomalies (and in some instances, fetal non-cardiac diagnoses were also 
identified).  Of those pregnant women with suspected cardiac abnormalities, they were 
categorised according to severity: mild (e.g. irregular heartbeats at 37 weeks); 
moderate (e.g. coarctation of the aorta; atrio-ventricular septal defect); and severe (e.g. 
hypoplastic left heart; aortic stenosis) [Dowie et al, 2004; Dowie et al, 2008].  As 
mentioned earlier, the incidence of fetal CHD is very low (1 in every 145 births) 
[Peterson et al, 2003], so only a limited number of abnormal cases would be detected 
in a 15-month period in a DGH with approximately 3,800 births per annum.   
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So in terms of measures of benefits which were recorded in the audit database, these 
were the number and severity of clinical fetal outcomes (i.e. normal, cardiac or non-
cardiac diagnosis) and no other maternal or neonatal long-term health benefit 
measures were recorded such as QALYs.  
 
4.3.4 My role in the project 
In July 2002, when the fieldwork was almost complete, I took over the role as the 
health economist for the TelePaed project.  I had no input or influence into the design 
of the study or how the postal surveys were conducted.  My main role for the project 
has been outlined earlier in the section on Publications and Authorship.  I contributed 
fully to the production of the four reports which were submitted to the Department of 
Health and the six papers which were published in peer-reviewed journals (two articles 
of which I was a lead author).   
 
4.3.5 Applying Drummond check-list to the TelePaed study  
Table 4.2 below shows the Drummond check-list for assessing economic evaluations 
[Drummond et al, 2005] being applied to the TelePaed case study which was 
presented in Chapter 2.  This was to check whether the study presented in Chapter 2 
was carried out in accordance with criteria required for a good „economic evaluation‟.  
As you can see from Table 4.2 where appropriate, the check-list was as complete as 
could be in accordance with the economic evaluation guidelines.  On a separate note, 
Bergmo (2009) had stated that the Dowie et al study (2007) was one of the eight 
studies (out of 33 economic evaluations) which had addressed all the key issues for an 
economic evaluation. 
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Table 4.2: A check-list for assessing economic evaluations 
Question Chapter 2: TelePaed study 
Was a well-defined question posed in an 
answerable form? 
Yes – the study set out to compare the costs and 
outcomes of patients referred to specialists via the 
telemedicine service or by conventional means.  The 
study was conducted from a hospital perspective. 
Was a comprehensive description of the 
competing alternatives given?  
Yes – the study described in detail the two referral 
methods for obtaining specialist advice: direct referral to 
London to see a specialist face-to-face for assessment or 
via a store-and-forward telemedicine service. 
Was the effectiveness of the programmes or 
services established? 
Yes – effectiveness data was obtained from the 
observational study; that is, the detection of cardiac cases 
prior to birth for each referral method. 
Were all the important and relevant costs 
and consequences for each alternative 
identified? 
Yes – the key resource use (costs) and consequences for 
each referral method were identified. 
Were costs and consequences measured 
accurately in appropriate physical units? 
Yes – key resource was measured in their appropriate 
physical units. 
Were costs and consequences valued 
credibly? 
Yes – unit costs were then applied to the key resources. 
Were costs and consequences adjusted for 
differential timing? 
Not applicable – length of study was less than a year. 
Was an incremental analysis of costs and 
consequences of alternatives preformed? 
No – as an incremental cost-effectiveness ratio would not 
be meaningful. 
Was allowance made for uncertainty in the 
estimates of costs and consequences? 
Yes – one-way sensitivity analyses were applied to 
changing the discount rate and lifetime of the 
telemedicine equipment. 
Did the presentation and discussion of study 
results include all issues of concern to 
users? 
Yes – study results were presented in a disaggregated 
form; no incremental ratio was presented. 
 
4.4 Next steps for this thesis 
As identified not only from the literature review in the previous chapter, but also due to 
the limitations with the TelePaed study, the three economic issues highlighted earlier 
are of importance when conducting economic evaluations of telemedicine 
interventions/services and will be looked at in further detail in this thesis.  
 
As the study was never properly randomised, the way patients were selected for 
referral to see a specialist may have led to selection bias and this may have resulted in 
biased costs and effects.  In Chapter 5, selection bias will be looked at in more detail 
and the methods which have been identified in the literature to reduce selection bias 
will be applied to see what impact this has on the costs and effects.  Chapter 5 will 
primarily look at the two groups of women who were referred for fetal cardiology (see 
Chapter 2 for more detail) and the costs and effects will be examined separately. 
 
As seen in Chapter 3 in the literature review the majority of studies were pilot (short-
term) or small implementation studies.  Therefore, in Chapter 6, the new analysis 
conducted will look at all women who underwent an anomaly scan at Medway hospital 
during the same time period as women who were referred to a perinatal cardiologist.  
By looking at all women (referred and non-referred women), we are not artificially 
introducing selection and this is probably the best way to deal with selection bias given 
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the available data.  Therefore, the aim will be to conduct a cost-effectiveness analysis 
of a service with telemedicine compared to a conventional service, that is, to look at 
what would happen to costs and effects if a telemedicine service was not available and 
also to look at the change in costs and effects over time (additional data has been 
collected for this purpose). 
 
In Chapter 2, patient costs were calculated for the sample of women for whom we had 
data.  Patient costs can have an impact on the financial situation for pregnant women, 
especially during their course of their pregnancy where they have to travel more than 
once to hospital.  Usually patient costs are not included in economic evaluations and 
they are not in the reference case for NICE [NICE, 2008].  So in Chapter 6, the impact 
on patient costs for these women will be explored.   
 
Finally, in Chapter 7, the third issue which was identified in the literature review: 
measures of benefits such as QALYs will be explored.  Most telemedicine studies only 
report clinical outcomes or averted costs.  Therefore, the thesis explores whether 
QALYs can be calculated for telemedicine services.  A decision analytical model will be 
used to look at lifetime costs and benefits (QALYs) of the introduction of a telemedicine 
screening service for pregnant women whose unborn babies are at a low risk of 
congenital heart disease compared to a screening service without telemedicine.  In this 
group of low-risk women, they are more likely to have a missed cardiac anomaly and 
the results will be expressed in terms of cost per QALY gained. 
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CHAPTER 5: ADJUSTING COSTS AND EFFECTS FOR SELECTION BIAS FOR 
THE TELEPAED DATA 
 
5.1 Introduction 
This chapter addresses the first of the three issues highlighted in the previous two 
chapters: selection bias.  The literature review in Chapter 3 found that the majority of 
telemedicine studies conducted were non-randomised, and because of this there is 
potential for selection bias.  The TelePaed case study described in Chapter 2 focused 
on comparing two groups of women who were referred for a specialist fetal cardiac 
opinion: women who were referred directly to a specialist hospital for face-to-face 
assessment (direct referral group) and women whose assessment was conducted via 
telemedicine, where pre-recorded videoed ultrasound images where relayed to the 
specialist (telemedicine group).  As mentioned in Chapter 4, individual patient 
randomisation was considered unethical for this cohort due to the urgent nature of the 
presenting conditions.  Therefore, the sonographers and district obstetricians decided 
whether a patient was to be assessed via the telemedicine link (used mainly for 
screening purposes) or to send them directly to see a specialist in a London hospital 
(used mainly for women who required an urgent opinion).  Although, there were no 
statistically significant differences in demographic characteristics between the two 
groups, the two groups of women were different.  The telemedicine women were 
specifically selected according to predefined eligibility criteria (see Chapter 2, section 
2.4.2) and most likely the women seen directly had evidence of a cardiac anomaly.  
That is, patients‟ risk factors played an important part in the clinician‟s choice of referral 
mode.  Since women were not selected on a random basis for the two referral modes, 
the estimation of cost and effect differences between the two groups may well have 
been biased.  Therefore, this chapter aims to assess this bias, and to reduce its effect 
on the analysis.  
 
This chapter begins with a literature review to find which methods can be applied to 
costs and/or effects to reduce selection bias and an overview of the methods identified.  
Then the various methods are applied to the TelePaed dataset to see whether it is 
possible to obtain more reliable estimates of costs and effects for these two groups of 
pregnant women.  
 
5.2 Selection bias 
The aim of this section is: 1) to describe the different types of biases that can arise in 
the evaluation of healthcare, focusing specifically on selection bias; and 2) to provide 
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an overview on the methods identified from a literature review which can be applied to 
reduce selection bias in healthcare.  
 
5.2.1 Introduction to selection bias in healthcare 
In primary health research, an appropriately powered RCT is often seen as the gold 
standard, because it has the lowest threat of bias.  In a RCT, individuals are randomly 
allocated to two or more groups.  The intervention group receives the new treatment, 
whereas the control group receives an alternative treatment.  RCTs are considered the 
gold standard for evaluation of interventions and technologies because the 
randomisation process should balance the covariates between the comparison groups 
[Deeks et al, 2003].  Randomisation is the only means of controlling for unknown and 
unmeasured differences, as well as those that are known and measured [Kunz et al, 
2005]. 
 
However, in some situations, RCTs may not be possible.  In these circumstances, non-
randomised studies (such as observational studies) may be the only way to assess the 
costs and effects of treatments.  Non-randomised studies tend to have broader 
selection criteria for patients, and maybe more representative of the wider population; 
have longer follow-up periods; study costs are usually lower; and the studies are 
conducted under more realistic conditions.  However, as participants in these studies 
are not randomised to either the treatment or control arm, there is potential for bias.   
 
Bias indicates systematic error in the design or conduct of research trials that results in 
a distortion of the data obtained [Kielhorn and Graf von der Schulenburg, 2000] and 
can arise at any stage of a clinical trial.  Several categorisations of bias exist in 
healthcare; where some have used an extensive listing of biases [Sackett, 1979; 
Delgado-Rodriguez and Llorca, 2004]; Feinstein (1985) and Cochrane (2005) have 
used four.  Feinstein (1985) consolidated biases that can arise during research into 
four categories: a) susceptibility bias refers to differences in baseline characteristics; b) 
performance bias refers to different experiences of treatment; c) detection bias refers to 
different measurement of outcomes; and d) transfer bias refers to differential losses to 
follow-up.  The Cochrane Collaboration Handbook (2005) highlighted four biases that 
can arise in non-randomised studies: 1) selection bias refers to systematic differences 
in comparison groups (meaning differences in baseline characteristics of individuals in 
different groups); 2) performance bias refers to systematic differences in care provided 
apart from the intervention being evaluated; 3) attrition bias refers to systematic 
differences in withdrawals from the trial; and 4) detection bias refers to systematic 
differences in outcomes assessed. 
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The four categories of bias for the Cochrane Collaboration are very similar to those four 
groups of bias by Feinstein.  The term susceptibility bias is sometimes used 
interchangeably with the term selection bias.  Feinstein defines the term selection bias 
as “susceptibility bias occurs if the maneuvers are received by groups whose collective 
baseline states have distinctly different prognostic expectations for the subsequent 
occurrence of the outcome event” [Feinstein, 1985].  In other words, the two groups of 
patients who have been selected before treatment may have baseline differences, and 
this can create bias even before the outcome occurs.  This term is very similar to the 
Cochrane meaning for selection bias, where selection bias is referred to as systematic 
differences in comparison groups at baseline.  Selection bias will be the focus of this 
chapter. 
 
In a sufficiently large trial, randomisation reduces selection bias.  Selection bias refers 
to an absence of comparability between the groups being studied and can happen 
during any stage of research.  Selection bias arises as a result of the interaction of 
treatments and omitted or unobserved patient characteristics that may influence 
treatment choice, but independently affect health outcomes: in other words, the 
participants in the intervention group have different characteristics from those allocated 
to the control group (and these differences affect outcomes).   
 
On average, selection bias tends to make treatment effects appear larger than they are 
and the size of these distortions can be as large or larger than the size of effects that 
are being measured [Kunz and Oxman, 1995].  Selection bias in studies may occur not 
only due to observed covariates, but may also be due to unobserved covariates.  Both 
the observed and unobserved covariates can be either known or unknown to the 
clinicians, as well as recorded or not recorded during the study.   
 
Despite the growing use of non-randomised studies to evaluate healthcare 
technologies, there is currently no „gold standard‟ approach to control for selection bias 
in non-randomised studies.  In the next section, an overview of the alternative methods 
used to control selection bias in non-randomised studies is provided.   
 
5.2.2 Literature search to identify methods to reduce selection bias in healthcare 
evaluation 
A literature search was conducted to identify methods which have been used to reduce 
selection bias in non-randomised studies.  The search strategy including search terms 
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and the databases which have been searched are highlighted in Appendix 6, section 
A6.1. 
   
5.2.3 Selection bias or endogeneity? 
One thing that became apparent from the literature review was that the terms selection 
bias and endogeneity were being used interchangeably.  However, the terms actually 
mean different things and therefore lead to two different solutions.  Millimet (2001) 
stated “Sample selection bias and endogeneity bias refer to two distinct concepts, both 
entailing distinct solutions.  In general, sample selection bias refers to the problems 
where the dependent variable is observed only for a restricted, nonrandom 
sample……Endogeneity refers to the fact that an independent variable included in the 
model is potentially a choice variable, correlated with unobservables relegated to the 
error term.  The dependent variable, however, is observed for all observations in the 
data”.   
 
For example, we have a model where the dependent variable is wages and one of the 
independent variables is gender.  There are 300 people in a dataset, where 200 are 
employed and 100 are unemployed.   
 Equation: Wages = α + β1Gender + error term 
With selection bias, observing wages is dependent on whether one is employed or not 
and the only available data is for the 200 employed people (i.e. the 100 unemployed 
observations are missing).  In relation to endogeneity, observing wages is dependent 
on whether one is employed or not AND also on another variable i.e. a choice variable 
such as educational status (this variable is accounted for in the error term).  Here, all 
300 observations would be observed and pooled together.  That is, the dependent 
variable is dependent on other things which are not included (i.e. in the error term). 
 
In relation to the TelePaed study, this means for selection bias, one would observe the 
costs and effects of a woman who was seen via telemedicine, only if they were 
assessed via telemedicine.  Likewise, one would observe the costs and effects of a 
woman who was seen directly, only if they had face-to-face assessment in London.  If 
one of the groups is not observed, then this groups costs and effects are unknown, 
whereas, with endogeneity the problem would be identified in two ways: firstly, a choice 
variable as an independent variable would be included in the regression equation.  The 
choice variable here would be one such as when the patient goes to the GP; the choice 
they have is on what day they see the GP or which GP they see (this would not apply 
in emergency situations), unfortunately we did not account for a variable like this in our 
data.  Secondly, the entire sample would be pooled, that is, all direct referral and 
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telemedicine women would be treated the same; hence, as the whole sample is used 
here there would be no issue of selection bias.  However, we know that the two referral 
groups are different, because selection was based on eligibility criteria.  Therefore, the 
two groups cannot be pooled together as they are not comparable, and instead each 
group has to be analysed separately; hence, this is an issue of selection bias.  So on 
this basis, the focus will be on the three methods which have explicitly said that they 
deal with selection bias and not endogeneity: regression analyses; propensity score 
methods; and sample selection models.  The other methods identified in the literature 
review have been summarised in the Appendix 6, section A6.2. 
 
5.2.4 Methods which can be applied to reduce selection bias in healthcare 
5.2.4.1 Regression analyses 
The traditional approach to control for selection bias is to use regression models.  
Regression models estimate how much each independent variable (such as a risk 
factor) relates to the dependent variable or the outcome.  After estimating the 
regression model, the coefficients from the regression model are used to solve the 
regression equation for the treatment groups.  When the comparison between the 
groups is made, the adjustments are added or subtracted from the estimated treatment 
effect to account for the impact of differences in each of the baseline variables 
according to their estimated relationship with the dependent variable [Deeks et al, 
2003].  The difference in the average values of the various factors between the groups 
or individuals is calculated, and the mean or overall proportion is used for the entire 
population for each independent variable [Estrada et al, 2000].  A statistically significant 
coefficient of treatment (or of an interaction) involving the treatment variable indicates a 
treatment effect.  In a regression model, the signs indicate the direction of the 
association between dependent and independent variables and the sizes of the 
coefficients indicate the strength of the magnitude of these associations. 
 
The most commonly used regression methods are bivariate (or multivariate) linear  
regression analysis which attempts to model the relationship between two (more than 
two) variables by fitting a linear equation to the observed data and is used for 
continuous outcomes; and logistic regression analysis is used to model the probability 
of occurrence of a binary variable such as whether or not the subject has a particular 
symptom and the regression equation will estimate the proportion of individuals who 
have that symptom. 
 
One of the main advantages of regression models is that they can include more 
variables than matching or stratification and can also examine the effect of each 
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independent variable on the dependent variable.  One of the main limitations of 
regression analyses is that they can only adjust for observed covariates, they cannot 
adjust for unobserved covariates.   
 
The pan-European SOHO (Schizophrenia Outpatient Health Outcomes) study was a 
three year, prospective, observational study of outcomes of antipsychotic treatment for 
schizophrenia in the outpatient setting.  Knapp et al (2008) conducted a cost-utility 
analysis comparing the drug olanzapine with other antipsychotic treatments in patients 
with schizophrenia.  The authors used multivariate regression analyses to adjust for 
baseline covariates (such as sex, age, weight, body mass index) to take into account 
the potential selection bias inherent in the study and after adjusting for selection bias 
the authors then estimated the incremental cost and utility gains for patients treated 
with olanzapine compared with the other treatments.  
 
5.2.4.2 Propensity scores 
Propensity score analysis can be used to address selection bias in the estimation of 
costs and effects.  Rosenbaum and Rubin (1984) defined a propensity score as, “the 
conditional probability of assignment to a particular treatment given a vector of 
observed covariates”.  In other words, a probability model is estimated to predict the 
likelihood (i.e. the probability) that individuals are assigned to the treatment group, 
compared to the control group, based on the values of the observed variables.  In 
observational studies we know for certain which treatment a patient receives; by 
estimating the propensity score, we can create a „quasi-randomised‟ experiment.  We 
may have two patients with the same propensity score, one in each group, and we can 
imagine these two subjects were „randomly assigned‟ to each group in the sense of 
being equally likely to be either a treated or control subject. 
 
The propensity score summarises all the background covariates (which are included in 
the calculation) such as age for each patient into a single-index variable (the propensity 
score).  The generation of one variable allows the assessment of whether the treated 
and control groups overlap enough on background characteristics.  When such overlap 
is present, the propensity score approach allows calculation of the estimated treatment 
versus control effects that reflect adjustment for differences in all observed background 
characteristics [Rubin, 1997].  So the propensity score is a balancing score i.e. the 
treatment and control groups have the same distribution on all observed covariates, as 
in a randomised experiment, and so selection bias is removed when comparisons are 
made between groups with the same propensity scores.  If there is insufficient overlap 
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between the groups in a relevant variable, then the two groups are not really 
comparable, and propensity scoring cannot deal with the problem. 
 
The most common method to obtain propensity scores for each patient is to conduct 
either a probit or a logit regression model.  For this type of model, the dependent 
variable is treatment assignment (0 = control group; 1 = treatment group) and the 
independent variables are background characteristics such as age.  By running a 
regression model for each patient in the study, a propensity score can be obtained.   
 
Another method used to estimate propensity scores is the „classification tree‟ approach.  
Stone and colleagues (1995) used a classification tree approach to obtain propensity 
scores for hospitalized and ambulatory patients with community acquired pneumonia.  
So essentially, a „classification tree‟ partitions data into subsets (i.e. it identifies a 
subset of patients who have similar propensities of being selected into one of the two 
groups).  For every partition, all observed variables remain available even if they have 
been used earlier in the construction of the tree.  So it is possible for a single variable 
to reappear at several points in the tree.  These subgroups are by definition the 
propensity score strata and a subset that is not further partitioned is called a final 
subset or strata.  The proportion of the treated patients in each subset is used as the 
estimate of the common propensity for that subset.   
 
Luellen at el (2005) said that classification trees have a number of advantages over 
logistic regression.  Firstly, the classification algorithm automatically selects variables 
for the model; secondly, the algorithm also automatically detects interactions in the 
data; and finally, the trees‟ terminal nodes supply the strata, therefore eliminate the 
need to identify a set of stratification cut-points. 
 
Propensity scores have the advantage of reducing selection bias in observed 
differences, but remain subject to bias from unobserved differences [Rubin, 1997; 
Laudrum et al, 2001].  Crown (2001) commented on propensity scores and said “it 
does not provide a direct test of the presence of selection bias, nor does it provide an 
estimate of the magnitude of selection bias if it is present”.  In other words, propensity 
scores only control for observed variables and by using this method you cannot tell the 
extent of selection bias that may still exist.  Propensity scores work better in larger 
samples, because achieving an overlap between the treatment and control group in 
terms of observed characteristics increases with the sample size [Rubin, 1997], unless 
allocation is systematic. 
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One of the main limitations of the propensity scores technique is the way it handles 
weak covariates which are included in the propensity score estimation.  A covariate 
which is related to treatment assignment, but not to outcomes, is treated the same as a 
covariate which is related to both treatment assignment and outcomes.  Propensity 
score analysis rests on the assumption of “strong ignorability”, which assumes that all 
variables related to both outcomes and treatment assignment are observed and are 
included, and that treatment assignment is unconfounded with potential outcomes 
conditional on observed covariates.  That is, the model assumes that these individuals 
are sorted into different treatments as if they are randomly assigned.  Foster et al 
(2003) said that “this assumption is strong; its plausibility depends on the particular 
treatment involved and on the range of covariates included in the analysis”. 
 
Once calculated, propensity scores have been applied in several ways to help reduce 
bias: matching, stratification and regression adjustment.   
 
1) Propensity score matching 
The propensity score matching method orders the treatment and control groups by 
propensity scores and then matches each patient who receives the treatment to a 
control patient with a similar propensity score.  Matching aims to create groups that are 
similar in terms of observable background characteristics and this reduces the 
observed selection bias.  
 
Matching on propensity scores is a way of matching on many variables indirectly, 
instead of matching directly on many variables, which becomes increasingly difficult 
with more variables.  The most common method of matching is nearest neighbour 
matching.  That is, patients in the treatment group are matched to patients in the 
control group who have the closest propensity score.  This can be done on a one-to-
one basis or a many-to-one or one-to-many basis [Dowie et al, 2003].  “Nearest 
neighbour” matching can be done with or without replacement.  Dehejia and Wahba 
(2002) commented that matching with replacement allows a control group patient to be 
selected more than once, and this could be beneficial in terms of bias reduction and the 
average quality of the matching will increase.  Matching without replacement is where a 
control group patient can only be selected once, and this could also improve the 
precision of the estimates as you ensure the smallest propensity-score distance 
between the treated and control units.  Another method of matching is known as 
“calliper” or radius matching, which would select all control units within a pre-defined 
radius [Dehejia and Wahba, 2002].  After treated patients are matched to control 
patients, the next step is then to calculate costs and outcomes for each group.   
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For example, Johnson and colleagues (2005) evaluated an asthma care support 
program in the USA.  The program aimed to reduce unnecessary hospital and 
emergency department visits through patient education and the use of clinical 
protocols.  The authors used a logistic regression model to predict each person‟s 
propensity for program enrolment.  Variables used in the logistic regression included 
demographic factors, comorbid conditions, medical service utilisation, prescription drug 
use, and clinical procedures.  For each program participant, a non-participant was 
chosen with the closest (nearest-neighbour) propensity score. 
 
2) Propensity score stratification 
For the propensity score stratification method, once propensity scores are obtained for 
each patient, this method consists of grouping subjects into strata, so each stratum 
contains patients from both groups, determined by observed background covariates.  
This method aims to reduce selection bias, so that any differences between the groups 
or strata are not due to background characteristics.  So patients with similar propensity 
scores form one group, and another group is formed from patients with similar 
propensity scores and so forth, with approximately the same total number of patients in 
each stratum (although this may not always be the case).  The investigator must decide 
on the cut-off points for the different strata (i.e. the strata are usually divided into equal 
propensity score ranges).  Once the strata are defined, treated and control patients 
who are in the same group or stratum are compared directly [D‟Agostino, 1998]; for 
each stratum, the mean propensity scores for each group are compared.     
 
Coyte and colleagues (2000) estimated the impact of alternative discharge strategies 
following joint replacement surgery on the total cost of care.  There were four discharge 
destinations: a rehabilitation hospital with subsequent discharge to home without home 
care; a rehabilitation hospital with subsequent discharge to home with home care; 
discharge to home with home care; and discharge to home with self-care.  The authors 
used a logistic regression to calculate the patient‟s propensity to be discharged to a 
given destination.  The covariates used in the logistic regression included: age, gender, 
comorbid conditions, case mix group, diagnosis, length of stay, urban/rural 
characteristic of patient residence, whether a joint replacement revision was performed, 
teaching status of hospital and year.  They subclassified patients on the basis of their 
propensity score to produce five strata in which both groups were balanced with 
respect to all of the observed covariates.  Then treatment costs and patient outcomes 
due to each discharge strategy were calculated within each stratum. 
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3) Propensity score regression adjustment 
For the propensity score regression adjustment method, once propensity scores are 
obtained for each patient, these are then added as an independent variable into the 
regression model.  Inclusion of propensity scores as a covariate in the regression 
model takes into account the likelihood for treatments, thereby reducing selection bias.  
That is, by adding the propensity scores into the regression equation, the component of 
correlation which is due to the assignment process can be eliminated.  The regression 
adjustment refers to a statistical procedure that adjusts estimates of the treatment 
effects by estimating the relationship between the dependent variable and the 
independent variables in each treatment group [Rubin, 1979].   
 
Mitra and Indurkhya (2005) used propensity score analysis to estimate the cost-
effectiveness of cystectomy versus no cystectomy in elderly patients with muscle 
invasive bladder cancer.  From the observational data the authors used a logistic 
regression model to estimate the propensity of patients to receive surgical treatment of 
their bladder cancer based on their background covariates which included age, sex, 
race, cancer stage and grade, income, marital status and comorbidity index and score.  
After adjustment, none of the background covariates were statistically significant (p < 
0.05).  The propensity score values were then used in a generalised linear model to 
estimate net monetary benefit adjusting for propensity score.   
 
Application of propensity scores 
Propensity scores can be calculated in Stata version 10 [StataCorp, 2007] using both 
the „pscore‟ and the „psmatch2‟ programmes.   
 
‘Pscore’ programme 
The „pscore‟ programme stratifies women into blocks according to their propensity 
score and the model identifies the optimal number of blocks to ensure that the mean 
propensity score is not different for treated and controls in each block.  The programme 
then checks that each covariate is balanced.  Each variable is tested separately for 
each block using a two-sample t-test with equal variances [Becker and Ichino, 2002].  
The estimated propensity scores can be used to obtain estimates of the average 
treatment effect on the treated (ATT) using various matching methods (see below).  
The ATT computes the difference in average outcomes between the two groups.  The 
pscore programme creates two new variables: 1) mypscore – individual propensity 
scores for each patient; and 2) myblock – block number of the estimated propensity 
score.  The various matching methods include: 
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a) The nearest neighbour matching, first sorts all records by the estimated propensity 
scores and then takes each telemedicine patient, searches forward and backward for 
the closest direct referral patient(s).  This method is usually applied with replacement, 
in a sense that the direct referral patient can be a match for more than one 
telemedicine patient and this method selects the smallest possible control group.  Once 
each telemedicine patient is matched with a direct referral patient, the difference 
between the outcome of the telemedicine patients and the outcome of the matched 
direct referral patients is computed i.e. the ATT.  If for a telemedicine patient forward 
and backward matches happen to be equally good, the nearest neighbour random 
draw version program randomly draws either the forward or backward matches [Becker 
and Ichino, 2002]; whereas, the nearest neighbour equal weights version program 
gives equal weight to the groups of forward and backward matches [Becker and Ichino, 
2002]. 
 
b) With radius matching, in order to compute the ATT, each telemedicine patient is 
matched only with the direct referral patients whose propensity score falls in a 
predefined radius [Becker and Ichino, 2002].  Because, the radius method can 
generate more controls than the nearest neighbour method, this can worsen the quality 
of the match on the propensity score and there is also greater variability in the sample.  
If the radius is set quite small, it is possible that some telemedicine patients are not 
matched because the radius does not contain direct referral patients.  On the other 
hand, the smaller the size of the radius, the better the quality of the matches.   
 
c) With kernel matching (most commonly used), in order to compute the ATT, all 
telemedicine patients are matched with a weighted average of all direct referral patients 
with weights that are inversely proportional to the distance between the propensity 
scores of telemedicine and direct referrals (i.e. downweighting "distant" observations) 
[Becker and Ichino, 2002].  Each match can be thought of as being weighted in 
proportion to the number of standard deviations away from the treated individual.  
Closer the match in terms of propensity scores, the greater the weight placed on the 
match. 
 
d) With stratification matching, this method consists of dividing the range of variation of 
the propensity score in intervals, so that within each interval telemedicine and direct 
referral patients have on average the same propensity score [Becker and Ichino, 2002].  
The same blocks identified by the model that estimates propensity score can be used.  
Difference in outcome measures between the telemedicine and direct referrals in each 
interval is computed i.e. the ATT.  
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‘Psmatch2’ programme 
The „psmatch2‟ programme [Leuven and Sianesi, 2003] uses both the nearest 
neighbour and kernel matching approaches.  However, for the nearest neighbour 
matching, this programme goes one step further and directly applies matching on a 
one-to-one basis and creates two new variables: 1) _id – a new identifier is created for 
all observations; and 2) _n1 – for every treatment observation it will store the 
observation number (i.e. the patient id) of the matched direct observation.   
 
5.2.4.3 Sample selection models 
Sample selection models controls for the bias due to both observed and unobserved 
factors associated with outcomes and are commonly referred to as the Heckman 
method [Heckman, 1979; Crown et al, 1998].  In the first stage, a probit model (for the 
Heckman model [Heckman, 1979; Crown et al, 1998]) or a logit model (for the Lee 
model [Lee, 1983]) of treatment selection is estimated.  Probit models are very similar 
to logit models, but assume that the error term is normally distributed.  
  
In the first stage, for example, a probit model of treatment selection is estimated (the 
probability of „selecting‟ into one of the treatment groups of interest).  Then the 
estimated probabilities from this probit model, are used to calculate a new variable, 
known as an adjustment factor (or  or inverse Mills ratio - this serves as an adjustment 
for potential selection bias) for each patient, which is the probability of not receiving the 
treatment given that the individual was „at risk‟ of receiving the treatment.  As the 
probability of receiving the treatment approaches 1, the adjustment factor approaches 
0.  In other words, for patients who actually receive the treatment, if the predicted 
probability of receiving the treatment is high based upon observable factors, the 
influence of unobservable variables is small and consequently the bias is small.  If the 
probability of receiving the treatment approaches 0, the adjustment factor approaches 
infinity.  As a result the potential for bias is large for patients who receive the treatment, 
but who are predicted not to receive the treatment based upon observable factors 
[Crown et al, 1998]. 
 
In the second stage, we want to predict the outcome of interest such as length of stay.  
So in the second stage regression equation (such as an ordinary least squares), this 
adjustment factor is included as one of the independent variables in the outcome 
model.  The significance and sign associated with the adjustment factor coefficient in 
the second model indicates the statistical significance and the magnitude of selection 
bias that would have been present in the estimates, if the adjustment factor had not 
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been included in the equation.  The adjustment factor permits a direct test of whether 
selection bias is present and if so, what the direction of its impact is.  If the coefficient 
on the adjustment factor, in the outcome equation is statistically significant, this 
indicates that selection bias is present and that the results of the treatment effect would 
have been biased had the adjustment not been made [Crown, 2001].  The sign on the 
adjustment factor also indicates the direction in which the results would have been 
biased.  If no selection bias is present, the sample selection model will produce the 
same regression coefficients as ordinary least squares estimation [Vogel et al, 2002]. 
 
The way sample selection models accounts for unobserved variables (bias) is similar to 
the instrumental variables method, where an instrumental variable is required (see 
Appendix 6, section A6.2.4 for more details).  So for example, in the regression model 
there is a variable for whether the mother has a family history of CHD but not for 
whether the mother has a previous pregnancy with an anomaly.  So in this case, the 
family history of CHD variable (identifier) is used as a proxy for previous pregnancy.  
That is, the family history of CHD variable would be the instrumental variable in this 
case.  This variable would have to be significant in the first part of the model, but not in 
the second part of the model.  Most articles claim that sample selection models deal 
with unobserved variables; however, they are not explicit in saying how they do this.   
 
The main problem with sample selection models is multicollinearity.  If the observed 
variables used to model the probability of receiving treatment are the same as those 
used to model the outcome variable in the second equation, the adjustment factor will 
be highly correlated with the observed variables in the second equation, leading to 
severe multicollinearity [Crown et al, 1998].  On the other hand, if it is possible to 
identify different sets of observable variables in the two stages (even if there is overlap 
between them), sample selection models tend to be more effective in controlling for 
selection bias [Crown et al, 1998].  Another drawback of sample selection models is 
that they require strong assumptions.  Firstly, the two regressions have to be 
simultaneously estimated i.e. jointly model the selection into treatment and outcome; 
and secondly, it also assumes that the error terms are jointly normally distributed. 
 
Sample selection models by themselves, may not be very useful in making conclusions 
about treatment effects, because they focus only on the treatment group.  A variant of 
the sample selection model is a treatment effects model which pools the sample for the 
treated and non-treated outcomes, and therefore the treatment effect variable in this 
equation can be included.  The adjustment factor used in this type of analysis includes 
values for both the treatment and non-treatment groups [Crown et al, 1998].  
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Crown et al (1998) used sample selection models to control for selection bias and to 
estimate the effects of alternative antidepressant therapies on a variety of cost 
measures such as total charges, physician charges, antidepressant and non-
antidepressant charges.  In the first stage, a probit regression model was conducted 
which showed the probability of being prescribed fluoxetine versus another 
antidepressant and allowed for the creation of the adjustment factor.  In the second 
stage regression, the authors entered the adjustment factor as an additional variable in 
the equation which predicted expenditures for physician visits using the observations 
for fluoxetine users only. The results showed that if the authors did not control for 
selection bias, then there were unobserved variables that differed between the 
fluoxetine and non-fluoxetine users that were correlated with expenditures and as a 
result estimates in the expenditure equation would have been biased. 
 
5.2.4.4 Summary of the methods identified to control for selection bias  
In summarising the three methods which were identified to reduce selection bias, the 
regression analysis method and the propensity scoring methods are very similar; 
however the sample selection method is not; see the few examples below (these 
examples have not been selected systematically from the literature).  Shah and 
colleagues (2005) conducted a systematic review to determine whether propensity 
scores gave different results from traditional regression modelling when adjusting for 
bias in observational studies.  They found that both methods produced similar results in 
terms of the strength or statistical significance of association between exposures and 
outcomes, although propensity scores gave slightly weaker associations.  However, 
they found that many of the reviewed studies did not implement propensity scores well.  
Vogel and colleagues (2002) looked at stroke patients‟ gain in overall, motor and 
cognitive functional status during rehabilitation which was measured using the 
functional independent measure.  They used both sample selection models and 
regression analyses to correct for selection bias.  They found statistically significant 
evidence of selection bias, and there was considerable differences in the results 
obtained from both the standard multiple regressions and the sample selection models.  
Dusheiko et al (2004) examined the effect of practice‟s fundholding status on the 
waiting times of its patients using methods to correct for selection bias including 
regression analysis, propensity score matching and the Heckman selection model.  
The authors found that the result from the sample selection method was significantly 
different from regression and propensity score results.  
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Table 5.1 highlights the key requirements of each method; strengths and limitations of 
each of the methods; and whether any of the methods are similar or different to other 
methods identified to control for selection bias.   
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Table 5.1: Summary of methods identified to control for selection bias  
Method Main idea behind method – ‘concept’ Key requirements Why is this method different from the 
others?  
Is this method similar to 
other methods? 
1) Regression 
analysis  
Estimates how each independent 
variable relates to the dependent 
variable and controls for the observable 
differences between treated and non-
treated subjects. 
-  Independent variables 
included in regression should 
not be highly correlated 
- Assumes linearity 
 
- Regression model uses all 
observations/variables 
- The regression predictions for patients who 
receive the treatment shift either up or down by 
the amount of the regression coefficient for the 
treatment variable and the method assumes 
that the slope coefficients are identical for 
those who do and do not receive treatment. 
Similar to propensity score 
regression adjustment if all 
the same variables are used; 
doesn‟t include the propensity 
score in regression equation. 
However, results obtained 
should be similar 
2) Propensity 
score  
- Easy to estimate using a probit or logit 
model of treatment selection to obtain 
propensity scores 
- Summarises all background 
characteristics into a single-index 
variable (the propensity score).  
- Balances the covariates in the two 
groups i.e. enough overlap in 
background variables means that the 
groups are comparable and so 
selection bias is removed when 
comparisons are made between groups 
with the same propensity scores.  
- Groups must overlap enough 
before matching, stratification or 
regression adjustment takes 
place   
- Rests on the assumption of 
“strong ignorability” (this means 
that no systematic, unobserved, 
pre-treatment differences exist 
between the two subjects) 
- Used with binary outcomes 
- Probability of treatment is 
correlated with outcome term  
- A single index variable is created 
- To adjust for selection bias, covariates that 
independently affect the chance of being 
treated are identified and either matching, 
stratification or regression adjustment using 
this score will, on average, remove all of the 
bias from the background covariates and in 
turn will obtain less biased treatment effect 
estimates. 
Similar to sample selection 
models first stage when 
calculating treatment 
selection probabilities  
2a) Propensity 
score matching 
Once propensity scores are obtained, 
then subjects can be matched based on 
their propensity score 
Tries to match each treated 
patient to a control patient with a 
similar propensity score 
There are various matching schemes i.e. 
nearest neighbour can be done with or without 
replacement 
Not the same as the 
regression method, because 
propensity score matching 
may not use all patients 
2b) Propensity 
score stratification 
Once propensity scores are obtained, 
strata or groups are formed, so subjects 
in each stratum can be compared 
directly 
Rosenbaum and Rubin (1984) 
suggest that 5 strata (or groups) 
are sufficient to remove 90% of 
the bias. 
- A single-index variable makes it easier to 
compare and create strata 
- Method can be used also for missing data 
imputation 
 
2c) Propensity 
score regression 
adjustment 
Once propensity scores are obtained 
they are added as an independent 
variable in the regression equation 
 It‟s only the inclusion on the propensity score 
variable as an extra independent variable, 
which makes it different to the multivariate 
regression method 
Similar to regression analysis 
if all the same variables are 
used, and results should be 
similar 
3) Sample 
selection models  
In the first stage, a treatment selection 
model is estimated and the estimated 
probabilities are used to construct an 
adjustment factor. In the second stage, 
this factor is included as one of the 
variables in the outcome model.  
- If variables are different in the 
two stages, then these models 
will be more effective in 
controlling for selection bias 
- Need some valid exclusion 
restrictions (i.e. variables that 
predict treatment but not 
outcome) 
 
- The inclusion of adjustment factor in the 
second stage permits a direct test of whether 
selection bias is present and if so, what the 
direction of its impact is 
- The adjustment factor captures the effects of 
unobserved variables on the outcome variable, 
which enables estimation of unbiased 
estimates for the parameters associated with 
the observed variables. 
Similar to propensity score 
methods in calculating the 
treatment selection 
probabilities in the first stage 
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Method What are the main weaknesses? What are the main strengths? Tests to check whether bias 
is reduced  
1) Regression analysis  - Can‟t control for unobserved variables, only controls 
for observed variables 
- Can‟t be sure that the covariates among the two 
groups are balanced (i.e. variables may not overlap 
enough) 
- The regression may not be as robust if variables are 
omitted (omitted variable bias) 
- If there is multicollinearity between independent 
variables, this may increase the standard error of the 
estimates 
- Easy to understand and implement 
- Can use more variables than matching or 
stratification methods 
- Can be used to predict values 
- Estimates a „mean effect‟ for each independent 
variable 
- Doesn‟t require any strong assumptions 
- Has more power than sample selection models 
- RESET test can be conducted 
to check that the model is not 
mis-specified (or suffer from 
omitted variables bias) 
- Hosmer-Lemeshow test can 
be done to check how well the 
model fits the data for logistic 
regressions 
2) Propensity score - Can‟t control for unobserved variables, only controls 
for observed variables.   
- Handling of weak covariates 
- As the covariates are combined it may possibly 
obscure important interactions, as it only estimates the 
overall treatment effect (can‟t see the effect of each 
independent variable on the treatment - such as in a 
regression analysis). 
- May not use all the observations for the analysis 
 
- Easy to implement, are efficient and more robust 
- Doesn‟t assume any functional form e.g. a linear 
relationship between each outcome and covariate 
within each group 
- Can control for observed variables better than some 
methods 
- Requires few assumptions 
- Has lower standard errors than regression models 
- Easy to understand and explain using histograms 
than sample selection models 
No specific tests 
 
2a) Propensity score 
matching 
- Matching on a one-to-many or many-to-one basis 
may reduce sample size 
- Depending on the criteria for matching some subjects 
may not be matched (matching range may be too 
narrow) and can lead to a smaller sample size 
- A smaller sample size, therefore there is less power, 
and the model may not be as robust 
- Makes it easier to match subjects on one variable (a 
score), than matching across various variables 
- Attempts to use all subjects in the matching process 
- Can calculate separate propensity scores for each 
pair of treatments 
No specific tests 
 
2b) Propensity score 
stratification 
Needs a large sample size to create five strata Can calculate separate propensity scores for each pair 
of treatments 
No specific tests 
 
2c) Propensity score 
regression adjustment 
If there is multicollinearity between independent 
variables, this may increase the standard error of the 
estimates. 
Estimates a „mean effect‟ for each independent 
variable 
No specific tests 
 
3) Sample selection 
models  
- Only controls for the unobserved variables in the 
treatment process 
- Problems with multicollinearity if observed variables 
in two stages are the same 
- Requires strong assumptions to estimate the model 
- May not be as robust as propensity scores 
- Controls for both observed and unobserved variables 
in treatment process 
- Doesn‟t assume any functional form e.g. a linear 
relationship between each outcome and covariate 
within each group 
- Sample selection models explicitly address bias 
caused by the regressor with omitted variables, by 
adding a term into the regression 
Adjustment factor which is 
created, can check whether 
selection bias is present 
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5.3 Methods for data analysis 
The previous section concluded that regression analysis, propensity score analysis and 
the Heckman method (sample selection model) were all appropriate methods to reduce 
selection bias.  This section will attempt to apply each of the three methods to the 
dataset which was used in Chapter 2 and to see what impact these methods have on 
the estimation of costs and effects.  The cost variable used in this analysis is the total 
costs of pregnancy and the effect variable used in this analysis is the detection of 
cardiac cases before birth (i.e. true positives), which has been coded 1 for a cardiac 
anomaly and 0 for no anomaly.  The first step was to identify variables such as 
demographic characteristics and risk factors from the dataset to use to „adjust‟ costs 
and effects for selection bias and to hypothesise which of these variables will have an 
influence on outcomes.  In Chapter 2, section 2.4.2 the TelePaed‟ eligibility criteria was 
set out. 
 
1) Binary variables 
 Method of referral to specialist (telemedicine coded 1 and direct referral coded 0): 
 Parity (first or subsequent pregnancy) – primaparous mothers may receive extra 
antenatal care, leading to higher antenatal costs.  They may also have higher 
obstetric costs because they are more likely to have a hospital birth than a home 
birth to minimise the risk of complications arising during delivery and they may also 
spend longer periods on postnatal wards after delivery than multiparous mothers 
[Mistry et al, 2007]; 
 Type of pregnancy – mothers expecting multiple births have higher antenatal and 
obstetric costs than mothers of singletons overall, because of the increased risk of 
both maternal complications and fetal difficulties (such as twin-to-twin transfer 
syndrome) [Mistry et al, 2007];  
 Pre-gestational diabetes - as the disease may precipitate maternal complications, 
[CEMACH, 2005] women with diabetes require extra antenatal care resulting in 
higher antenatal and obstetric costs; 
 Down‟s syndrome risk and/or an elevated serum risk – Down‟s syndrome may also 
bring about further maternal complications [Wald et al, 2003] and if the woman has 
an elevated serum level above the cut-off level they may require extra care resulting 
in higher antenatal and obstetric costs; 
 Epilepsy - this disease may also precipitate maternal complications [Morrow et al, 
2006], so women on anti-epileptic therapy may require additional care resulting in 
higher antenatal and obstetric costs;  
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 Family history of CHD - maternal CHD may also lead to complications, so these 
women may require extra antenatal and obstetric care, leading to higher antenatal 
and obstetric costs [Uebing et al, 2006]; and 
 Previous pregnancy with an anomaly – women who have had previous pregnancy 
with an anomaly may be given extra monitoring (i.e. antenatal care), leading to 
higher antenatal costs. 
 
2) Continuous variables  
 Mother‟s age – as mother‟s age increases, obstetric costs increase since age is a 
confounder with respect to preterm delivery, induction of labour and caesarean 
section [Mistry et al, 2007]; 
 Gestation (in weeks) at time of anomaly scan - if women have an anomaly scan 
before 19 weeks, they may have additional antenatal check-ups before delivery, 
leading to higher antenatal costs; 
 Gestation (in weeks) at birth – if a mother is delivered prematurely because of 
complications, she may require additional obstetric care, which results in higher 
obstetric costs; and   
 Differential distance - defined as the distance in miles from patients‟ home to 
specialist hospital minus the distance in miles from patients‟ home to nearest 
hospital.  This variable shouldn‟t have an impact on health service costs; thus this 
variable is linked to treatment in the sense where does a patient receive specialist 
care?  
 
The demographic characteristics and risk factors for the two groups of women have 
previously been presented in Chapter 2 (see Table 2.3).  All variables were checked for 
normality (i.e. whether they were normally distributed) before being used in the 
analysis.  
 
All variables listed above were included in the analyses conducted in this chapter apart 
from type of pregnancy.  Type of pregnancy was excluded as only one mother was 
expecting a multiple birth and inclusion of this variable in a logistic regression model 
would have removed this patient from the analysis.  This is because there is no 
relationship with the dependent variable as only one mother was expecting a multiple 
birth.  Technically this woman should have been removed from the analysis, however 
as the sample size was small for the direct referral group (n = 24), this woman has 
been included in the analyses. 
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Gestation in weeks at birth as a continuous variable included six patients‟ who had a 
termination of pregnancy (coded 0 for these patients) and including this variable in the 
models will distort the results.  Therefore, to take into account termination of 
pregnancy, this variable was recoded into a categorical variable: 0 = termination, 1 = 
pre-term birth (babies born before 37 weeks of pregnancy) and 2 = full-term birth 
(babies born between 37 and 42 weeks of pregnancy) [Steer, 2005] and has been 
renamed as pregnancy duration.  
 
Four variables were combined, as only a few pregnant women had certain risk factors.  
Including these risk factors in as separate variables in each of the models would mean 
that there is a high chance of these patients who have the disease in question being 
removed from the analysis due to the low variation (i.e. there is no or very little 
relationship with the dependent variable and Stata would remove them from the 
model).  Firstly, the variable whether the mother has an elevated serum risk was 
combined with the variable does the unborn baby have a high risk of Down‟s syndrome 
(the variable has been renamed as Down‟s).  An elevated serum test is a blood test 
which assesses the women‟s risk (low or high) of having a baby born with Down‟s 
syndrome.  Even if a high risk is detected, it is not always certain that the baby will 
have Down‟s syndrome, therefore further tests are needed to confirm the diagnosis 
[Wald et al, 2003].  Secondly, the variable representing a family history of CHD was 
combined with whether the patient had a previous pregnancy with an anomaly (the 
variable has been renamed as family history).  For their previous pregnancy, the 
pregnant woman‟s fetus or baby would have had a chromosomal abnormality.  This 
abnormality could either have been a fetus with Down‟s syndrome or a CHD defect 
which was terminated or they had a child which was born with Down‟s syndrome or a 
CHD defect [Carvalho et al, 2002]. 
 
The comparative analyses between the two groups are presented.  For the regression 
analyses, firstly, as total costs of pregnancy were skewed, a generalised linear 
regression model was conducted; and secondly, as cardiac abnormalities was a binary 
variable a logistic regression was conducted.  All statistical analyses were conducted in 
Stata version 10 [StataCorp, 2007] and a p-value ≤ 0.05 was considered to be 
statistically significant for the comparative analyses. 
 
5.4 Results from methods applied to reduce selection bias in this case study 
5.4.1 Observed results 
During the period May 2001 to July 2002, a total of 76 pregnant women were referred 
for specialist opinion following a routine anomaly scan: 52 (68.4%) were assessed via 
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the telemedicine link, and 24 women saw a specialist in London.  As seen in Chapter 2, 
the overall total costs of pregnancy for the telemedicine group were higher than direct 
referral group, a difference of £539 which was not significant (p = 0.202) and the direct 
referral group were more likely to have had a cardiac abnormality (p = 0.043).   
 
5.4.2 Regression analyses 
Table 5.2 below shows the generalised linear regression model results to examine the 
relationship between costs and referral mode and the logistic regression model results 
to examine the relationship between effects and referral mode, controlling for all other 
variables: age, gestation at time of anomaly scan, pregnancy duration (termination was 
set as the base case, pre-term or full-term birth), parity, diabetes, Down‟s, epilepsy and 
family history, in order to see whether referral mode is a significant predictor of costs 
and/or effects.  Pregnancy duration and diabetes were significant predictors of the total 
costs of pregnancy.  Women assessed by telemedicine had higher costs than direct 
referral women (an extra £84), this is in the same direction as the observed cost 
results, but of a much smaller magnitude and is not significant.  For the cardiac 
anomalies which were detected before birth, the fitted model explained 39% of the 
variation and only pregnancy duration was a significant predictor.  Women who were 
assessed by telemedicine had a lower underlying prevalence rate of cardiac anomalies 
than direct referral women (0.6000), this is in the same direction as the observed effect 
results.  This means that the women assessed by telemedicine were 60.0% less likely 
to have a cardiac anomaly (detected) compared to the direct referral group. 
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Table 5.2: Results from regression analyses taking into account demographic 
characteristics and risk factors 
 Coefficient Standard error z statistic p-value 
Generalised linear model: Total costs of pregnancy 
Referral mode 
Mother‟s age 
Gestation 
Pre-term 
Full-term 
Parity 
Diabetes 
Downs  
Epilepsy 
Family history  
Constant 
83.55 
15.95 
-33.22 
3708.41 
3328.01 
-364.76 
1220.61 
-483.98 
-382.14 
-567.14 
1559.98 
373.10 
26.31 
89.87 
706.46 
656.54 
357.67 
512.50 
609.60 
535.25 
441.24 
2205.68 
0.22 
0.61 
-0.37 
5.25 
5.07 
-1.02 
2.38 
-0.79 
-0.71 
-1.29 
0.71 
0.823 
0.544 
0.712 
< 0.001 
< 0.001 
0.308 
0.017 
0.427 
0.475 
0.199 
0.479 
 Odds ratio Standard error z statistic p-value 
Logistic regression: Cardiac anomalies 
Pseudo R
2
 = 0.393, Likelihood ratio
2
10 26.02, p = 0.004 
Referral mode 
Mother‟s age 
Gestation 
Pre-term 
Full-term 
Parity 
Diabetes 
Downs  
Epilepsy 
Family history  
0.6000 
1.0533 
1.2668 
0.0232 
0.0320 
0.2084 
0.2714 
0.0996 
0.2621 
0.1172 
0.6156 
0.0789 
0.2324 
0.0392 
0.0487 
0.2413 
0.3781 
0.1652 
0.3685 
0.1538 
-0.50 
0.69 
1.29 
-2.23 
-2.26 
-1.35 
-0.94 
-1.39 
-0.95 
-1.63 
0.619 
0.489 
0.197 
0.026 
0.024 
0.176 
0.349 
0.164 
0.341 
0.102 
 
Both regression models were checked to see whether they were well specified.  For the 
generalised linear model, the p value from the link test was not significant (p = 0.743), 
indicating that the model was well specified.  After the logistic regression model, the 
Hosmer-Lemeshow test was conducted to consider the classification power of the 
logistic regression, by regrouping data according to predicted probabilities and then 
creating equal size groups [Hosmer and Lemeshow, 1989].  The Hosmer-Lemeshow 
test was not significant (
2
8
  = 6.68, p = 0.571), indicating a good fit for the logistic 
model.  
 
5.4.3 Propensity score analyses 
Propensity scores were estimated using a logit model, where the dependent variable 
was the method of referral to specialist (telemedicine = 1 and direct referral = 0).  The 
independent variables used to estimate the propensity scores were: age, gestation at 
time of anomaly scan, pregnancy duration, parity, diabetes, Down‟s, epilepsy and 
family history.  The results from the model (see Table 5.3) showed that only gestation 
in weeks at time of the anomaly scan was a significant predictor in the calculation of 
propensity scores (p ≤ 0.05).   
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Table 5.3: Propensity score logistic regression model 
 Odds ratio Standard error z statistic p-value 
Pseudo R
2
 = 0.223, Likelihood ratio
2
9 21.13, p = 0.012 
Mother‟s age 
Gestation 
Pre-term birth 
Full-term birth 
Parity 
Diabetes 
Downs  
Epilepsy 
Family history  
0.9505 
0.5899 
4.2297 
11.5210 
2.2990 
1.0032 
0.1317 
3.6454 
0.5296 
0.0484 
0.1555 
5.4104 
14.6854 
1.5599 
1.0331 
0.1601 
4.8615 
0.4803 
-1.00 
-2.00 
1.13 
1.92 
1.23 
0.00 
-1.67 
0.97 
-0.70 
0.318 
0.045 
0.260 
0.055 
0.220 
0.998 
0.095 
0.332 
0.483 
 
The Hosmer-Lemeshow test was not significant (
2
8
  = 12.92, p = 0.115), indicating a 
good fit for the logistic model.  Figure 5.1 below shows that there was some overlap 
between the estimated propensity scores for both groups.   
 
Figure 5.1: Checking whether the estimated propensity scores overlap 
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Once the propensity scores were obtained, then matching was applied in three different 
ways.  The first two methods of matching were available in Stata version 10: pscore 
and psmatch2, which used various matching methods to obtain estimates of the ATT.  
The ATT estimates the difference in average costs or effects between the two groups.  
For the final method, the estimated propensity scores were matched by „hand‟. 
 
5.4.3.1 ‘pscore’ matching 
The „pscore‟ program identified that five blocks were needed to ensure that the mean 
propensity score is not different for telemedicine and direct referrals and also the 
balancing property was satisfied.  The estimated propensity scores were used to obtain 
estimates of the ATT using various methods.   
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Table 5.4: Average Treatment effect on Treated (ATT) results for the different 
matching methods using ‘pscore’ 
Method of matching Number of matched cases
5
 ATT 95% confidence 
interval using bias 
corrected method 
Telemedicine 
group 
Direct referral 
group 
Total costs of pregnancy 
Nearest neighbour 
(random draw) 
52 14 156.13 -1237.74 to 1097.08 
Nearest neighbour 
(equal weights) 
52 14 156.13 -1604.31 to 1488.18 
Kernel  52 19 295.18 -550.31 to 1227.41 
Stratification 52 19 182.83 -927.44 to 1058.23 
Radius (0.10) 52 19 264.98 -469.00 to 1864.78 
Cardiac anomalies 
Nearest neighbour 
(random draw) 
52 14 -0.212 -0.8250 to 0.1087  
Nearest neighbour 
(equal weights) 
52 14 -0.212 -0.7447 to 0.0536 
Kernel  52 19 -0.202 -0.6303 to 0.0488 
Stratification 52 19 -0.162 -0.5918 to 0.1111 
Radius (0.10) 52 19 -0.173 -0.5272 to 0.0449 
 
In Table 5.4 above, using nearest neighbour matching (either random draw or equal 
weights version) 52 telemedicine patients have been matched to 14 direct referral 
patients.  Both the nearest neighbour matching gave the same ATT results, but the 
95% confidence intervals are different.  For the other three methods, 52 telemedicine 
patients have been matched to 19 direct referral patients.  The ATT suggests that by 
using either of the nearest neighbour matching methods, those patients in the 
telemedicine group had higher costs (£156 higher) compared to patients in the direct 
referral group.  With the other three methods the costs were again higher for the 
telemedicine group, ranging from £183 (stratification matching) to £295 (kernel 
matching).  For all five matching methods, the telemedicine group was less likely to 
have cardiac anomalies than the direct referral group.  For example, with the 
stratification method, telemedicine group was 16.2% less likely to have a cardiac 
anomaly compared to the direct referral group. 
 
5.4.3.2 ‘psmatch2’ matching 
The „psmatch2‟ programme using the nearest neighbour approach directly applies 
matching on a one-to-one basis.  In total, 24 telemedicine patients were matched to all 
24 direct referral patients.  Twenty-eight (36.8%) patients were not matched using this 
method.  The „pmatch2‟ programme also calculates the ATT and results are shown 
below in Table 5.5. 
                                                 
5 The pscore programme identifies the number of matched cases in each group, however, it does not 
provide a list of which telemedicine unit(s) is matched to which direct referral unit(s). 
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Table 5.5: Average Treatment effect on Treated (ATT) results for the different 
matching methods using ‘psmatch2’ 
Method of matching Coefficients ATT 95% confidence 
interval using bias 
corrected method 
Telemedicine 
group 
Direct referral 
group 
Total costs of pregnancy 
Nearest neighbour  3961.76 3824.78 136.99 -717.85 to 917.25 
Kernel  4363.31 4048.41 314.90 -555.69 to 1245.95 
Cardiac anomalies 
Nearest neighbour  0.1250 0.2917 -0.1667 -0.6429 to -0.0500 
Kernel  0.0962 0.3055 -0.2094 -0.6512 to 0.0606 
 
The results from the psmatch2 method found that using the nearest neighbour 
matching, the telemedicine group had higher costs than the direct referral group (£137 
higher), however, these results are based only on the 24 matched cases.  However, 
taking all cases in account, for the kernel matching the telemedicine group still had 
higher costs than the direct referral group (£315 higher), which is very similar to the 
costs from the pscore kernel matching programme (£295).  With both matching 
methods, the telemedicine group was less likely to have cardiac anomalies compared 
to the direct referral group.  Likewise, the psmatch2 ATT value for kernel matching for 
cardiac anomalies was similar to the pscore ATT value for kernel matching. 
 
The psmatch2 programme also provides an indication of whether the propensity score 
method is a good estimator and provides a comparison between the unmatched and 
matched samples.  The propensity score is a good estimator if after matching, the 
mean average standardised bias and Pseudo R26 are lower than before matching.  For 
the nearest neighbour matching the mean average standardised bias has fallen from 
40.94 to 25.73 and the Pseudo R2 has fallen from 0.224 to 0.085, and likewise for the 
kernel matching the mean average standardised bias has fallen from 40.94 to 15.11 
and the Pseudo R2 has fallen from 0.224 to 0.067, implying that propensity score 
matching is a good estimator. 
 
5.4.3.3 Propensity score matching by ‘hand’ 
Using both the „pscore‟ and „psmatch2‟ matching methods, not all patients were 
matched.  So the task of matching telemedicine cases to direct referral cases was 
undertaken (by hand), using the nearest neighbour approach without replacement 
[Dehejia and Wahba, 2002] for the estimated propensity scores.  For this approach, all 
patients are first sorted by their estimated propensity score, and then matching for 
telemedicine patients by searching forward and backward for the direct patient(s) with 
                                                 
6
 R
2
 values range from 0 to 1, which makes sense because it is a proportion and a squared correlation.  
The higher this value this indicates a better fitting model.  However, Pseudo R
2
 cannot be interpreted the 
same as an R
2
 because most Pseudo R
2
 do not range from 0 to 1.  Furthermore, Pseudo R
2
 cannot be 
interpreted independently, it only has meaning when compared with another Pseudo R
2
 in the same 
dataset. 
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the closest score.  Matching patients using this approach was based on a one-to-many, 
or a many-to-one basis [Dowie et al, 2003].  This approach meant that a telemedicine 
patient could be matched to more than one direct patient with a similar propensity 
score or a direct patient could be matched to more than one telemedicine patient.  If no 
exact match was found for a patient (i.e. a propensity score to 5 decimal places), then 
matching was based within 4 decimal places, then within 3 decimal places, then within 
2 decimal places and finally within 1 decimal place, similar to an approach used by 
Gum and colleagues [Gum et al, 2001]. 
 
All 52 telemedicine patients were matched to 24 patients who were seen by direct 
referral.  After weightings were applied, the number of cases in each group was 13.  In 
order to make a direct comparison between the telemedicine case(s) and the direct 
case(s), for example, for the total costs of pregnancy for the patients forming the cases, 
they were adjusted in accordance with their „weights‟.  So if two telemedicine patients 
formed a case, then the cost for each patient was multiplied by the weight (0.5) and 
summed together to obtain a final cost per case.  In terms of effects, the same method 
was applied, but if the number was below 0.5 this was coded as 0 (no cardiac anomaly) 
and if it was equal to or above 0.5 this was coded as 1 (cardiac anomaly).  Results 
from the propensity score matching are shown below in Table 5.6. 
 
Table 5.6: Results from propensity score matching± 
 Telemedicine group  Direct referral group  
Total costs of pregnancy (Bootstrapped) 
Number of cases 
Mean (SD) 
95% CI 
13 
£4,016 (£371) 
£3,290 to £4,743 
13 
£4,072 (£258) 
£3,567 to £4,577 
Confirmation of abnormality 
Number of cases 
Mean 
2 
0.1538 
4 
0.3077 
± 
Statistical tests conducted: paired t tests. 
 
After propensity score matching, the telemedicine group had lower mean costs than the 
direct referral group and the difference in mean costs for the two groups was reduced 
to £56 (observed incremental cost was £539), and again this cost difference was not 
statistically significant (p = 0.907).  The telemedicine group was less likely to have 
cardiac anomalies compared to direct referral group.  The mean difference in 
effectiveness between the two groups was also smaller after propensity score matching 
(-0.1955 to -0.1538) and this difference was not statistically significant (p = 0.370).    
 
Table 5.7 below presents the demographic characteristics and risk factors for the 
pregnant women after applying propensity score matching.  Thus, after applying 
propensity score matching, the variable gestation in weeks at time of anomaly scan 
was no longer statistically significant, indicating that the two groups were „balanced‟.   
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Table 5.7: Demographic characteristics and risk factors after propensity score 
matching± 
 Telemedicine 
group (n = 13) 
Direct referral 
group (n = 13) 
Parity 
Primaparous 
Multiparous 
 
Does the mother have diabetes? 
Yes 
No 
 
Does the unborn baby have a high risk of Down’s syndrome or 
does the mother have an elevated risk serum? 
Yes 
No 
 
Is the mother on any anti-epilepsy drug therapy? 
Yes 
No 
 
Does the mother have a family history of CHD or had a previous 
pregnancy with an anomaly? 
Yes 
No 
 
Maternal age 
Mean (SD) 
Range 
 
Gestation (in weeks) at anomaly scan 
Mean (SD) 
Range 
 
Gestation (in weeks) at birth
#
 
Mean (SD) 
Median 
IQR 
 
6 (46.2%) 
7 (53.8%) 
 
 
2 (15.4%) 
11 (84.6%) 
 
 
 
1 (7.7%) 
12 (92.3%) 
 
 
1 (7.7%) 
12 (92.3%) 
 
 
 
7 (53.8%) 
6 (46.2%) 
 
 
28.2 (6.2) 
17 to 43 
 
 
21 (0.6) 
20 to 22 
 
 
35.8 (5.7) 
38 
34 to 39 
 
6 (46.2%) 
7 (53.8%) 
 
 
3 (23.1%) 
10 (76.9%) 
 
 
 
2 (15.4%) 
11 (84.6%) 
 
 
1 (7.7%) 
12 (92.3%) 
 
 
 
6 (46.2%) 
7 (53.8%) 
 
 
27.6 (5.5) 
20 to 36 
 
 
21 (1.2) 
20 to 25 
 
 
35.3 (7.1) 
38 
36 to 39 
#
Does not include terminations 
± 
Statistical tests conducted: t tests for age and gestation at anomaly scan; chi-squared tests for parity and 
previous pregnancy with anomaly; Kruskal Wallis tests for gestation in weeks at birth; Fisher‟s Exact tests 
for diabetes, Down‟s syndrome risk, and anti-epilepsy drug therapy. 
 
5.4.3.4 Propensity score stratification 
For this part of the analysis five blocks were used for the stratification and the overall 
mean cost and effect results of the five blocks are shown below.   
 
Table 5.8: Results from propensity score stratification± 
 Telemedicine group  Direct referral group  
Total costs of pregnancy (Bootstrapped) 
Number of blocks 
Mean (SD) 
95% CI 
5 
£3,814 (£455) 
£2,922 to £4,705 
5 
£3,696 (£314) 
£3,081 to £4,312 
Confirmation of abnormality 
Mean 0.2000 0.2000 
± 
Statistical tests conducted: paired t tests. 
 
After propensity score stratification (see Table 5.8), the telemedicine group had higher 
mean costs than the direct referral group and the difference in mean costs for the two 
groups after propensity score stratification was reduced from £539 to £118, and this 
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cost difference was not statistically significant (p = 0.855).  For the telemedicine group 
the mean cost was much lower than observed mean cost (a difference of £667).  The 
telemedicine group was as likely to have the same detection rate of cardiac anomalies 
as the direct referral group. 
 
5.4.3.5 Propensity score regression adjustment 
Once the propensity scores were obtained, they were then entered as a covariate into 
a regression equation (see Table 5.9 below).  Pre-term birth and diabetes were 
significant predictors of the total costs of pregnancy.  Women assessed by 
telemedicine had higher costs than direct referral women (an extra £57).  This is similar 
to the results from the generalised linear model (see Table 5.2).  For the cardiac 
anomalies which were detected before birth, the fitted model explained 43% of the 
variation and only pre-term birth was a significant predictor.  For women who were 
assessed by telemedicine there was a decreased likelihood of having a cardiac 
anomaly compared to direct referral (0.6123), this is in line with results from the logistic 
regression model (see Table 5.2).  Furthermore, the pscore value in each model is for 
each individual patient, which was positive and not significant.  
 
Table 5.9: Results from the propensity score regression analyses  
 Coefficient Standard error z statistic p-value 
Generalised linear model: Total costs of pregnancy 
Referral mode 
Mother‟s age 
Gestation 
Pre-term birth 
Full-term birth 
Parity 
Diabetes 
Downs  
Epilepsy 
Family history  
Pscore 
Constant 
56.69 
31.76 
130.78 
3135.70 
2452.50 
-647.54 
1168.89 
234.58 
-720.53 
-412.46 
2080.20 
-2906.35 
376.30 
34.25 
243.59 
1061.65 
1375.97 
530.17 
519.31 
1164.98 
711.73 
491.60 
2870.02 
6547.71 
0.15 
0.93 
0.54 
2.95 
1.78 
-1.22 
2.25 
0.20 
-1.01 
-0.84 
0.72 
-0.44 
0.880 
0.354 
0.591 
0.003 
0.075 
0.222 
0.024 
0.840 
0.311 
0.401 
0.469 
0.657 
 Odds ratio Standard error z statistic p-value 
Logistic regression: Cardiac anomalies 
Pseudo R
2
 = 0.427, Likelihood ratio
2
11
28.32, p = 0.003 
Referral mode 
Mother‟s age 
Gestation 
Pre-term birth 
Full-term birth 
Parity 
Diabetes 
Downs  
Epilepsy 
Family history 
Pscore  
0.6123 
1.2043 
4.7532 
0.0003 
0.0001 
0.0164 
0.1755 
18.1081 
0.0071 
0.5607 
4808925 
0.6338 
0.1672 
5.2460 
0.0013 
0.0002 
0.0412 
0.2618 
78.4508 
0.0241 
1.0055 
0.0001 
-0.47 
1.34 
1.41 
-2.08 
-1.78 
-1.64 
-1.17 
0.67 
-1.45 
-0.32 
1.29 
0.636 
0.181 
0.158 
0.038 
0.075 
0.102 
0.243 
0.504 
0.146 
0.747 
0.197 
 
Including a variable which is a function of all variables may lead to double counting or 
the over-identifying restriction in the model.  If this is the case, then a variable needs to 
be removed.  For both models, the least significant variable in both cases was referral 
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mode (this was not an appropriate variable to remove from the equations), instead the 
next least significant variable was removed from each model.  The incremental costs 
and effects were similar to the model in Table 5.9 i.e. the referral mode coefficient for 
costs was £55 and for the odds ratio for effects was 0.5737.  This means that the 
results in Table 5.9 where all variables were used is okay to use as the model was not 
over-identified. 
 
5.4.4 Results from the Heckman sample selection model 
The variables used in the sample selection model included: referral mode, age, 
gestation at time of anomaly scan, pregnancy duration, parity, diabetes, Down‟s, 
epilepsy, family history and differential distance.  This latter variable was included in 
the analysis as it may have an influence on the referral mode which is chosen (that is 
how quickly a patient would be assessed), but has no impact on costs and effects.  The 
results from the Heckman sample selection model are shown in Table 5.10.  Thus, 
when looking at the correlation between differential distance and method of referral, 
differential distance was very weakly correlated with method of referral (r = 0.066).  So 
for this part of the analysis, differential distance is not likely to be a good identifier 
(variable) for the model; however, there were no other variables in the dataset which 
were potential identifier variables.  The model only computes values for those 52 
patients who were assessed by telemedicine (treated patients).  The model assumes 
that for the 24 direct referral patients, their outcomes are censored. 
 
The first part shows the regression equation i.e. the model predicting total costs of 
pregnancy.  Pregnancy duration was the only significant predictor of costs.  The 
constant value was big (£8,527) and not statistically significant.  The second part 
shows the results of the probit analysis of the selection process i.e. the model 
predicting referral method.  Gestation in weeks at time of the anomaly scan and full-
term birth were the only significant predictors of referral mode.  The final part of the 
output provides the selection bias statistics.  Rho gives an estimate of the correlation 
between the error terms of the first and second equations (rho = -0.2775).  Sigma is the 
standard error of the residuals for the total costs of pregnancy equation and lamba is 
rho*sigma.  Finally, for the model a likelihood ratio test of independent equations is 
conducted and the p value for rho = 0.591.  As the p value is not significant, the model 
indicates there is no evidence of sample selection bias (if the p value was significant, 
there is evidence of sample selection bias).  As there is no evidence of sample 
selection bias, a multivariate regression model should be conducted.   
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Table 5.10: Results from Heckman sample selection model 
 Coefficient Standard error z statistic p-value 
Total costs of pregnancy: Wald
2
9 32.77, p < 0.001 
Mother‟s age 
Gestation 
Pre-term birth 
Full-term birth 
Parity 
Diabetes 
Downs  
Epilepsy 
Family history  
Constant 
30.86 
-347.32 
3407.00 
2921.97 
-809.24 
1139.08 
-1020.61 
-299.56 
-427.06 
8527.03 
37.00 
240.43 
1215.05 
1195.59 
499.52 
708.63 
1058.83 
693.34 
619.57 
5009.23 
0.83 
-1.44 
2.80 
2.44 
-1.62 
1.61 
-0.96 
-0.43 
-0.69 
1.70 
0.404 
0.149 
0.005 
0.015 
0.105 
0.108 
0.335 
0.666 
0.491 
0.089 
Referral mode 
Mother‟s age 
Gestation 
Pre-term birth 
Full-term birth 
Parity 
Diabetes 
Downs  
Epilepsy 
Family history 
Distance  
Constant 
-0.0285 
-0.3290 
0.9343 
1.5266 
0.5220 
-0.0624 
-1.2745 
0.7207 
-0.4361 
0.0012 
6.8326 
0.0286 
0.1574 
0.7677 
0.7462 
0.4133 
0.5604 
0.7057 
0.7497 
0.5328 
0.0225 
4.0612 
-1.00 
-2.09 
1.22 
2.05 
1.26 
-0.11 
-1.81 
0.96 
-0.82 
0.05 
1.68 
0.319 
0.037 
0.224 
0.041 
0.207 
0.911 
0.071 
0.336 
0.413 
0.958 
0.092 
rho 
sigma 
lambda 
-0.2775 
1362.91 
-378.26 
0.3970 
150.92 
561.87 
 
Likelihood ratio test:
2
1
 0.29, p = 0.591 
 
A Heckman probit model was also conducted for the effect variable: cardiac anomaly or 
no cardiac anomaly.  Firstly, the model dropped three variables: Down‟s, epilepsy and 
family history - as these three variables predicted the dependent variable perfectly (i.e. 
there was perfect correlation between the variables, that is, the Heckman model was 
identifying which group the variables go into) and leaving them in the model caused 
numerical instability in the estimation.  So the Heckman probit model was rerun without 
these three variables and results from the model were not able to be estimated.  Thus, 
the Heckman probit sample selection model was really unstable for this cohort and 
therefore results could not be obtained and have not been presented here.  
 
The Heckman model for costs has been presented here for illustration purposes.  
Essentially to conduct this model you need some good variable(s) like an instrumental 
variable (i.e. variables that predict treatment, but not outcome).  However, the dataset 
did not have any other variable(s) which were appropriate and differential distance is a 
rather a poor variable for this type of model. 
 
5.4.5 Comparison of results from the various methods  
Table 5.11 below shows a comparison of the results obtained from the different 
methods and the aim of this Chapter was to find a method which would obtain a 
minimum estimate of difference between the two groups and to reduce the observed 
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selection bias.  The results from the generalised linear model analysis showed that the 
cost difference between the two groups was reduced compared to observed estimates 
(costs: a reduction to £84).  The results also highlighted that only diabetes and 
pregnancy duration were significant predictors of costs and again pregnancy duration 
was a significant predictor of cardiac anomalies which were likely before birth.  These 
results also highlight that after adjusting for regression analyses the differences 
between the two groups was smaller than the observed results.   
 
Using the various propensity score matching methods in order to estimate the ATT, the 
cost differences between the two groups ranged from £156 to £315; whereas the effect 
differences between the two groups ranged from -0.1620 to -0.2120.  These 
differences may be due to the way the matching method works and the number of 
cases they select for matching.  After propensity score matching (by hand), the cost 
differences between the two groups were reduced to £55 and likewise the effect 
difference was reduced to -0.1538, thereby increasing the homogeneity and reducing 
the variance.  Even though both the propensity score matching method (by hand) and 
the regression method used all patients, the cost and effect differences between the 
two methods may be due to the fact that the propensity score model was based on a 
weighting method (and the matching that was used) and the resulting small sample 
meant that there was a lot more uncertainty in the cost and effect results compared to 
the regression method.  The results from the propensity score stratification method 
showed that the cost differences between the two groups was lower than the difference 
between the observed costs and telemedicine was actually cheaper (difference: -£117); 
however, there was no difference in effects between the two groups.  The propensity 
score regression adjustment results highlighted that the cost differences between the 
two groups were slightly smaller than the observed difference (£57).   
 
The Heckman selection model results showed that the mean difference in costs 
between direct referral and telemedicine was £747 (an increase of £208 compared to 
the observed difference) and the effect differences between the two groups could not 
be computed.  All methods except the Heckman selection model applied to this dataset 
reduced the cost and effect differences between the two groups.  This indicated these 
methods may have increased the homogeneity and reduced the variance in the 
adjusted costs and effects; that is, these methods may have reduced the observed 
selection bias between the two groups for this dataset.  
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Table 5.11: Comparison of results from the different methods 
Results  Difference in total costs of 
pregnancy 
Difference in the detection 
of cardiac anomalies 
Observed £539 -0.1955** 
Regression £84 -0.5108** 
PS matching („pscore‟)  
– ATT (difference) 
    
 Nearest neighbour (RD) £156 -0.2120 
 Nearest neighbour (EW) £156 -0.2120 
 Kernel  £295 -0.2020 
 Stratification £183 -0.1620 
 Radius £265 -0.1730 
PS matching („psmatch2‟)  
– ATT (difference) 
    
 Nearest neighbour  £137 -0.1667 
 Kernel £315 -0.2094 
PS matching (by hand) -£55 -0.1538 
PS stratification  -£117 0.0000 
PS regression  £57 -0.4905** 
Heckman model  £747 n/a* 
* A value hasn‟t been included here as it could not be computed; ** These values have been reported as 
coefficients instead of odds ratio 
PS = propensity score; RD = random draw; EW = equal weights 
 
5.5 Discussion 
To obtain unbiased estimates of cost and effect differences, we need large, adequately 
powered RCTs.  However, this is not always possible and non-randomised studies are 
often used.  The women in this dataset were selected for referral to see a specialist 
according to specific criteria, and this may create selection bias.  So in this instance, 
the observed costs and effects which were presented in Chapter 2 are said to be 
biased.  This chapter has provided a quick overview on what selection bias is and the 
methods which can be applied to reduce selection bias.  These methods were then 
applied to the dataset to reduce selection bias in the estimation of costs and effects.  
One point to note is that these methods cannot eliminate selection bias, we can only 
reduce it.   
 
First, a generalised linear model and a logistic regression model was used to see 
whether referral mode is a significant predictor of costs and effects, respectively; 
however, this method in reality only deals with observed covariates.  Second, the 
various propensity score methods (matching, stratification and regression adjustment) 
were used to balance the sizes and compositions of the two referral groups in order to 
reduce the element of bias in the estimation of costs and effects for telemedicine and 
direct referral patients.  This method also only looks at observed variables and not at 
unobserved variables which may also influence costs and/or effects.  Third, the 
Heckman sample selection method was applied to the dataset which attempts to deal 
with both observed and unobserved variables, to see what impact this may have on 
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both costs and/or effects and to see whether selection bias between the two referral 
groups was reduced.   
 
However, the analysis cannot prove which of these methods is more accurate for this 
dataset, only some direction on which method may be the best way forward can be 
provided.  Propensity score matching may be a more reliable way of obtaining cost and 
effect estimates, because after matching the groups were similar in terms of 
background characteristics (i.e. „balanced‟) and the psmatch2 method indicated that 
the mean average standardised bias and Pseudo R2 values had fallen after matching, 
indicating that the matching method was a good estimator.  With regards to the 
regression or the Heckman models, they may not have explicitly balanced the 
covariates among the groups; therefore the two groups may not be similar.  Regression 
models can indicate differences in costs and effects between a dependent variable 
(e.g. referral method) and other covariates and the results from the regression analysis 
indicated that referral method is not a significant predictor of costs and/or effects.  The 
propensity score technique cannot indicate differences between the dependent variable 
and individual covariates, because all covariates are collapsed into a single index 
variable, possibly obscuring important interactions.  An advantage of using propensity 
score matching is that matching does not have to assume linearity (i.e. assume a 
constant relationship between an outcome and the covariate within each treatment 
group), whereas with regression analyses a linear relationship is assumed.  However, 
both regression analyses and propensity score methods only controlled for observed 
variables and both of these methods cannot control for unobserved variables.  The 
Heckman method was not a good model for this dataset, as the dataset did not have 
any good identifier variables; that is, variables that could be used as proxy variables for 
unobserved variables which may have caused selection bias in this dataset.  
 
Deeks et al (2003) considered different methods for evaluating selection bias in non-
randomised studies and none of the methods which were applied (regression, 
stratification and propensity scoring) successfully removed bias in cohort studies.  They 
found that most methods applied to reduce selection bias were not standardised and 
also some covariates are sometimes missing (not at random) which in itself can also 
lead to bias.  They also highlighted that some methods were not relevant or meaningful 
in some contexts and that adequate adjustment for selection bias can only be made in 
an unrealistic situation when selection depends on a single factor that is measured and 
included in the model.  
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In a recent simulation study comparing propensity scores with multivariable regression 
models, the authors concluded that propensity scores performed better in situations 
with less than 8 cases per covariate [Cepeda et al, 2003].  Peduzzi et al (1996) stated 
that usually 10 cases per covariate are considered to be a minimum requirement for 
stable estimates in multivariate regression models.  For the regression models, nine 
variables were included (including the dependent variable), so in total the number of 
cases required for stable estimation should be 90, however, the number of cases in this 
dataset was just under at 76.  Apart from this specific condition there is little, if any 
practical guidance for researchers regarding when the use of propensity scores will 
produce different, and in particular, better estimates compared with conventional 
regression models.  The small sample size may have also created an additional 
problem for the propensity score matching.  Small sample sizes can increase the 
variance of estimated effects, making identification of significant effects difficult.  Also, 
fewer matches may be available, therefore by picking distant matches increases the 
variance. 
 
The fact that several types of propensity score matching techniques exist, then raises 
the question of which is the most appropriate one?  The literature does not offer 
guidelines for making this choice.  In principle, for matching it shouldn‟t matter which 
matching method is used, the answer should be similar.  If the control group is small, 
then matching with replacement is the preferred option, as the average quality of 
matching increases and the bias decreases.  However, if the control group is large, 
then kernel and radius matching work better [Baser, 2006]. 
 
Propensity score methods and Heckman model can be used in the same situations, as 
the ultimate goal for both approaches is the same, to turn an observational comparison 
of two groups into a quasi-randomised experiment.  However, the Heckman model 
claims to allow for unobservable differences (but doesn‟t show how) and was really 
unstable for the effect variable, indicating that this type of model was not suited to this 
type of data.  This may be partly due to the small number of observations (women) and 
also partly due to the identifier variable which had a low correlation with referral mode.  
 
The analysis was confined to patient-related observed variables that were recorded 
routinely in hospital records.  There may be other characteristics which were not 
recorded in the dataset such as social class, education, income, ethnicity or smoking 
which may affect the cost and effect results.  Other unobserved variables which may 
have a possible impact on costs and effects, but have not been included in the data 
collection include: patient‟s preference for referral method, clinician‟s preference for 
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referral method and the quality of care which the patient receives at the specialist or 
local hospital.   
 
One of the main limitations of this analysis is that all the models were conducted on a 
small sample size; however, in practice most of these models are usually conducted on 
bigger sample sizes.  The small sample size of the dataset and the exclusion of 
variables such as health status, ethnicity and clinician‟s choice of referral mode may 
have affected the precision of the costs and effects estimates.  Nevertheless, there is 
some confidence in the adjusted costs and effect estimates, as they reduced the 
difference (incremental) in costs and effects between the two groups.  
 
After adjusting for selection bias, most of the adjusted cost differences were smaller 
than the observed differences between the two groups (except for the Heckman 
method); whereas for effects, these differences were similar to the observed effect 
differences.  This means that reviewing the literature from non-randomised 
telemedicine studies and also from small non-randomised telemedicine studies, where 
both types of studies have not been adjusted for selection bias, the results from these 
studies should be interpreted for caution.  This is because we don‟t know how much 
selection bias was in the dataset and what the direction of the bias is.  As the results 
from this study have shown, the direction (and/or magnitude of association) of 
differences between the two groups can go either way.    
 
There is no set criterion to judge which method is the most appropriate in controlling for 
selection bias in observational studies.  Below are some pointers which may help:   
a)  Three types of variables(s) are required: 1) variables that only affect costs and/or 
effects but not the dependent variable; 2) variables that only affect the dependent 
variable but not costs and/or effects; and 3) variables that affect costs and/or 
effects and the dependent variable. 
b)  Does the method work best for observed or unobserved variables or for both? 
c)  Does the method work best for recorded or unrecorded variables or for both? 
d)  Are the coefficients obtained from each model behaving in the way we would 
expect them to?  That is, the signs indicate the direction of association between the 
variables and the sizes indicate the strength of magnitude for these associations. 
e) Conduct goodness of fit tests and provide summary statistics such as R2.  For 
example, for the logistic regression the Hosmer-Lemeshow test can be conducted.   
f) How does each method reduce selection bias and what tests can be applied to see 
whether selection bias has been controlled for?  The sample selection model, for 
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example, provides an adjustment factor and the p-value for the test to shows how 
much selection bias is still present.   
g) What is the most appropriate sample size for each of the methods?  Cut-off points 
are required to define small, medium and large sample sizes.  This well also help 
determine which is the best sample size for each method to see either an 
economically important or policy relevant difference. 
h) Finally, we need to compare the results obtained from these models with results 
from existing literature and see whether the results seem plausible. 
 
As these results have varied greatly between each of these different methods, this 
means that a researcher cannot simply use the results from one method of correcting 
for selection bias to represent all methods especially for this dataset; rather, an 
argument has to be made concerning which model is best to accept.  Also, due to the 
size and nature of this dataset, the bias adjustment still does not provide a clearer 
picture of how much selection bias remains in the dataset and what the direction is.  
However, I believe that the propensity scoring methods worked better for this dataset, 
because after propensity score matching, the two groups were similar in terms of 
background characteristics and the adjusted cost differences were smaller.  After all, 
there is no method to check after adjustment for the other two methods whether the 
groups were balanced.  
 
This chapter has provided a review of one of the three economic challenges associated 
with telemedicine which was identified from the literature review: selection bias.  The 
analysis in this chapter still cannot conclude which of these methods is the most 
accurate; however, for this dataset the propensity scoring methods seemed the most 
reliable methods in reducing selection bias, although the research would suggest that 
using all these approaches appropriately in order to reduce bias.  The next chapter 
(Chapter 6) will look at the second economic challenge associated with telemedicine: 
patient costs and the following chapter (Chapter 7) will look at the final issue: benefit 
measures such as QALYs.  
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CHAPTER 6: EXTENSION OF THE ECONOMIC EVALUATION OF THE TELEPAED 
PROJECT AND THE CALCULATION OF PATIENT COSTS  
 
6.1 Introduction 
This Chapter will be presented in two parts.  In the first part of this Chapter (section 
6.2), the analysis presented in Chapter 2 will be extended; that is, looking at the costs 
and effects not only of the referred women but also the non-referred women, who were 
seen during the same time period at Medway hospital.  In the second part of this 
Chapter (section 6.3), the second economic issue associated with telemedicine which 
was highlighted in Chapters 3 and 4: patient costs, will be discussed.   
 
One of the main limitations of the dataset presented in Chapter 2, was that it focused 
on a small number of women who were referred to a perinatal cardiologist after a 
routine anomaly scan (n = 76).  As the allocation of women to these two groups was 
based on eligibility criteria (i.e. not random), the issue of selection bias and how to deal 
with selection bias was the main focus of Chapter 5.  Therefore, the aim of this Chapter 
is to look at the whole screening programme within the hospital and to conduct a cost-
effectiveness analysis by comparing a service with telemedicine to a service without 
telemedicine.  This Chapter extends the analysis conducted in Chapter 2 and includes 
all women screened: 1) those women referred to a perinatal cardiologist and 2) those 
„non-referred women‟ who were managed in the DGH who had also undergone an 
anomaly scan at 20-22 weeks gestation at Medway hospital during May 2001 to July 
2002.  Thus, by including all women who had undergone an anomaly scan during this 
period; is the best way to deal with selection bias given the available data, as it does 
not artificially introduce „selection‟.  However, looking at the total population during this 
period, also raises a number of issues which this Chapter will aim to address. 
 
Firstly, only a sample of non-referred women‟s costs and outcomes were observed, so 
costs and outcomes will be extrapolated to all non-referred women who had undergone 
an anomaly scan during the same time period.  Secondly, to conduct a cost-
effectiveness analysis of a service with telemedicine compared to a service without 
telemedicine, what assumptions would have to be made if there was no telemedicine 
service?  If there was no telemedicine service, the women who are in the telemedicine 
group would be reclassified to be either managed in the DGH or be sent directly to 
London for face-to-face assessment; so the key assumptions that need to be made for 
this comparative analysis of both costs and outcomes need to be outlined.  Thirdly, 
what happens to costs and outcomes over time i.e. when the telemedicine service is in 
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a steady state?  Additional data have been collected for this purpose.  Finally, costs 
and outcomes will be combined into a cost-effectiveness analysis. 
 
6.2 Extension of the TelePaed project and additional data for thesis 
As mentioned in Chapters 2 and 4, the RBH in London set up a telecardiology service 
in four DGHs for the provision of specialist advice to clinicians in obstetric and 
paediatric departments [Dowie et al, 2007].  The main fieldwork for the TelePaed 
project was conducted over a 15-month period.  However, only one of the district 
hospitals (Medway Hospital) used the telecardiology service for fetal referrals alongside 
the existing arrangement for referring women directly to London specialist centres.  The 
eligible pregnant women identified for the project (see Chapter 2, section 2.4.2) and the 
resource use and unit costs (see Chapter 2, section 2.5.1) have been discussed 
earlier.   
 
The aim of this section is to see whether a service with telemedicine in addition to 
standard care (direct referral to specialists in London or for care to be provided for in 
DGH) is a cost-effective alternative compared to a service without telemedicine 
(consisting of only standard care); and also to see the change over time.  So for this 
cost-effectiveness analysis, additional data on resources used and effectiveness data 
for pregnant women a few years after implementation of the telemedicine service 
(when the service was in a steady state) were also collected.  This phase covered 
women who had an anomaly scan in 2005/2006.  Permission was obtained from the 
Deputy General Manager for Children‟s and Women‟s Care at Medway hospital, on 
10th October 2007, to obtain this additional dataset.   
 
This additional dataset in an anonymised form included the following information on 
patient demographics: date of birth; parity; number of fetuses; and risk factors such as 
diabetes, whether on lithium or anti-epileptic therapy, Down‟s syndrome risk, elevated 
serum risk, family history of CHD or previous pregnancy with abnormality, or no risk 
factor.  Resources used during antenatal care from time of anomaly scan for each 
pregnant women included: type of antenatal scans and dates, types of antenatal and 
outpatient clinic attendances and dates, dates of specialist consultations either face-to-
face (direct referral to specialist) or by telemedicine, type of termination procedure and 
date (if applicable), counselling for those women who were seen in London, and any 
prenatal inpatient admissions including dates of admission and discharge.  Resources 
used during maternal delivery included: length of inpatient stay prior to transfer to 
labour ward, mode of delivery, delivery place and length of stay in labour/delivery ward 
and length of stay on the postnatal ward (all lengths of stay included admission and 
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discharge dates).  This information was collected and entered onto data extraction 
forms (see Appendix 7: Data Extraction Form) by the project facilitator at Medway 
hospital and then the data were entered onto Microsoft Excel spreadsheets to carry out 
subsequent analyses. 
 
6.2.1 A few years after implementation of telemedicine at Medway hospital  
The time period for this additional data collection and analysis was from 1st May 2005 
to 31st July 2006 (this time period was then comparable to that of the earlier data).  This 
later time period was chosen to see what the effect on costs and outcomes would be 
when the telemedicine service was in a steady state of use.  The average referral 
number during 2005/2006 for women being sent directly to KCH (multi-organ plus 
cardiac anomaly referrals) or to QCH (cardiac anomaly referrals) was approximately 30 
patients, the rest of the women who required a specialist opinion were assessed via 
telemedicine (approx. n = 70) [Personal communication with Sonographer A, October 
2007].  The sonographers also received additional training from staff who were based 
at the Tiny Tickers Charity and also from Specialist A.   
 
In terms of utilising the telemedicine service during this time period, there was a more 
established pattern.  Telemedicine clinics were scheduled monthly, on average they 
lasted 45 minutes to an hour and the average number of patients seen in each clinic 
was between 12 and 15.  So each patient was reviewed for approximately 4 to 5 
minutes.  If a woman was sent to London for referral, they were given an hour slot for 
the specialist scan and counselling. 
 
Specialist A at RBH provided the project facilitator with dates of each patient‟s 
specialist contact (either via telemedicine or direct referral), plus the patient‟s id and 
diagnosis.  This enabled the project facilitator to identify all women who were seen by 
the specialists in London.  A random sample of non-referred women at „medium risk‟ 
and „low risk‟ whose care was provided for in the DGH were identified for this time 
period (see section 6.2.3.1 for categorisation of women into risk groups) by the project 
facilitator using hospital appointment calendars (approximately ten women each 
month). 
 
6.2.2 Effectiveness 
For the economic evaluation there were two measures of effectiveness: 1) detection of 
cardiac abnormalities before birth, and 2) number of cardiac abnormalities which were 
„missed‟ at the anomaly scan (or at other subsequent antenatal scans) and only 
detected at birth. 
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1) Detection of cardiac abnormalities before birth 
The project facilitator noted the findings from the anomaly scan: 1) a normal heart or 2) 
an abnormal heart.  Further diagnosis of the heart was confirmed at either the 
telemedicine consultation or at the face-to-face meeting with the fetal cardiologist in 
London (referred women only).  If a cardiac anomaly was found at one of these time 
points, this gave the women the opportunity to be informatively counselled and to 
decide whether or not to continue with the pregnancy.   
 
2) Number of cardiac abnormalities which were ‘missed’ at the anomaly scan and only 
detected at birth 
The project facilitator noted the findings of the newborn‟s birth outcome.  This included 
whether the birth was a live birth or a still birth; and also the newborn‟s cardiac status: 
1) a normal heart or 2) an abnormal heart.  If the baby was born with a cardiac defect 
and this was not detected prenatally, then this was recorded as a „missed‟ anomaly.  
 
To make sure that the number of all cardiac anomalies detected before birth (even 
those that were terminated) and the number of all missed cardiac anomalies were 
correct, with the help of Specialist A, the Central Cardiac Audit Database Registry 
(CCAD) for the specified time periods in the analysis was checked.  The CCAD is a UK 
clinical audit project involving cardiac surgeons, cardiologists and cardiac 
anaesthetists.  The registry holds patient-specific data on major heart diseases that 
need coronary intervention (surgery or catheterisation) and their outcomes.  
 
6.2.3 Statistical analysis 
6.2.3.1 Comparative analyses 
For the comparative analyses, the women who formed the dataset were categorised 
into three main groups: 
1. Women who had an elevated risk factor for CHD or were suspected of having a 
fetal anomaly and were referred to a specialist via telemedicine (telemedicine 
group); 
2. Women who had an elevated risk factor for CHD or were suspected of having a 
fetal anomaly and were referred directly to see a specialist face-to-face (direct 
referral group); and 
3. Women whose care was managed in the DGH: 
a. Medium risk women who had an elevated risk factor for CHD or Down‟s 
syndrome, but were not considered „urgent‟ to be referred to a perinatal 
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cardiologist and therefore their care was managed in the DGH (medium risk 
women);  
b. Low risk women („normal women‟) included women with a low risk of having a 
baby born with CHD and whose care was managed in the DGH (low risk women). 
 
6.2.3.2 Without a telemedicine service 
To determine what would happen to the costs and effects if the telemedicine service 
was not available, all women assessed via telemedicine were reclassified as either 
women who are „seen by direct referral‟ in London or women whose care is managed 
in the DGH as „medium risk‟ women.  Specialist A confirmed that no women who were 
assessed by telemedicine would come under the category of „low risk‟.  Specialist A 
also confirmed that the following women would be seen directly in London: diabetic 
women; women on epileptic or lithium therapies; women with a previous child requiring 
surgery for CHD or a family history of CHD; women with an increased nuchal 
translucency risk (> 3.5mm); and women with a suspicion of cardiac anomaly.  
Conversely, women with an increased risk of Down‟s syndrome; women with multiple 
pregnancies; and all other women who were seen by telemedicine would be managed 
in the DGH as „medium risk‟ women.  So on the cost side, the cost of a telemedicine 
consultation would be replaced by a specialist consultation cost, if the patient was 
assumed to have been seen directly.  For those patients whose care would now be 
managed in a DGH, the cost of a telemedicine consultation was removed.  On the 
effect side, Specialist A also asserted that all telemedicine women whose fetus had a 
cardiac anomaly would have all been assessed by direct referral, so there would not 
have been any missed cardiac cases if the telemedicine service was not available.  
 
6.2.3.3 Regression analyses for total costs of pregnancy for the observed sample 
population 
The two datasets also obtained demographic, clinical and resource use data for a 
sample of „medium‟ and „low‟ risk women.  This information was used to calculate the 
total costs of pregnancy for these women (see Chapter 2, section 2.5.1 for more 
information).  Using this information and to determine what risk factors were important 
predictors of the total costs of pregnancy, multiple regression models were fitted to 
observed caseloads of women.  Firstly, unadjusted total costs of pregnancy are 
presented (these are the same as the observed costs); and secondly, a multiple 
regression model for the total costs of pregnancy is presented, adjusting for all risk 
factors which included: parity; mother‟s age at anomaly scan; number of fetuses; 
gestation in weeks at time of the anomaly scan; and also whether the woman had one 
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of the following risk factors: diabetes; an elevated serum risk; a high risk of Down‟s 
syndrome; family history of CHD; or a previous pregnancy with an anomaly.   
 
6.2.3.4 Extrapolating sample costs and effects to population costs and effects 
As mentioned in the previous section, for both time periods (2001/2002 and 
2005/2006), due to the time and resource constraints only a sample of medium and low 
risk patients‟ resource use and effectiveness data have been collected (all referred 
women in each time period were identified).  For each of the time periods, the total 
number of births (including still births), maternities, multiple pregnancies and 
terminations were obtained from Medway hospital [Personal communication with 
Medway Hospital administrative assistant, September 2008].  During the 2001/2002 
period, all possible women who were of „medium risk‟ of a fetal CHD anomaly 
(excluding seven women) had been identified in the TelePaed audit.  Sonographer B 
and the project facilitator confirmed that on average, approximately the same number 
of women during each time period would be classed as „medium risk‟ (this included 
women who would have had a multiple pregnancy7 or a CHD or Down‟s syndrome risk 
factor which was not of concern, therefore they could be managed in the DGH).  So the 
proportion of women during this period who were classed as „medium risk‟, this ratio 
was used for the latter time period for the medium risk women.  The remainder of 
women in each time period were then allocated to the low risk group.   
 
The next step was to extrapolate the sample costs to the population costs (i.e. to the 
rest of the women who were managed in the DGH – medium and low risk women for 
whom we had no resource use data for), taking into account the different numbers of 
women in each group.  All women with missed cardiac anomalies in their fetuses and 
all women with cardiac anomalies which were detected before birth had been identified 
in the two samples.  Multiple regression models were fitted to observed caseloads of 
women in each sample (in 2001/2002 and 2005/2006) to predict costs for women with 
missing resource use and cost data.  Total costs of pregnancy were predicted for each 
risk group, in each time period, for patients with „no cardiac anomaly‟.  The costs were 
adjusted for the following risk factors: parity; mother‟s age at anomaly scan; number of 
fetuses; gestation in weeks at time of anomaly scan; diabetes; an elevated serum risk; 
a high risk of Down‟s syndrome; family history of CHD; and a previous pregnancy with 
an anomaly.  The mean costs were obtained for each group (in each time period) and 
were then allocated to the rest of the women in each group (in each time period) who 
did not have a cost.  
                                                 
7
 Multiple pregnancy was a factor for the TelePaed eligibility criteria, but not for the Medway eligibility 
protocol. 
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6.2.3.5 Comparison of cost scenarios  
The time horizon for each study period was from the time of the anomaly scan (i.e. 20-
22 weeks gestation) until just after delivery or where applicable after termination of 
pregnancy.  To keep costs for all different time periods in the same financial year, cost 
results are presented in 2005/2006 prices.  Given the one-year short time frame, costs 
(and effects) were not discounted.  
 
So to summarise, costs and effects were calculated for four main time periods: 
1) 2001/2002 period – observed costs and effects with a telemedicine service; 
2) 2001/2002 period – costs and effects adjusted for a service without telemedicine; 
3) 2005/2006 period – observed costs and effects with a telemedicine service; and  
4) 2005/2006 period – costs and effects adjusted for a service without telemedicine. 
 
The cost analysis compares a service with telemedicine to a service without 
telemedicine: 
a) 1 vs. 2 
b) 3 vs. 4 
 
As there was no difference in the number of missed cases for each time period8, a 
cost-effectiveness analysis was not appropriate and results for a cost-consequences 
analysis study are presented. 
 
6.2.3.6 Statistical tests 
Statistical analyses were conducted using Stata version 10 [StataCorp, 2007].  If 
distributions were normal: means, SD and ranges are presented and chi-squared, t 
tests and F tests conducted.  If distributions are not normal: means, SDs, medians and 
IQRs are presented and Kruskal Wallis tests (if more than 2 groups) or Wilcoxon sign-
rank tests (if two groups) are conducted.  All statistical tests were two-sided unless 
otherwise stated.  A p-value ≤ 0.05 was considered to be statistically significant.  As 
cost data were skewed, bootstrapping was used (see Chapter 2, section 2.5.3 for 
further information).  
 
                                                 
8
 There was no difference in effectiveness when comparing 2001/2002 with and without a telemedicine 
service and when comparing 2005/2006 with and without a telemedicine service; however, we must note 
that there is a major difference in effectiveness „over time‟ and this will be discussed later in the Chapter.  
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6.2.4 Results 
6.2.4.1 Patient numbers for the sample and total populations 
The total number of births recorded for the two 15-month time periods: 2001/2002 and 
2005/2006 were 5,211 and 5,492 respectively (see Table 6.1).  These figures also take 
into account women who gave birth to more than one baby.   
 
Table 6.1: Total number of births, maternities and type of pregnancy  
 1/5/2001 to 31/7/2002 1/5/2005 to 31/7/2006 
Total number of births 5,211 5,492 
Total number of maternities 5,114 5,407 
Type of pregnancy 
Single 
Twin  
Triplet 
 
5,018 
95 
1 
 
5,323 
83 
1 
 
During the two time periods, the total number of women (total population) seen by a 
specialist face-to-face in London, or via telemedicine, or managed in the DGH - 
medium and low risk are shown in Table 6.2 below.  
 
Table 6.2: Total number of maternities, cardiac cases detected and number of 
missed cardiac anomalies for each group in each time period 
 1/5/2001 to 31/7/2002 1/5/2005 to 31/7/2006 
 
 
Total 
N 
Cardiac 
cases 
detected* 
Missed 
cardiac 
anomalies 
Sample 
N 
Total N Cardiac 
cases 
detected 
Missed 
cardiac 
anomalies 
Sample 
N 
TM 52 
24 
252 
4,786 
7 0 52 72 
29 
321 
9 0 72 
DR 8 0 24 15 0 29 
MR 7 2 245 0 0 90 
LR 3 5 87 4,985 0 1 147 
Total 5,114 25 7 408 5,407 24 1 338 
Referred women: TM = telemedicine; DR = Direct referral;  
Non-referred women: MR = medium risk; LR = Low risk; 
* 3 Cases (1 in DR and 2 in TM) were really insignificant cardiac anomalies which had corrected 
themselves before the baby was born 
Sources: 2001/2002 data from TelePaed dataset; 2005/2006 data from Sonographers A and B. 
 
The number of women in the two samples for whom data were available are also 
shown in Table 6.2.  The number for the sample of medium risk women in each of the 
two time periods was different, because for the earlier time period the project facilitator 
collected this data prospectively, so that (nearly) all the medium risk women during this 
time period were identified; whereas for the latter time period, the project facilitator 
picked women randomly from hospital calendars and they could either belong to the 
medium or low risk group, hence not all medium risk women were identified during this 
extra data collection and also Medway eligibility criteria did not include women with 
multiple pregnancies.  Figure 6.1 below shows the process and numbers of pregnant 
women in both the sample and total populations for the two time periods. 
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Figure 6.1: Process diagram showing from sample to total population 
2001/2002 data 
 
Pregnant women 
at anomaly scan 
 
 
 
    Referred                   Non-referred  
women                       women 
    (see specialist)          (managed in DGH) 
 
 
                            TM        DR                     MR          LR 
Sample             (n=52)   (n=24)               (n=245)   (n =87) 
 
 
 
Extrapolation 
 
 
 
Total                 (n=52)   (n=24)               (n=252)   (n =4,786) 
 
2005/2006 data 
 
Pregnant women 
at anomaly scan 
 
 
 
    Referred                   Non-referred  
women                       women 
    (see specialist)          (managed in DGH) 
 
 
                            TM        DR                     MR          LR 
Sample             (n=72)   (n=29)               (n=90)   (n =147) 
 
 
 
Extrapolation 
 
 
 
Total                 (n=72)   (n=29)               (n=321)   (n =4,985) 
 
Key: TM = telemedicine; DR = Direct referral; MR = medium risk; LR = Low risk; 
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Table 6.3: Referred women according to risk status of pregnancy 
 2001/2002 2005/2006 
Telemedicine 
n = 52 
Direct referral 
n = 24 
Telemedicine 
n = 72 
Direct referral 
n = 29 
Risk status of pregnancy 
Down‟s/cardiac risk 46 (88.5%) 18 (75.0%) 63 (87.5%) 21 (72.4%) 
Low risk 6 (11.5%) 6 (25.0%) 9 (12.5%) 8 (27.6%) 
Cardiac anomalies detected by risk status 
Total number of cardiac 
anomalies detected 
7 (13.5%) 8 (33.3%) 15 (20.8%) 9 (31.0%) 
Down‟s/cardiac risk 3 (42.8%) 4 (50.0%) 7 (46.7%) 5 (55.6%) 
Low risk 4 (57.1%)  4 (50.0%) 8 (53.3%) 4 (44.4%) 
 
Table 6.3 shows that according to risk status of pregnancy the overall number of 
detected cases for the referred women in the two 15-month periods.  The table clearly 
highlights the relatively large detection of abnormalities amongst the women who were 
classed as „low risk‟ (i.e. these women had no risk factors for a fetal anomaly, and only 
when the anomaly scan was conducted an anomaly was found; hence these women 
were then referred to a perinatal cardiologist).  When looking at the numbers detected 
and missed for the women who are of „low risk‟ (see Tables 6.2 and 6.3), these 
numbers are: 2001/2002 – 8 detected and 5 missed (13 in total) and 2005/2006 – 12 
detected and 1 missed (13 in total).  This emphasises the importance of screening for 
CHD in low risk women (Chapter 7 will discuss this further).  
 
6.2.4.2 Patient demographics for a sample population 
Tables 6.4a to 6.4b show the demographic characteristics for the observed samples of 
pregnant women.  For 2001/2002 period, the mean age for women in each group was 
similar and not statistically different (p = 0.142); there were no significant differences 
between the groups in terms of parity (p = 0.470); a third of patients in the medium risk 
group had a multiple pregnancy; for all groups, over half of the women had their 
anomaly scan at 21 weeks; and 50% of women gave birth between 38 to 40 weeks 
gestation.  For the 2005/2006 time period, there were significant differences in the 
mean age of women (p < 0.001), the women of medium risk who were cared for in the 
DGH were slightly older than the other three groups of women; there were no 
significant differences in terms of parity in each group (p = 0.139); nearly all women in 
this sample were expecting one baby; over half of the women (except the direct referral 
group) had their anomaly scan at 21 weeks; and similar to the earlier time period, 50% 
of women gave birth between 38 to 40 weeks gestation. 
 
When looking at demographic characteristics across the two time periods, the mean 
age for all women was 29 years and there were no statistically significant differences in 
maternal age (p = 0.358); there were significant differences in parity (p < 0.001), in the 
2001/2002 period there where more multiparous women compared to the other time 
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period where the ratio between primaparous and multiparous was approximately 50-50; 
there were also significant differences in terms of the type of pregnancy (single versus 
multiple births) as there where more multiple pregnancies in 2001/2002 data collection 
(p < 0.001 – Medway criteria did not include multiple pregnancies); there were no 
significant differences in the mean number of weeks gestation when the anomaly scan 
was conducted (p = 0.124); and there were no significant differences in the mean 
number of weeks gestation at birth (p = 0.132). 
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  Table 6.4a: Demographic characteristics of pregnant women for 2001/2002 period 
2001/2002 period TM group (n = 52) DR group (n = 24) MR women (n = 245) LR women (n = 87) All women  (n = 408) 
Maternal age 
N 
Mean (SD) 
Range 
 
Parity 
N 
Primaparous 
Multiparous 
 
Type of pregnancy* 
N 
Singleton 
Multiple 
 
Gestation at anomaly scan* 
N 
Mean (SD) 
Range 
≤ 19 weeks 
20 weeks 
21 weeks 
22 weeks 
≥ 23 weeks 
 
Gestation at birth* 
N 
Mean (SD) 
Median 
IQR 
≤ 30 weeks 
31-35 weeks 
36-37 weeks 
38-39 weeks 
40 weeks 
≥ 41 weeks 
 
52 
27.7 (6.1) 
16 to 43 
 
 
52 
19 (36.5%) 
33 (63.5%) 
 
 
52 
52 (100.0%) 
0 (0.0%) 
 
 
52 
20.8 (0.9) 
18 to 23 
4 (7.7%) 
12 (23.1%) 
28 (53.8%) 
7 (13.5%) 
1 (1.9%) 
 
 
50 
38.1 (2.8) 
39 
37 to 40 
2 (4.0%) 
5 (10.0%) 
6 (12.0%) 
16 (32.0%) 
16 (32.0%) 
5 (10.0%) 
 
24 
28.6 (6.8) 
19 to 43 
 
 
24 
12 (50.0%) 
12 (50.0%) 
 
 
24 
23 (95.8%) 
1 (4.2%) 
 
 
24 
21.8 (3.0) 
19 to 33 
1 (4.2%) 
4 (16.7%) 
12 (50.0%) 
5 (20.8%) 
2 (8.3%) 
 
 
20 
37.6 (2.2) 
38 
36 to 39 
0 (0.0%) 
3 (15.0%) 
6 (30.0%) 
7 (35.0%) 
2 (10.0%) 
2 (10.0%) 
 
245 
29.6 (5.6) 
16 to 43 
 
 
245 
93 (38.0%) 
152 (62.0%) 
 
 
245 
157 (64.1%) 
88 (35.9%) 
 
 
245 
21.0 (1.2) 
17 to 32 
11 (4.5%) 
49 (20.0%) 
141 (57.6%) 
37 (15.1%) 
7 (2.9%) 
 
 
240 
37.7 (3.1) 
38  
36 to 40 
5 (2.1%) 
38 (15.8%) 
53 (22.1%) 
61 (25.4%) 
42 (17.5%) 
41 (17.1%)  
 
87 
29.4 (5.3) 
16 to 42 
 
 
87 
39 (44.8%) 
48 (55.2%) 
 
 
87 
87 (100.0%) 
0 (0.0%) 
 
 
87 
20.9 (0.7) 
19 to 24 
1 (1.1%) 
18 (20.7%) 
58 (66.7%) 
7 (8.0%) 
3 (3.4%) 
 
 
87 
39.2 (1.8) 
39 
39 to 40 
1 (1.1%) 
2 (2.3%) 
7 (8.0%) 
35 (40.2%) 
24 (27.6%) 
18 (20.7%) 
 
408 
29.3 (5.7) 
16 to 43 
 
 
408 
163 (40.0%) 
245 (60.0%) 
 
 
408 
319 (78.2%) 
89 (21.8%) 
 
 
408 
21.0 (1.3) 
17 to 33 
17 (4.2%) 
83 (20.3%) 
239 (58.6%) 
56 (13.7%) 
13 (3.2%) 
 
 
397 
38.1 (2.9) 
39 
37 to 40 
8 (2.0%) 
48 (12.1%) 
72 (18.1%) 
119 (30.0%) 
84 (21.2%) 
66 (16.6%)  
± 
Statistical tests conducted: t tests or F tests for age, gestation at anomaly scan and birth; chi-squared tests for parity and type of pregnancy. 
* p < 0.05 
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Table 6.4b: Demographic characteristics of pregnant women for 2005/2006 period 
2005/2006 period TM group (n = 72) DR group (n = 29) MR women (n = 90) LR women (n = 147) All women (n = 338) 
Maternal age* 
N 
Mean (SD) 
Range 
 
Parity 
N 
Primaparous 
Multiparous 
 
Type of pregnancy* 
N 
Singleton 
Multiple 
 
Gestation at anomaly scan* 
N 
Mean (SD) 
Range 
≤ 19 weeks 
20 weeks 
21 weeks 
22 weeks 
≥ 23 weeks 
 
Gestation at birth* 
N 
Mean (SD) 
Median 
IQR 
≤ 30 weeks 
31-35 weeks 
36-37 weeks 
38-39 weeks 
40 weeks 
≥ 41 weeks 
 
72 
28.6 (6.1) 
17 to 43 
 
 
72 
33 (45.8%) 
39 (54.2%) 
 
 
72 
70 (97.2%) 
2 (2.8%) 
 
 
72 
21.3 (1.7) 
20 to 33 
0 (0.0%) 
13 (18.1%) 
41 (56.9%) 
12 (16.7%) 
6 (8.3%) 
 
 
72 
37.8 (2.8) 
38 
37 to 40 
1 (1.4%) 
10 (13.9%) 
10 (13.9%) 
30 (41.7%) 
12 (16.7%) 
9 (12.5%) 
 
29 
27.8 (6.4) 
17 to 42 
 
 
29 
19 (65.5%) 
10 (35.5%) 
 
 
29 
29 (100.0%) 
0 (0.0%) 
 
 
29 
20.1 (2.0) 
17 to 25 
12 (41.4%) 
2 (6.9%) 
10 (34.4%) 
3 (10.3%) 
2 (6.9%) 
 
 
27 
38 (3.1) 
38 
37 to 40 
1 (3.7%) 
1 (3.7%) 
5 (18.5%) 
12 (44.4%) 
3 (11.1%) 
5 (18.5%) 
 
90 
33.8 (6.4) 
18 to 44 
 
 
90 
54 (60.0%) 
36 (40.0%) 
 
 
90 
81 (90.0%) 
9 (10.0%) 
 
 
90 
21.2 (0.9) 
19 to 24 
1 (1.1%) 
13 (14.4%) 
50 (55.6%) 
19 (21.1%) 
7 (7.8%) 
 
 
86 
38.1 (3.8) 
40 
37 to 40 
6 (7.0%) 
7 (8.1%) 
10 (11.6%) 
20 (23.3%) 
24 (27.9%) 
19 (22.1%) 
 
153 
28.1 (6.0) 
17 to 42 
 
 
147 
74 (50.3%) 
73 (49.7%) 
 
 
147 
147 (100.0%) 
0 (0.0%) 
 
 
147 
21.1 (0.8) 
19 to 26 
2 (1.4%) 
16 (10.9%) 
97 (66.0%) 
27 (18.4%) 
5 (3.4%) 
 
 
147 
38.9 (2.2) 
39 
38 to 40 
1 (0.7%) 
6 (4.1%) 
14 (9.5%) 
58 (39.5%) 
42 (28.6%) 
26 (17.7%) 
 
338 
29.7 (6.6) 
17 to 44 
 
 
338 
180 (53.3%) 
158 (46.7%) 
 
 
338 
327 (96.7%) 
11 (3.3%) 
 
 
338 
21.1 (1.2) 
17 to 33 
15 (4.4%) 
44 (13.0%) 
198 (58.6%) 
61 (18.0%) 
20 (5.9%) 
 
 
332 
38.4 (2.9) 
39 
38 to 40 
9 (2.7%) 
24 (7.2%) 
39 (11.7%) 
120 (36.1%) 
81 (24.4%) 
59 (17.8%) 
± 
Statistical tests conducted: t tests or F tests for age, gestation at anomaly scan and birth; chi-squared tests for parity and type of pregnancy. 
* p < 0.05 
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6.2.4.3 Effectiveness results for the total population  
Table 6.2 also showed the total number of cardiac anomaly cases detected before birth 
for each of the two time periods.  These numbers include pregnant women who went 
on to have a termination.  In total, the number of cardiac anomaly cases detected 
before birth for the two time periods (2001/2002 and 2005/2006) were 25 (0.5%) and 
24 (0.4%) cases, respectively. 
 
The table also showed the total number of „missed‟ cardiac anomalies not detected 
prenatally.  None of the „missed‟ cases were from women in either the direct referral or 
telemedicine groups.  The 2001/2002 time period indicated that there were a total of 
seven missed cardiac anomalies, whereas during the 2005/2006 period there was only 
one missed cardiac anomaly.  During the earlier time periods, temporary staff were 
called in to scan pregnant women when there was a staff shortage or staff were on sick 
leave.  These temporary staff members who had varied training and experience, may 
have led to an increase in the number of missed cases [Personal communication with 
Sonographer A and Sonographer B, October 2007].  The lower number of missed 
anomalies in the 2005/2006 period could also reflect the fact that staff were more 
confident and were better trained in detecting fetal heart anomalies.  This is better 
reflected in Table 6.5, which shows that over time the detection rate at the anomaly 
ultrasound scan has improved and the number of „missed‟ cardiac cases has fallen.  
 
Table 6.5: Number of ‘missed’ cardiac anomalies based on year when anomaly 
scan was undertaken (data obtained from Medway hospital and Central Cardiac 
Audit Database) 
Year Total number of births Total missed cases Rates of missed cases 
per 1,000 births 
2000 
2001 
2002 
2003 
2004 
2005 
2006 
2007 
4,035 
4,092 
4,184 
4,216 
4,265 
4,260 
4,449 
4,623 
7 
7 
3 
3 
1 
2 
0 
1 
1.73 
1.71 
0.72 
0.71 
0.23 
0.47 
0.00 
0.22 
 
6.2.4.4 Resource use analysis and hospital utilisation patterns for a sample 
population 
Tables 6.6a to 6.6b show the frequency of resources used by a sample of women in 
each group in each time period.  One point to note for Table 6.6a (2001/2002 period) 
for the following items of resource use: prenatal maternity bed day (prior to transfer to 
labour); mode of obstetric delivery; and postnatal bed day includes missing values 
which have been imputed.  Of the 60 women who had missing values imputed, 1 
patient was in the direct referral group; 11 women were in the telemedicine group; 27 
 159 
women were in the medium risk group; and 21 women were in the low risk group (see 
Chapter 2, section 2.5.1.1 for more details). 
 
For the sample data on average, for the women in the 2001/2002 period (Table 6.6a) 
compared to the women in the 2005/2006 period (Table 6.6b), they had slightly more 
antenatal scans (2.9 vs. 2.4 scans); more antenatal clinic visits (9.9 vs. 7.5 visits); and 
had more caesarean births (41.6% vs. 26.5% - due to the higher proportion of multiple 
pregnancies) which contributed to the higher mean total costs of pregnancy in the 
earlier time period.  This is highlighted in Table 6.6c which shows the proportions of the 
total costs of pregnancy (i.e. the direct costs to the hospital) attributable to each 
component for each of the two time periods.  The biggest cost driver during antenatal 
care was antenatal/outpatient clinic attendances and during maternal delivery, the 
biggest cost driver was the mode of delivery.  Over 60% of the costs for each period 
were made up of the following components: labour/delivery bed stay, mode of delivery 
and postnatal bed stay. 
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Table 6.6a: Resource components and the number of women who used the resource items for 2001/2002 period 
20001/2002 period  TM group (n = 52) DR group (n = 24) MR women (n = 245) LR women (n = 87) All women  (n = 408) 
Resource use at district hospital 
1. Antenatal ultrasound scans 
Mean number of scans per patient (SD) 
Median (Inter-quartile range) 
 
2. Antenatal or outpatient clinics 
Mean number of clinics per patient (SD) 
Range 
 
3. Termination of pregnancy 
 
4. Prenatal maternity bed day 
a) During antenatal period 
Mean number of days per patient (SD) 
Median (Inter-quartile range) 
 
b) Prior to transfer to labour ward 
Mean number of days per patient (SD) 
Median (Inter-quartile range) 
 
5) Mode of obstetric delivery* 
Normal birth 
Forceps birth 
Ventouse birth 
Caesarean birth (without complications) 
Home birth 
 
6) Postnatal maternity bed day 
Mean number of days per patient (SD) 
Median (Inter-quartile range) 
 
Resource use at specialist hospital 
1. Specialist ultrasound scans 
Mean number of scans per patient (SD) 
Median (Inter-quartile range)  
2. Counselling 
 
52 (100%) 
2.8 (1.5) 
3 (2 to 4) 
 
50 (96.2%) 
11.4 (6.7) 
1 to 35 
 
2 (3.9%) 
 
 
19 (36.5%) 
3.3 (2.5) 
2.0 (1.0 to 5.0) 
 
17 (34.0%) 
0.9 (0.8) 
0.4 (0.3 to 1.0) 
 
 
32 (64.0%) 
0 (0.0%) 
1 (2.0%) 
16 (32.0%) 
1 (2.0%) 
 
39 (78.0%) 
4.5 (3.9) 
4.0 (2.0 to 5.4) 
 
 
6 (11.5%) 
1.2 (0.4) 
1 (1 to 1) 
5 (9.6%) 
 
24 (100.0%) 
2.8 (1.3) 
2 (2 to 4) 
 
20 (83.3%) 
10.5 (5.6) 
1 to 24 
 
4 (16.7%) 
 
 
4 (16.7%) 
2.5 (1.3) 
2.5 (1.5 to 3.5) 
 
4 (16.7%) 
2.4 (1.9) 
2.5 (0.8 to 4.0) 
 
 
11 (55.0%) 
0 (0.0%) 
1 (5.0%) 
8 (40.0%) 
0 (0.0%) 
 
18 (90.0%) 
3.9 (2.5) 
3.0 (2.0 to 6.0) 
 
 
24 (100.0%) 
1.1 (0.3) 
1 (1 to 1) 
9 (37.5%) 
 
245 (100.0%) 
3.2 (1.8) 
3 (2 to 4) 
 
240 (98.0%) 
10.1 (4.5) 
1 to 26 
 
5 (2.0%) 
 
 
80 (32.7%) 
4.1 (5.3) 
2.0 (1.0 to 4.0) 
 
62 (25.8%) 
3.6 (6.8) 
1.6 (0.6 to 3.0) 
 
 
94 (39.2%) 
11 (4.6%) 
11 (4.6%) 
117 (48.8%) 
6 (2.5%) 
 
214 (89.2%) 
3.8 (2.6) 
3.0 (2.0 to 4.7) 
 
 
0 (0.0%) 
n/a 
 
0 (0.0%) 
 
87 (100.0%) 
2.2 (1.3) 
2 (1 to 3) 
 
87 (100.0%) 
8.3 (4.2) 
1 to 24 
 
0 (0.0%) 
 
 
33 (37.9%) 
2.3 (2.1) 
2.0 (1.0 to 2.0) 
 
27 (31.0%) 
0.7 (0.9) 
0.4 (0.2 to 0.5) 
 
 
54 (62.1%) 
2 (2.3%) 
2 (2.3%) 
24 (27.6%) 
5 (5.7%) 
 
73 (83.9%) 
2.7 (1.8) 
2.5 (1.6 to 3.2) 
 
 
0 (0.0%) 
n/a 
 
0 (0.0%) 
 
408 (100.0%) 
2.9 (1.7) 
2 (2 to 4) 
 
397 (97.3%) 
9.9 (4.9) 
1 to 35 
 
11 (2.7%) 
 
 
136 (33.3%) 
3.5 (4.3) 
2.0 (1.0 to 4.0) 
 
110 (27.7%) 
2.4 (5.3) 
1.0 (0.4 to 3.0) 
 
 
191 (48.1%) 
13 (3.3%) 
15 (3.8%) 
165 (41.6%) 
12 (3.0%) 
 
344 (86.6%) 
3.7 (2.7) 
3.0 (2.0 to 4.0) 
 
 
30 (7.4%) 
1.1 (0.3) 
1 (1 to 1) 
14 (3.4%) 
* One woman in medium risk group had a water birth 
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Table 6.6b: Resource components and the number of women who used the resource items for 2005/2006 period 
2005/2006 period  TM group (n = 72) DR group (n = 29) MR women (n = 90) LR women (n = 147) All women (n = 338) 
Resource use at district hospital 
1. Antenatal ultrasound scans 
Mean number of scans per patient (SD) 
Median (Inter-quartile range) 
 
2. Antenatal or outpatient clinics 
Mean number of clinics per patient (SD) 
Range 
 
3. Termination of pregnancy 
 
4. Prenatal maternity bed day 
a) During antenatal period 
Mean number of days per patient (SD) 
Median (Inter-quartile range) 
 
b) Prior to transfer to labour ward 
Mean number of days per patient (SD) 
Median (Inter-quartile range) 
 
5) Mode of obstetric delivery* 
Normal birth 
Forceps birth 
Ventouse birth 
Caesarean birth (without complications) 
Home birth 
 
6) Postnatal maternity bed day 
Mean number of days per patient (SD) 
Median (Inter-quartile range) 
 
Resource use at specialist hospital 
1. Specialist ultrasound scans 
Mean number of scans per patient (SD) 
Median (Inter-quartile range) 
2. Counselling 
 
72 (100.0%) 
2.9 (1.7) 
3.0 (2.0 to 4.0) 
 
72 (100.0%) 
7.3 (3.3) 
1 to 20 
 
0 (0.0%) 
 
 
42 (58.3%) 
3.3 (3.8) 
2.0 (1.0 to 4.0) 
 
4 (5.6%) 
1.3 (0.9) 
1.5 (0.6 to 2.0) 
 
 
37 (51.4%) 
4 (5.6%) 
5 (6.9%) 
24 (33.3%) 
2 (2.8%) 
 
61 (84.7%) 
3.0 (2.2) 
2.8 (1.0 to 4.0) 
 
 
9 (12.5%) 
1.1 (0.3) 
1.0 (1.0 to 1.0) 
5 (6.9%) 
 
29 (100.0%) 
2.0 (1.3) 
2.0 (1.0 to 2.0) 
 
27 (93.1%) 
7.3 (2.4) 
1 to 17 
 
2 (6.9%) 
 
 
16 (55.2%) 
2.0 (1.5) 
1.0 (1.0 to 2.5) 
 
0 (0.0%) 
n/a 
 
 
 
17 (63.0%) 
0 (0.0%) 
1 (3.7%) 
8 (29.6%) 
1 (3.7%) 
 
25 (92.6%) 
2.9 (2.6) 
2.0 (1.0 to 4.0) 
 
 
29 (100.0%) 
1.4 (1.5) 
1.0 (1.0 to 1.0) 
13 (44.8%) 
 
90 (100.0%) 
2.7 (1.9) 
2.0 (1.0 to 3.0) 
 
86 (95.6%) 
9.6 (2.2) 
2 to 15 
 
4 (4.4%) 
 
 
21 (23.3%) 
3.2 (3.5) 
2.0 (1.0 to 3.0) 
 
6 (6.9%) 
1.5 (0.5) 
1.5 (1.0 to 2.0) 
 
 
43 (50.0%) 
5 (5.8%) 
6 (7.0%) 
28 (32.6%) 
4 (4.7%) 
 
73 (84.9%) 
2.9 (4.2) 
2.0 (1.0 to 4.0) 
 
 
0 (0.0%) 
n/a 
 
0 (0.0%) 
 
147 (100.0%) 
2.1 (1.5) 
2.0 (1.0 to 3.0) 
 
147 (100.0%) 
6.5 (1.8) 
1 to 20 
 
0 (0.0%) 
 
 
61 (41.5%) 
2.5 (1.7) 
2.0 (1.0 to 3.0) 
 
5 (3.4%) 
1.0 (0.0) 
1.0 (1.0 to 1.0) 
 
 
96 (65.3%) 
5 (3.4%) 
8 (5.4%) 
28 (19.0%) 
10 (6.8%) 
 
115 (78.2%) 
2.3 (2.1) 
2.0 (1.0 to 3.0) 
 
 
0 (0.0%) 
n/a 
 
0 (0.0%) 
 
338 (100.0%) 
2.4 (1.7) 
2.0 (1.0 to 3.0) 
 
332 (98.2%) 
7.5 (2.6) 
1 to 20 
 
6 (1.8%) 
 
 
140 (41.4%) 
2.8 (2.8) 
2.0 (1.0 to 3.0) 
 
15 (4.5%) 
1.3 (0.6) 
1.0 (1.0 to 2.0) 
 
 
193 (58.1%) 
14 (4.2%) 
20 (6.0%) 
88 (26.5%) 
17 (5.1%) 
 
274 (81.1%) 
2.7 (2.9) 
2.0 (1.0 to 3.0) 
 
 
38 (11.2%) 
1.3 (1.4) 
1.0 (1.0 to 1.0) 
18 (5.3%) 
*1 woman in the TM group and 3 women in the direct referral group gave birth in London 
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Table 6.6c: Total cost of pregnancy and % total (observed cases) 
 2001/2002 period with 
telemedicine (n = 408) 
2005/2006 period with 
telemedicine (n = 338) 
Resource use £’s
#
 % total £’s
#
 % total 
Antenatal ultrasound scans 42,710 2.5% 29,687 2.5% 
Antenatal/outpatient clinics 315,305 18.2% 202,434 16.7% 
Telemedicine consultations 8,450 0.5% 10,001 0.8% 
Specialist scans and 
counselling 
2,447 0.1% 3,724 0.3% 
Termination of pregnancy 9,419 0.5% 5,138 0.4% 
Prenatal bed stay 176,012 10.2% 99,492 8.2% 
Labour/delivery bed stay 164,737 9.5% 132,660 11.0% 
Mode of obstetric delivery 714,462 41.3% 550,877 45.5% 
Postnatal bed stay 297,254 17.2% 177,121 14.6% 
Total 1,730,796 100.0% 1,211,133 100.0% 
#
 In 2005/2006 prices 
 
6.2.4.5 Bootstrapped costs results for a sample population  
The cost results presented below are for the total events during the second and third 
trimesters of pregnancy.  For the scenario without telemedicine, according to the 
criteria as described in section 6.2.3.2, all telemedicine women who were seen in each 
time period, have been reclassified as either women who were assessed by direct 
referral in London or who were managed in the DGH as „medium risk‟ women.  One 
point to note is that the bootstrapped mean costs for the low risk women for all cost 
scenarios with and without the telemedicine service have stayed the same for each 
time period.  This is because no telemedicine woman would have been reclassified as 
a low risk woman (the low risk women are not relevant to this comparison, but are 
shown here as a baseline).   
 
During 2001/2002, of the 52 women who were assessed by telemedicine, if the 
telemedicine service had not been available, 45 women had risk factors to be assessed 
directly in London and 7 women would have reclassified as medium risk and their care 
would have been managed in the DGH.  During 2005/2006 of the 72 women who were 
assessed by telemedicine, if the telemedicine service had not been available, 54 
women would have been seen directly in London and the other 18 women would have 
been managed in the DGH as medium risk patients. 
 
a) Comparison of costs with a telemedicine service 
The mean cost per woman for each of the time periods for events from the time of 
anomaly scan up until just after delivery (or in a few cases after termination of 
pregnancy) are shown in Table 6.7.  The marginal extra cost to the hospital of a 
teleconsultation over a specialist consultation in 2001/2002 was £87.32 and in 
2005/2006 was £50.37.  For the 2005/2006 period, the costs for the telemedicine group 
were slightly lower than the previous period.  This is because there were more women 
during this period that could share the cost of line rental and call charges and also for 
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this latter period, there were no additional telemedicine and training support costs 
provided by the telemedicine coordinator from the RBH.  The lower cost may also be 
partly due to fewer antenatal clinic visits now taking place at Medway hospital 
compared to the earlier time period.  The NICE guidelines introduced in October 2003 
(updated in March 2008) on antenatal care, provided a recommended guide of the 
number of antenatal clinic attendances that should take place during antenatal care 
and what should happen at each appointment [NCCWCH, 2003; NCCWCH, 2008].   
 
Table 6.7: Bootstrapped total mean costs of pregnancy per group in 2005/2006 
prices± 
 Telemedicine 
group 
Direct referral 
group 
Medium risk 
women 
Low risk 
women 
Total for 
sample 
2001/2002 period – with telemedicine 
N 
Mean (SD) 
95% CI 
52 
£4,363 (£238) 
£3,896-£4,830 
24  
£3,825 (£311) 
£3,215-£4,435 
245  
£4,446 (£116) 
£4,220-£4,672 
87 
£3,712 (£153) 
£3,412-£4,011  
408 
£4,242 (£85) 
£4,075-£4,410 
2001/2002 period – without telemedicine 
N 
Mean (SD) 
95% CI 
 
n/a 
69 
£4,055 (£185) 
£3,692-£4,418 
252 
£4,455 (£117) 
£4,225-£4,685 
87 
£3,712 (£153) 
£3,412-£4,011 
408 
£4,229 (£88) 
£4,057-£4,401 
2005/2006 period – with telemedicine 
N 
Mean (SD) 
95% CI 
72 
£4,051 (£175) 
£3,709-£4,393 
29 
£3,612 (£233) 
£3,155-£4,069 
90 
£3,705 (£167) 
£3,378-£4,032 
147 
£3,274 (£94) 
£3,089-£3,458 
338 
£3,583 (£76) 
£3,435-£3,732 
2005/2006 period – without telemedicine 
N  
Mean (SD) 
95% CI 
 
n/a 
83 
£3,877 (£157) 
£3,570-£4,184 
108 
£3,728 (£152) 
£3,430-£4,026 
147 
£3,274 (£94) 
£3,089-£3,458 
338 
£3,567 (£75) 
£3,420-£3,714 
± 
Statistical tests conducted: t tests for all costs when comparing two groups; and F tests for all costs when 
comparing more than two groups 
 
After costs of other events were taken into account, costs for the telemedicine group 
were higher, although not significantly so, than the direct referral group (2001/2002: p = 
0.202; 2005/2006: p = 0.166).  For the 2001/2002 period, nearly half of the women in 
the medium risk group had caesarean sections compared to the other three risk 
groups, as this was the most costly mode of delivery this accounted for the slightly 
higher mean cost for the medium risk group compared to the other three risk groups.  
For the latter time period, the total cost may also be a reflection on the type of delivery 
mode: the rate of caesarean sections for the three risk groups (telemedicine, direct 
referral and medium risk) was about a third (far fewer multiple pregnancies in this data 
collection), whereas for the low risk group the rate of caesarean section was only 20%.  
During 2001/2002, the costs of the medium risk women were approximately £600 
greater than direct referral group, a difference which was not significant (p = 0.111); 
however for the 2005/2006 period the costs were approximately similar (£3,612 vs. 
£3,705: p = 0.777).  Overall, the total costs for pregnancy for the earlier time period 
were higher for each risk group and for the observed sample population than the latter 
time period; this is mainly due to the number of antenatal clinic visits which were taking 
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place at Medway hospital and the higher percentage of multiple pregnancies in the 
medium risk group (see Tables 6.4a and 6.4b).  When comparing the total costs for 
events during pregnancy combined for each of the risk groups, the costs for year 
2001/2002 were significantly higher than the 2005/2006 period (p < 0.001). 
 
b) Comparison of costs without a telemedicine service 
Table 6.7 also shows the total mean costs of pregnancy without a telemedicine service.  
So when comparing the overall observed costs (with a telemedicine service) with the 
estimated costs (without a telemedicine service) for the 2001/2002 period, they are 
estimated to be £13 lower and for the 2005/2006 period, they are estimated to be £16 
lower; these differences are not statistically significant (2001/2002: p = 0.915; 
2005/2006: p = 0.880).  If those patients who were seen by telemedicine are classified 
as being assessed by direct referral, the mean cost for the direct referral group 
increases by £231 for the 2001/2002 period and by £265 for the 2005/2006 period, 
although the differences in mean costs for the direct referral groups at the two different 
time points are not significant (2001/2002: p = 0.535; 2005/2006: p = 0.379).   
 
c) Comparison of unadjusted with adjusted costs 
The comparison of unadjusted (observed) and adjusted costs are shown in Appendix 8.  
When adjusting costs for risk factors, the results are in a similar direction and 
magnitude to those presented in Table 6.7 and it does not change the cost results 
conclusions.   
 
6.2.4.6 Bootstrapped costs results for total population 
Table 6.8 shows the bootstrapped total mean costs of pregnancy for all women 
delivered at Medway for each cost scenario, after estimating costs for those women (in 
both the medium and low risk groups) in each time period for whom there were no 
demographic or resource use data for (see section 6.2.3.4 for more explanation).   
 
Table 6.8: Bootstrapped total costs of pregnancy during each time period in 
2005/2006 prices± 
 2001/2002 period 
(with 
telemedicine) 
2001/2002 period 
(without 
telemedicine) 
2005/2006 period 
(with 
telemedicine) 
2005/2006 period 
(without 
telemedicine) 
Total costs of pregnancy for all women delivered 
N 
Mean (SD) 
95% CI 
5114 
£3,675 (£7) 
£3,660 to £3,689 
5114 
£3,689 (£7) 
£3,674 to £3,703 
5407 
£3,414 (£5) 
£3,404 to £3,423 
5407 
£3,416 (£5) 
£3,406 to £3,426 
± 
Statistical tests conducted: t tests for all costs when comparing two time periods 
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Costs have not been presented by risk group, because for the direct referral and 
telemedicine groups, costs have remained the same as those presented in Table 6.6 
and for the medium risk women, the cost magnitudes are very similar.  Likewise, for the 
low risk women, their mean cost is very similar to the total cost for each time period, 
due to the volume of women who form the low risk category (e.g. about 94% of all 
mothers for the 2001/2002 period).  For both time periods, a service without 
telemedicine was very similar, although slightly more expensive than a service with 
telemedicine.  
 
6.3 Addition of patient costs 
The literature review in Chapter 3 found that the majority of studies only looked at costs 
from the healthcare perspective i.e. the direct medical costs, and did not estimate the 
costs which fall on the patients and their families.  Patient costs are important to 
include in economic evaluations as this gives an indication to policy makers and to 
individual patients of the likely costs they will face when attending hospitals for 
treatment or consultations; this is especially important if patients have to attend hospital 
more than once during a specific time period. 
 
In the next section of this Chapter the various types of costs which may fall under the 
category of „patient‟ costs (both monetary and time costs) and which of these costs 
should be included in an economic evaluation will be discussed.  Also, the main 
approach to calculating patient costs in economic evaluations will be highlighted.  
Finally, the analysis presented in the previous section will be extended (and also in 
Chapter 2) to include both hospital and patient costs of a service with telemedicine 
compared to a service without telemedicine.  
 
6.3.1 Why are patient costs important? 
In Chapter 3, costs were categorised into three categories: 1) direct medical costs are 
the costs related to the use of resources due to either the disease or treatment, these 
are the costs to the health service; 2) direct non-medical costs are costs incurred by 
patients and family members, which contribute to the treatment process; and 3) indirect 
costs are resources lost due to treating a disease and can reflect two different costs 
depending on the perspective.  If a patient perspective is adopted, this may reflect the 
loss of time (whether this is work or non-work time) to the individual in attending for 
treatment.  If a societal perspective is adopted, time costs incurred by individuals in 
receiving treatments reflect the loss of production to society, whether paid or unpaid.   
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In this section, patient costs which are a sub-category of direct non-medical costs are 
of interest.  Patient costs are important to include in economic evaluations as this gives 
an indication (i.e. behavioural implications) to policy makers and to individual patients 
of the likely out-of-pocket expenses they may incur.  For example, pregnant women 
have to attend hospital not only for ultrasound scans, but also for antenatal clinics 
during the course of their pregnancy and these out-of-pocket expenses such as travel 
costs can add up.  Also, for some screening programmes if patient costs are 
considerable, this may influence the uptake rate of that specific screening programme 
[Bryan et al, 1995; Robinson et al, 2007].   
 
In the reference case analysis for NICE, costs relate to resources used for NHS and 
PSS9 only.  NICE have specifically stated that “Productivity costs and costs borne by 
patients and carers that are not reimbursed by the NHS or PSS are not included in 
either the reference-case or non-reference-case analyses” [NICE, 2008].  If patient 
costs are reimbursed by the NHS or PSS then they can be included in economic 
evaluations for NICE.  When patient costs are included in an economic evaluation they 
should be included in a non-reference case analysis (explicit methods of valuation are 
required by NICE) and they should be reported separately to those of NHS/PSS costs.  
However, patient costs should not be included in the incremental cost-effectiveness 
ratio, especially if the outcome measure used is QALYs.  In this case, including patient 
costs in an economic evaluation makes them less comparable to other interventions in 
the context of NICE. 
 
NICE do not explicitly state the reasons why patient costs should not be included in 
economic evaluations.  However, as they are an NHS organisation, they prefer costs 
and outcomes to be from a healthcare perspective.   So for example, if a societal 
perspective was to be adopted, not only would the costs have to be from a societal 
viewpoint (i.e. including education, social care costs etc), but the outcomes would also 
have to be from a societal viewpoint.  Although costs are easier to collect and analyse, 
outcomes are not.  However, there may also be a problem of double counting, because 
some benefits may be classed as both costs and benefits. 
 
6.3.2 What type of patient costs should be included in an economic evaluation? 
Costing is an integral part of any economic evaluation and understanding the costs that 
fall upon patients‟ (and their families) is clearly important.  For each type of cost 
identified, decisions have to be made as to whether its inclusion in an economic 
evaluation is relevant.  Patients may incur costs whilst attending hospital for treatment 
                                                 
9
 PSS = personal social services  
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or an intervention and these costs can fall into two main categories: monetary costs 
and time costs.  Monetary costs include: travel costs, and other out-of-pocket expenses 
such as subsistence costs (i.e. food, drink, and accommodation), and care of children 
and/or other dependents.  If a societal perspective is adopted we would also include 
loss of pay and loss of productivity.  Time costs include: time spent travelling and time 
spent at hospital (i.e. treatment/consultation time plus waiting time).  In some cases, 
the opportunity cost of patients‟ time when receiving an intervention or treatment, have 
also been referred to as indirect costs [Luce and Elixhauser, 1990].   
 
An example of monetary costs is provided by Elford et al (2001) who evaluated a PC-
based videoconferencing system for child psychiatry assessments.  Thirty children 
(aged 5-16 years) accompanied by a parent completed a psychiatric assessment using 
the videoconferencing system.  Alternatively, they would have had to travel to a 
specialist centre (St John‟s) for assessment, which was approximately 670km away 
across the island in Newfoundland, Canada.  The parents completed a cost 
questionnaire.  The cost analysis looked at what mode of transportation the patients 
would have taken to St John‟s (an economy return flight booked at least two weeks in 
advance, or a return trip in a car, or a Greyhound return bus trip); what type of 
accommodation they would have stayed in and how many nights they would have 
stayed (an inexpensive hotel or a hostel, or if they stayed with family, the authors 
assumed that they would not have to pay anything).  Food expenses were taken into 
account if they stayed at the hotel or the hostel.  The authors did not take into account 
any other costs, such as loss of income from missing work, babysitting costs and any 
incidentals.  Using these figures, each patient‟s estimated total cost (for travel, 
accommodation and food) was generated.  
 
The study by Loane and colleagues (2000) who compared the costs of real-time 
teledermatology with store-and-forward teledermatology looked at patient time costs.  
Ninety-six patients attended a health centre and in the company of a GP were seen by 
a hospital dermatologist over a videolink (real-time).  Before the videolink took place, 
the GP took instant photographs of the skin lesion and these photographs were posted 
along with a standard referral letter to another hospital dermatologist (store-and-
forward).  For both of these methods the authors looked at the mean total patient time 
involved which included travel time (to and from appointment), waiting time and 
consultation time.  On average the store-and-forward consultation was shorter than the 
real-time consultation (41.5 mins vs. 52.2 mins).  The authors from this information 
then estimated the cost of patient time, which was calculated by taking the average 
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annual income divided by 220 working days, divided by 8 working hours, divided by 60 
minutes, and then multiplied by the total patient time.  
 
Another example of time costs is provided by Halvorsen and Kristiansen (1996) who 
wanted to determine the costs of providing a rural population with radiology services 
under three different systems.  The teleradiology system was compared to the existing 
system (a small x-ray unit at the remote site and all other examinations at the nearest 
radiology dept (the host site)) and to all examinations at the host site.  The authors 
looked at the annual direct medical costs, direct non-medical (travel) costs, and indirect 
costs (lost production) of the three options.  With regards to the cost of time the authors 
claimed that having a radiological examination represents a loss of leisure or of 
production for those employed.  The production loss was assumed to be equivalent to 
the number of hours absent from work multiplied by the national wage rate.  The cost of 
leisure was assumed to be zero (this was varied in the sensitivity analysis).  
 
6.3.3 Different approaches to calculating patient costs 
As mentioned in the Chapter 3, the information provided in the articles varied from 
detailed cost analyses to simply mentioning some of the costs and that a telemedicine 
service was cost-effective or cost-saving.  Most studies provided very little explanation 
of the methods used to estimate the costs or what was included in the cost calculation.  
To the best of my knowledge, I am not aware of any „gold standard‟ for estimating 
patient costs.  A UK Working Party on patient costs was set up [Thompson et al, 2001] 
in 1999 with the specific remit of producing a standard „patient‟ cost questionnaire for 
use in evaluating health care interventions.  The aim of the project was to produce a 
questionnaire for measuring inputs into the health production function that relate 
directly to patients and informal caregivers, where patients could be used as a source 
of information.  The questionnaire included these categories: single or multiple visits to 
health care facilities; domiciliary care costs; productivity losses due to illness; 
medication and medical supplies; and private consultations. The first two categories 
are relevant to this thesis and similar questions were used in the TelePaed 
questionnaire and the items included were: patient travel costs; patient time costs; 
companion costs; and other childcare and other dependent costs. 
 
For example, in the study mentioned earlier by Loane et al (2000), the authors stated 
that patients completed a questionnaire which detailed the time involved and costs 
incurred when attending the appointment, along with details of their annual income.  
They grouped costs into two categories: fixed costs which described the equipment 
and depreciation costs; and variable costs which estimated the participants‟ time and 
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travel costs.  However, they did not provide any more detail than this, whereas, Jacklin 
and colleagues (2003) in their economic evaluation of joint teleconsultation (virtual 
outreach) compared with conventional outpatient consultation, described in detail how 
they calculated patient costs.  The authors used a postal questionnaire to collect data 
on the travel costs incurred by patients or anyone accompanying them when they 
attended their appointment.  The questionnaire also recorded the time taken, including 
travel time, to attend the consultation.  There was also information in the questionnaire 
about the impact on patients and their companions on paid work.  If any work time was 
lost, the questionnaire asked about whether pay was reduced or whether anyone had 
taken annual leave.   
 
The majority of studies evaluating patient costs in detail have been in the area of 
screening.  For example, Bryan et al (1995) looked at the patient costs associated with 
abdominal aortic aneurysm screening; and Robinson et al (2007), looked at patient 
costs associated with a Chlamydia screening programme.  Both studies, as mentioned 
earlier, felt it was important to look at patient costs, as these costs may have an 
influence on the uptake of screening rates.  These two studies were similar in respect 
to the methods employed to calculate patient costs.  Both studies used questionnaires 
to collect information from patients on travel and time costs at the end of their visit 
before leaving hospital or GP surgery.  The questionnaires asked about travel 
arrangements for the journey to and from the appointment including the distance 
travelled, the mode of transport, the time taken and the cost.  Costs for travel by car 
were calculated using published motoring costs (the travel cost was obtained from the 
journey distance in miles multiplied by an average cost per mile, allowing for fixed 
costs, depreciation and running costs) and actual return travel costs were used for 
other modes of transport such as bus or train.  In addition, patients were asked about 
the time spent travelling to and from the appointment, time spent at the clinic/hospital 
(both waiting time and consultation time) and the activities forgone when attending their 
appointment.  The opportunity cost of time lost from work was estimated from the mean 
weekly wage rate (minus tax, pension and National Insurance contributions).  Other 
activities such as leisure time were valued at 40% of the mean average wage rate 
[Bricker et al, 2000].  The study by Bryan et al (1995) also included the travel costs and 
time costs for companions, assuming that the companion did not have an appointment 
at the hospital or surgery themselves.   
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6.3.4 Calculation of patient costs for the sample and the total population 
Sample population 
In Chapter 2, patient costs were calculated for a sample of women who were sent a 
questionnaire (including those who were not referred (n = 96) – these results were not 
presented in Chapter 2).  In order to look at the patient costs for all patients who were 
observed during the study period the following assumptions and calculations were 
made.  It was assumed that a patient would incur a travel cost for a return journey to 
the district hospital for ultrasound scans (anomaly scan and any further scans later in 
pregnancy i.e. growth or fetal wellbeing scans), and any antenatal or outpatient visits; 
and to the specialist hospital for a specialist scan (including counselling where 
appropriate which was costed as one visit).  Travel costs for terminations, prenatal 
admissions and labour admissions were excluded, as majority of these visits would 
have been classed as an emergency and not all women would have travelled by car or 
public transport.  Travel costs for telemedicine consultations were also excluded as 
anomaly scans were videoed and women would not have had to travel again to the 
hospital for the telemedicine consultation.   
 
For those patients who filled in a questionnaire and indicated which mode of transport 
they used, this was assumed to be their method of transport throughout their 
pregnancy.  Reflecting the proportions in the TelePaed data, 80% of the women were 
randomly allocated to travelling by car and the remainder by public transport.  Using 
postcode data from the AA [AA website, 2008a], this source was used to calculate the 
road distance (in miles) between the home address and the district or specialist 
hospital.  A cost per mile of travel of 44 pence was applied to each mile travelled [AA 
website, 2008b].  For each hospital visit, the appropriate car parking charge was also 
added (see next paragraph).  For those who travelled by public transport, a mean value 
was used from the TelePaed data sample, depending on whether the visit was to the 
district or specialist hospital.  All travel costs are in 2005/2006 prices.   
 
Based on the TelePaed data sample, on average women who went to London for an 
appointment spent 99 minutes in hospital and women who went to the district hospital 
for an appointment spent 75 minutes in hospital (this included time for the actual 
appointment and also any waiting time).  Using this information, an average estimation 
was made for each woman for their car parking charge for each visit to the hospital.  
Car parking charges were obtained from the two hospitals [Medway hospital website, 
2008; Personal communication with receptionist at Queen Charlottes Hospital, 
December 2008] in 2008 prices and were deflated back to 2005/2006 prices [Curtis, 
2008].   
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Loss of pay was also calculated for each woman based on an hourly wage rate for 
women in 2005/2006 prices as £7.76 (inflated from 2001/2002 prices) using the New 
Earnings Survey for 2002 [ONS, 2002].  Based on the TelePaed data sample, 40% of 
the women were randomly allocated to paid employment and the remainder to 
undertaking household duties or looking after children.  For those women who were not 
in paid employment, their time was valued at 40% of the mean female wage rate 
[Bricker et al, 2000].  The analysis does not include any additional costs, such as the 
cost of childcare or care for other dependents for each of these visits, as not enough 
information was available.  Finally, no allowance was made if the patient had a 
companion accompanying them on their hospital visit. 
 
Total population 
To determine patient costs (travel plus additional costs) for the total population, multiple 
regression models were fitted to the observed caseloads of women for each of the time 
periods.  The costs were adjusted for all risk factors which included: parity; mother‟s 
age at anomaly scan; number of fetuses; gestation in weeks at the anomaly scan; and 
also whether the woman had one of the following risk factors: diabetes; an elevated 
serum risk; a high risk of Down‟s syndrome; family history of CHD; or a previous 
pregnancy with an anomaly.  The mean costs were obtained for each time period (and 
group) and were then allocated to the rest of the women in each group who did not 
have a patient cost.  
 
6.3.5 Addition of patient costs to sample and total population cost results 
Table 6.9 shows the total hospital and patient costs for the observed sample 
populations for a service with and without telemedicine.  Looking at patient costs (this 
includes patient travel costs and additional costs that patients may have incurred) as 
expected, the direct referral group incurred more costly journeys than the other risk 
groups, as these women had to travel to London for a specialist scan(s) (and for some 
women they also had counselling) for the two time periods when telemedicine was in 
use.  When patient costs were added to the total costs of pregnancy, for the year 
2001/2002 with telemedicine, the medium risk group had slightly higher total costs than 
the other risk groups (again the influence of multiple pregnancies was evident); 
whereas, for the latter time period when telemedicine was in steady state of use, the 
telemedicine group had higher total costs than the other three risk groups.  For the two 
scenarios without telemedicine, for 2001/2002 period the medium risk group had higher 
costs than the direct referral group and for the 2005/2006 period the direct referral 
group had higher costs than the medium risk group.  So on average, during the second 
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and third trimesters of pregnancy, women would have to pay out approximately £150-
£200 out of their own pocket for travel and any other additional costs. 
 
Table 6.9: Bootstrapped total hospital and patient costs for sample population (in £’s in 
2005/2006 prices)± 
 Telemedicine 
group 
Direct referral 
group 
Medium risk 
group 
Low risk group Total 
2001/2002 period with telemedicine 
Total patient costs (patient travel costs plus additional costs) 
N 52 24 245 87 408 
Mean (SD) 
95% CI 
£199 (£16) 
£169 to £230 
£249 (£26) 
£197 to £300 
£204 (£8) 
£188 to £219 
£163 (£11) 
£142 to £185 
£197 (£6) 
£186 to £209 
Total costs of pregnancy plus patient costs 
Mean (SD) 
95% CI 
£4,562 (£250) 
£4,072 to £5,053 
£4,073 (£331) 
£3,424 to £4,723 
£4,649 (£118) 
£4,418 to £4,880 
£3,875 (£157) 
£3,567 to £4,183 
£4,439 (£90) 
£4,264 to £4,615 
2001/2002 period without telemedicine 
Total patient costs (patient travel costs plus additional costs) 
N 0 69 252 87 408 
Mean (SD) 
95% CI 
n/a 
 
£233 (£13) 
£207 to £258 
£204 (£8) 
£188 to £219 
£163 (£11) 
£142 to £185 
£199 (£6) 
£188 to £211 
Total costs of pregnancy plus patient costs 
Mean (SD) 
95% CI 
n/a £4,287 (£196) 
£3,904 to £4,671 
£4,659 (£121) 
£4,422 to £4,896 
£3,875 (£157) 
£3,567 to £4,183 
£4,429 (£89) 
£4,254 to £4,604 
2005/2006 period with telemedicine 
N 72 29 90 147 338 
Total patient costs (patient travel costs plus additional costs) 
Mean (SD) 
95% CI 
£158 (£10) 
£139 to £177 
£217 (£22) 
£173 to £260 
£172 (£9) 
£154 to £189 
£126 (£5) 
£117 to £136 
£153 (£4) 
£144 to £162 
Total costs of pregnancy plus patient costs 
Mean (SD) 
95% CI 
£4,209 (£177) 
£3,862 to £4,555 
£3,829 (£243) 
£3,352 to £4,306 
£3,877 (£173) 
£3,537 to £4,216 
£3,400 (£95) 
£3,214 to £3,587 
£3,736 (£76) 
£3,587 to £3,886 
2005/2006 period without telemedicine 
N 0 83 108 147 338 
Total patient costs (patient travel costs plus additional costs) 
Mean (SD) 
95% CI 
n/a £199 (£11) 
£177 to £221 
£166 (£8) 
£150 to £181 
£126 (£5) 
£117 to £136 
£157 (£5) 
£148 to £166 
Total costs of pregnancy plus patient costs 
Mean (SD) 
95% CI 
n/a £4,081 (£161) 
£3,766 to £4,395 
£3,895 (£155) 
£3,590 to £4,199 
£3,400 (£95) 
£3,214 to £3,587 
£3,725 (£76) 
£3,576 to £3,875 
 
 
Table 6.10 shows the total costs of pregnancy plus patient costs for the total 
population.  The costs are in the same direction and of similar magnitudes with the 
results presented in Table 6.8.  Overall, a service with telemedicine does not 
significantly reduce the total costs of pregnancy, even with the addition of patient costs.   
 
Table 6.10: Bootstrapped total hospital and patient costs for total population (in 
£’s in 2005/2006 prices)± 
 2001/2002 period 
(with 
telemedicine) 
2001/2002 period 
(without 
telemedicine) 
2005/2006 period 
(with 
telemedicine) 
2005/2006 period 
(without 
telemedicine) 
Total costs of pregnancy plus patient costs 
N 
Mean (SD) 
95% CI 
5114 
£3,862 (£7) 
£3,847 to £3,877 
5114 
£3,876 (£7) 
£3,862 to £3,891 
5407 
£3,549 (£5) 
£3,539 to £3,559 
5407 
£3,551 (£5) 
£3,541 to £3,562 
± 
Statistical tests conducted: t tests for all costs when comparing two time periods 
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6.4 Discussion 
This chapter set out to determine whether a service with telemedicine is a cost-
effective alternative to a service without telemedicine and also to see what the effect is 
over time.  The perspective adopted for the cost analysis was that of the hospital and 
all costs were presented in pounds sterling (£) in 2005/2006 prices.  Patient costs were 
also presented in a separate analysis.  The effectiveness measure was the number of 
missed cardiac cases.   
 
In terms of costs, for the two periods that used telemedicine compared to the same two 
periods, when adjusting costs if the telemedicine service was not in use, telemedicine 
did not add much to the total mean costs of pregnancy for the total population of 
delivered women.  When patient costs were added to the total costs of pregnancy, 
patient costs did not add much to the overall total mean costs of pregnancy and the 
overall costs were in the same direction and of similar magnitudes.  Finally, in relation 
to costs, the change over time in antenatal screening protocols, and the fewer 
antenatal clinic visits, along with fewer multiple pregnancies in the 2005/2006 data 
collection have meant that the overall costs in the second and third trimesters of 
pregnancy have fallen slightly.   
 
In terms of effects, when comparing a telemedicine service to a service without 
telemedicine for both time periods (each time period was assessed separately), there 
was no change in the effectiveness outcome (the number of missed cases).  That is, 
Specialist A confirmed that none of the telemedicine women (52 women during 
2001/2002 and 72 women during 2005/2006) would have had a missed cardiac 
anomaly if the telemedicine service was not available.  So on this basis, a cost-
effectiveness analysis was not appropriate and a cost-consequences analysis was 
sufficient.   
 
However, over time there has been a reduction in the number of missed anomalies 
amongst the low risk women, partly due to sonographers being more confident in 
checking fetal heart structures and also due to the additional training they received to 
carry out more detailed fetal heart examinations.  This change in the effectiveness over 
time may be explained by a number of reasons.  Firstly, when telemedicine was 
introduced in 2001, staff were provided with training, not only on how to operate the 
telemedicine equipment, but also on how to operate the ultrasound machine more 
optimally (e.g. the velocity level settings and the Doppler settings to ensure that the 
videoed images were of an acceptable quality).  But, as a prerequisite of using the 
telemedicine equipment they were also provided with training specifically in checking 
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the fetal heart structures for cardiac anomalies.  Over time, the sonographers have 
received further training so they are more confident in conducting more detailed 
examinations to look at the „extra views: 5 views‟ (which included the 4-chambers and 
the position of the vessels („cross over‟ views)) and this may have been a factor for the 
reduction in missed cases.  This detailed training in checking the fetal heart structure 
applied to all women (including low risk women) who had an anomaly scan at 20-22 
weeks gestation, and not just to women who were referred to a perinatal cardiologist.  
Looking at this extra detail in the anomaly scan, isn‟t an extra burden time wise for the 
sonographers, as each woman is given a 20 minute slot for their anomaly scan, this is 
enough time to have a good look at the vessels and the heart [Personal communication 
with Sonographer A, October 2007].  There may have also been a „learning curve 
effect‟, because over time the sonographers performance in conducting anomaly scans 
improved the detection rate.  This learning curve effect was highlighted in a study by 
Dumville and colleagues (2006) who looked at different options for female urinary 
stress incontinence and the authors stated that the less experienced surgeons will 
have to undergo a learning curve on the first patients they operate and these patients‟ 
would be more at risk of post-operative complications. 
 
Secondly, changing practice over time: obstetric staff have become more aware of the 
telemedicine service.  When pregnant women go to the hospital for their booking scan 
(at approx. 11-13 weeks gestation), doctors are alerted when women are booked 
whether they are at a „high risk‟ of fetal CHD.  The hospital has now adopted a protocol 
for identifying high risk women which is far wider than the criteria set up for the 
TelePaed project; e.g. the protocol includes women with high body mass index.  In 
addition, since the introduction of nuchal translucency screening in 2007, this has had 
an impact on the detection rate (as mentioned in Chapter 2, section 2.2, NT has 
stronger relationship with CHD, than established risk factors).  Midwives are pretty 
good at identifying high risk cases and during the first trimester nuchal scan more high 
risk women are being identified, so more women are sent for a telemedicine 
consultation or referred straight away to the specialist if it is urgent.  As these women 
are identified a lot earlier, then plans can be made for them to see a specialist (note 
that telemedicine is not suitable before 18 weeks gestation).  So, telemedicine has 
helped to achieve a change in practice. 
 
The great majority of costs during pregnancy such as antenatal clinics or ultrasound 
scans are borne by the health service.  When patients attend hospital for consultations 
they also incur out-of-pocket expenses and time costs.  Currently, there is no gold 
standard in the methods employed to calculate patient costs; however, the 
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methodologies used to calculate patient costs by various screening studies have been 
broadly similar.   
 
There are two main methods for estimating productivity costs: 1) human capital 
approach and 2) friction cost approach.  The human capital approach was used in this 
thesis and has also been used in other screening studies.  This method assumes that 
humans are like machines as they contribute to Gross National Product.  When wages 
paid are equal to the marginal product of labour, this gives an indication of the wage 
paid [Fox-Rushby and Cairns, 2005]. However, some argue that this method 
overestimates costs and work is not replaced.  The friction cost method is an 
alternative method which assumes that any output lost is temporary and workers will be 
replaced [Fox-Rushby and Cairns, 2005].  The thesis did not employ the latter 
approach as there was not enough information on replacing pregnant women at work 
and also the thesis focussed on patients‟ costs and not employers‟ costs. 
 
One study that estimated patient costs in pregnancy is the study by Henderson and 
colleagues (2002).  The authors estimated resource use and costs associated with 
antenatal ultrasound screening from both the NHS and women‟s perspectives.  They 
used questionnaires to assess women‟s costs of attending hospital for an ultrasound 
scan (i.e. for one hospital visit).  These costs included the opportunity cost of time lost 
from work (estimated using the gross female weekly wage rate and a mean time away 
from work); if the patient took annual leave this was estimated at 40% of the mean 
female wage rate; and if women were not in paid employment, the opportunity cost of 
them attending the hospital was approximated to cleaning work or informal care.  Costs 
for travel by car were calculated using published motoring costs and actual travel costs 
were used for other modes of transport.  They also costed their companions if they 
were accompanied on their hospital visit depending on whether they were working or 
not.  Costs to women and their families and friends were estimated £16.59 per scan for 
one hospital visit (2005/2006 prices - costs inflated from 1998/99 prices) [Curtis, 2007].  
The results obtained from the Henderson et al study (2002) are slightly lower than the 
results obtained from TelePaed study for one hospital visit (£21.69 for both direct 
referral and telemedicine groups).  This can be partly explained by the shorter 
distances to travel to the hospital: return distance in miles: 14.0 miles [Henderson et al, 
2002] vs. 24.8 miles (for both direct referral and telemedicine groups); see Chapter 2 
for more details.   
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The estimates of the cost borne by pregnant women during the second and third 
trimesters of pregnancy for both the observed samples and the total women delivered 
involved a number of assumptions: 
 Based on the TelePaed sample, it was assumed that 80% of pregnant women 
travel by car and the remainder (20%) use public transport.  It may be that not 
everyone has a car, and for some pregnant women it may have been more 
convenient to travel by public transport and/or for some women who live close 
to the district hospital to actually walk (or maybe cycle?) to the hospital for their 
appointments, so in this instance for some patients, travel costs may have been 
overestimated.   
 Travel costs were excluded for prenatal admissions, labour stay and 
terminations and for some of these journeys, patients may have travelled by car 
to the hospital and also had to pay for car parking for these visits, so in this 
instance for some patients, travel costs may be underestimated.   
 A mean cost for those that have travelled by public transport was used and this 
may have underestimated the patient costs for these women. 
 If the patient was accompanied by a partner or a family member or a friend on 
each visit, these companions may have also incurred travel costs if they had 
travelled by public transport.   
 With regard to additional costs, for some patients this may have been 
overestimated.  It was assumed that 40% of patients would have been working 
(based on the TelePaed sample), as the precise number of women who would 
have been in paid employment were unknown.  Of those patients who were 
paid employment, the following information was unknown: how many received 
time off with pay, how many had taken annual leave, how many would have had 
to make time up, how many took time off work with loss of pay and how many 
went outside work hours.  Also, if the woman travelled to the hospital with a 
companion, their companion may have had to take time off from work with loss 
of pay.   
 With regards to additional costs, in each of the two time periods we had no data 
on how many women had to pay for someone to care for their children or other 
dependents whilst they attended hospital; and also whether the pregnant 
woman (and/or companion) may have experienced other out-of-pocket 
expenses such as food and drink. 
 
This analysis provides important information about patient costs associated with a 
woman‟s pregnancy during the second and third trimesters; and these costs provided 
here can be used as a guideline.  However, to get more comprehensive costs, a full 
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patient cost survey can be conducted to provide more accurate costs for a sample of 
patients for each of their visits to the hospital as their circumstances may change 
throughout pregnancy (i.e. a woman later in her pregnancy may not be able to drive to 
the hospital for an appointment or may be on maternity leave).  This patient survey 
could also include health status instruments at various time points to find out how the 
woman‟s anxiety and depression levels change throughout pregnancy and also for this 
short time period, some utility data can be collected to enable calculation of QALYs. 
 
One further point to note is that the low risk women have been presented in this 
Chapter as a baseline; however, they have not really been of interest.  Thus, in terms 
of extending the telemedicine programme to all low risk women (2001/2002 had the 
most missed cardiac cases; in the same time period, eight of the cardiac cases 
detected were from women who were in the „low risk‟ category – see Table 6.3) and the 
implications of this will be shown in Chapter 7.  
 
So to summarise the main findings from this chapter: the additional cost of the 
telemedicine can largely be offset by savings downstream; patient costs did not add 
much to the total costs of pregnancy; and there were no missed cardiac cases amongst 
pregnant women who were referred to a perinatal cardiologist.  Therefore, the aim of 
the next chapter is to see what the impact on costs and effects would have been, if 
telemedicine was offered to all low risk women in order to reduce the number of missed 
cardiac cases during this same time period.  Using decision analytical modelling, a 
cost-effectiveness analysis comparing a screening programme with telemedicine to a 
screening programme without telemedicine will be conducted for low risk women.  
Thus, the next Chapter looks at the third economic issue which has been highlighted 
throughout this thesis: benefit measures such as QALYs. 
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CHAPTER 7: MODELLING LIFETIME COSTS AND BENEFITS FOR A 
TELEMEDICINE SCREENING PROGRAMME USED TO DETECT CHD IN UNBORN 
CHILDREN  
 
7.1 Introduction 
This chapter will look at the third economic issue associated with telemedicine which 
was highlighted in Chapters 3 and 4: use of benefit measures such as QALYs.  There 
are various health and non-health benefits associated with telemedicine (some of 
which have been summarised in Chapter 3).  For example, some of the health benefits 
of telemedicine include the possibility of earlier diagnosis which may mean bringing 
treatment forward in time which may have some benefit.  The non-health benefits of 
telemedicine include the transfer of skills between the specialist and local clinicians and 
the speed of service.  The great majority of studies identified in the literature review in 
Chapter 3 only looked at the costs, and not at the benefits of telemedicine.  Some of 
the studies which looked at the „benefits‟ from telemedicine services classed resource 
use in terms of transfers, hospitalisations and consultations avoided rather than clinical 
improvement as a measure of benefit; however, in economic terms these measures are 
not regarded as benefits, instead they should be classed as „costs averted‟.   
 
The outcomes that are included in an economic evaluation are important as this will in 
turn determine the type of evaluation which is carried out.  Gold et al (1996) suggested 
the use of the quality-adjusted life year (QALY) as the unit of effectiveness in a cost-
effectiveness analysis, as it allows decision makers such as NICE “to compare 
interventions whose effects on health are qualitatively different, such as prevention of 
coronary artery disease and treatment of arthritis”.  This unit of outcome measure has 
become the norm, as it allows decisions about value for money to be made across 
different technologies and across different disease areas.  In Chapter 3, the thesis 
looked at what QALYs were and whether they are appropriate for telemedicine.  
However, in practice it may be difficult to calculate QALYs for telemedicine 
interventions or services, because the benefits of reduced mortality and morbidity 
associated with telemedicine are difficult to calculate.  That is, QALYs may not be 
sensitive enough to detect small changes in health outcomes which telemedicine 
services are most likely to produce.  
 
Chapter 2 compared the costs and effects of two groups of women who were referred 
directly or via telemedicine to a perinatal cardiologist after a routine anomaly scan for 
screening of the fetus, or to confirm in suspected cases whether or not there really was 
a cardiac abnormality.  There were no missed cardiac diagnoses among either group.  
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In Chapter 6, this analysis was extended to look at all women who had undergone an 
anomaly scan at Medway hospital during the same time period and the Chapter 
considered conducting a cost-effectiveness analysis comparing a service with 
telemedicine to one without telemedicine (i.e. „telemedicine women‟ were regrouped as 
direct referral or medium risk women in the without telemedicine scenario).  Regarding 
outcomes for Chapter 6, benefits were measured in terms of „missed cardiac case 
avoided‟.  However, a cost-effectiveness analysis was not appropriate, because no 
woman in the telemedicine group were assumed to have a „missed cardiac anomaly‟ if 
the service had not been available.  Due to this assumption, a cost-consequence 
analysis was conducted.   
 
In Chapter 6, for the 2001/2002 period we ascertained that the majority of missed 
cardiac anomalies were amongst the low risk women and there were also two missed 
cases for the medium risk women.  However, for the latter time period there was only 
one missed case and this woman was in the low risk group.  In terms of conducting a 
cost-effectiveness analysis of a screening programme with telemedicine compared to a 
screening programme without telemedicine, it would be more appropriate to use the 
latter data; however, as there was only one missed case it was not feasible.  Therefore, 
the data used in this chapter focuses on the low risk women from the 2001/2002 
period.  The Chapter does not consider the medium risk women for the 2001/2002 
period, because for the 2005/2006 period there were no missed anomalies for this risk 
group.  One further point to note is that as this Chapter considers all low risk women, 
then there is no issue of „selection‟ (see Chapter 5 for more details); hence, costs and 
effects in this Chapter have not been adjusted for selection bias.  
 
This Chapter explores what the impact on costs and effects would be if telemedicine 
(this is cheaper and less time consuming in the long-run compared to direct referral) 
was offered to all low risk women in order to reduce the number of missed cardiac 
cases.  Therefore, by using cost-effectiveness analysis, the main aim of this chapter is 
to compare a screening programme with telemedicine to a screening programme 
without telemedicine for low risk women and by comparing these two programmes, the 
lifetime costs and benefits (QALYs) for children born with and without congenital heart 
disease can be estimated.   
 
The structure for this chapter is as follows: firstly, to look at various antenatal screening 
programmes for conditions such as Down‟s syndrome, to see how they have calculated 
the longer-term costs and benefits associated with such screening programmes; 
secondly, to explore the literature on costs and benefits of screening programmes to 
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help inform the decision model; and in the final part of this chapter, an estimate of the 
lifetime costs and benefits of introducing a screening service with telemedicine for 
pregnant women whose unborn babies are at a low risk of CHD compared to a 
screening service without telemedicine using a decision tree will be provided.   
 
7.2 Background to the longer-term costs and benefits of antenatal screening 
programmes 
Economic analysis of prenatal screening programmes 
Literature in the public domain was reviewed on the cost-effectiveness of other 
antenatal screening programmes to establish what methods had been used, including 
the calculation of long-term costs and benefits.  The three main sets of issues are:  
1) what are the averted costs? 
2) what are the benefits considered?; and 
3) what could otherwise happen?  
 
Over the last thirty years, there have been a growing number of studies looking at the 
economics of antenatal screening programmes [e.g. Shackley, 1993; Shackley and 
Cairns, 1993; Karnon et al, 2007].  Antenatal screening programmes focus on the 
detection of fetal abnormalities, and if a fetal abnormality is detected, a decision can be 
made as to whether to continue with, or to terminate the pregnancy.  In economic 
terms, if a pregnancy is terminated, cost savings are estimated.  However, if the fetal 
abnormality was not detected through screening and only when the baby is born the 
anomaly is detected, the costs incurred throughout a child‟s lifetime to treat such a 
condition are then estimated.  Usually these lifetime costs of a child with an anomaly 
are more than the cost of replacing an affected pregnancy with a child without the 
condition [Karnon et al, 1997].  These screening programmes have looked at averted 
costs such as the extra costs to the health service, the additional education costs and 
labour market productivity costs.  The benefits from such programmes have focused on 
estimating the future costs which would be avoided by detecting and terminating 
affected fetuses.  Also, most of these studies suggested that if a positive screening 
result was found, women would elect to terminate their pregnancy.  This may not 
always be the case.   
 
One of the first cost analyses published in this area considered preventing the birth of 
infants with Down‟s syndrome and introduced the idea of replacement [Hagard and 
Carter, 1976].  The authors evaluated the economic benefits (costs averted) resulting 
from terminating pregnancies affected with Down‟s syndrome, in both replacement and 
no replacement situations.  Replacement is where the woman becomes pregnant again 
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after terminating an affected fetus (and the outcome of the new pregnancy is assumed 
to be normal) and no replacement is where the woman does not become pregnant 
again after terminating an affected fetus.  In terms of the net economic benefit to the 
community of preventing the birth of a person with Down‟s syndrome, the costs that 
arise in both of these situations would then be compared to the resources saved 
(averted costs) of caring for a person with Down‟s syndrome (i.e. the cost to the 
community for their care).  The averted costs in this study comprised permanent care 
costs, education costs and lost maternal income. 
 
Further examples of cost analyses of preventing the births of disabled children followed 
[Hagard et al, 1976; Henderson, 1982a; Henderson, 1982b; Gill et al, 1997].  In each of 
the examples, the authors looked at the costs of introducing a programme for the mass 
screening of pregnancies for the detection and termination of affected fetuses.  The 
issue of replacement was discussed with different assumed rates of replacement and 
the delay in replacing a pregnancy.  Hagard et al (1976) estimated the total costs to the 
health service of running a mass screening programme for spina bifida for 20 years.  
They found that spina bifida patients used more resources – medical, educational, 
social and personal - than patients without spina bifida i.e. „normal‟ patients and they 
calculated the average savings in excess costs of resources used, through births 
prevented as a result of the programme.  However, the authors did not look at any 
benefits from such screening programmes.  Henderson (1982a) conducted an 
economic appraisal of the costs of a mass screening programme for the prenatal 
detection of fetuses affected by spina bifida.  He compared the net costs to society of 
the cohort of disabled individuals born in the absence of a screening programme with 
the cohort of individuals who would be born if the programme was implemented.  He 
estimated the net costs with different assumed rates of replacement for terminated 
pregnancies (0%, 50%, 100%, 150% and 200%), and the different assumed delays in 
replacing a pregnancy was between 6 months and 2 years (an estimate of 1 year was 
used).  He used different life expectancies for the disabled and non-disabled children 
by using age-specific and sex-specific mortality ratios.  In a subsequent paper, 
Henderson (1982b) adopted a similar approach in respect to the costs of screening for 
open neural tube defects i.e. comparing a cohort of disabled children born if there was 
no screening programme, with a cohort of „replacement‟ non-disabled children born if 
there was a screening programme.  The difference between the two is the cost of the 
screening programme itself, which has been subtracted to provide an estimate for the 
expected net benefit [Henderson, 1982b].  The author assumed that: 1) the 
replacement of pregnancies may be less than 100%; 2) individuals with neural tube 
defects have a shorter life-expectancy than non-disabled children; and 3) the cohort of 
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replacement individuals will be born a year later after the termination of an affected 
fetus, so their costs must be discounted by this extra year.  Gill and colleagues (1987) 
looked at the direct and indirect costs of a screening programme for Down‟s syndrome 
taking into account maternal age and serum alpha fetoprotein concentration levels; 
they did not take into account any benefits associated with the screening programme.  
The authors looked at the lifetime costs of individuals born with and without Down‟s 
syndrome and these costs included: lost parental output and their own output, use of 
healthcare services and other non-NHS services, education and fostering and adoption 
costs.  The authors also assumed replacement rates for pregnancy after termination of 
affected fetuses (0%, 50%, and 100%) and they assumed that replacement could occur 
any time after nine months, although in most cases the authors acknowledged it could 
be longer.   
 
In summary, from these earlier studies the common themes occurring was the 
comparison of the costs of a cohort of disabled individuals born in the absence of a 
screening programme with a cohort of individuals born if a screening programme was 
implemented.  The authors assumed: 1) different rates of replacement pregnancies 
(anything between 0% and 200%); 2) different delays in replacing a pregnancy (usually 
an estimate of a year was used); and 3) the outcome of the replacement pregnancy 
was „normal‟.  The authors only looked at the „averted costs‟ i.e. the resources used 
and did not consider any benefits in clinical terms associated with the screening 
programme.  
 
Antenatal screening programmes using decision analytical models 
Next stage was to search for other information available in the public domain on other 
antenatal screening programmes and how the longer-term costs and benefits were 
calculated.  The earlier studies calculated „costs‟ associated with and without screening 
programmes and did not use decision modelling.  The latter studies used decision 
analytical modelling to see whether a screening programme was cost-effective or not, 
and the benefits associated with these screening programmes were no longer in terms 
of averted costs, but instead clinical outcomes such as the number of cases detected 
and generic utility measures such as QALYs were used.  For example, Fletcher et al 
(1995) used decision analysis to compare different screening policies such as maternal 
serum testing for Down‟s syndrome across a broad range of outcome measures 
including live births with and without Down‟s syndrome; miscarriages with Down‟s 
syndrome; and cases of Down‟s syndrome detected antenatally.  They found that 
offering serum testing to women of all ages would prevent the birth of approximately 
one more baby with Down‟s syndrome per year, than would a screening policy for 
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women aged 30 years or older.  Gilbert et al (2001) conducted a cost-effectiveness 
analysis of comparing antenatal screening strategies for Down‟s syndrome.  The main 
outcome measures included the number of babies born with Down‟s syndrome, 
miscarriages due to chorionic villus sampling (CVS) or amniocentesis and the 
additional miscarriages per additional affected live birth prevented by adopting a more 
effective strategy.  They found that compared with no screening, nuchal translucency 
screening would result in 7.6 fewer babies born with Down‟s syndrome, at a total cost 
of £171,000 per 10,000 pregnant women (in 1998 prices).  Thus, the additional cost per 
additional Down's syndrome live birth prevented was £22,000.   
 
Rowley et al (1998) conducted an economic evaluation for prenatal screening for cystic 
fibrosis carriers using decision analytical modelling.  They adopted a societal 
perspective and considered the impact on the quality of life and earnings of a couple 
who had a cystic fibrosis child.  For each couple, they looked at the outcome of a single 
pregnancy, unless this pregnancy was terminated due to cystic fibrosis and if the 
pregnancy was terminated, a replacement pregnancy was also considered (birth 
outcome for the replacement pregnancy could be with or without cystic fibrosis).  
Utilities were estimated using the time-trade off method.  They found that if a 
pregnancy was terminated due to cystic fibrosis and was replaced, the marginal cost 
for prenatal cystic fibrosis carrier screening was estimated to be US$8,290 per QALY 
(in 1996 prices). 
 
In another study, Harris and colleagues (2004) used cost-utility analysis to compare 
CVS and amniocentesis versus no invasive testing10 for women aged 35 and older, or 
for women who were at high risk of giving birth to an infant with Down‟s syndrome.  The 
decision model followed women from the 10th week of pregnancy (before any 
diagnostic testing was undertaken) and then followed the patient through the rest of 
their pregnancy, including during birth and then throughout the remainder of the 
woman‟s life expectancy.  The outcomes from diagnostic testing included: a baby born 
with or without a chromosomal abnormality, miscarriage, termination after positive test 
results, and whether a future birth occurs after a pregnancy loss.  They used data 
where possible from randomised trials and case registries to populate their model.  
Preference weights (utilities) for health states were derived using a time-trade off 
exercise from a large sample of pregnant women (n = 534) from a broad ethnic and 
socioeconomic mix, aged between 16 and 47 years; where 0 = maternal and fetal 
death and 1 = perfect health.  Where possible, published cost data were used and 
                                                 
10
 One point to be aware of is that there are no invasive risks associated with echocardiography/anomaly 
ultrasound scans, unlike invasive tests for Down‟s syndrome such as CVS and amniocentesis. 
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costs and outcomes were discounted at 3%.  They found that compared with no 
testing, amniocentesis costs less than US$15,000 per QALY gained for women all 
ages and risk levels (in 2003 prices).  CVS was more costly and less effective (i.e. 
dominated) than amniocentesis for all options.  
 
In relation to congenital heart disease, Odibo and colleagues (2006) wanted to 
determine whether a policy of universal fetal echocardiography for all pregnant diabetic 
women was a cost-effective screening tool for congenital heart defects in the second 
trimester.  They used a decision analytical model based on a cohort of 40,000 pregnant 
diabetic women and compared four strategies: 1) no ultrasound screening; 2) selective 
fetal echocardiography after abnormal ultrasound results; 3) fetal echocardiography for 
women with elevated haemoglobin A1C levels; and 4) universal fetal echocardiography 
for all diabetics.  Costs, utilities which were then converted to QALYs and the sensitivity 
and specificity for each strategy were obtained from a literature search.  The authors 
found that strategy 2 costs less per QALY gained for cardiac defect screening; whereas 
universal fetal echocardiography was associated with a higher detection rate for 
cardiac defects, although it was more costly. 
 
However, even though the majority of antenatal screening studies used decision 
modelling or cost-utility analysis, these type of economic evaluations may not be the 
most appropriate when it comes to quantifying health benefits.  This is because some 
of the benefits may fall outside the healthcare sector such as process benefits (i.e. 
speed or reassurance) or it may even be in terms of cost savings to patients.  Instead, 
a cost-consequences analysis may be more relevant.  With a cost-consequences 
analysis, all the different types of outcomes can be taken into account and each of the 
different outcomes can be presented alongside each other; or perhaps if benefits were 
to fall outside the healthcare sector, then it maybe more applicable to use a cost-
benefit analysis which would look at both costs and outcomes in monetary terms, 
although this is likely to be unfeasible. 
 
Systematic reviews of antenatal screening programmes  
Only one systematic review and critique of studies of economic evaluations of 
antenatal screening programmes has been published to date.  This paper published in 
2000 by Petrou and colleagues, which predates some of the studies which used 
QALYs, identified 566 studies which were published after 1991, of which only 41 were 
classed as economic evaluations.  Fourteen of these 41 studies focused on antenatal 
screening programmes for Down‟s syndrome or for routine ultrasonography for the 
detection of fetal anomalies.  The authors found that results varied in terms of the 
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methodology and reporting of results for the economic evaluations.  Of those 14 
studies, only three adopted a societal perspective which incorporated direct and 
indirect costs associated with each screening strategy [see Chapter 3 for more detail 
on the different types of costs].  Two studies did not provide enough information on 
costs associated with new screening programmes such as staff training.  Two studies 
on Down‟s syndrome also looked at the costs attributable to a replacement pregnancy.  
All 14 studies, if appropriate, discounted future costs into present values; however, five 
of the 14 studies did not conduct any sensitivity analysis on the key economic 
parameters.  The review also highlighted the narrow definition for benefits which was 
adopted throughout the literature.  For example, five studies used cases detected as 
the primary outcome measure; another four studies measured outcomes in terms of 
cases of a particular disorder being prevented by screening and it was assumed that 
this positively diagnosed fetus would be terminated; and a further two studies looked at 
outcomes in terms of averted costs.  
 
QALYs for the fetus or the mother? 
One of the main issues that arise with measuring benefits for screening programmes is 
whose QALYs to estimate: 1) those for the pregnant woman; 2) those for the unborn 
child; 3) or both - the pregnant woman and the unborn child?  Shackley and Cairns 
(1996) raised the issue of whose QALYs are relevant – those of the pregnant woman 
and/or the unborn child, and suggested that there are potential difficulties in calculating 
QALYs for both groups of patients.  For example, if QALYs are calculated at the point 
of birth of the child, this would not take into account any QALY losses associated with 
termination of pregnancy to the mother.  However, if QALYs are calculated at some 
time point during pregnancy i.e. at the anomaly scan, the QALY losses to the mother 
can be avoided, as aborted fetuses (terminations) are included.  The main controversy 
is whether to include QALYs of the terminated fetus?  One argument for including the 
utility of the pregnant mother into QALY calculations is that some pregnancies do not 
reach full term (i.e. terminations) and this may still have an impact on the quality of life 
of the pregnant mother and any future birth that she may have and whether this child 
has a congenital heart defect or not.   
 
7.3 Modelling lifetime costs and benefits for a telemedicine for a telemedicine 
screening service 
Following on from the literature on antenatal screening programmes, this section aims 
to calculate the lifetime costs and outcomes for children born with and without CHD 
when comparing a screening programme with telemedicine to a screening programme 
without telemedicine using a decision-analytical model.  The main aim is to see 
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whether telemedicine should be offered to all low risk women who have undergone an 
ultrasound anomaly scan (this group of women had the highest number of missed 
cardiac anomalies) and to see whether such a screening strategy with telemedicine is 
cost-effective.   
 
A cost-effectiveness analysis was undertaken and a UK NHS perspective was adopted.  
This Chapter does not consider patient costs as it was ascertained in Chapter 6 that 
patient costs did not significantly add to the total costs of pregnancy.  Evidence on 
outcomes and costs were based on patient level data from Chapter 6.  Extrapolation 
beyond the end of the study (just after delivery) was carried out for the lifetime for the 
children who were born with and without CHD.  Expert opinion and data from published 
sources was used to populate the decision model.  The main outcome was QALYs and 
results were presented as cost per QALY.  Future costs and benefits were discounted 
at an annual rate of 3.5% [HM Treasury, 2003].  All costs are presented in UK pounds 
sterling in 2005/2006 prices.  Various one-way sensitivity analyses were conducted to 
compare the differences in costs and outcomes for a screening programme with 
telemedicine compared to a screening programme without telemedicine.  
 
7.3.1 Literature review on costs and benefits and other information for the CHD 
decision model 
This section will provide a brief overview of some of the literature which were available 
to help populate the decision model in terms of resource use, costs and utilities. 
 
Resource use and unit cost data 
A review of the literature found that there was no comprehensive information on the 
resource use over the lifetime of children who were born with different types of CHD.  
Mackie and colleagues (2007) quoted “the number of adults with congenital heart 
disease is increasing.  However, rates of health care resource utilization in this 
population are unknown”; likewise, Moons and colleagues (2001) said that “information 
on utilization of resources in adults with congenital heart disease is scarce”.   
 
Various studies (see examples below) have looked at resource use for CHD patients of 
different ages, but not resources used over the lifetime of CHD patients.  In addition 
some studies with the different age groups, including the various stages when 
resources may have been incurred may not be appropriately applied in the analysis of 
prenatal screening.  Some studies have looked at resource use for CHD patients in 
different countries, but it is quite hard to generalise to the UK setting the resources 
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used from other countries.  Also, any earlier data would not really be applicable now, 
as paediatric cardiology over time has changed.  For example: 
 Garson and colleagues (1994) assessed the cost of CHD among six centres in the 
United States.  They looked at patients from birth to 21 years and from 22 to 40 
years of age.  Patients were split into three CHD categories: benign disease (mild), 
acyanotic disease (which includes atrial septal defect and ventricular septal defect) 
and cyanotic disease (which includes tetralogy of Fallot and hypoplastic left heart 
syndrome).  For each centre, the authors estimated the percentage of patients that 
fell into each CHD category and for each CHD category the number of clinic visits, 
hospitalisations and number of years of drug use.  The authors said that this data 
had to be estimated for two reasons: “such detailed data were not available on 
patients for the last 21 years and the practice of pediatric cardiology has changed 
markedly during the last 21 years”.  The paper did not provide a breakdown of 
resource utilisation for each of the CHD sub-categories.  They found that for 
patients with cyanotic disease, their cost was almost double that of patients who 
had acyanotic disease (in 1992 prices).   
 Garson et al (1996) in a follow-up paper looked at the variations in cost of CHD 
and clinical practice across nine countries.  Five „typical‟ patients, each with a 
different type of CHD were presented to each clinician at each centre for them to 
estimate the likely course of health care resource utilisation for patients from birth 
to 21 years of age.  Again, this paper did not provide a comprehensive breakdown 
of resource utilisation for each of the CHD sub-categories.   
 Mackie et al (2007) looked at the health care resource utilisation in adults with 
CHD from 1996 to 2000 in Quebec, Canada.  A five-year time period was chosen 
to capture resource use as patients with mild CHD may receive infrequent health 
care.  They measured the impact of severity of CHD on the use of health care 
resources using multivariate models to adjust for age, gender, Charlson co-
morbidity score and the duration of follow-up.  The authors found (as expected) 
that patients with severe CHD had higher adjusted rates of outpatient visits to 
cardiologists, emergency department visits, days in hospital and days in critical 
care units than patients with other congenital cardiac lesions.   
 More recently, Knowles et al (2005) developed a decision analytical model based 
on 100,000 live births to determine the most cost-effective newborn screening 
strategy for congenital heart defects.  The three strategies included: 1) clinical 
examination alone; 2) clinical examination with pulse oximetry; and 3) clinical 
examination with screening echocardiography; in making a timely diagnosis before 
the infant develops life-threatening symptoms of cardiovascular collapse or before 
death.  The authors only provided the costs of screening such as staff and 
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equipment costs; they did not provide information on other resource use such as 
the number of bed days a neonate stayed in the hospital or the number of 
outpatient visits they may have had.  The authors concluded that the addition of 
pulse oximetry to clinical examination is likely to be a cost-effective strategy, 
whereas screening newborns by echocardiography is unlikely to be cost-effective.   
 
Health State Utilities 
A review of the literature found that there was also no comprehensive information on 
the health state utilities of patients who were born with different types of CHD; instead 
the health state utilities focused mainly on patients with cardiovascular diseases such 
as heart failure or coronary heart disease.  
 
In relation to CHD, the studies identified through the literature search reported 
information on quality of life but not on health state utilities.  For example, Latal et al 
(2009) published a systematic review on the quality of life in children and adolescents 
following open-heart surgery for CHD.  They conducted a review because of the little 
evidence that existed regarding the long-term health-related quality of life in children 
with CHD who required open-heart surgery.  The literature search looked at studies 
which were published between 1990 and 2008 and found only 12 studies which 
focused on the quality of life.  Of these 12 studies, 7 various health questionnaires 
were used to measure quality of life such as the Child Health Questionnaire, PedsQL 
and the Pediatric Cardiac Quality of Life Inventory; however, none of these instruments 
are used to estimate or calculate health state utilities.  There has been an attempt to 
develop a new measure of quality of life for children and adolescents with CHD: the 
ConQol [Macran et al, 2006].  In the paper, Macran and colleagues talk about the 
process they went through in constructing the questionnaire, the piloting and the 
development of a weighted scoring system.  The questionnaire was used on a sample 
size of 640 people who were recruited from six regional cardiology centres in the UK.  
The ConQol has two versions, one designed for use for children aged 8 to 11 years, 
and the other for adolescents aged 12 to 16 years.  However, the ConQol just provides 
an index score and cannot be used to calculate health state utilities.   
 
The majority of economic evaluations conducted alongside clinical trials for 
cardiovascular disease (CVD) used health-related quality of life measures alongside 
clinical outcomes to measure the health status of individual patients.  One of the most 
common measures which has been used to assess the stage of heart failure is the 
New York Heart Association (NYHA) functional classification system [NYHA 
Committee, 1994].  This classification system relates symptoms to everyday activities 
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and the patient's quality of life and has been mainly used for older children and adults 
with heart failure.  Heart failure was categorised into four categories:  Class I and II 
relating to mild heart failure; Class III relating to moderate heart failure; and Class IV 
relating to severe heart failure.  There are generic measures which are routinely being 
used to measure health-related quality of life in CVD patients such as the EQ-5D.  
There are also disease-specific instruments such as: the Seattle Angina Questionnaire 
[Spertus et al, 1995] which is a self-administered 19-item questionnaire measuring five 
dimensions of coronary artery disease (physical limitation, anginal stability, angina 
frequency, treatment satisfaction and disease perception); and the MacNew Heart 
Disease health-related quality of life instrument [Höfer et al, 2004], which is a self-
administered questionnaire consisting of 27 items that fall into three domains (physical 
limitations, emotional function and social function).   
 
A recently published study conducted a structured literature search using keywords 
relating to CVD and the EQ-5D [Dyer et al, 2010].  The authors identified 147 papers, 
of which 66 of these met their selection criteria for further review.  Sixty studies 
reported EQ-5D scores (VAS or self-classification) and 10 studies presented evidence 
on the validity or reliability of the EQ-5D.  Overall, the authors concluded that “the 
published evidence generally supports the validity and reliability of the EQ-5D as an 
outcome measure within the cardiovascular area” [Dyer et al, 2010].  Even though 
there was some variation in the results reported, they thought this was due to the 
differences in CVD in terms of disease stage and patient characteristics.  They thought 
their review provided useful utility estimates across a range of CVD subgroups and 
would be useful for future modelling of utilities and QALYs in economic evaluations of 
CVD. 
 
Several studies have attempted to calculate health state utilities for CHD patients who 
also had other underlying health conditions and the health state utilities from these 
studies (along with other studies) will be used in the decision model.   
a) During pregnancy: 
For QALY calculations during pregnancy, the model will consider the mother‟s utility 
until birth and when the child is born, the child‟s utility will be measured (a combined 
mother and child outcome).  This has been the standard norm when looking at mother 
and child outcomes during pregnancy and after birth. 
 Kupperman et al (1999) conducted a cross-sectional study of 72 women aged 35 
or older on how they value the outcomes of two prenatal diagnostic tests: CVS and 
amniocentesis.  The authors said that the two tests have different miscarriage risks 
and in deciding which test to use, women should be aware of the short-term (e.g. 
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pregnancy loss) and long-term consequences (e.g. whether a termination of 
pregnancy is followed by a future birth).  Preferences for outcomes (utilities) of 
testing were measured using the standard gamble approach. The authors found no 
difference in mean utilities assigned to first versus second trimester pregnancy 
losses.  However, utilities for pregnancy losses followed by future birth were higher 
than for utilities without a future birth [This study is linked to the Harris et al (2004) 
paper]. 
b) From birth onwards: 
 Caviness et al (2004) looked at the use of bacterial endocarditis prophylaxis for 
children aged 0 to 24 months who have cardiac lesions and are about to undergo 
urinary catheterization.  Outcomes were based on bacterial endocarditis incidence 
and QALYs.  QALYS were calculated using the Years of Healthy Life measure and 
the average life expectancy for congestive heart failure.  Probabilities were derived 
from the medical literature and costs were obtained from local and national 
sources.  The authors concluded that the use of bacterial endocarditis prophylaxis 
for patients with cardiac lesions was not a cost-effective use of resources.  
 Brown and colleagues (2009) conducted an economic evaluation of extracorporeal 
membrane oxygenation (ECMO) as a bridge to transplant for 75 children with end-
stage heart failure due to dilated cardiomyopathy.  An expert panel established 
QALY weights for health states using the HUI mark II measure.  Results were 
expressed in terms of cost per QALY.  The authors found that bridging was 
effective but expensive. 
 Yount and Mahle (2004) conducted an economic analysis of the use of palivizumab 
in infants with CHD.  Palivizumab is used in the prevention of respiratory syncytial 
virus infections and is recommended for infants that have CHD.  The authors said 
that “utility data (to evaluate quality of life) in children and adults with CHD is 
lacking”.  Therefore, the authors extrapolated utility data from adults with 
congestive heart failure to the CHD population.   
 Kirsch and McGuire (2000) asked 64 respondents aged between 26 and 65 years 
to provide health state valuations for the four different NYHA classifications of 
disease progression using the EQ-5D.  The authors found consistent mappings 
between the disease classification and the EQ-5D.  
 
Survival probabilities and life expectancy 
The majority of studies looking at the different types of CHD did not provide information 
on patients‟ life expectancy.  Many studies were more than five years old and survival 
rates for CHD surgery and the life expectancies for the different types of CHD may now 
be different. 
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Knowles et al (2005) conducted a systematic review of the literature and found 104 
papers reporting actuarial survival rates for the different types of CHD and this was 
reported along with the main complications and causes of death for each type of study.  
For example, for a CHD patient with hypoplastic left heart syndrome survival rates 
ranged from 33% to 59% (1 year) and for patients with tetralogy of Fallot, survival rates 
ranged from 75% to 98% (20 years).  
 
Other studies identified which were particularly relevant; although they did not provide 
comprehensive information, included: 
 Williams et al (2000) examined the survival and quality of life of 106 children with 
CHD who had undergone surgery for hypoplastic left heart syndrome (surgery 
consists of three stages) between 1990 and 1999.  Median age for surgery stages 
1, 2 and 3 were 6 days, 9 months and 34 months respectively.  They found that the 
1-year and 5-year actuarial survival rate using the Kaplan Meier method was 58% 
and 54% respectively.  The authors found these rates comparable to other 
hypoplastic left heart syndrome survival rates after surgery.  The authors quoted 
survival rates but did not say anything about life expectancy of these CHD patients.    
 Walker and colleagues (2002) wanted to look at the survival and quality of life of 
CHD patients who had undergone repair of tetralogy of Fallot.  They quoted that 
survival after repair of tetralogy of Fallot at 20 years was reported ranging from 
84% to 93.7% and with survival at 25 years being 90.9%.   
 Mahle et al (2005) conducted a cost-utility analysis for salvage cardiac ECMO 
therapy in children with CHD.  The quality of life status of survivors was determined 
with the HUI mark II.  The authors assumed that life expectancy for children with 
single-ventricle heart lesions was assumed to be 40 years.  The authors found that 
salvage cardiac ECMO results in reasonable survival and was cost effective 
(<US$25,000 per QALY saved). 
 Garson et al (1994) calculated the expected lifetime of patients with CHD as the 
age by which 50% of subjects would be expected to die.  The expected lifetimes for 
acyanotic patients was 64.9 years and for cyanotic patients was 49.0 years.  
 
Diagnostic accuracy of telemedicine for CHD 
A literature search was undertaken to identify studies which have looked at the 
diagnostic accuracy of telemedicine in fetal cardiology.  However, no studies looked at 
this issue in detail for pregnant women; instead the diagnostic accuracy focused on 
fetal echocardiography screening.  For example, Stümpflen et al (1996) assessed the 
prenatal detection of CHD by detailed fetal echocardiography in an unselected, 
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consecutive group of 3,085 pregnant women in Austria; of which 540 women had 
maternal risk factors for CHD.  Forty-six cases of CHD were detected prenatally and 6 
cases had not been detected prenatally.  There were no false positives and the 
diagnostic accuracy of fetal echocardiography was: sensitivity – 85.5% and specificity – 
100.0%.  
 
However, a study by Grant et al (2010) seemed the most appropriate (that is, a UK 
based population cohort) and also used a second opinion to confirm diagnosis (i.e. 
telemedicine used a screening tool like the TelePaed study) for the information needed 
for the model.  The authors wanted to determine the accuracy of remote diagnosis of 
CHD in infants by real-time transmission of echocardiographic images via ISDN lines in 
Northern Ireland.  CHD was diagnosed in 84 of the 109 infants (39 infants had major 
CHD and 45 infants had minor CHD).  The initial diagnosis by the paediatrician in the 
DGH was accurate in 58% cases (63 cases).  However, when the echocardiogram was 
then transmitted via telemedicine to a paediatric cardiologist accuracy significantly 
increased (sensitivity 97% and specificity 96%). 
 
Similar specificity rates were found in another study (although this was an older study) 
which used a low cost telemedicine link to diagnose neonatal CHD [Mulholland et al, 
1999].  Echocardiographic images from neonates suspected of having CHD were 
transmitted by a telemedicine link to a regional paediatric cardiology unit for 
interpretation by a consultant paediatric cardiologist.  Sixty-three patients‟ 
echocardiographic images were transmitted.  CHD was diagnosed in 42 patients (14 
patients with major CHD and a further 28 with less serious CHD).  Accuracy of 
diagnosis was improved to 91.0% when transmitted via telemedicine.  The mean 
sensitivity rate was 90.5% and the mean specificity rate was 97.0%.  
 
7.4 Methods 
7.4.1 Patient group 
Pregnant women who had undergone an anomaly scan at Medway hospital from May 
2001 to July 2002 were classified into four categories by Specialist A, these were 
based on the classification of congenital heart defects by Knowles et al (2005): 
1. No disability – a fetus or baby who is classified as „normal‟. 
2. Mild CHD disability – a fetus or baby with mild CHD such as a small ventricular 
septal defect, which is not significant. 
3. Moderate CHD disability – a fetus or baby with a moderate CHD such as 
tetralogy of Fallot.  
193 
 
4. Severe CHD disability - a fetus or baby with a rather complex CHD, such as 
hypoplastic left heart syndrome. 
Knowles et al (2005) in their report referred to mild CHD as clinically non-significant; 
moderate CHD as clinically significant; and severe CHD as life threatening.   
 
7.4.2 Model structure and assumptions 
Decision analytical modelling represents the various clinical pathways for alternative 
treatments and quantifies the probability of a patient following each pathway.  For each 
pathway, the range of possible costs and health-related outcomes can be calculated.  
A decision tree model was considered to be the most appropriate model for this study, 
given the short-term nature of the decision problem [Fletcher et al, 1995; Gekas et al, 
2009] and was used to compare the different options.  The starting point of the model is 
from the time of the anomaly scan; hence lifetime costs and outcomes for children born 
with and without CHD were calculated from this point.   
 
Figure 7.1 shows the overall structure for the decision tree for all low risk women.  
There are two main options:  
1)  After the anomaly scan is conducted no low risk woman is offered telemedicine 
(TM).  If no anomaly is suspected, the pregnant woman‟s ultrasound scan is not 
further reviewed by a specialist and any antenatal care for the patient is 
provided in the DGH.  However, if an anomaly is suspected then a patient is 
seen by a specialist (direct referral); and  
2) After the anomaly scan each patient‟s scan is further reviewed by a specialist 
using a store-and-forward approach via the telemedicine service (i.e. this is not 
a selective use of telemedicine and telemedicine was used for further 
clarification, that these pregnant women are not carrying a fetus with CHD) and 
any antenatal care for the patient is provided in the DGH.   
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Figure 7.1: Decision tree
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No telemedicine for low risk women 
Assuming that telemedicine was not offered to any women, at the anomaly ultrasound 
scan, sonographers may detect a cardiac anomaly.  If an anomaly was found, then a 
woman is seen by a specialist (direct referral) and can then choose to terminate or to 
continue with the pregnancy.  If they continue with the pregnancy, the baby can be 
born with a heart defect or in a few instances, the defect may have repaired itself so 
the child would be classified as „normal‟.  If no anomaly was found at the scan, the 
woman would continue with the pregnancy.  If they continue with the pregnancy, the 
baby can be born „normal‟ i.e. no heart defect or with a heart defect – in this instance 
this would be recorded as a „missed cardiac anomaly‟. 
 
Telemedicine for all low risk women 
Assuming that telemedicine is offered to all low risk women, telemedicine can then be 
used as screening tool to confirm whether the patient had a cardiac anomaly or not.  If 
the woman had a fetus with a cardiac anomaly, plans can be made whether to 
terminate or to continue with the pregnancy. 
 
If telemedicine is offered to all low risk women, there would have to be a team of 
specially trained staff e.g. sonographers at the specialist hospital to review the anomaly 
scans that would come through in the telemedicine store-and-forward sessions.  For 
example, if a specialist was on average able to assess 12 women during a 
telemedicine session which lasted approximately an hour, and assuming that person 
works 37.5 hours a week, for one person to assess 4,786 low risk women (total number 
of low risk maternities during this period) by telemedicine this would take up just under 
11 working weeks of the person‟s time over 15-months.  Furthermore, extra time would 
also have to be allocated to the district hospital sonographers for sending all the pre-
recorded videoed anomaly scans by telemedicine.   
 
Missed cardiac cases 
In Chapter 2, it was established when looking at the referred women (direct referral and 
telemedicine women) that there were no missed cardiac cases i.e. all cases that were 
screened by telemedicine or seen by a specialist face-to-face were either a „true 
positive‟ or a „true negative‟.  This may be partly due to the sonographers obtaining 
second opinions for these women i.e. by screening of the fetal heart and to confirm any 
heart abnormalities.  All cardiac cases were detected before birth for these two groups 
and there was a slightly higher prevalence rate in the direct referral group compared to 
the telemedicine group, as this group contained the more „selected‟ high risk women 
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who needed a second opinion straightway and any delay in waiting for a „monthly‟ 
scheduled telemedicine clinic was not considered to be appropriate.   
 
However, if telemedicine was used in routine practice and because of the higher 
throughput, then sensitivity and specificity may actually fall (i.e. there may be a change 
in the performance levels); on this basis, one would consider that telemedicine would 
no longer be 100% sensitive and 100% specific.  Instead, it was assumed telemedicine 
has a 97% sensitivity and 96% specificity rate [Grant et al, 2010].   
 
Replacement births 
If a woman had a confirmation of a cardiac anomaly and chose to terminate her 
pregnancy, would she choose to replace this aborted pregnancy with another 
pregnancy?  If a pregnancy is replaced, for simplicity it has been assumed that the 
outcome of this future pregnancy is normal [Hagard and Carter, 1976; Henderson, 
1982a; Gill et al, 1987].  As seen from the earlier papers, there were different rates for 
replacement of terminated pregnancies and there were also delays in replacing a 
pregnancy.  For these analyses, a 50% replacement of terminated pregnancies11 has 
been assumed [Henderson, 1982a; Gill et al, 1987] and the delay in replacing a 
pregnancy would be one year [Henderson, 1982a; Henderson, 1982b].   
 
7.4.3 Base-case analysis 
1. No woman receives telemedicine after the second trimester anomaly scan (no 
telemedicine). 
2. All women receive telemedicine after the second trimester anomaly scan and 50% 
of the affected fetuses detected prenatally are terminated12 and there is a 50% 
replacement of all terminated cases (all with telemedicine). 
 
7.4.4 Model probabilities 
Table 7.1 below shows the model probabilities based on the actual numbers of 
women who followed each pathway.  
 
                                                 
11
 A 50% replacement rate was chosen for terminated pregnancies as this seemed much more plausible. 
In the sensitivity analysis, two other scenarios will be explored: no replacement of terminated cases and 
100% replacement of terminated cases. 
12
 For the base-case analysis, the termination rate is based on the number of direct referrals and 
telemedicine women who detected an anomaly prenatally and then subsequently went on to terminate the 
pregnancy (see Chapter 2 for more details).  
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Table 7.1: Model probabilities 
 Number/Event rate Base-case probability 
Total number of women 4,786 - 
Total number of anomalies 8 - 
No telemedicine 
Probability of detecting an anomaly 3 0.375 
Probability of missing an anomaly 5 0.625 
All telemedicine* 
Probability of detecting an anomaly 7 0.875 
Probability of missing an anomaly 1 0.125 
*Assuming telemedicine is 97% sensitive & 96% specific 
 
7.4.5 Life expectancy 
Table 7.2 below shows the life expectancy at birth.  For babies with no CHD disability, 
this was based on the average life expectancy of a male and a female combined [ONS, 
2008].  For babies with a mild CHD, moderate CHD or severe CHD disability these 
values were obtained from expert opinion [Personal communication with Specialist A, 
September 2009].  
 
Table 7.2: Life expectancy for normal and CHD babies 
Variable Base case value Source 
No disability 
Mild CHD disability 
Moderate CHD disability 
Severe CHD disability 
78 years 
78 years 
50 years 
30 years 
ONS (2008) 
Specialist A 
Specialist A 
Specialist A 
 
7.4.6 Resource use and unit cost data 
Data for resource use was obtained from expert opinion.  With the help of Specialist A, 
another Specialist (Specialist B) who was based at the Adult Congenital Heart Unit at 
the RBH and also a representative from the Grown Up Congenital Heart Patients 
Association (GUCH Patient Representative), provided the relevant resource use for an 
„average‟ CHD patient who was classed as either „mild, „moderate‟ or „severe‟.  Table 
7.3 shows the amount of resources consumed during a lifetime for an „average‟ patient 
who was classed as either „normal‟, „mild, „moderate‟ or „severe‟.   
 
A substantial proportion of patients born with CHD are treated in the first few years of 
life and do not require regular follow-up in adulthood [Moons et al, 2001].  Based on 
this assumption, the cost of surgery was only included for moderate and severe CHD 
patients during the neonatal period.  For example, for a patient who has tetralogy of the 
Fallot (moderate CHD) which is one of the most common types of congenital heart 
defects, where four heart malformations (pulmonary stenosis, overriding aorta, 
ventricular septal defect, and right ventricular hypertrophy) present together [Knowles 
et al, 2005], surgical repair is recommended and is conducted when the child is a 
neonate.  The outcome following surgery is very good and there are relatively few 
further problems [Knowles et al, 2005].  Whereas, for a patient who has hypoplastic left 
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heart syndrome (severe CHD), surgery is usually conducted in three stages because of 
the complexity of the defect.  Without surgery, hypoplastic left heart syndrome can lead 
to early heart failure or even death [Knowles et al, 2005].  The cost of surgery was 
obtained from the NHS reference costs [Department of Health, 2008] (see Table 7.4). 
 
GUCH patient representative and Specialist B provided information on the most 
common drugs that either a moderate or a severe CHD patient would be prescribed.  A 
moderate CHD patient would be prescribed about 3 drugs (Digoxin, Frusemide and 
Warfarin) they are most likely to take every other day, whereas, with severe CHD 
patients, they would be prescribed about 7 drugs (Digoxin, Frusemide, Warfarin, 
Amioderone, Bisoprolol, Verapamil, and Ramipiril) and most of these drugs are taken 
daily.  So based on these assumptions and using the British National Formulary [BNF, 
2005] as a guide to work out the approximate dosages for both children and adults, the 
yearly cost of drugs intake for an average moderate and an average severe CHD child 
and adult was estimated.  Furthermore, if a patient had a „missed cardiac anomaly‟, 
both Specialist A and Specialist B asserted that any additional resource use for these 
patients would be incurred during the neonatal period.   
 
Unit costs for the resource items presented in Table 7.3 are shown in Table 7.4 in 
2005/2006 prices.  Unit costs taken from other financial years were adjusted to 
2005/2006 prices using UK Hospital and Community Health Service indices [Curtis, 
2008].  For hospital admissions (inpatient stays and outpatient visits) and tests and 
investigations, these unit costs were obtained from the NHS reference costs 
[Department of Health, 2006; Department of Health, 2008].  The cost for the 
cardiologist was obtained from the Unit Costs of Health and Social Care 2006 [Curtis 
and Netten, 2006] and the cost of the chest x-ray was provided by Medway finance 
department.  Unit costs for drugs were obtained from the British National Formulary 
[BNF, 2005].  It was assumed that each patient (normal to severe CHD disability) would 
incur a cost to the NHS i.e. for prescriptions or a visit to the hospital other than for CHD 
and this would be a recurring annual cost for these patients in the model.  These 
recurring annual costs were obtained from the report on costing NHS care for pre-term 
birth of neonates to 18 years of age [Mangham et al, 2009] and these costs vary by 
age.  For simplicity, it was assumed that these costs would also remain the same 
during their adult lifetime.   
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Table 7.3: Resource use data 
Variable Resource use Source 
During pregnancy  
From time of anomaly scan until just after 
delivery or after termination of pregnancy 
 
Neonatal care (from birth to 1 year) 
No disability 
 
Mild CHD disability 
 
Mild CHD disability (missed*) 
 
Moderate CHD disability 
 
 
 
Moderate CHD disability (missed*) 
 
Severe CHD disability 
 
 
 
Severe CHD disability (missed*) 
 
Children and Adult (2 + years)  
Mild CHD disability  
 
 
 
Moderate CHD disability 
 
 
 
 
 
 
Severe CHD disability 
 
This includes all costs incurred during pregnancy for low risk women who were seen with or 
without telemedicine 
 
 
Normal care in neonatal unit (1.7 days) 
 
Normal care (1.7 days) & special care (3.7 days) in neonatal unit 
Echocardiogram (outpatient)  
Same as above plus 2 outpatient visits 
 
Normal care (1.7 days), special care (3.7 days) & high dependency care (5.5 days) in 
neonatal unit 
Surgery 
Echocardiogram (inpatient); Drugs (3 drugs taken every other day) 
Same as above plus additional inpatient stay: special care (2.5 days) in neonatal unit  
 
Normal care (1.7 days), special care (3.7 days), high dependency care (5.5 days) & intensive 
care (6 days) in neonatal unit 
Surgery 
Echocardiogram (inpatient); Drugs (7 drugs taken daily) 
Same as above plus additional inpatient stay: special care (2.5 days) & high dependency care 
(5 days) in neonatal unit  
 
Outpatient clinic every 4 years. Each outpatient clinic includes ECG, chest x-ray and 
transthoracic echo (plus 30 mins of cardiologists time) 
Inpatient stay (2 day) every 15 years 
 
Outpatient clinic every year. Each outpatient clinic includes ECG and chest x-ray (plus 30 
mins of cardiologists time) 
Inpatient stay (2 day) every 3 years 
Echo (outpatient) every 2 year; Cardiac MRI scan every 3 years 
Exercise test every 3 years; Catheter every 15 years 
Drugs 
 
Bi-annual outpatient clinic. Each outpatient clinic includes ECG and chest x-ray (plus 30 mins 
of cardiologists time) 
Inpatient stay (1 day) every 2 years 
Echo (outpatient) every 2 years; Cardiac MRI scan every 3 years 
Exercise test every 3 years; Catheter every 10 years 
Drugs 
 
TelePaed study data 
 
 
 
Mangham et al (2009) 
 
Mangham et al (2009) 
Specialist B  
Assumption 
 
Mangham et al (2009) 
 
Specialist B 
GUCH PR + Specialist B 
Assumption 
 
Mangham et al (2009) 
 
Specialist B 
GUCH PR + Specialist B 
Assumption 
 
 
Specialist B + GUCH PR 
 
Specialist B + GUCH PR 
 
Specialist B + GUCH PR 
 
Specialist B + GUCH PR 
Specialist B  
Specialist B  
GUCH patient representative 
 
Specialist B + GUCH PR 
 
Specialist B + GUCH PR 
Specialist B  
Specialist B  
GUCH patient representative 
GUCH PR = Grown Up Congenital Heart Patient Representative; * Missed during antenatal period 
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Table 7.4: Unit costs for resource use (in 2005/2006 prices) 
Variable Base case value (standard error*) Distribution Source 
Neonatal care 
Normal care 
Special care 
High dependency care 
Intensive care 
 
£412 
£412 
£726 
£1,020 
 
Gamma  
Gamma  
Gamma  
Gamma  
 
DH reference costs 2005/2006  
DH reference costs 2005/2006  
DH reference costs 2005/2006  
DH reference costs 2005/2006 
Surgery costs
#
 
Cases detected prenatally 
Moderate CHD disability 
Severe CHD disability 
Missed cases 
Moderate CHD disability 
Severe CHD disability  
 
 
£8,738 
£24,406 
 
£7,818 
£31,248 
 
 
Gamma  
Gamma  
 
Gamma  
Gamma  
 
 
DH reference costs 2006/2007 + Specialist B 
DH reference costs 2006/2007 + Specialist B 
 
DH reference costs 2006/2007 + Specialist B 
DH reference costs 2006/2007 + Specialist B 
Cost of health states (for all ages) 
Normal disability 
Mild CHD disability 
Moderate CHD disability 
Severe CHD disability 
 
£315 (£59) 
£611 (£95) 
£660 (£121) 
£1,206 (£237) 
 
Gamma  
Gamma  
Gamma  
Gamma 
 
Mangham et al (2009) 
Mangham et al (2009)  
Mangham et al (2009)  
Mangham et al (2009) 
Hospital admissions 
Outpatient visits 
Paediatric cardiology follow-up attendance 
Adult cardiology follow-up attendance 
Consultant cardiology cost (20 mins) 
Inpatient admissions 
Congenital disorders (regular admission) 
 
 
£173 
£97 
£50 
 
£361 
 
 
Gamma  
Gamma  
Gamma 
  
Gamma 
 
 
DH reference costs 2006/2007 
DH reference costs 2006/2007 
Curtis and Netten (2006) 
 
DH reference costs 2005/2006 
Tests and investigations 
ECG 
Chest X-ray 
Exercise test 
MRI scan 
Echocardiogram (outpatient) 
Echocardiogram (inpatient) 
Catheter ≤ 18 years 
Catheter ≥ 18 years 
 
£26 
£16 
£57 
£192 
£117 
£2,254 
£199 
£329 
 
Gamma 
Gamma 
Gamma 
Gamma 
Gamma 
Gamma 
Gamma 
Gamma 
 
DH reference costs 2006/2007 
Medway Finance Department 
DH reference costs 2006/2007 
DH reference costs 2006/2007 
DH reference costs 2006/2007 
DH reference costs 2006/2007 
DH reference costs 2006/2007 
DH reference costs 2006/2007 
Drug (actual net prices from BNF)† 
Digoxin 
Frusemide 
Warfarin 
Amioderone 
Bisoprolol 
Verapamil 
Ramipiril 
Children (1 to 18 years) 
£0.70  
£12.07 
£1.47 
£1.33 
£1.68 
£1.11 
£3.74 
Adults (18+ years) 
£1.04 
£0.62 
£1.47 
£2.43 
£1.68 
£0.62 
£3.74 
 
 
 
British National Formulary (Sept 2005) 
British National Formulary (Sept 2005)  
British National Formulary (Sept 2005)  
British National Formulary (Sept 2005)  
British National Formulary (Sept 2005)  
British National Formulary (Sept 2005)  
British National Formulary (Sept 2005) 
# See section on resource use and unit cost data for more information; † These are the actual net prices from the BNF – however, the dosages and strength for 
each drug is different; * If standard error was not available, it was assumed to be 0.1 of the mean value [Drummond and McGuire, 2001; Mangham and Petrou, 2008] 
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7.4.7 Health State Utilities 
As the utility data were hard to obtain for patients with different types of CHD, utility 
values from patients with heart failure were used to populate the model [Personal 
communication with Specialist B, October 2009].  Table 7.5 below shows the 
categorisation of patients with different types of CHD into the different heart failure 
categories [Personal communication with Specialists A and B, October 2009].   
 
Table 7.5: Classification of CHD patients into heart failure categories 
Class Patient Symptoms (NYHA) Categorisation for model 
Class I (Mild) No limitation of physical activity. 
Ordinary physical activity does not 
cause undue fatigue, palpitation, 
or dyspnea (shortness of breath). 
Mild CHD patients These patients have 
excellent prognosis, as most of these defects 
decrease in size or close. They also have no 
activity restrictions (from birth to 20 years of 
age). 
Class II (Mild) Slight limitation of physical 
activity. Comfortable at rest, but 
ordinary physical activity results in 
fatigue, palpitation, or dyspnea. 
Mild CHD patients These patients may also 
have some activity restrictions (from 21 
years of age). 
Moderate CHD patients These patients who 
have undergone surgery will have good to 
excellent cardiac function with some to no 
exercise intolerance (from birth to 20 years 
of age).  
Class III (Moderate) Marked limitation of physical 
activity. Comfortable at rest, but 
less than ordinary activity causes 
fatigue, palpitation, or dyspnea. 
Moderate CHD patients These patients after 
5-20 years of surgery usually have reduced 
exercise capacity (from 21 years of age). 
Class IV (Severe) Unable to carry out any physical 
activity without discomfort. 
Symptoms of cardiac insufficiency 
at rest. If any physical activity is 
undertaken, discomfort is 
increased. 
Severe CHD patients These patients have a 
good chance of survival but will experience 
chronic problems for the rest of their lives. 
They may be advised to limit their physical 
activities to their own endurance.  
 
In order to estimate QALYs the decision model required utility values.  Table 7.6 shows 
the utility values which were used in the base case analysis.  Utility values were 
obtained for five main categories: for the mother during pregnancy, no disability, mild 
CHD disability, moderate CHD disability and severe CHD disability. 
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Table 7.6: Utility values 
Variable Base case value (standard error*) Distribution Source 
During pregnancy for the mother    
No test, unaffected birth 0.918 Beta Harris et al (2004); Kuppermann et al (1999) 
Test, unaffected birth 0.960 (0.0153) Beta Kuppermann et al (1999) 
Termination (no future birth) 0.840 (0.0318) Beta Kuppermann et al (1999) 
Termination (future unaffected birth) 0.910 (0.0259) Beta Kuppermann et al (1999) 
Fetal death (still birth) 0.070 Beta Odibo et al (2006) 
    
Defects detected prenatally    
Mild cardiac defect 0.900 Beta Assumption 
Moderate cardiac defect  0.700 Beta Assumption 
Severe (major) cardiac defect  0.500 Beta Odibo et al (2006) 
No disability for the child**    
0 to 5 years 0.940 Beta Erickson et al (1995) 
6 to 24 years 0.940 Beta Kind et al (1999) 
25 to 34 years 0.930 Beta Kind et al (1999) 
35 to 44 years 0.910 Beta Kind et al (1999) 
45 to 54 years 0.850 Beta Kind et al (1999) 
55 to 64 years 0.800 Beta Kind et al (1999) 
65 to 74 years 0.780 Beta Kind et al (1999) 
75 + years  0.730 Beta Kind et al (1999) 
Mild CHD disability for the child**    
0 to 25 years 0.850 Beta Brown et al (2009) 
26 to 45 years 0.834 (0.02705) Beta Kirsch and McGuire (2000) 
46 to 65 years 0.697 (0.03306) Beta Kirsch and McGuire (2000) 
66 + years 0.697 (0.03306) Beta Assumption 
Moderate CHD disability for the child**    
0 to 25 years 0.750 (0.03962) Beta Yount and Mahle (2004) 
26 to 45 years 0.531 (0.06311) Beta Kirsch and McGuire (2000) 
46 to 65 years 0.488 (0.06170) Beta Kirsch and McGuire (2000) 
Severe CHD disability for the child**    
0 to 2 years 0.400 Beta Caviness at al (2004) 
3 to 18 years 0.390 Beta Brown et al (2009) 
19 to 25 years 0.390 Beta Assumption 
26 to 45 years 0.323 (0.06505) Beta Kirsch and McGuire (2000) 
Assumed test = telemedicine 
* If standard error was not available, it was assumed to be equal to 0.1 of the mean value [Fox et al, 2007] 
** These utility values are based on a mean value for the males and females combined 
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During pregnancy, for those women whose fetuses were classed as „normal‟, the utility 
values were based on pregnant women who have undergone second trimester test 
(telemedicine arm) or have not undergone second trimester test (no telemedicine arm); 
utility values for women who had a test were higher than those women who did not 
[Kuppermann et al, 1999; Harris et al, 2004] – this may be because the majority of 
women who had a test were also carrying ‟normal‟ fetuses.  Kupperman et al (1999) 
also provided utility values for women who had undergone a termination of pregnancy 
with the view of not having a future pregnancy or a having a future pregnancy (where 
outcome of future birth is normal).  Odibo and colleagues (2006) provided utilities for 
the pregnant mother for fetal death (i.e. if it was a still birth) and also for a major 
(severe) cardiac defect.  Using this as a basis, assumptions were made for moderate 
and mild CHD defects which were detected prenatally (see Table 7.6). 
 
For babies and children with no disability aged from 0 to 5 years, utility values were 
obtained from healthy individuals [Erickson et al, 1995] and for children aged 6 years 
and older, the utility values were based on the UK general population norms [Kind et al, 
1999].  For children and adults with some form of CHD disability, as mentioned before, 
these values were based on heart failure utilities (see Table 7.6 for more detail on the 
utility values and sources).  For example, Yount and Mahle (2004) used utilities from 
adults with congestive heart failure for the CHD population (infants and children), 
whereas for patients aged from 26 to 65 years, heart failure values from Kirsch and 
McGuire (2000) have been used.  One point to note is that for mild CHD patients, the 
utility values from NHYA Class II were used instead of Class I, because Class I utility 
values were higher than the EQ-5D norm [Kirsch and McGuire, 2000].  Subsequently, 
these utility values were used in a Health Technology Assessment report by Fox et al 
(2007) who looked at the clinical and cost-effectiveness of cardiac resynchronisation 
therapy for people with heart failure.  Unfortunately, there were no utility values for mild 
CHD patients aged above 66 years, so it was assumed this would be the same as the 
utility values for patients aged between 46 and 65 years.  For patients with moderate 
CHD disability (aged 26 to 65 years) these were based on NYHA Class III [Kirsch and 
McGuire, 2000] and for severe CHD disability (aged 26 to 45 years) these were based 
on NYHA Class IV [Kirsch and McGuire, 2000] as they seemed to be most appropriate 
for this patient population.   
 
7.4.8 Cost-effectiveness analysis 
Using a decision analytical model for the base-case analysis, and focusing on the low-
risk women, it was assumed that on average each child would live to their expected 
lifetime (see Table 7.2).  For each year of survival for an average normal child and a 
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CHD child, the appropriate costs were calculated and the relevant utility values were 
inputted into the model.  Cost-effectiveness was measured in terms of the incremental 
cost per QALY gained.  Discount rates of 3.5% were applied to both costs and QALYs 
[HM Treasury, 2003].  As both cost and effectiveness data were skewed bootstrapping 
was used, whereby the distribution of cost-effectiveness ratios are generated by 
repeated sampling of the data (to stabilise the mean), with replacement and, in the 
absence of any other data from the population, gives a guide to its distribution [Manly, 
1997].  Bootstrapping was performed by taking 1,000 iterations of the data and these 
bootstrapped iterations were plotted along the cost-effectiveness plane.   
 
7.4.9 Sensitivity analyses  
Different one-way sensitivity analyses were undertaken to determine the key 
determinants of cost-effectiveness: 
1) Changes in replacement rates of terminated pregnancies.  In the base-case, a 
50% replacement rate for the terminated pregnancies was assumed.  For the 
sensitivity analyses, the assumptions were: a) no replacement; and b) a 100% 
replacement of all terminated cases. 
2) Changes in unit costs. In the base-case, the mean reference costs for: neonatal 
bed days, surgery, inpatient admissions, outpatient visits and tests and 
investigations (where available) have been used.  For one analysis, the lower 
quartile costs and in the other, the upper quartile costs have been used. 
3) Changes in discount rates. In the base-case, a value of 3.5% was used to discount 
costs and outcomes after the first year.  For the sensitivity analyses, two further 
discount rates were explored: 0% and 6%. 
4) Changes in life expectancy.  
Base-case values are provided in Table 7.2, for the sensitivity analyses: 
a. It was assumed that the life expectancy of a mild CHD child is 75 years.   
b. For children with moderate CHD, it was assumed that they will live to 40 years 
of age.  It has been quoted that 95% of patients die by the age of 40 years 
[Patient.Co.UK website, 2010]. 
c. For children with severe CHD, it was assumed that they will live to 20 years of 
age.  Life expectancy of patients with severe CHD to date is unknown, but there 
are many patients already in their early 20s enjoying life [Personal 
Communication with Specialist A, September 2009]. 
5) Changes in utility value assumptions.  
a. For patients with mild CHD disability aged 66+ years, in the base-case it was 
assumed they have the same utility value as patients aged 46 to 65 years.  For 
this analysis, a utility value of 0.56 for the patients aged 66+ years was used 
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(the difference in utility value between the 26-45 years old and the 46-65 years 
old, which has been subtracted from the utility value used in the base-case). 
b. For patients with severe CHD disability aged 19 to 25 years old, it was  
assumed they have the same utility value as those aged 3 to 18 years old.  For 
this analysis, a utility value of 0.3365 was used (the mean of the utility values 
for 3-18 years old and the 26-45 years old). 
6) Replacement pregnancy not normal.  In the base-case, if a terminated pregnancy 
was replaced, it was assumed the outcome would be normal.  For this analysis, it 
was assumed that the replacement pregnancy was not normal and each child 
would be born with moderate CHD. 
7) Utility for pregnant women for telemedicine and no telemedicine is the same.  In 
the base-case, the utility value of pregnant women with a „normal‟ fetus who were 
assessed via telemedicine was higher than those who were not assessed via 
telemedicine. In this sensitivity analysis, it was assumed that the utility value is the 
same. 
8) Changes in specificity and sensitivity rate13.  In the base-case, it was assumed that 
telemedicine had a 97% sensitivity and a 96% specificity rate [Grant et al, 2010].  
For this analysis, it was assumed that telemedicine has a 100% sensitivity and 
specificity rate i.e. that there will be no missed cases (as was the case in Chapter 
2).  
9) Changes in the type of missed cases.  For this analysis, the impact on the cost-
effectiveness ratio will be explored if all missed cases were severe or moderate or 
mild (or any other combination).  
10) Replacement of still births.  In the base-case, it was assumed that women who 
had a still birth they would not replace their pregnancy.  In this sensitivity analysis, 
the impact on the cost-effectiveness ratio is explored when women choose to 
replace a pregnancy following a still birth. 
11) Changes in termination rates.  In the base-case analysis it was assumed that 
50% of affected fetuses would be terminated; however, in reality this figure maybe 
lower.  In this sensitivity analysis, termination rates are varied. 
12) CHD prevalence in England and Wales.  Using data from the Office of National 
Statistics for the total number of births (including still births) in England and Wales 
in 2005 [ONS, 2008b] and the estimated number of CHD births (1 in every 145 
births), along with the incidence of simple and complex CHD births [Petersen et al, 
2003] (see Chapter 2 for more details), the cost-effectiveness of a screening 
                                                 
13
 The sensitivity analysis values went up rather than down to reflect the fact that with an additional screen 
there will be fewer missed anomalies.  
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programme with telemedicine compared to a screening programme without 
telemedicine in detecting congenital heart defects is estimated for England and 
Wales.  
13) Extrapolating to 2005/2006 data. Using data from 2005/2006 which was 
presented in Chapter 6, this analysis explores whether offering telemedicine to all 
low-risk women was a cost-effective option (in this group of women there was only 
one missed case and no other cardiac cases were detected). 
 
To further explore the impact of joint uncertainty in resource use (and cost) estimates 
and the utility values, probabilistic sensitivity analyses were conducted to obtain cost-
effectiveness acceptability curves (CEACs).  For the probabilistic sensitivity analysis, 
the gamma distribution was used for costs and the beta distribution was used for utility 
values [Briggs et al, 2006].  Where only a mean value was provided in the literature, an 
assumption was made for the standard error in order to calculate the alpha and beta 
values for the probabilistic sensitivity analysis.  For example, for utilities the standard 
error was assumed to be 0.1 of the mean value [Fox et al, 2007] and for the variation in 
mean cost, a coefficient of variation of 0.1 of the mean value was used to obtain the 
standard errors [Drummond and McGuire, 2001; Mangham and Petrou, 2008]. 
 
7.5 Results 
As reported in Chapter 6, the total number of maternities during the period 1st May 
2001 to 31st July 2002 was 5,114.  Of these 5,114 women, 52 were assessed by 
telemedicine, 24 were seen by face-to-face assessment in London and for the rest of 
the women their care was managed in the DGH (252 women were classed „medium 
risk‟ and 4,786 women were classed as „low risk‟).  For this analysis, only the 4,786 low 
risk women were of interest; as this group of women had the highest number of missed 
cases (5 or 1.04 per 1,000 women - see Chapter 6). 
 
7.5.1 Base-case analysis results 
The results from the base case analysis are shown in Tables 7.7a and 7.7b.  In Table 
7.7a the overall costs for a screening strategy with telemedicine were slightly lower 
than a screening strategy without telemedicine.  The mean number of cases detected 
via telemedicine was more than without telemedicine and there were fewer missed 
cardiac cases with telemedicine compared with no telemedicine i.e. telemedicine 
dominates.  Incremental cost-effectiveness ratios (ICER) are not helpful and therefore 
have not been presented here. 
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Table 7.7a: Results from the base-case analyses for low risk women only 
Mean results per child’s 
lifetime# 
Costs per child’s 
lifetime 
Mean no. of 
cardiac cases 
detected 
Mean no. of 
missed cases  
Deterministic results  
No patients receive telemedicine  £11,451 0.00084 0.00104 
All patients receive telemedicine 
and a 50% replacement 
£11,425 0.00233 0.00006 
# Figures have been rounded up 
 
The incremental cost per QALY gained for a screening strategy with telemedicine 
compared to screening strategy without telemedicine for children born with and without 
CHD to low risk women are shown in Table 7.7b.  Both the deterministic and 
probabilistic sensitivity analyses provided similar results.  The results from the model 
show that offering telemedicine to all low risk women is the dominant strategy i.e. that 
the costs are lower and the QALYs are higher (that is, telemedicine is more effective).  
In the case of replacement, we are assuming that they would have ‘normal child 
QALYs’; hence, the QALYs for replacement are higher than no replacement (see Table 
7.8 for more detail). 
 
Table 7.7b: Results from the base-case analyses for low risk women only (using 
QALYs) 
Mean results per child’s lifetime Costs per 
child’s lifetime 
QALYs per 
child’s lifetime 
ICER* 
Deterministic results  
No patients receive telemedicine  £11,451 23.2400 n/a 
 All patients receive telemedicine and a 50% replacement £11,425 23.2822 Dominant 
Probabilistic results  
No patients receive telemedicine  £11,483 23.2380 n/a 
 All patients receive telemedicine and a 50% replacement £11,457 23.2826 Dominant 
*ICER = cost per QALY gained 
 
The uncertainty around the mean estimates is demonstrated in Figure 7.2.  For the 
base-case analysis, the majority of observations were in the bottom right quadrant.  So 
in this case, telemedicine is cheaper and more effective.    
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Figure 7.2: Scatterplot of mean bootstrapped ICERs for low risk women only 
 
Figure 7.3: Cost-effectiveness acceptability curve for low risk women only 
 
Figure 7.3 shows the CEAC for the base-case analysis and the curve indicates the 
probability of a screening strategy with telemedicine being more cost-effective than a 
screening strategy without telemedicine for a range of potential maximum amounts 
(ceiling ratio) that a decision-maker is willing to pay.  For example, if the decision-
maker is prepared to pay £2,000 per QALY the probability of a screening strategy with 
telemedicine being cost-effective is nearly 90%.  If the decision-maker is prepared to 
pay £20,000 per QALY, the probability of a screening strategy with telemedicine being 
cost-effective is nearly a 100%. 
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Table 7.8: Results from the sensitivity analyses for low risk women 
Deterministic results Costs per patient 
lifetime 
QALYs per patient lifetime ICER* 
Base-case analysis  
No patients receive telemedicine  £11,451 23.2400 n/a 
All patients receive telemedicine and there is a 50% replacement £11,425 23.2822 Dominant 
Changes in replacement rates of terminated pregnancies 
No patients receive telemedicine  £11,451 23.2400 n/a 
All patients receive telemedicine and there is no replacement £11,424 23.2819 Dominant 
All patients receive telemedicine and there is a 100% replacement £11,425 23.2824 Dominant 
Changes in unit costs (lower quartile)  
No patients receive telemedicine  £11,324 23.2400 n/a 
All patients receive telemedicine and there is a 50% replacement £11,309 23.2822 Dominant 
Changes in unit costs (upper quartile)  
No patients receive telemedicine  £11,548 23.2400 n/a 
All patients receive telemedicine and there is a 50% replacement £11,519 23.2822 Dominant 
Changes in discount rates (0% for both costs and outcomes)  
No patients receive telemedicine  £26,613 64.0841 n/a 
All patients receive telemedicine and there is a 50% replacement £26,583 64.1390 Dominant 
Changes in discount rates (6% for both costs and outcomes)  
No patients receive telemedicine  £8,490 14.9100 n/a 
All patients receive telemedicine and there is a 50% replacement £8,468 14.9504 Dominant 
Changes in life expectancy  
No patients receive telemedicine  £11,447 23.2391 n/a 
All patients receive telemedicine and there is a 50% replacement £11,424 23.2820 Dominant 
Changes in utility value assumptions 
No patients receive telemedicine  £11,451 23.2399 n/a 
All patients receive telemedicine and there is a 50% replacement £11,425 23.2821 Dominant 
Changes in replacement pregnancy not being normal 
No patients receive telemedicine  £11,451 23.2400 n/a 
All patients receive telemedicine and there is a 50% replacement £11,445 23.2781 Dominant 
Utility value is the same for pregnant women with a ‘normal’ fetus for both telemedicine and no telemedicine arms 
No patients receive telemedicine  £11,451 23.2785 n/a 
All patients receive telemedicine and there is a 50% replacement £11,425 23.2822 Dominant 
Changes in telemedicine accuracy (100% for both sensitivity and specificity)  
No patients receive telemedicine  £12,397 25.1718 n/a 
All patients receive telemedicine and there is a 50% replacement £12,373 25.2178 Dominant 
Replacement of still births 
No patients receive telemedicine  £11,451 23.2400 n/a 
All patients receive telemedicine and there is a 50% replacement £11,425 23.2833 Dominant 
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Table 7.8: Results from the sensitivity analyses for low risk women (continued) 
Changes in termination rates 
No patients receive telemedicine  £11,451 23.2400 n/a 
All patients receive telemedicine and a 50% replacement (25% termination rate) £11,430 23.2942 Dominant 
All patients receive telemedicine and a 50% replacement (75% termination rate) £11,420 23.2734 Dominant 
All patients receive telemedicine and a 50% replacement (33% termination rate) £11,429 23.2909 Dominant 
All patients receive telemedicine and a 50% replacement (66% termination rate) £11,422 23.2771 Dominant 
Changes in CHD prevalence in England and Wales 
No patients receive telemedicine  £11,468 23.1519 n/a 
All patients receive telemedicine and there is a 50% replacement £11,551 23.2412 £923 
Using data from 2005/2006 low risk women 
No patients receive telemedicine  £11,189 23.2633 n/a 
All patients receive telemedicine and there is a 50% replacement £11,198 23.3016 £248 
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7.5.2 Sensitivity analyses results 
Several key uncertain parameters within the model have been explored within different 
sensitivity analyses to assess the robustness of the model (see Table 7.8).  Offering 
telemedicine to all low risk women remained the dominant strategy i.e. cheaper and 
more effective, as in the base-case analysis for the following: changes in replacement 
rate of terminated pregnancies, changes in unit costs, changes in discount rates, 
changes in life expectancies, changes in utility value assumptions, changes in the 
replacement pregnancy not being normal; utility value for pregnant women for 
telemedicine and no telemedicine being the same; changes in sensitivity and specificity 
rate; replacement of still births; and changes in termination rates, implying that the 
model was robust to the estimates and assumptions which were explored and the new 
cost and QALY estimates were in the expected direction.   
 
However, a couple of scenarios were not robust to the assumptions explored within the 
model.  Firstly, when looking at the CHD prevalence in England and Wales for the total 
population, a screening strategy with telemedicine was more costly and more effective, 
than a screening strategy without telemedicine.  However, this is based on the 
assumption that the additional cost of the telemedicine service would be the same for 
each hospital, even though this may not be the case as throughput may differ.  There 
may also be other factors such as staff costs and number of clinics for all patient 
groups (pregnant women, child, adult) which may have an impact on both costs and 
outcomes and these various factors have not been taken into account.  Secondly, 
using data from 2005/2006, there was only one missed cardiac case amongst the low 
risk women and all cardiac cases during this time period that had been detected before 
birth were to women who were in either the direct referral or telemedicine group (even 
though some of these women may have initially been low risk – see Chapter 6).  If 
telemedicine was offered to all low risk women versus not offering any low risk women 
telemedicine, telemedicine was slightly more costly and more effective.  For low risk 
women during 2005/2006 period, the costs were lower and the QALYs were higher 
than 2001/2002 period (cost results are in the same direction as those presented in 
Chapter 6).  
 
Finally, when looking at changing the type of missed cases (i.e. mild, moderate, and 
severe) and to see what impact this had on the cost-effectiveness ratio (these results 
have not been presented in Table 7.8).  If all missed cases were severe or moderate, 
then a screening strategy with telemedicine was still the dominant strategy; however, if 
the number of mild cases was four or more, then telemedicine was no longer the 
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dominant strategy – although it was more effective, this additional increase in QALYs 
came at an extra cost.  
 
7.6 Discussion 
This chapter has extended the analysis presented in Chapter 6 by conducting a cost-
effectiveness analysis of a screening programme with telemedicine compared to a 
screening programme without telemedicine, in order to estimate the lifetime costs and 
QALYs for children born with and without CHD.  Thus, the third economic issue: 
QALYs were explored.  For the screening strategy with telemedicine, it was assumed 
that all low risk pregnant women would have a second opinion via telemedicine and 
that 50% of affected fetuses detected prenatally would be terminated; and of those 
terminated pregnancies 50% would be replaced and the delay in replacing a pregnancy 
was assumed to be a year.   
 
The results from the decision model concluded that offering telemedicine screening to 
all low risk women was the dominant strategy (cheaper and more effective).  For a 
decision-maker who is willing to pay £20,000 per QALY for a screening strategy with 
telemedicine, the probability of this strategy being cost-effective is nearly 100%.  The 
results from the various sensitivity analyses concluded that model was robust to the 
data inputs and assumptions made, and that telemedicine remained the cost-effective 
strategy.  
 
The main strength from this analysis showed that if telemedicine screening is offered to 
all women, a telemedicine service can help to reduce the number of missed cardiac 
cases.  If a heart defect is detected in a fetus prenatally (i.e. a true positive result), then 
decisions can be made as to whether to continue or to terminate the pregnancy, and if 
parents decide to continue with the pregnancy this allows for earlier treatment.  Earlier 
treatment or intervention can also be associated better quality of life in the future for 
children born with CHD.  
 
The model created was the most appropriate one using the available data; thus, the 
data inputs for the model were not perfect.  Thus, there are also a few limitations with 
the model: firstly, the estimates of resource use were based upon expert opinion and 
the analysis looked at „typical‟ patients with mild, moderate or severe CHD.  However, 
in practice a CHD patient with the same characteristics, having the same treatment and 
surgery, may not always have the same outcome.  In practice, utilisation of health care 
resources by patients with CHD disease may vary quite widely.  This is due to clinical 
characteristics, such as cyanosis, type of operation, or occurrence of heart failure, 
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which are all associated with higher utilisation rates and consequently increased costs 
[Garson et al, 1994; Moons et al, 2001].  One way of obtaining more accurate resource 
use estimates may have been to obtain expert opinion via an expert panel or using a 
Delphi panel method.  Unfortunately, due to time constraints with the thesis this was 
not practical.   
 
Secondly, the analysis presented in this chapter was just restricted to a health service 
perspective.  The Chapter neglects the financial costs effects to patients and their 
families of attending hospital if they had a disability.  For example, if the patient 
attended hospital say for an outpatient visit, there would not only be travel costs to 
consider, but other incidental costs and also if the patient is an adult what about the 
time away from work and the loss of pay?  If the patient was a child, what about the 
loss of pay and time away from work for their parents?  In Chapter 6, the addition of 
patient costs to the total costs of pregnancy did not change the direction of the cost 
estimates; based on this assumption it is unlikely the direction of the cost estimates 
would have changed, although the magnitude of cost difference may change.  As 
mentioned in Chapter 6, NICE prefer patient costs not to be included in the cost-
effectiveness ratio, especially if the outcome measure is QALYs.  Also, the analysis in 
this Chapter did not take into account the wider effects to families and communities of 
caring for a disabled child such as carer costs, as these are quite difficult to ascertain; 
the loss of earnings to parents if they have to give up the work to care for a disabled 
child, or costs of adaptations to the house (if needed).  Thirdly, there may also be some 
emotional impact, anxiety and burden on families for caring with children and/or adults 
with disabilities, which has not been taken into account in the cost-effectiveness ratio.   
 
Fourthly, in relation to replacement birth rates, there was no up-to-date information and 
the older references which have been used in this analysis can be seen as a limitation 
of the thesis.  Fifthly, in terms of utility and expected lifetimes there are also some 
limitations:  
a) Utility values for patients with CHD were based on patients who have heart failure, 
as utility values were not available for this cohort of patients.  More accurate utility 
estimates are needed for this patient cohort via the use of direct measurements such 
as the standard gamble or the time trade-off approach;  
b) The utility values used in the model have been valued using different instruments: 
for example, Years of Healthy Life [Caviness et al, 2004], HUI mark II [Brown et al, 
2009] and the EQ-5D [Kirsch and McGuire, 2000].  There are various papers that have 
explored the effects of using different instruments for utility scores and the impact this 
has on the cost-effectiveness ratio, and generally they have concluded that differences 
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are evident and caution should be used when comparing health state utility values from 
different instruments [Brazier et al, 2004; Grieve et al, 2009; McDonough and Grove, 
2005].  Bearing this is mind, caution needs to be taken when interpreting the results 
from this model;  
c) It was assumed that each child will live to their expected „lifetime‟ according to the 
CHD status, this may not be the case in practice, as these children can also die of 
„other causes‟ and for those children who have surgery for CHD, some may not survive 
post-operatively;  
d) It was assumed that each child born has a combined utility for a male and a female, 
and for those who are female they may have a future pregnancy and if this is the case, 
the prevalence rate of CHD in this population has not been taken into consideration in 
the model; and  
e) Finally, in relation to the health outcomes i.e. whose utility value to use during 
pregnancy - the mother, the unborn child, or both?  There is no consistent approach 
and it is conceptually difficult to measure and there was not a lot of literature in the 
public domain about this.  For the model, during pregnancy the mother‟s utility value 
was used and from birth onwards, the child‟s utility value was used (a combined mother 
and child outcome).  One thing that that was not taken into account is the disutility for 
the rest of the mother‟s life associated with a disabled child.  For example, Haberland 
et al (2002) in their cost-benefit analysis looking at the perinatal screening for Group B 
Streptococci did not incorporate parental disutilities for losing a child or raising a 
disabled child as they were difficult to quantify.  In any economic evaluation, disutilities 
are quite difficult to measure, however, they are important.   
 
There are various quality of life instruments as mentioned earlier in the thesis that 
measure adult‟s health state utilities such as the EQ-5D, SF-6D and HUI mark 3.  It has 
been argued that we simply cannot use adult utility measures to measure children‟s 
utility because of the rapid developmental changes which take place in childhood and 
adolescence [Petrou, 2003; Griebsch et al, 2005].  Instead, various utility measures 
have been developed for children, namely, the HUI mark 2 which is used for children 5 
years and older as a proxy assessment and 8 years and older for self assessment 
[Torrance et al, 1996]; and more recently, the EQ-5D-Y (the youth version) for children 
8 years and older [Wille et al, 2010]; and the Child Health Utility 9D (CHU-9D) which is 
used for children between 7 to 11 years for self completion [Stevens, 2010].  However, 
there is an argument as to whether children can really value their own quality of life and 
the difficulties that may arise.  Griebsch and colleagues (2005) highlighted two main 
reasons why QALY measurement and valuation is more difficult in children than adults: 
firstly, children undergo changes in growth and function at different rates and therefore 
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it is difficult to attribute improvements to health care interventions rather than to normal 
development; and secondly, young children (under the age of five years) do not have 
cognitive ability to comprehend and complete valuation or even measurements tasks.   
 
Most screening studies are conducted in the context of a randomised trial and most of 
them estimate QALYs for adults and not children.  Prenatal screening is different as it 
may not be ethical to conduct a RCT; that is, randomising patients to different 
screening interventions may have an effect on the health status of the fetus or the 
mother or both.  Prenatal screening is different to other screening programmes for a 
number of reasons: a) it may be unethical to randomise women to each arm of the trial, 
because any delay in the consultation, management or treatment will delay the 
opportunity for antenatal intervention and planned delivery; b) the option to continue 
with or to terminate a pregnancy, is usually the primary choice after prenatal screening; 
however, if women wish to continue with their pregnancy, then reassurance is needed 
for parents of the appropriate treatment or intervention which will be provided 
immediately after birth; c) if a termination is allowed based on the clinical diagnosis, we 
would then have to compare the costs and benefits of this life lost with a life which was 
saved and disabled; d) screening may also raise the number of false positives and in 
turn, this may increase anxiety in say 90% of the women who are considered to be 
healthy; e) are the risks of prenatal screening such as using amniocentesis or CVS 
tests which are considered to be invasive tests, worth the potential benefit?; and finally, 
f) there are also questions around how people value disabled people in society. 
 
The Chapter did not explore the option of the medium risk women getting a second 
opinion via telemedicine and only explored the low risk women (this group had the 
most missed anomalies during the 2001/2002 period).  As Chapter 6 had shown that 
over time the detection of cardiac anomalies at the anomaly scan had improved and for 
the latter time period (2005/2006) there was only one missed anomaly and this woman 
was in the low risk group. 
 
In terms of policy implications, is offering telemedicine to all women on a local scale, a 
good way to identify all congenital heart defects prenatally?  This would partly depend 
on the perspective which is undertaken.  For example, if a healthcare perspective is 
adopted, then both the costs and outcomes to the NHS would have to be considered.  
Based on the results from the decision model for Medway hospital, a screening 
strategy with telemedicine is cost-effective for all low risk women.  However, when 
exploring whether the introduction of a telemedicine service for all total births in 
England and Wales, taking into account CHD prevalence, this analysis was not cost-
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effective.  Thus, there were a number of issues which were not looked into further such 
as staff numbers, cost of setting up the telemedicine service in each hospital etc.  
Therefore, if telemedicine was to be implemented in other hospitals in the area, listed 
below are some of the factors which should be taken into account: 
 Are the clinicians in favour of obtaining second opinions for all women via a 
store-and-forward telemedicine service? 
 How would the introduction of a telemedicine service in one hospital impact on 
other services such as cancer care provided by the hospital? 
 What about the impact on the other services provided by the specialist hospital?   
 If more than one DGH set up such screening services, what would be the 
impact on specialist(s), as there are very few perinatal cardiologists across 
England and Wales. 
 Who would pay for the initial telemedicine equipment and set-up costs? 
 Who would pay for the telemedicine equipment maintenance costs and the 
ongoing costs (i.e. line rental and call charges)? 
 Would a telemedicine co-ordinator have to be employed? 
 Extra staff would have to be employed at both ends of the telemedicine link to 
carry out this service.  Would extra staff be employed or would current staff 
have to conduct this extra work in addition to the current duties? 
 Providing staff with training in using the telemedicine equipment and providing 
extra fetal heart training. 
 
A few studies have looked at whether a screening strategy for all women is cost-
effective in identifying congenital defects prenatally and results are similar to the model 
presented in this Chapter; that is, offering telemedicine to all low risk women is cost-
effective.  Odibo and colleagues (2006) wanted to find out whether all pregnant diabetic 
women should be offered universal fetal echocardiography as a screening tool for 
congenital heart defects.  Their results showed that option 2 (selective fetal 
echocardiography after abnormal ultrasound results) was the most cost-effective 
strategy compared to option 4 (universal fetal echocardiography); although option 4 
was associated with a higher detection rate for cardiac defects, it was more expensive.  
However, they argue that if the “financial implications of missing these cases exceed 
this net saving (using option 2), then a policy of universal fetal echocardiogram should 
be continued”.  The authors found that the ideal policy for screening cardiac defects 
could be influenced by various factors, for example, if the emphasis was on utilities or 
on QALYs, then option 2 was preferred; however, if the emphasis of the policy was 
societal i.e. to prevent cardiac defects, then option 4 was preferred.  They also noted 
that depending on which strategy was seen as cost-effective would depend on the 
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thresholds that were suggested as reasonable for the cost per QALY.  The authors also 
noted the limitations of their model (some of which mirror the limitations in the model 
presented in this Chapter): they only took into account direct medical costs; they had 
difficulty obtaining reliable and generalisable point estimates for the model probabilities; 
and they found that there was an absence of utility estimates which were specific to 
cardiac malformations in infants of diabetic mothers.   
 
In the paper by Harris and colleagues (2004), they used a decision model to assess the 
cost-utility of CVS and amniocentesis compared to no diagnostic testing for pregnant 
women of all ages and risk levels.  The authors found that prenatal testing for 
chromosomal disorders is cost-effective irrespective of maternal age or risk of carrying 
an affected fetus and they argued that there was no economic evidence to support the 
existing guidelines in the USA that recommend offering testing to women above a 
certain age (35 years or older) or to women of a similar risk as determined by maternal 
serum screening or ultrasonography, or both.  They concluded that universal prenatal 
diagnostic testing should be offered to all pregnant women on economic grounds.   
 
Finally, Buskens et al (1997) developed a decision analytical model to assess the 
potential impact of fetal ultrasound screening of pregnant women at low risk for CHD in 
their unborn child.  The authors stated the option of screening for high risk women was 
not included in the model, as its merits had already been established.  The decision 
model for a Dutch population (1 million pregnancies) took into account the prevalence 
and history of CHD, characteristics of ultrasound, pregnancy terminations and a 
literature search was undertaken to obtain probabilities for the model.  The results 
suggested that screening programs may prevent the birth of approximately 1,300 
severely affected newborns per million second-trimester pregnancies.  However, this 
meant that over 2,000 terminations of pregnancy would be required, and a further, 
9,900 false-positive screening results would occur which required referral.  They 
concluded that the impact of routine screening for CHD was relatively small and further 
data were needed to fully assess the prenatal screening programmes.  Although this 
study provided some useful information on screening for low risk women, it did not look 
at the impact on the short-term (during screening) and the long-term (life-time) costs 
and benefits such as QALYs for children born with and without CHD. 
 
In summary, even though the data used in the model was not perfect, the findings from 
the model suggest that offering telemedicine to all low risk women is a cost-effective 
strategy.  The next chapter will bring together the three economic issues identified in 
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this thesis, and the strengths and limitations of the thesis will be discussed.  Finally, 
some concluding remarks and the implications for further research will be provided.    
 
 
  219 
CHAPTER 8: GENERAL DISCUSSION AND CONCLUDING REMARKS 
 
8.1 Introduction 
Ever increasing pressures on healthcare budgets have made it necessary to show that 
healthcare technologies such as telemedicine, not only demonstrate their safety and 
efficacy, but also to show that they are a cost-effective use of resources.  When 
markets are not „perfectly competitive‟ such as within healthcare, economic evaluations 
can help provide information on whether healthcare technologies are an efficient use of 
resources by comparing the costs and benefits of one healthcare technology, to the 
costs and benefits of another healthcare technology.  So when healthcare budgets are 
limited, scarce healthcare resources should be allocated towards those technologies 
where the incremental benefits outweigh the incremental costs.  Thus, this thesis 
aimed to find out whether the use of telemedicine was a cost-effective use of resources 
in obtaining specialist advice for fetal cardiology. 
 
Starting from the TelePaed study which was presented in Chapter 2, the thesis looked 
at how the case study analysis can be improved in the light of the literature review and 
some of the issues which arose.  The primary aim of this thesis was to address these 
economic issues which came to light from the literature review on costs and benefits of 
telemedicine and to see how these issues could be addressed in the context of an 
economic evaluation.  These issues were: selection bias; patient costs and benefit 
measures such as QALYs.  These concerns are not specific to telemedicine, but are 
perceived as a particular problem for telemedicine technologies.  This final chapter will 
summarise: the main contributions of the thesis; the limitations of the thesis; discuss 
the policy implications of the results; summarise issues for future research; and some 
concluding comments will be provided. 
 
8.2 Overview of thesis and contributions made to literature 
This thesis has aimed to fill a gap in the literature by providing new evidence as to 
whether telemedicine should be used in a hospital to provide specialist advice in fetal 
cardiology to all low risk women.  Furthermore, the thesis has also addressed some of 
the economic issues which were associated with telemedicine.  Currently, telemedicine 
is only used routinely for „high risk‟ women, but it is within the low risk population where 
many cases of CHD occur [Simpson, 2009].  
 
The thesis began by looking at the data and results from the TelePaed case study 
(Chapter 2), that is, comparing the costs (total costs of second and third trimesters of 
pregnancy) and the effects (detection of cardiac cases before birth) for two groups of 
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women who were referred for specialist cardiac advice for fetal cardiology (direct 
referral women who saw a specialist face-to-face in London or telemedicine women 
whose assessment was conducted in their absence via a store-and-forward 
telemedicine service).  The results suggested that telemedicine was slightly more 
expensive than direct referral and that the direct referral group had a higher prevalence 
of cardiac anomalies than the telemedicine group.  This was due to the selection and 
eligibility criteria that the obstetricians and sonographers used at Medway hospital; that 
is, women with suspected fetal abnormalities were seen mainly by direct referral 
(unless a telemedicine clinic was scheduled to take place in the next few days).  
Telemedicine was mainly used for screening purposes.  This is important as the 
telemedicine link reduces the time taken to assess a woman and screen the fetal heart.  
There were also no missed cardiac cases amongst these two groups of referred 
women (that is, all cardiac anomalies were detected during the antenatal period).   
 
In Chapter 3, a literature review was conducted to see what existing evidence there 
was on the costs and benefits of telemedicine.  Even though more studies have been 
added, the results from the literature review were consistent with previous findings 
[Whitten et al, 2002; Bergmo, 2009] and the conclusions have remained the same.  
Despite this, the findings from the literature review made a contribution to the literature, 
as there were some specific economic issues which may be of concern which were 
identified when conducting economic evaluations of telemedicine.  For example, one of 
the issues which arose was that the majority of studies did not give enough details 
about the study design or they had weak methodologies and for this reason there was 
no consistency in the cost analyses across the studies.  If studies reported appropriate 
methodology on how costs (and/or outcomes) are collected, calculated and reported, 
then it would be easier for the reader to understand how the author(s) came to their 
results and conclusions.  Also, one thing that became apparent from the literature 
review is that if investigators were more transparent on how they conducted and 
reported findings on telemedicine interventions this may lead to different conclusions.  
Transparency would also ensure that all the relevant statistical information are included 
in each study, so that a meta-analysis on costs (and/or cost-effectiveness) of 
telemedicine can be conducted.   
 
In Chapter 4, following on from the findings in the literature review, a critique of the 
TelePaed study and a reflection on some of the problems with the design of the study 
which was determined prior to my involvement was provided.  The design of the study 
in part influenced the uptake and usage of the telemedicine service and the information 
which was collected for the economic evaluation.  Within this Chapter, the „Drummond 
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et al checklist‟ [Drummond et al, 2005] was applied to the case study and the analysis 
which was presented in Chapter 2 was in line with economic evaluation guidelines 
[Bergmo, 2009].  However, the three economic issues identified in the literature review 
showed how the study could be improved and these three issues were highlighted in 
this Chapter: selection bias, repeated measurement of patient costs and measures of 
benefits such as QALYs.   
 
The next step for the thesis was to address these three economic issues.  In Chapter 5, 
the first economic issue, selection bias was examined.  Selection bias existed within 
the dataset, because pregnant women were selected for referral for further assessment 
from a perinatal cardiologist due to the nature of their presenting demographic 
characteristics and risk factors.  Thus, the observed costs and effects which were 
presented in Chapter 2 are said to be biased.  Various methods were identified in the 
literature review to reduce selection bias and these methods were applied to the 
dataset.  However, the analysis cannot conclude which method was the most accurate 
for this dataset due to the nature and size of the dataset; only some direction on which 
method may be the best way forward could be provided.  Propensity score matching 
was a more reliable way of obtaining cost and effect estimates, because after matching 
the groups were similar in terms of background characteristics (i.e. „balanced‟).  Both 
the regression and the Heckman models may not have explicitly balanced the 
covariates among the groups; therefore the two groups may not be similar.  The 
analysis suggested that both regression analyses and propensity scoring methods (the 
Heckman selection model was not appropriate for the dataset) when applied to the 
dataset may have reduced the observed selection bias between the two groups, 
because after adjustment, the differences between the two groups were smaller, 
thereby increasing the homogeneity and reducing the variance in the adjusted costs 
and effects.  The majority of studies which have used these methods to reduce 
selection bias have been conducted on large sample sizes.  In Chapter 5, these 
methods were explored on a small sample size, but it was difficult to tell which method 
is the most appropriate and if only one method was used, then the results should be 
interpreted with caution.  Chapter 5 has contributed to the literature, because it is the 
first study, I believe, which has applied these methods for reducing selection bias in a 
fetal cardiology dataset given a small sample size.  
 
In the previous chapters (Chapters 2, 4 and 5), the thesis showed that the data had 
some limitations.  As mentioned earlier the two groups (referral methods) were not 
strictly comparable (unless adjustments are made) because of the selection criteria for 
each referral method.  Therefore, the next step in Chapter 6 was not only to look at the 
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two groups of women who were referred to a perinatal cardiologist, but at all pregnant 
women (this included women who were not referred to a specialist and were managed 
in the DGH: both medium risk and low risk women) who had an anomaly scan at 
Medway hospital during the same time period (May 2001 to July 2002) to see what 
would happen to costs and effects if the telemedicine service had not been available.  
By looking at all women during the same time period, we are not artificially introducing 
„selection‟.  It was ascertained that if telemedicine service had not been available, then 
those women who were in the „telemedicine group‟ would have been categorised as 
either „direct referral‟ or „medium risk‟ women, and there would have been no „missed‟ 
cardiac cases amongst these women.  As there was no difference in the number of 
missed cases avoided when comparing the same time periods (with and without a 
telemedicine service), a cost-effectiveness analysis was not appropriate, and results for 
a cost-consequence study were presented in Chapter 6 and the results showed that a 
service with telemedicine was slightly cheaper than a service without telemedicine.   
 
In Chapter 6, additional data were presented to look at changes over time.  There was 
no change in the effectiveness data when comparing a service with telemedicine to a 
service without telemedicine for the latter time period, so again only costs were 
compared.  Changes in antenatal screening protocols, fewer antenatal clinic visits and 
fewer multiple pregnancies (in the data collection) have meant that the overall costs in 
the second and third trimesters of pregnancy have fallen slightly over time.  In addition 
Chapter 6 showed that over time (from 2001/2002 to 2005/2006) the number of missed 
cardiac cases had fallen amongst the low risk women and this was partly due to 
sonographers being confident in checking fetal heart structures, after receiving 
additional training to carry out more detailed fetal heart examinations.  
 
Within Chapter 6, the thesis addressed the second economic issue: patient costs.  
Patient costs are important to include in economic evaluations as this gives an 
indication to individual patients of the likely costs they will face when attending 
hospitals for treatment or consultations; this is important if patients have to attend 
hospital more than once during a specific time period.  There is currently no „gold 
standard‟ for estimating patient costs.  When patient costs (travel costs and loss of pay) 
were added to the total costs of pregnancy for all women who were seen during this 
time period (total population of women delivered), patient costs did not add much to the 
total costs of pregnancy; that is, the total costs were in the same direction and were of 
similar magnitudes.  Chapter 6 has made a contribution to the literature, as it is the first 
study to have calculated patient costs for more than one time point during the second 
and third trimesters of pregnancy.  
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Chapter 7 first explored how other antenatal screening programmes had calculated the 
lifetime costs and benefits associated with such programmes (because short-term 
screening costs are not helpful and longer-term analyses are needed) and literature 
searches were undertaken to determine the data inputs for the decision model.  A 
hypothetical decision model was developed to address this final economic issue: 
QALYs.  Thus, the cost-effectiveness analysis compared a screening programme with 
telemedicine to a screening programme without telemedicine for all low risk women 
and by comparing these two programmes, the lifetime costs and QALYs for children 
born with and without CHD were estimated.  This chapter only looked at low risk 
women, because in Chapter 6, it was ascertained that the majority of missed cardiac 
anomalies were amongst the low risk women.  Consequently, the model aimed to show 
that for this cohort, if an additional screen is provided, whether this upfront telemedicine 
cost is justified.  The deterministic results from the decision model suggested that 
offering telemedicine to all low risk women was the dominant strategy (cheaper and 
more effective).  For a decision-maker who is willing to pay £20,000 per QALY for a 
screening strategy with telemedicine, the likelihood this strategy being cost-effective is 
nearly 100%.  The model in Chapter 7 was a simple decision analytical model that 
allowed for extensive sensitivity analyses to be undertaken so that the robustness of 
the model could be rigorously tested and priorities for future data collection could be 
determined.  Given the available data, the model is the most appropriate.  Although, 
future research priorities can look at refining these data inputs.   
 
Chapter 7 has filled a gap in research and contributed to the literature, because it is the 
first study which has compared a screening programme with telemedicine to a 
screening programme without telemedicine in order to calculate the lifetime costs and 
QALYs for children born with congenital heart disease (mild, moderate, severe) and 
without congenital heart disease (normal).  The Chapter provided new evidence that 
QALYs can be calculated for telemedicine services.   
 
8.3 Limitations of the thesis 
Whilst this thesis has contributed to the existing literature, it also has a number of 
shortfalls. 
 
To determine whether providing specialist advice via telemedicine compared with direct 
referral was a cost-effective use of resources, ideally the data for this economic 
evaluation should have been collected alongside a RCT as they produce the least 
biased estimates of costs and effects.  However, for the TelePaed study it was deemed 
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unethical to randomise individual patients because of the urgency of cases of 
suspected abnormalities and any delay in the specialist assessment was not 
appropriate for these patients.  As individual patients could not be randomised (in 
theory, medium risk women could have been randomised, it was the women with 
suspected abnormalities which were considered urgent), the use of a cluster RCT may 
have been a more appropriate study design.  This is where different hospitals or units 
are randomised instead of individual patients, and this type of trial is said to be the 
least biased.  However, there was always a question as to whether the TelePaed study 
as mentioned in Chapter 4 was set-up a cluster randomised trial; because even by 
study design two clusters in each arm is questionable, especially when you look at it in 
terms of statistical power which are required to detect statistical differences in RCTs.   
Due to time constraints and the slow uptake of the telemedicine service for the 
TelePaed study, a cluster randomised trial of the project was not feasible and instead 
an observational study was conducted.  Steps were undertaken in Chapter 5 to 
minimise selection bias between the two referral groups.  
 
Results from the literature review concluded that there is a need for telemedicine 
studies to be transparent in reporting their methodologies and results.  Cost-
effectiveness of telemedicine depends not only on the service being evaluated, its 
comparator, the perspective of the analysis, patient group and sample size, type of 
economic analysis and how the costs and outcomes were measured and valued, but 
also on the take-up rate and the usage of the service.  Decision makers and readers 
must be cautious as to the degree to which they can apply the results of such 
assessments to their own circumstances.  Further research needs to be done in which 
telemedicine interventions and their comparators are conducted in accordance with 
general standards for health economic evaluations.   
 
The results from the meta-analysis of telemedicine cost studies which was presented in 
Appendix 3 was for illustration purposes only and was not really informative; as 100 of 
the 109 studies had insufficient statistical information and could not be included in the 
meta-analysis.  A further limitation in Chapter 3 was that a meta-analysis of costs 
(and/or cost-effectiveness) of telemedicine studies could not be conducted for each 
health area separately as again there was not enough statistical information in each of 
the studies.  These differences were primarily due to the different studies reporting 
variations in patient populations, study design, intervention and comparator groups and 
not enough appropriate information was reported in each of the studies.   
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The limitations of the analysis which was presented in Chapter 5 to reduce selection 
bias between the two referral groups included: 1) all the methods explored were 
applied to a small sample; however, in practice most of these models are usually 
conducted on bigger sample sizes; 2) the exclusion of variables such as income and 
smoking which are routinely observed but were not recorded in the audit dataset, as 
well as unobserved variables which are not routinely recorded such as a patient‟s 
preference for referral method or the quality of care which the patient receives at the 
hospital; and 3) the Heckman model was not suited to the dataset and this may be 
partly due to the small number of observations (women) and also partly due to the 
identifier variable (instrument) which had a low correlation with referral mode.  Each of 
these limitations may have affected the precision of the costs and effects estimates.  
Nevertheless, there is some confidence in the adjusted costs and effect estimates, as 
the regression and propensity scoring methods reduced the difference (incremental) in 
costs and effects between the two groups.  
 
The resource use data in Chapters 2 and 5 was based on the TelePaed project and 
data were collected prospectively during 2001/2002 for patients who were referred to a 
perinatal cardiologist.  The analysis for this section is based on a small number of 
referred women (n = 76) and this might increase the level of uncertainty in the cost and 
effect calculations and limits the generalisation to other patients who may need a 
specialist opinion.  However, in Chapter 6 data were extrapolated from the sample of 
patients (referred women, medium and low risk women) for whom resource use data 
was available for, to all maternities over a 15-month period (by looking at the whole 
population we are not introducing „selection‟).  Extrapolating the cost data was 
undertaken by the use of multiple regression models which were fitted to observed 
caseloads of women to predict total costs of pregnancy for women for whom there was 
no resource use data.  A mean estimate of the total costs of pregnancy was assigned 
to each woman who had missing data; this may in some cases have under- or over-
estimated the total costs of pregnancy for the cohort (this also applies to the 2005/2006 
data, as total costs of pregnancy were extrapolated from the sample to the total 
population).  
 
In Chapter 6, patient costs were estimated for each woman for each antenatal visit 
during the second and third trimesters of their pregnancy to see what the total 
additional out-of-pocket expenses would be and these estimated costs can be used as 
a guideline.  As only a sample of patients provided patient costs for one visit, 
assumptions were made so that extrapolation of costs could take place beyond this 
one visit for the remainder of their pregnancy, as well as for the total population for 
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whom there was no patient cost information for.  The assumptions which were made 
including the mode of travel to hospital (i.e. by car or public transport) and the number 
of women who may have been in employment during this period, may have led to 
patient costs being under- or over-estimated.  However, to get more comprehensive 
costs, a full patient cost survey could be conducted for a sample of patients for each of 
their visits to the hospital as their circumstances may change throughout pregnancy 
(i.e. in the later months, a woman may not be able to drive to the hospital for an 
appointment or may be on maternity leave).   
 
There is a large amount of uncertainty in the data inputs used in the decision model in 
Chapter 7, as it was largely based on assumptions and expert opinion.  Firstly, the data 
assumptions for resources used by children and adults with CHD were based on 
limited expert opinion.  One way of obtaining more accurate resource use estimates 
may have been to obtain expert opinion via an expert panel or using a Delphi panel 
method.  Secondly, utility values for patients with CHD were based on patients who 
have heart failure, as directly elicited utility values were not available for this cohort of 
patients.  More accurate utility estimates are needed for this patient cohort (patients 
with different types of CHD, as well as for those that undergo surgery for a CHD) via 
the use of direct measures such standard gamble or the time trade-off methods or 
indirect measures such as the EQ-5D or SF-6D measures.  Thirdly, accurate estimates 
are also needed on the life expectancy of patients with CHD.  Ideally, a prospective 
study estimating lifetime costs and QALYs for patients with different types of CHD is 
needed. 
 
8.4 Implications of findings for researchers 
Given that various studies on telemedicine from the literature review have provided 
conflicting results about whether telemedicine is cost-effective or not, researchers 
should strive towards a consistent approach in the information that is collected, 
reported and analysed for telemedicine evaluation.  Telemedicine evaluations need to 
be more transparent in reporting their methodologies and results, especially in terms of 
the economics issues which were identified in Chapter 3 namely: study design and 
methodologies; time frame; study perspective; sample size justification; choice of 
alternatives; economic importance of question; type of economic evaluation conducted; 
costs and benefits how they are measured, valued and reported; and whether an 
incremental approach, discounting and sensitivity analyses are reported.  By following 
guidelines such as the Drummond checklist [Drummond et al, 2005], results from 
economic evaluations of telemedicine studies will enable readers to make comparisons 
in their own settings and ensure that results are transferable and generalisable.  If 
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these economic issues are adhered to, then robust economic evaluations of 
telemedicine services can be reported; and in turn, by having the appropriate statistical 
information a meta-analysis of telemedicine costs (and/or cost-effectiveness) evidence 
can be performed. 
 
The literature review also identified a few points which journal editors could bear in 
mind when assessing an article for publication: 
 Research teams don‟t always have health economists on their team for the 
costing studies;  
 Papers published are too restrictant on word length, therefore all methodology 
and findings can‟t be reported; and  
 Publication relies on the data analysis being completed and reported, and this 
may be a few years out of date since the fieldwork was actually completed.  
 
In Chapter 5, after adjusting for selection bias, the results varied greatly between each 
of the different analytical methods; this means that a researcher cannot simply use the 
results from one method of correcting for selection bias to represent all methods 
especially for a dataset of this kind, rather an argument has to be made concerning 
which method is best to accept.  Also, due to the size and nature of this dataset, the 
bias adjustment still does not provide a clearer picture of how much selection bias 
remains in the dataset and what the direction of selection bias is.  In addition, reviewing 
the literature from non-randomised telemedicine studies where these studies have not 
been adjusted for selection bias, the results from these studies should be interpreted 
for caution.  This is because we don‟t know how much selection bias was in their 
datasets and what the direction of the bias was.   
 
8.5 Implications of findings for policy makers 
The results from the decision model showed that a screening strategy with 
telemedicine for all low risk women is more likely to be cost-effective than for a 
screening strategy without telemedicine.  In addition, as women are getting a „second 
opinion‟, the number of missed cardiac cases is also likely to fall and if a cardiac 
anomaly is detected before birth then the appropriate plans can be made by parents as 
to whether to terminate or to continue with the pregnancy.  These findings provide 
some important implications for policy makers if telemedicine was to become part of 
routine antenatal screening. 
 
For example as highlighted in Chapter 7, in terms of policy implications, is offering 
telemedicine to all women on a local scale, a good way to identify all congenital heart 
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defects prenatally and to minimise the number of missed cardiac cases?  If the number 
of missed cardiac cases is reduced, over the longer-term this will generate savings for 
both the NHS and patients (the costs of telemedicine are offset by savings 
downstream).  If telemedicine were to be introduced in other hospitals in the area it 
may have a considerable effect on the organisation of health services (this is especially 
true for the specialist hospital, where the specialists will have to assess all patients‟ 
anomaly scans).  That is, an increase in the demand for the service may lead to an 
increased cost to the provider.  Decision makers would then have to decide on the level 
of telemedicine technology and in how many hospitals it should be implemented.  
Some factors which should be taken into account include:  
 The introduction of telemedicine services may have consequences for resource 
allocation for other public sector services in the local region;  
 What impact would the introduction of a telemedicine service have on other 
services provided by both hospitals (DGH and the specialist)? 
 Would the telemedicine service complement or substitute existing services in a 
district hospital?  
 The telemedicine service should be both feasible and acceptable to clinicians; 
 Each hospital would have to decide on what telemedicine service they want: 1) 
diagnostic work – ad hoc „live scanning‟ (which would be more costly and time 
consuming) or 2) „store-and-forward‟ scanning. 
 Who pays for the equipment and the maintenance costs, along with the line 
rental and call charges? 
 Would a telemedicine co-ordinator have to be employed to organise the 
telemedicine activities? 
 Would extra staff be employed or would current staff have to carry out this extra 
work in addition to the current duties? That is, would additional sonographers 
be needed to send anomaly scans via the telemedicine store-and-forward link, 
and likewise, perinatal cardiologists are needed to interpret and provide a 
diagnosis for the anomaly scans.   
 Sonographers at the district hospitals would have to be trained properly in 
conducting and interpreting anomaly scans.  There are training implications as 
there are so few perinatal cardiologists at present. 
 In addition, extra training for staff would be required for using the telemedicine 
equipment. 
 
Karnon et al (2007) provided a critique of methods for model-based cost-utility analysis 
of screening programmes including antenatal screening programmes.  The report 
provides guidance to policy makers regarding the development of screening 
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programmes and the guidelines were grouped into seven categories: research 
question; general modelling approach; model structure; modelling technique; model 
population; validation and calibration; and issues specific to antenatal screening.  The 
latter point included issues such as termination of affected pregnancies as an option 
and the complex issues around the estimation of QALYs (these issues were looked at 
in this thesis). 
 
Finally, Broens et al (2007) conducted a qualitative literature review of 45 conference 
papers to find out what important determinants had influenced successful telemedicine 
implementations.  They classified the findings into categories: 1) technology - which 
includes support and training that was given to users and the technical quality of the 
technology; 2) acceptance – by both clinician and patients; 3) financing – who pays the 
costs associated with the implementation of technology including the maintenance and 
operating costs; and 4) organisation – telemedicine may influence the structure of the 
current healthcare organisation and this may lead to changes with staffing structures. 
 
8.6 Issues for future research 
This thesis has highlighted some of the economic issues which surround telemedicine 
interventions.  However, future research is important and listed below are ways to 
improve and address these economic issues. 
 
Non-randomised studies and selection bias 
If sufficient resources are available for the evaluation, researchers should ideally collect 
data for economic evaluations alongside randomised clinical trials.  Sometimes, 
individual patients or subjects cannot be randomised, and as mentioned earlier, a 
cluster randomised trial may be a more appropriate study design for telemedicine 
services, were different hospitals or units are randomised instead of individual patients 
and this type of trial would aim to produce the least biased estimates for costs and 
effects.  However, as shown in the thesis, it is not always possible to conduct a 
randomised trial.  When such data were not available, then the use of the data 
obtained from non-randomised studies should be used appropriately and its limitations 
should also be acknowledged.  Adjustments should be made when there are known 
biases and the appropriate data has not been collected.   
 
It is worth pointing out that economic evaluations of telemedicine services in general 
require more consistency in their conduct, so that the methodology and results are 
appropriate, reliable and comparable with other studies, and thus, a meta-analysis of 
telemedicine studies can also be conducted. 
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Patient costs 
NICE states that patient costs should not be included in economic evaluations for the 
reference case analyses (and non-reference case analyses) [NICE, 2008].  However, 
patient costs are particularly important if patients have to travel more than once to a 
hospital and if the specialist hospital is not in the local area.  It would be more useful, if 
NICE in their „Methods of Technology Appraisal‟ Guide, suggested specific 
circumstances in which patient costs should be included, because of the impact these 
costs may have on patients and their families and of course, patient costs may be 
relevant for non-NICE economic evaluations. 
 
For any clinical trial especially screening studies, it would be useful to include 
instruments such as questionnaires to collect information on patient costs.  The results 
from these questionnaires could inform other future providers or users of telemedicine 
of what the time and cost implications might be of setting up and using a telemedicine 
service.  Maybe some sort of „gold standard‟ questionnaire to collect this information is 
needed; therefore making it easier for other researchers who need to calculate patient 
costs and also to help compare across different screening programmes. 
 
Measures of benefits such as QALYs 
Cost-benefit analysis is a type of economic evaluation which requires both costs and 
outcomes to be measured and valued in monetary units.  Here, benefits are valued in 
monetary terms using valuations of peoples‟ observed (choices that people make in 
practice) or stated preferences (choices that people make in hypothetical situations).  
Two methods for eliciting stated preferences are: contingent valuation and discrete 
choice experiments.  
 
Contingent valuation asks people the maximum they are willing to pay for a good or 
service [Donaldson, 1990].  This approach asks people to attach to healthcare, the 
amount they would be willing to pay to obtain the benefits or to avoid certain events.  
The value that an individual places on a health care intervention or service will depend 
on the perceived benefits to them.  For example, Ryan et al (1997) used willingness to 
pay to value alternative models of antenatal care.  Discrete choice experiments (DCEs) 
are also used to elicit preferences for healthcare services, and have the ability to take 
into account the non-health benefits to a patient associated with a particular service or 
intervention.  McIntosh and Cairns (1997) claimed “by using a technique which can 
measure changes in utility arising through changes in the „process‟ of care, any benefit 
arising from telemedicine can be assessed in terms of how people value the service”.  
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DCEs are based on the notion that any good or service can be described by its 
characteristics (or attributes), and it is peoples‟ preferences for these attributes that 
determine the overall preference for a good.  The technique can show how individuals 
are willing to trade between attributes of services, to estimate the relative importance of 
the different attributes, to estimate whether an attribute is important, and to predict the 
demand for a given service given its attributes [Ryan and Farrar, 2000; Drummond et 
al, 2005; Lancsar E and Louviere J, 2008].  There are five key steps in undertaking a 
DCE: 1) characteristics of the service must be identified; 2) levels need to be assigned 
to each of the characteristics; 3) scenarios need to be drawn up that describe all the 
possible outcomes of the characteristics and levels chosen; 4) preferences for the 
scenarios included in the survey are elicited by discrete choices (respondents given 
various choices and asked for their preferred choice i.e. do they prefer A or B); 5) data 
are analysed using regression techniques [Ryan and Farrar, 2000].  DCEs can look at 
the important aspects around telemedicine, but not necessarily QALYs; that is, it is 
conceptually difficult to measure both the quantity and quality of life.  However, the aim 
of this thesis was to focus on QALYs. 
 
The QALY was used as an outcome measure in Chapter 7 to look at the benefits from 
a screening programme with telemedicine compared to a screening programme with 
telemedicine.  However, utilities which were used to derive the QALYs were based on 
literature for heart failure patients and these utilities have not captured all the benefits 
associated with telemedicine (including the non-health benefits such as speed of 
service).  Hence, DCEs can be used instead to take into account the health and non-
health benefits associated with telemedicine, while utility measures such as the SF-6D 
and EQ-5D can be used to derive QALYs.  Furthermore, the QALY is the preferred 
outcome measure for NICE and can help decision makers to make decisions when 
using the incremental cost per QALY ratio to make comparisons across different 
interventions or treatments or across different disease areas. 
 
One recent study which used DCEs for telemedicine was in the area of endoscopy 
services [van der Pol and McKenzie, 2010].  The authors looked at the costs and 
benefits for two clinics: 1) a tele-endoscopy clinic and 2) a conventional, mainland clinic 
in Scotland.  The benefits from the two clinics were estimated from a sample of general 
public using a DCE survey, where a monetary value was derived.  The relevant 
attributes were: type of service or clinic, one-way drive time, waiting time, and cost.  
Based on these attributes, 16 hypothetical scenarios were developed.  The authors 
found that if more than 27 patients were seen in each year, the average cost per 
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patient was lower for the tele-endoscopy clinic (£353) than for the mainland clinic 
(£381).  Assuming equal waiting times, individuals preferred the tele-endoscopy clinic 
to the mainland clinic.  The net benefits were larger for tele-endoscopy clinics as long 
as the additional waiting time was not longer than four weeks. 
 
Other issues for future research 
Further research is needed to refine the model assumptions and data inputs in order to 
generate „good cost-effectiveness estimates‟.  One could use value of information 
analysis [Claxton, 1999] to help provide a framework for analysing uncertainty within an 
economic model, by focusing on the value of reducing uncertainty in terms of which 
intervention is cost-effective through further information or additional research.  For 
example, value of information may be able to highlight whether the uncertainty around 
resource use estimates for children with mild, moderate and severe CHD would have 
an impact on the cost-effectiveness ratio and whether this would mean that another 
study should be undertaken to collect such information needed for a model. 
 
8.7 Final thoughts  
The purpose of this thesis was to see how the TelePaed study analysis could have 
been improved in light of the economic issues which were highlighted in the literature 
review and to address some of these issues associated with telemedicine: selection 
bias, patient costs and measures of benefits, namely QALYs.   
 
There have been increasing pressures on healthcare technologies to show that not 
only they are safe and efficacious, but that they are also an efficient use of resources.  
The thesis looked at the use telemedicine in providing specialist advice to pregnant 
women who were at risk of a fetal cardiac anomaly and how these three economic 
issues can be addressed in terms of an economic evaluation.  Overall, with the 
available data and the decision model which was developed, the results demonstrated 
that if telemedicine is implemented as part of a screening programme for all low risk 
women in one hospital, it can be a cost-effective use of resources and help to prevent 
future „missed‟ cardiac anomalies.  In the future, with better model data inputs, 
telemedicine as part of antenatal screening programme maybe cost-effective. 
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APPENDIX 1: SEARCH STRATEGY  
MEDLINE search strategy 
1. exp Cost-Benefit Analysis/ (41359) 
2. (cost effective$ or cost-effective$).mp. (41927) 
3. (cost utility$ or cost-utilit$).mp. (1123) 
4. (cost benefit$ or cost-benefit$).mp. [mp=ti, ot, ab, nm, hw] (43973) 
5. (willingness to pay or wtp or willingness-to-pay or willingness to accept or willingness-to-
accept or net benefit or net-benefit or contingent valuation).mp. (1630) 
6. (Pharmacoeconomic$ or pharmaco-economic$ or Economic analy$ or Economic 
evaluation$).mp. (7047) 
7. (economic adj2 (evaluation$ or analy$ or study or studies)).mp. (6148) 
8. (cost adj2 (evaluation$ or analy$ or study or studies or effective$ or benefit$ or utili$ or 
consequence$)).mp. (105992) 
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 (109709) 
10. exp quality adjusted life year/ (3105) 
11. quality adjusted life year.mp. (1131) 
12. (QALY or QALYs).mp. (1872) 
13. utilit$.mp. (63539) 
14. (EuroQol or Euro Qol or Euro-Qol or EQ 5D or EQ5D or EQ-5D).mp. (1158) 
15. (health utilities index or health-utilities-index or HUI).mp. (551) 
16. (SF 6D or SF6D or SF-6D).mp. (83) 
17. (quality of wellbeing or quality of well-being or QWB).mp. (216) 
18. (health years equivalent or hyes or hye).mp. (48) 
19. (time trade off or time trade-off or time-trade-off or TTO).mp. (518) 
20. (standard gamble or standard-gamble or SG).mp. (3670) 
21. (15 D or 15D).mp. (2182) 
22. ((willing$ adj2 pay) or WTP).mp. (1256) 
23. 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 (74290) 
24. exp telemedicine/ (8670) 
25. (telehealth or telecare or telemonitoring).mp. (954) 
26. exp telecommunications/ (33471) 
27. tele$.mp. (88576) 
28. 24 or 25 or 26 or 27 (95719) 
29. 9 or 23 (177685) 
30. 28 and 29 (2907) 
31. limit 30 to english language (2743) 
32. limit 31 to humans (2279) 
33. remove duplicates from 32 (2252)
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CINAHL search strategy 
1. exp Cost-Benefit Analysis/ (5920) 
2. (cost effective$ or cost-effective$).mp. (7377) 
3. (cost utility$ or cost-utilit$).mp. (165) 
4. (cost benefit$ or cost-benefit$).mp. [mp=ti, ot, ab, nm, hw] (6483) 
5. (willingness to pay or wtp or willingness-to-pay or willingness to accept or willingness-to-
accept or net benefit or net-benefit or contingent valuation).mp. (220) 
6. (Pharmacoeconomic$ or pharmaco-economic$ or Economic analy$ or Economic 
evaluation$).mp. (1703) 
7. (economic adj2 (evaluation$ or analy$ or study or studies)).mp. (1761) 
8. (cost adj2 (evaluation$ or analy$ or study or studies or effective$ or benefit$ or utili$ or 
consequence$)).mp. (16307) 
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 (17376) 
10. exp quality adjusted life year/ (0) 
11. quality adjusted life year.mp. (172) 
12. (QALY or QALYs).mp. (232) 
13. utilit$.mp. (4917) 
14. (EuroQol or Euro Qol or Euro-Qol or EQ 5D or EQ5D or EQ-5D).mp. (488) 
15. (health utilities index or health-utilities-index or HUI).mp. (152) 
16. (SF 6D or SF6D or SF-6D).mp. (21) 
17. (quality of wellbeing or quality of well-being or QWB).mp. (626) 
18. (health years equivalent or hyes or hye).mp. (1) 
19. (time trade off or time trade-off or time-trade-off or TTO).mp. (75) 
20. (standard gamble or standard-gamble or SG).mp. (214) 
21. (15 D or 15D).mp. (65) 
22. ((willing$ adj2 pay) or WTP).mp. (170) 
23. 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 (6515) 
24. exp telemedicine/ (1740) 
25. (telehealth or telecare or telemonitoring).mp. (1243) 
26. exp telecommunications/ (24416) 
27. tele$.mp. (20509) 
28. 24 or 25 or 26 or 27 (30951) 
29. 9 or 23 (23075) 
30. 28 and 29 (843) 
31. limit 30 to english language (838) 
32. limit 31 to humans (838) 
33. remove duplicates from 32 (838) 
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EMBASE search strategy 
1. ('cost benefit'/exp OR 'cost benefit') AND ('analysis'/exp OR 'analysis') (17647) 
2. ('cost effective' OR 'cost-effective') (16973) 
3. ('cost utility' OR 'cost-utilit') (1820) 
4. ('cost benefit' OR 'cost-benefit') (18066) 
5. ('willingness to pay' OR 'WTP' OR 'willingness-to-pay' OR 'willingness to accept' OR 
'willingness-to-accept' OR 'net benefit' OR 'net-benefit' OR ('contingent valuation'/exp OR 
'contingent valuation')) (1132) 
6. (pharmacoeconomic* OR 'pharmaco-economic' OR 'economic analy' OR 'economic 
evaluation') (34250) 
7. (economic AND 2 AND (evaluation* OR analy* OR ('study'/exp OR 'study') OR studies)) 
(16423) 
8. (('cost'/exp OR 'cost') AND 2 AND (evaluation* OR analy* OR ('study'/exp OR 'study') OR 
studies OR effective* OR benefit* OR utili* OR consequence*)) (61648) 
9. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 (101419) 
10. ('quality adjusted life year'/exp OR 'quality adjusted life year') (2950) 
11. (('QALY'/exp OR 'QALY') OR QALYs) (3132) 
12. utilit* (34913) 
13. (EuroQol OR 'Euro Qol' OR 'Euro-Qol' OR 'EQ 5D' OR EQ5D OR 'EQ-5D') (992) 
14. (('health'/exp OR 'health') AND utilities AND index OR health-utilities-index OR HUI) 
(2867) 
15. (('SF'/exp OR 'SF') AND 6D OR SF6D OR 'SF 6D') (97) 
16. (quality AND of AND ('wellbeing'/exp OR 'wellbeing') OR quality AND of AND ('well 
being'/exp OR 'well being') OR QWB) (5714) 
17. (('health'/exp OR 'health') AND years AND equivalent OR hyes OR hye) (1472) 
18. (('time'/exp OR 'time') AND trade AND off OR ('time'/exp OR 'time') AND 'trade off' OR 
time-trade-off OR TTO) (617) 
19. (('standard'/exp OR 'standard') AND gamble OR 'standard gamble' OR SG) (15978) 
20. ('15-D' OR '15D') (2830) 
21. ((willing* AND 2 AND pay) OR WTP) (651) 
22. 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 (66223) 
23. ('telemedicine'/exp OR 'telemedicine') (1615) 
24. (('telehealth'/exp OR 'telehealth') OR telecare OR ('telemonitoring'/exp OR 
'telemonitoring')) (1010) 
25. ('telecommunications'/exp OR 'telecommunications') (3502) 
26. tele* (33618) 
27. 23 OR 24 OR 25 OR 26 (33619) 
28. 9 OR 22 (160784) 
29. 27 AND 28 (2470) 
30. 29 remove duplicates (2464) 
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Web of Science search strategy 
1. TI = Cost-Benefit Analysis (1058) 
2. TI = (cost effective* or cost-effective*) (8202) 
3. TI = (cost utility* or cost-utilit*) (424) 
4. TI = (cost benefit* or cost-benefit*) (2253) 
5. TI =-(willingness to pay or wtp or willingness-to-pay or willingness to accept or 
willingness-to-accept or net benefit or net-benefit or contingent valuation). (1263) 
6. TI = (Pharmacoeconomic* or pharmaco-economic* or Economic analy* or Economic 
evaluation*) (6166) 
7. TI = (economic AND (evaluation* or analy* or study or studies)) (5625) 
8. TI = (cost AND (evaluation* or analy* or study or studies or effective* or benefit* or utili* 
or consequence*)) (13740) 
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 (20952) 
10. TI = quality adjusted life year (9) 
11. TI = (QALY or QALYs) (98) 
12. TI = utility* (15453) 
13. TI = (EuroQol or Euro Qol or Euro-Qol or EQ 5D or EQ5D or EQ-5D) (156) 
14. TI = (health utilities index or health-utilities-index or HUI) (158) 
15. TI = (SF 6D or SF6D or SF-6D) (20) 
16. TI = (quality of wellbeing or quality of well-being or QWB) (373) 
17. TI = (health years equivalent or hyes or hye) (12) 
18. TI = (time trade off or time trade-off or time-trade-off or TTO) (283) 
19. TI = (standard gamble or standard-gamble or SG) (390) 
20. TI = (15-D or 15D) (84) 
21. TI = ((willing* AND pay) or WTP) (749) 
22. 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 (17604) 
23. TI = telemedicine (1079) 
24. TI = (telehealth or telecare or telemonitoring) (307) 
25. TI = telecommunications (2926) 
26. TI = tele* (44461) 
27. 24 or 25 or 26 or 27 (44461) 
28. 9 or 23 (37319) 
29. 27 and 28 (180) 
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APPENDIX 2: LITERATURE REVIEW RESULTS 
 
No. Authors 
Publication 
Year Country Study Design Sample size 
Technology and 
comparators  
Clinical area or 
application Method Viewpoint 
 
1 Agha Z et al 1999 USA Non-randomised NS 
TM vs. CC (on-site care or 
transfer by courier) Pathology CMA 
Healthcare 
system 
 
2 Agha Z et al 2002 USA Non-randomised 65 patients  
TM vs. CC (patient travel or 
on-site care) 
Outpatient pulmonary 
care CEA Societal 
3 
Aoki N et al 2004 USA Non-randomised 10,000 patients TM vs. CC (on-site care) Diabetes CEA 
Healthcare 
system  
4 
Armstrong AW et al 2007 USA Non-randomised 451 patients TM vs. CC (face-to-face clinic) Dermatology CMA 
Healthcare 
system 
 
5 Auerbach H et al  2006 Germany Non-randomised NS 
TM (2 applications) vs. CC 
(no-TM) A&E CEA Societal 
6 Bailes JE et al 1997 USA Non-randomised 100 patients TM vs. CC (patient transfer) Neurology CA NS 
 
7 Barker G et al 2004 USA Non-randomised NS TM vs. CC (face-to-face clinic) Different health areas 
Costing 
model 
Healthcare 
system 
 
8 Bergmo TS 1996 Norway  Non-randomised 
6,000 patients per 
year TM vs. CC (visiting specialist) Radiology CA 
Healthcare 
system 
 
9 Bergmo TS 1997 Norway  Non-randomised 
100 patients per 
year 
TM vs. CC (visiting specialist 
or patient travel) Ear, nose & throat CA Societal 
 
 
10 Bergmo TS 2000 Norway Non-randomised 
TM = 375; CC = 
100 
TM vs. CC (visiting specialist & 
patient travel or patient travel 
or on-site care) Dermatology CMA 
Healthcare 
system 
 
11 Berman M & Fenaughty A 2005 USA Non-randomised 
TM = 240; CC = 
836  TM vs. CC (patient travel) Ear, nose & throat 
Costing 
model NS 
 
12 Bishai DM et al 2003 USA Non-randomised 90 patients 
TM vs. CC (on-site care or 
visiting specialist) Cancer CA Societal 
13 Bjorvig S et al 2002 Norway Non-randomised 42 patients TM vs. CC (face-to-face clinic) Diabetes CMA NS 
14 Bracale M et al 2002 Italy Non-randomised NS TM vs. CC (patient transfer) Different health areas CCA NS 
15 Breslow MJ et al 2004 USA Non-randomised 1,240 patients Before and after TM Intensive care CCA NS 
16 Brumage MR et al 2001 USA Non-randomised TM = 323; CC = 33  TM vs. CC (patient transfer) Radiology CA NS 
 
17 Brunicardi BO 1998 USA Non-randomised NS TM vs. CC (patient transfer) Prison service CA 
Prison health 
service  
18 Burgiss SG et al 1997 USA Non-randomised 87 patients  Before and after TM Dermatology CA NS 
19 Bynum AB et al 2003 USA Non-randomised 236 patients Before and after TM Different health areas CA Patient 
20 Callahan CW et al 2005 USA Non-randomised 267 patients TM vs. CC (patient transfer) Paediatrics CA NS 
 
21 Castillo-Riquelme MC et al 2004 UK Non-randomised 235 patients 
TM vs. CC (visiting specialist 
or transfer of images) Ophthalmology CEA 
Healthcare 
system 
 
22 Chan HH et al 2000 
Hong 
Kong Non-randomised 74 patients 
TM vs. CC (patient transfer or 
visiting specialist) Dermatology CA NS 
23 Chodroff PH 1999 USA Non-randomised 329 patients TM vs. CC (patient transfer) Neurology CA NS 
 
24 Chua R et al 2001 
Northern 
Ireland Randomised TM = 76; CC = 65 TM vs. CC (face-to-face clinic) Neurology CA NS 
25 Crowe BL et al 1996 Australia Non-randomised NS TM vs. CC (patient transfer) Radiology CA NS 
 
26 Darkins A et al 1996 
UK and 
Ireland Non-randomised 51 TM patients  TM vs. CC (on-site care) Minor injuries  CA NS 
27 
Daucourt V et al 2006 France Non-randomised NS TM vs. CC (patient transfer) Radiology CMA 
Healthcare 
system 
 
28 Davis MC 1997 USA Non-randomised 
2,000 patients per 
year TM vs. CC (transfer by courier) Radiology CA NS 
29 Davis P et al  2001 Canada Non-randomised 52 patients TM vs. CC (face-to-face clinic) Rheumatology CA NS 
30 de la Torre A et al 2004 USA Non-randomised NS TM vs. CC (face-to-face clinic) Different health areas CA Societal 
31 Deodhar J 2002 India Non-randomised 182 patients TM vs. CC (patient transfer) Neonatal care CA NS 
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32 Doolittle GC et al 1998 USA Non-randomised 
TM = 103; CC: 
patient travel = 
2,400 & on-site 
care = 81  
TM vs. CC (face-to-face clinic 
or visiting specialist) Cancer CA NS 
33 Doolittle GC 2000 USA Non-randomised NS TM vs. CC (on-site care) Hospice care CA NS 
34 Doolittle GC et al 2003 USA Non-randomised 286 patients TM vs. CC (on-site care) Paediatrics CA NS 
35 Doolittle GC et al 2004 USA Non-randomised NS TM vs. CC (face-to-face clinic) Cancer CA NS 
36 Doze S et al 1999 Canada Non-randomised 90 patients TM vs. CC (visiting specialist) Psychiatry CA NS 
37 Elford DR et al 2001 Canada Non-randomised 30 patients TM vs. CC (face-to-face clinic) Psychiatry CA NS 
38 Ferris DG et al 2004 USA Non-randomised 264 patients TM vs. CC (on-site care) Cancer CA NS 
39 Finley JP et al 1997 Canada Non-randomised 135 patients TM vs. CC (patient transfer) Cardiology CA NS 
 
40 
Halvorsen PA & 
Kristiansen IS 1996 Norway Randomised 597 patients 
TM vs. CC (on-site care or 
patient travel) Radiology CMA Societal 
41 Harley J 2006 UK Non-randomised NS TM vs. CC (face-to-face clinic) Psychiatry CA NS 
 
42 Harno KS 1999 Finland Non-randomised NS 
TM vs. CC (patient transfer or 
on-site care) 
 
Different health areas CA NS 
43 Harno K et al 2000 Finland Non-randomised 292 patients  TM vs. CC (face-to-face clinic) Different health areas CMA NS 
44 Harno K et al 2001 Finland Non-randomised TM = 57; CC = 362 TM vs. CC (face-to-face clinic) Orthopaedics CMA NS 
45 Hassall S et al 2003 Australia Non-randomised NS TM vs. CC (face-to-face clinic) Different health areas CA NS 
 
46 Himpens B 2003 Belgium Non-randomised NS TM vs. CC (patient travel) 
Administration, 
education & clinical CA NS 
 
47 Hui E & Woo J 2002 
Hong 
Kong Non-randomised NS 
TM vs. CC (face-to-face clinic 
or on-site care) Care for elderly CA NS 
 
48 Ippolito A et al 2003 Italy Non-randomised 
TM = 162; CC = 
2,710 deliveries. TM vs. CC (on-site care) Cardiology CA NS 
 
49 Jacklin PB et al 2003 UK Randomised 
TM = 1,051; CC = 
1,043 TM vs. CC (face-to-face clinic) 
Patients who visited the 
GP CCA Societal 
50 Jin AJ et al 2004 Canada Non-randomised 339 patients TM vs. CC (patient travel) Diabetes CEA NS 
 
 
51 Johnston K et al 2004 
UK & 
South 
Africa Non-randomised 90 patients Use of TM in 2 countries Ophthalmology CEA NS 
52 Jong M 2004 Canada Non-randomised 71 patients TM vs. CC (face-to-face clinic) Mental health CA NS 
53 Kesler C & Balch D 1995 USA Non-randomised NS TM vs. CC (patient transfer) Prison service  CA NS 
 
54 
Kildemoes HW & 
Kristiansen IS 2004 Denmark Non-randomised NS 
TM vs. CC (public campaign 
only) Cardiology CEA 
Healthcare 
system 
55 Kitt SM & Clayton L 2002 Australia Non-randomised NS TM vs. CC (face-to-face clinic) Different health areas CA NS 
56 Kristo DA et al 2001 USA Non-randomised 54 patients TM vs. CC (on-site care) Sleep studies CA NS 
 
57 
Kumar S et al 2006 Australia Non-randomised 118 patients 
TM vs. CC (face-to-face clinic 
or on-site care or patient 
transfer) Ophthalmology CA 
Healthcare 
system 
58 
Lamminen H et al 2000 Finland Non-randomised 25 patients TM vs. CC (patient travel) Dermatology CA 
Healthcare 
system 
 
59 Lamminen H et al 2001 Finland Non-randomised TM = 42; CC = 249 TM vs. CC (patient travel) 
Ophthalmology & 
dermatology CA NS 
 
60 Loane MA et al 2000 
Northern 
Ireland Non-randomised 96 patients TM vs. CC (transfer by courier) Dermatology CA Societal 
 
61 Loane MA et al 2001a 
Northern 
Ireland Randomised 
TM = 126; CC = 
148 TM vs. CC (face-to-face clinic) Dermatology CA Societal 
 
62 Loane MA et al 2001b 
New 
Zealand Randomised TM = 109; CC = 94 TM vs. CC (face-to-face clinic) Dermatology CMA Societal 
63 Malone FD et al 1998 USA Non-randomised 300 patients TM vs. CC (transfer by courier) Pregnant women CA NS 
64 Marcin JP et al 2004 USA Non-randomised TM = 47; CC = 90 TM vs. CC (patient transfer) Paediatrics CA NS 
65 McCue MJ et al 1997 USA Non-randomised 165 patients TM vs. CC (patient transfer) HIV CA NS 
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66 McCue MJ et al 1998 USA Non-randomised NS TM vs. CC (face-to-face clinic) Different health areas CMA 
Prison health 
service  
67 McCue MJ et al 2000 USA Non-randomised NS TM vs. CC (face-to-face clinic) Cardiology CA NS 
68 McIntosh WA et al 2003 USA Non-randomised NS TM vs. CC (face-to-face clinic) Different health areas CA NS 
69 Mielonen ML et al 2000 Finland Non-randomised 14 patients TM vs. CC (face-to-face clinic) Psychiatry CA Societal 
70 Modai I et al 2006 Israel Non-randomised TM = 39; CC = 42 TM vs. CC (face-to-face clinic) Psychiatry CA NS 
 
71 Navein J et al 1999 
USA and 
Europe Non-randomised 2000 air referrals TM vs. CC (patient transfer) Different health areas CA NS 
72 Nguyen LT et al 2004 USA Non-randomised 294 patients TM vs. CC (face-to-face clinic) Burns CA NS 
73 Noble SM et al 2005 UK Randomised TM = 191; CC = 62 TM vs. CC (face-to-face clinic) Minor injuries  CCA Societal 
74 Norum J et al 2007 Norway Non-randomised 130 patients TM vs. CC (face-to-face clinic) Pregnant women CA Societal 
 
75 Ohinma A & Scott R 2006 Canada Non-randomised NS TM for various activities 
Administration, 
education & clinical 
Costing 
model 
Healthcare 
system 
76 Ohinmaa A et al 2002 Finland Randomised TM = 69; CC = 76 TM vs. CC (face-to-face clinic) Orthopaedics CMA NS 
77 Peng PW et al 2006 Canada Non-randomised 8 patients TM vs. CC (face-to-face clinic) Chronic pain CA NS 
 
78 Persaud DD et al 2005 Canada Non-randomised TM = 86; CC = 129 TM vs. CC (face-to-face clinic) 
Psychiatry and 
dermatology  CA Societal 
79 Preston J 1995 USA Non-randomised NS Before and after TM Different health areas CA NS 
80 Redlick F et al 2002 Canada Non-randomised NS TM vs. CC (patient travel) Burns CA NS 
 
81 Rendina MC et al 1998 USA Non-randomised TM = 48; CC = 39 TM vs. CC (transfer by courier) Cardiology CA 
Healthcare 
system  
 
82 Rendina MC et al 2001 USA Non-randomised 
2,142 infants 
admitted to NICU TM vs. CC (face-to-face clinic) Cardiology CA NS 
83 Rumpsfeld M et al 2005 Norway Non-randomised 9 patients TM vs. CC (patient travel) Dialysis  CMA Societal 
84 
Ruskin PE et al 2004 USA Randomised TM = 59 ; CC = 60 TM vs. CC (on-site care) Psychiatry CCA 
Healthcare 
system 
85 Santamaria N et al 2004 Australia Randomised 93 patients TM vs. CC (on-site care) Wound care CCA NS 
 
86 Schaafsma J et al 2007 Canada Non-randomised NS TM vs. CC (patient travel) 
Administration, 
education & clinical CA Societal 
 
87 Scuffham PA & Steed M 2002 UK Non-randomised 18 patients 
TM vs. CC (on-site care vs. 
patient travel) Dentistry CMA Societal 
88 Sezeur A et al 2001 France Non-randomised 16 patients TM vs. CC (patient transfer) Cancer CA NS 
 
89 Sicotte C et al 2004 Canada Non-randomised 78 patients 
TM vs. CC (on-site care or 
patient travel) Cardiology CEA Societal 
90 Simpson J et al 2001a Canada Non-randomised 230 patients TM vs. CC (patient travel) Psychiatry CA Patient 
91 
Simpson J et al 2001b Canada Non-randomised 379 patients TM vs. CC (on-site care) Psychiatry CA 
Healthcare 
system 
92 
Smith AC et al 2007 Australia Non-randomised NS TM vs. CC (face-to-face clinic) Paediatrics CA 
Healthcare 
system 
93 Specht JK et al 2001 USA Non-randomised NS TM vs. CC (face-to-face clinic) Chronic pain CMA Societal 
94 Stalfors J et al 2005 Sweden Non-randomised TM = 45; CC = 39 TM vs. CC (face-to-face clinic) Cancer CMA NS 
 
95 Stensland J et al 1999 USA Non-randomised NS TM vs. CC (face-to-face clinic) 
Orthopaedic & 
dermatology  CA Societal 
 
96 Stoeger A et al 1997 Austria Non-randomised 116 patients 
TM vs. CC (patient transfer or 
transfer by courier) Radiology CA NS 
97 Takizawa M et al 1998 Japan Non-randomised TM = 18; CC = 20 TM vs. CC (face-to-face clinic) Lung disease CA NS 
98 Trott P & Blignault I 1998 Australia Non-randomised 50 patients TM vs. CC (patient transfer) Psychiatry CA NS 
99 Tsitlakidis C et al 2005 Greece Non-randomised 38 patients TM vs. CC (patient transfer) General health advice  CMA NS 
100 Tuulonen A et al 1999 Finland Non-randomised TM = 29; CC = 41 TM vs. CC (face-to-face clinic) Ophthalmology CA NS 
 
101 Vincent JA et al 1997 USA Non-randomised 96 patients 
TM vs. CC (face-to-face clinic 
or on-site care) Cardiology CEA NS 
102 Vuletic S 2001 Croatia Non-randomised 442 patients TM vs. CC (patient transfer) Radiology CA NS 
103 Whited JD et al 2003 USA Randomised TM = 135; CC = TM vs. CC (face-to-face clinic) Dermatology CA & Healthcare 
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140  CEA system 
104 
Whited JD et al 2005 USA Non-randomised NS TM vs. CC (face-to-face clinic) Ophthalmology CEA 
Healthcare 
system 
 
105 Wong HT et al 2006 China Randomised 
TM = 239; CC = 
471 
TM vs. CC (face-to-face clinic 
or a video-consultation) Neurology CEA NS 
 
106 Wootton R et al 2000 
Northern 
Ireland Randomised 
TM = 102; CC = 
102 TM vs. CC (face-to-face clinic) Dermatology CBA Societal 
107 Young TL & Ireson C 2003 USA Non-randomised NS TM vs. CC (face-to-face clinic) Acute care CA NS 
108 Zincone LH Jr et al 1997 USA Non-randomised NS TM vs. CC (face-to-face clinic) Prison service CA Societal 
 
109 Zollo S et al 1999 USA Non-randomised 274 patients TM vs. CC (patient transfer) Different health areas CA 
Prison health 
service  
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           APPENDIX 2: RESULTS FROM THE LITERATURE REVIEW (CONTINUED) 
 
No. Authors 
Publication 
Year 
Time 
frame Costs Patient costs Benefits Discounting 
Sensitivity 
analyses Cost results 
 
1 Agha Z et al 1999 1 year DMC None None Yes Yes 
Courier method < TM & TM < 
on-site care 
 
 
2 Agha Z et al 2002 1 year 
DMC, 
DNMC, IC 
Travel and 
accommodation costs 
Healthcare access for 
patients who received 
outpatient consultations Yes  Yes TM < CC  
 
3 Aoki N et al 2004 NS DMC None 
QALYs calculated using a 
Markov model Yes  Yes TM < CC 
4 Armstrong AW et al 2007 18 months DMC None None No Yes TM < CC 
 
 
5 Auerbach H et al  2006 11 years 
DMC, 
DNMC 
Personal injury costs i.e. 
hospital admissions and 
rehabilitation Life years gained Yes Yes Both TM methods > CC 
6 Bailes JE et al 1997 1 year DMC None None No No TM < CC 
7 Barker G et al 2004 1 year DMC None None No No TM > CC 
8 Bergmo TS 1996 NS DMC None None No Yes TM < CC 
 
 
 
9 Bergmo TS 1997 1 year 
DMC, 
DNMC 
Travel costs, 
subsistence costs and 
cost of care to look after 
child or adult. None No No 
TM cost saving above certain 
patient throughput 
 
10 Bergmo TS 2000 1 year 
DMC, 
DNMC Travel costs None No Yes TM < CC  
 
11 
Berman M & 
Fenaughty A 2005 2 years 
DMC, 
DNMC 
Travel, food & 
accommodation costs None No No TM < CC 
 
12 Bishai DM et al 2003 1 year 
DMC, 
DNMC, IC Travel costs  None No Yes TM > CC 
13 Bjorvig S et al 2002 1 year DMC None None No No TM < CC  
14 Bracale M et al 2002 2 years DMC None None No No TM < CC 
15 Breslow MJ et al 2004 18 months DMC None Mortality and length of stay No No TM < CC 
 
16 Brumage MR et al 2001 2 months DMC, PSav None 
Transfers and 
hospitalisations avoided No Yes TM < CC 
 
17 Brunicardi BO 1998 1 year DMC None None No No 
TM cost saving above certain 
patient throughput 
18 Burgiss SG et al 1997 17 months DMC None None No No TM < CC 
19 Bynum AB et al 2003 2 years DNMC, IC Travel costs None No No TM reduces patients costs 
 
 
20 Callahan CW et al 2005 1 year 
DMC, 
DNMC, 
PSav 
Travel and 
accommodation costs None No No TM < CC 
 
21 
Castillo-Riquelme MC 
et al 2004 16 months DMC None 
QALYs based on survival 
and utility weights Yes  Yes TM > CC 
22 Chan HH et al 2000 NS DMC None None No No TM < CC 
23 Chodroff PH 1999 35 months  DMC None None No No TM < CC 
 
24 Chua R et al 2001 NS 
DMC, 
DNMC Travel costs None No No TM > CC 
 
25 Crowe BL et al 1996 3 months DMC None None No No 
TM has potential to be cost 
saving 
26 Darkins A et al 1996 1 year DMC None None No No TM < CC 
 
 
27 Daucourt V et al 2006 1 year DMC, PSav None 
Number of transfers, 
hospitalisations & 
consultations avoided No Yes 
TM has potential to be cost 
saving 
28 Davis MC 1997 2 years DMC None None No No TM < CC 
29 Davis P et al  2001 NS DMC None None No No TM costs were similar to CC 
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30 de la Torre A et al 2004 1 year 
DMC, 
DNMC, IC Travel costs None No No TM > CC 
 
 
31 Deodhar J 2002 18 months DMC None 
Number of transfers, 
hospitalisations and 
consultations avoided No No 
 
TM < CC 
 
32 Doolittle GC et al 1998 1 year DMC None None No No 
Patient travel< TM & TM < 
on-site care 
33 Doolittle GC 2000 NS DMC None None No No TM < CC 
 
34 Doolittle GC et al 2003 9 months 
DMC, 
DNMC 
Travel costs & out-of-
pocket expenses None No No 
TM cost saving above certain 
patient throughput 
 
35 Doolittle GC et al 2004 NS DMC None None No No 
TM has potential to be cost 
saving 
 
36 Doze S et al 1999 9 months DMC None None No Yes 
TM has potential to be cost 
saving 
 
37 Elford DR et al 2001 3 months 
DMC, 
DNMC 
Travel, food & 
accommodation costs None No No TM < CC 
38 Ferris DG et al 2004 23 months DMC None None No No TM > CC 
 
 
39 Finley JP et al 1997 2 years 
DMC, 
DNMC, 
PSav 
Travel and 
accommodation costs None No No TM < CC 
 
40 
Halvorsen PA & 
Kristiansen IS 1996 1 year 
DMC, 
DNMC, IC Travel costs None No Yes TM > CC 
 
41 Harley J 2006 6 months  
DMC, 
DNMC Travel costs  None No Yes TM < CC 
 
42 Harno KS 1999 1 year DMC None None No No 
TM has potential to be cost 
saving 
 
43 Harno K et al 2000 8 months 
DMC, 
DNMC Travel costs  None No No TM < CC 
 
44 Harno K et al 2001 8 months 
DMC, 
DNMC Travel costs  None No No TM < CC 
 
45 Hassall S et al 2003 3 months DMC None None No Yes 
TM cost saving above certain 
patient throughput 
 
46 Himpens B 2003 3 years 
DMC, 
DNMC Travel costs  None No No TM reduces patients costs 
47 Hui E & Woo J 2002 1 year DMC None None No No TM < CC 
48 Ippolito A et al 2003 1 year DMC None None No No TM costs were similar to CC 
 
49 Jacklin PB et al 2003 6 months  
DMC, 
DNMC, IC Travel costs  SF-12 as a utility measure No Yes TM > CC 
 
50 Jin AJ et al 2004 1 year 
DMC, 
DNMC 
Travel, food & 
accommodation costs None No No TM < CC 
 
51 Johnston K et al 2004 1 year DMC None DALYs No Yes 
TM has potential to be cost 
saving 
 
52 Jong M 2004 1 year 
DMC, 
DNMC 
Travel, food & 
accommodation costs None No No TM < CC 
 
53 Kesler C & Balch D 1995 NS DMC None None No No 
TM has potential to be cost 
saving 
 
54 
Kildemoes HW & 
Kristiansen IS 2004 Lifetime DMC None Life years gained Yes Yes TM > CC 
55 Kitt SM & Clayton L 2002 NS DMC None None No No TM < CC 
56 Kristo DA et al 2001 7 months  DMC None None No No TM < CC 
57 Kumar S et al 2006 1 year DMC None None No Yes TM < CC 
 
58 Lamminen H et al 2000 8 months 
DMC, 
DNMC Travel costs  None No No TM costs were similar to CC 
 Lamminen H et al 2001 9 months DMC, Travel costs  None No No TM cost saving above certain 
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59 DNMC patient throughput 
 
60 Loane MA et al 2000 1 year 
DMC, 
DNMC, IC Travel costs  None No Yes 
TM has potential to be cost 
saving 
 
61 Loane MA et al 2001a 2 years 
DMC, 
DNMC, IC Travel costs  None No Yes TM > CC 
 
62 Loane MA et al 2001b 10 months 
DMC, 
DNMC, IC Travel costs  None No No TM < CC 
 
63 Malone FD et al 1998 2 months DMC None None No No 
TM has potential to be cost 
saving 
 
64 Marcin JP et al 2004 2 years DMC None None No No 
TM has potential to be cost 
saving 
65 McCue MJ et al 1997 7 months DMC None None No Yes TM < CC 
66 McCue MJ et al 1998 1 year DMC None None No No TM < CC 
 
67 McCue MJ et al 2000 3 years DMC None None No No 
TM cost saving above certain 
patient throughput 
 
68 McIntosh WA et al 2003 2 years 
DNMC, IC, 
PSav 
Cost to patient for 
specialty consultation None No No TM > CC 
69 Mielonen ML et al 2000 11 months DMC None None No No TM < CC 
 
70 Modai I et al 2006 1 year 
DMC, 
DNMC Travel costs  
Patient satisfaction was 
measured No No TM > CC 
 
71 Navein J et al 1999 NS 
DMC, 
DNMC 
Travel and 
accommodation costs None No No 
TM has potential to be cost 
saving 
72 Nguyen LT et al 2004 5 years DMC None None No No TM < CC 
 
 
73 Noble SM et al 2005 NS 
DMC, 
DNMC 
Travel and subsistence 
costs 
Safety and clinical 
effectiveness at 7 days after 
presentation No Yes TM > CC 
 
74 Norum J et al 2007 8 months 
DMC, 
DNMC, IC Travel costs  None No No TM > CC 
75 Ohinma A & Scott R 2006 1 year DMC None None Yes  Yes TM > CC 
 
76 Ohinmaa A et al 2002 NS 
DMC, 
DNMC, IC 
Travel costs and cost of 
home help None No Yes 
TM cost saving above certain 
patient throughput 
 
77 Peng PW et al 2006 NS DNMC 
Travel, food & 
accommodation costs None No No TM < CC 
 
78 
Persaud DD et al 2005 NS 
DMC, 
DNMC 
Travel costs, out-of-
pocket and 
accommodation costs None No No TM > CC 
 
79 Preston J 1995 NS DMC, PSav None None No No 
TM has potential to be cost 
saving 
 
 
80 Redlick F et al 2002 1 year 
DMC, 
DNMC 
Travel, food, childcare 
and accommodation 
costs 
Patient satisfaction was 
measured No No TM < CC 
 
81 Rendina MC et al 1998 NS DMC None 
Mortality, length of stay and 
transfer rate No No TM > CC 
 
82 Rendina MC et al 2001 3 years PSav None None No No 
TM has potential to be cost 
saving 
 
83 
Rumpsfeld M et al 2005 8 months 
DMC, 
DNMC, 
PSav Travel costs  
Travel and hospitalisations 
avoided No No TM > CC 
 
84 
Ruskin PE et al 2004 6 months DMC None 
Scales for depression, 
anxiety, functioning and SF-
12. No No TM > CC 
 
85 Santamaria N et al 2004 12 months 
DMC, 
DNMC Travel costs  Healing rate difference No No TM < CC 
 Schaafsma J et al 2007 17 months DMC, Travel, food & None No Yes TM has potential to be cost 
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86 DNMC, IC accommodation costs saving 
 
87 
Scuffham PA & Steed 
M 2002 1 year 
DMC, 
DNMC, IC Travel costs  None No Yes 
TM > on-site care & TM < 
patient travel 
88 Sezeur A et al 2001 NS DMC None None No No TM < CC 
89 
Sicotte C et al 2004 4 years 
DMC, 
DNMC Travel costs  
Avoidance of patient 
journeys No Yes TM > CC 
90 
Simpson J et al 2001a NS DNMC, IC Travel costs  
Patient satisfaction was 
measured No No TM < CC 
 
91 Simpson J et al 2001b 2 years DMC None None No Yes 
TM cost saving above certain 
patient throughput 
 
92 Smith AC et al 2007 5 years 
DMC, 
DNMC 
Travel and 
accommodation costs Travel avoided No Yes TM < CC 
 
 
93 Specht JK et al 2001 NS 
DMC, 
DNMC, 
PSav Travel costs  None No No TM < CC 
 
94 Stalfors J et al 2005 1 year 
DMC, 
DNMC, IC Travel costs  None No Yes TM < CC 
 
95 Stensland J et al 1999 1 year 
DMC, 
DNMC, IC Travel costs  None No Yes 
TM cost saving above certain 
patient throughput 
 
96 Stoeger A et al 1997 13 months DMC None None No No 
TM < patient transfer & TM > 
courier transfer 
97 Takizawa M et al 1998 11 months DMC None None No No TM < CC 
98 Trott P & Blignault I 1998 1 year DMC None None No No TM < CC 
 
99 Tsitlakidis C et al 2005 1 year 
DMC, 
DNMC, IC 
Travel and 
accommodation costs None No Yes 
TM cost saving above certain 
patient throughput 
100 Tuulonen A et al 1999 NS DMC None None No No TM costs were similar to CC 
101 Vincent JA et al 1997 3 years DMC None None No No TM < CC 
102 Vuletic S 2001 2 years PSav None None No No TM < CC 
 
103 Whited JD et al 2003 1 year 
DMC, 
DNMC Travel costs  
Effectiveness measured in 
days to intervention No Yes TM > CC 
 
 
104 Whited JD et al 2005 1 year DMC None 
No. of patients who needed 
treatment & number of cases 
of severe vision loss averted No Yes TM > CC 
 
105 Wong HT et al 2006 3 years DMC None 
Range of outcomes including 
mortality No No TM costs were similar to CC 
 
106 Wootton R et al 2000 1 year 
DMC, 
DNMC, IC Travel costs  None No Yes TM > CC 
 
 
107 Young TL & Ireson C 2003 2 years 
DMC, 
DNMC, 
PSav Travel costs  None No No TM reduces patients costs 
 
108 Zincone LH Jr et al 1997 NS DMC None None No Yes 
TM cost saving above certain 
patient throughput 
 
109 Zollo S et al 1999 1 year DMC None None No No 
TM cost saving above certain 
patient throughput 
 
Key: 
Method: CA = cost analysis; CCA = cost-consequences analysis; CBA = cost-benefit analysis; CMA = cost-minimisation analysis; CEA = cost-effectiveness analysis 
Technology & comparators: TM = telemedicine; CC = Conventional Care 
Conventional Care: on-site care = care at local hospital or in an outreach clinic; patient travel or face-to-face clinic = patient travels to specialist hospital for assessment; patient transfer = 
patient is transferred to specialist hospital for treatment/care; visiting specialist = visiting specialist visits local hospital 
Costs: DMC = direct medical costs; DNMC = direct non-medical costs; IC = indirect costs; PSav = potential savings 
NS = not stated 
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APPENDIX 3: RESULTS FROM THE META-ANALYSIS 
 
Of the 109 studies, 100 studies (91.7%) had insufficient statistical information in order 
for a meta-analysis to be conducted.  Of those studies which were excluded the 
number of studies reporting only: 1) total costs, mean costs and sample size; and 2) 
means costs and sample size, for the telemedicine arm were: 37 (37.0%) and 20 
(20.0%), and for the conventional arm were: 28 (28.0%) and 23 (23.0%) respectively.  
However, when looking at both the telemedicine and control arms, these figures were: 
28 (28.0%); and 18 (18.0%).  If those studies which reported mean costs and sample 
sizes, also included either standard deviations or p- or t- values from statistical tests, 
then these studies could have been included in the meta-analysis.    
 
Only nine studies could be included in the meta-analysis.  Of these 7 studies [Jacklin et 
al, 2003; Redlick et al, 2002; Ruskin et al, 2004; Stalfors et al, 2005; Takizawa et al, 
1998; Vincent et al, 1997; Wong et al, 2006] reported information on mean costs, 
sample sizes and p-values.  A further two studies [Berman and Fenaughty, 2005; 
Wootton et al, 2000] reported information on mean costs, standard deviations and 
sample sizes, and using this information a p-value was computed. 
 
Figure A1: Random effects meta-analysis of telemedicine cost studies (using 
means, samples sizes and p-values) 
Study name Statistics for each study Sample size Std diff in means and 95% CI
Std diff Lower Upper 
in means limit limit p-Value Telemedicine Conventional
Berman -0.286 -0.430 -0.142 0.000 240 836
Jacklin 0.095 0.009 0.181 0.030 1051 1043
Redlick -1.009 -1.769 -0.249 0.009 15 15
Ruskin 0.619 0.251 0.987 0.001 59 60
Stalfors -0.283 -0.714 0.148 0.199 45 39
Takizawa -1.300 -2.001 -0.599 0.000 18 20
Vincent -0.426 -0.750 -0.102 0.010 75 75
Wong 0.075 -0.105 0.255 0.413 239 235
Wootton 0.556 0.276 0.836 0.000 102 102
-0.105 -0.348 0.138 0.399 1844 2425
-2.00 -1.00 0.00 1.00 2.00
Telemedicine Conventional
Telemedicine cost studies
Random Effects Meta Analysis
 
 
Figures A1 above shows the random effects meta-analysis results from the 9 studies.  
Overall the random effects meta-analysis concludes that telemedicine is cheaper than 
conventional care, although differences are not significant (-10.5% (95% CI: -34.8% to 
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13.8%), p = 0.399).  Four studies were significantly (p ≤ 0.05) in favour of telemedicine 
[Berman and Fenaughty, 2005; Redlick et al, 2002; Takizawa et al, 1998; Vincent et al, 
1997]; whereas three studies were significantly in favour of the conventional arm 
[Jacklin et al, 2003; Ruskin et al, 2004; Wootton et al, 2000].  The meta-analysis for the 
telemedicine cost studies using a random effects procedure most closely reflects the 
health services being analysed as the sample sizes of the various studies were 
different and the procedure has the ability to control for between study variations.  The 
results also showed that there was significant heterogeneity between the studies 
(heterogeneity test: Q = 74.73, df = 8, p < 0.001) and that there was also evidence of 
funnel plot asymmetry.   
 
Conclusions cannot be made precisely from these nine studies as one can‟t be 100% 
sure that the costs included in each study have been collected appropriately i.e. that 
each of the studies have defined costs in the same way; that they used similar methods 
to collect and analyse the cost data; and finally, the same valuation technique was 
used for the costs.  As telemedicine has been used in a different context for each 
study, it makes it quite difficult to come to some generalisable conclusions.  
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APPENDIX 4: USE OF TELEMEDICINE IN SPECIFIC HEALTH AREAS 
 
Detailed below are studies of telemedicine interventions in four specific health areas 
which were identified in the literature review: ten studies in dermatology, nine studies in 
psychiatry and eight studies each in radiology and cardiology.  
 
a) Dermatology. The first study by Armstrong and colleagues (2007) was a cost-
minimisation analysis of interactive teledermatology compared with conventional care 
(outpatient face-to-face dermatology clinic) in the USA.  The study was conducted for a 
period of 18 months and 451 new patient and follow-up visits were made to the 
interactive teledermatology clinic.  The two hour clinic sessions occurred weekly and in 
each session, four patients were seen in an hour.  The costs of teledermatology 
included the costs of the videoconferencing equipment, clinic space, personnel and 
overhead costs.  For conventional clinics, the costs included room space, overheads 
and staff costs.  Total hourly operating costs for teledermatology were lower than 
conventional clinic (US$274 vs. US$346).  The lower cost of teledermatology was due 
to the low cost of the technology and reduced rental charge for clinic space in rural 
areas.  The authors concluded that from a healthcare provider perspective, 
teledermatology can be economically viable means of providing dermatological care to 
remote regions. 
 
Bergmo (2000) compared real-time teledermatology to three alternative methods of 
providing dermatology care to patients living in remote areas in northern Norway.  The 
alternatives were a combination of visiting service and patient travel; patient travel to 
the nearest secondary care centre; and a locally employed dermatologist.  Three 
hundred and seventy five patients were seen by teledermatology and 100 patients 
visited the outpatient clinic during the course of the year.  The costs for 
teledermatology included a videoconferencing unit including two monitors, connected 
by ISDN lines, video camera, a phototherapy machine and staff costs.  Costs for 
conventional care included travel costs and salary costs for the specialist, GP and 
nurse.  Costs common to all methods, such as drugs costs and hospitalization costs 
were excluded.  The cost-minimisation analysis from the healthcare perspective found 
that for a workload of 375 patients, teledermatology cost NKr470,780; while the visiting 
service and patient travel to hospital cost NKr880,530; patient travel to the nearest 
secondary-care centre cost NKr1,635,075; and a locally employed dermatologist cost 
NKr958,660.  The authors found that generalisation of the study results, depends on 
the workload, whether the visiting specialist service is an available option and the 
actual travel costs.  The cost analysis shows that telemedicine was the cheapest 
method for workloads above 195 per year. 
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The effect of teledermatology consultations on the cost of care for patients in rural 
areas in the USA was assessed by Burgiss and colleagues (1997).  The study was a 
before and after comparison of teledermatology.  In total, 119 visits were made by the 
87 patients who were referred for teledermatology over a 17-month period.  The 
telemedicine costs included the costs of the video equipment and special cameras for 
observing dermatologic lesions.  Other costs included the hospital room costs, 
medication costs, procedure and test costs and staff costs.  The cost analysis found 
that the average cost of care for all patients during an average period of 8 months prior 
to teledermatology was US$294, compared with US$141 for the 6 months after 
diagnosis by teledermatology.  The authors stated that teledermatology can be 
effective for dermatology consultation in new patients and that the data indicated 
teledermatology can decrease the cost of care for the diagnosed conditions. 
 
A pilot study to look at the costs of establishing a teledermatology centre for a 
community in Hong Kong was conducted by Chan and colleagues (2001).  
Teledermatology at an elderly person‟s centre was compared to sending patients to a 
speciality clinic and monthly visits from a dermatologist.  Seventy-four patients were 
recruited into the study.  The teledermatology costs included the costs of the 
equipment, maintenance costs, cost of the ISDN lines and installation and staff costs.  
The conventional costs included the costs of the transportation, escort costs and staff 
costs.  The cost analysis found that the cost per patient for teledermatology was 
HK$57.70; cost per patient for sending patients to a specialty clinic was HK$322.80; 
and total cost per patient of sending a dermatologist to a centre was HK$445.90.  
Therefore, the total saving per patient seen via teledermatology was HK$265.10.  The 
authors found that teledermatology is a cost-saving means for providing a service to 
elderly persons. 
 
Lamminen et al (2000) conducted a study from a health service perspective of real-time 
teledermatology using low cost equipment compared to conventional consultations in 
Finland.  Costs for the real-time teledermatology included the cost of the 
videoconferencing equipment, annual maintenance cost, document camera, a 
dermatoscope, telecommunication costs and staff costs.  For the conventional 
consultations the costs included cost of specialist and GP, and cost of travel.  The 
average time the patient spent in travelling for the conventional consultations was 24 
minutes (one-way), whereas the mean duration of a teleconsultation was 15 minutes.  
Over the eight months, the cost analysis found that the cost of teleconsultations for the 
18 patients who avoided travel was FM18,627 and the cost of the 18 conventional 
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consultations would have been FM18,034.  The authors concluded that the equipment 
was generally reliable and easy to use and that the main economic benefits of 
videoconferencing were attributable to the reduced travelling and hospital costs.  
 
A cost analysis comparing real-time versus store-and-forward teledermatology in 
Northern Ireland was conducted by Loane et al (2000).  During the course of the year, 
96 patients attended their GP health centre and were seen by a hospital dermatologist 
over the video link (real-time teledermatology).  Before the video link started, the GP 
took photographs and posted them with a referral letter to a different hospital 
dermatologist (store-and-forward).  Fixed costs included the cost of the 
videoconferencing unit, installation of ISDN lines, and a video camera for real-time 
consultations and a camera for store-and-forward consultations.  The variable costs 
were participant‟s time and travel costs.  The average time for real-time consultations 
was 15.7 minutes and for store-and-forward consultations was 1.6 minutes.  From a 
societal perspective, the net societal cost of the initial real-time consultation was 
£132.10 per patient compared with £26.90 per patient for the initial store-and-forward 
consultation.  The authors concluded that the store-and-forward consultation was 
cheaper, but less clinically efficient, compared with the real-time consultation.  
 
Loane and colleagues (2001a) within their randomised controlled trial assessed the 
costs of real-time teledermatology compared with conventional dermatology care for 
patients from urban and rural areas in Northern Ireland from a societal perspective.  
Over the two years, 126 patients (46%) were randomised to telemedicine consultation 
and 148 (54%) to a conventional hospital outpatient consultation.  The costs for 
teledermatology included videoconferencing units, installation of ISDN lines, line rental 
costs, call costs, video camera and staff costs.  The conventional care costs included 
the cost of clinician‟s time, patient‟s time, and patient travel.  The observed marginal 
cost per patient of the initial real-time teledermatology consultation was £52.85 (urban 
areas) and £59.93 per patient (rural areas).  The observed marginal cost of the initial 
conventional consultation was £47.13 for urban patients and £48.77 for rural patients.  
The total observed costs of teledermatology were higher than the costs of conventional 
care in both urban and rural areas, mainly because of the fixed equipment costs.  The 
authors concluded from a patient perspective, telemedicine was cheaper than 
conventional care, as it involved less travel and time costs; however, from a healthcare 
perspective telemedicine was not the cheaper option. 
 
A cost-minimisation analysis of real-time teledermatology compared with conventional 
hospital care in New Zealand was conducted by Loane et al (2001b).  Over 10 months, 
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109 (54%) patients were randomised to teledermatology and 94 (46%) patients 
randomised to conventional care.  Teledermatology costs included ISDN line 
installation and rental, cost of capital equipment, call costs and staff costs.  
Conventional care costs included cost of clinician‟s time, patient‟s time and patient 
travel.  The total cost of the 123 teledermatology consultations was NZ$34,346 and the 
total cost of the 106 conventional hospital consultations was NZ$30,081.  The average 
societal cost of the teledermatology consultation was NZ$279.23 compared with 
NZ$283.79 for the conventional hospital consultation.  The marginal cost of seeing an 
additional patient was NZ$135 via teledermatology and NZ$284 via conventional 
hospital appointment.  From a societal viewpoint, and assuming an equal outcome, 
teledermatology was a more cost-efficient use of resources than conventional hospital 
care. 
 
Whited et al (2003) conducted a cost analysis and cost-effectiveness analysis of a 
store-and-forward teledermatology service compared to usual care in USA from a 
healthcare perspective.  One hundred and forty patients were randomised to usual care 
(patients assessed in a dermatology clinic) and 135 patients to teledermatology.  The 
data for these patients was then extrapolated to the total population served by the 
dermatology clinic in 2001 (n = 5,440).  The costs for the teledermatology included the 
equipment (a digital camera, laptop, desktop computers, and printer), maintenance, 
training and line installation, and also labour, overheads, space and travel costs.  Usual 
care costs include staff and travel costs.  Teledermatology was not cost-saving when 
compared to usual care using observed costs and outcomes.  The decision model 
estimated that the base-case annual total cost of serving 5,440 dermatology patients 
was US$198,016 with teledermatology and US$116,416 with usual care.  Expected 
costs were US$36.40 per teledermatology patient and US$21.40 per usual care 
patient.  Total incremental cost of teledermatology was US$81,600 and per patient 
incremental cost was US$15.00.  Benefits were measured in terms of days to the 
intervention.  The incremental cost-effectiveness ratio of teledermatology was US$0.17 
per patient per day of time to initial intervention saved (the incremental cost of 
teledermatology (US$15.00) divided by the incremental effectiveness of 
teledermatology (87.5 days)).  Sensitivity analyses indicated that teledermatology has 
the potential to be cost-saving if clinic visit costs, travel costs, or averted clinic visits 
were higher than observed in the study.   
 
As part of a multicentre randomised trial, real-time teledermatology was compared with 
conventional dermatological care in terms of clinical outcomes, cost-benefits and 
patient re-attendance in Northern Ireland [Wootton and colleagues, 2000].  During the 
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year, 102 patients were randomised to telemedicine and 102 patients randomised to a 
conventional hospital outpatient care.  Fixed costs included the cost of the 
videoconferencing units, installation of ISDN lines, line rental costs and video camera.  
Variable costs were the costs of the clinician‟s time, patient‟s time, patient travel and 
call costs.  No major differences were found in the reported clinical outcomes.  Of the 
patients randomised to teledermatology, 55 (54%) were managed within primary care 
and 47 (46%) required at least one hospital appointment.  Of the patients randomised 
to conventional care, 46 (45%) required at least one further appointment, 15 (15%) 
required general practice review, and 40 (39%) required no follow-up visits.  The net 
societal cost of the initial consultation was £132.10 per patient for teledermatology and 
£48.73 for conventional consultation.  Real-time teledermatology was clinically feasible, 
but not cost-saving compared with conventional care.  However, the authors stated that 
if the equipment were purchased at current prices and the travelling distances greater, 
teledermatology would be cost-saving. 
 
In the ten articles mentioned above on dermatology: three studies were conducted in 
Northern Ireland and another three studies were from the USA.  Five studies were cost 
analyses, three were cost-minimisation analyses, one was a cost analysis combined 
with a cost-effectiveness analysis and the final study was a cost-benefit analysis.  All 
nine studies which reported a time-frame, were conducted in a period of 2 years or 
less; six studies conducted some sort of sensitivity analyses; and no studies undertook 
discounting.  Four studies were from the healthcare perspective and four from a 
societal perspective, and the other two studies did not state a perspective.  
Telemedicine was cheaper than conventional care in five studies, for three studies 
telemedicine was more expensive, in one study telemedicine had the potential to be 
cost-saving and in the final study, telemedicine produced similar costs results to 
conventional care. 
 
b) Radiology. Bergmo (1996) conducted a cost analysis to see whether teleradiology 
was more or less expensive than a visiting radiologist in Norway.  The study was 
conducted from a health service perspective, with an average workload of 25 patients 
per day or 6,000 patients (8,000 examinations) per year.  The journey takes two and a 
half hours for a visiting radiologist and each session typically lasts five hours.  Costs of 
the teleradiology service included the costs of the equipment plus maintenance, 
personnel costs and call charges; whereas for the visiting radiologist the costs included 
cost of senior radiologist, travel costs, costs of an x-ray processor and emergency 
patient transfer costs.  Costs common to both arms were not included, such as 
electricity and the radiographer who assisted in taking radiographs.  Total cost of 
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teleradiology was NKr646,900 per year; compared with visiting radiologist cost 
NKr1,069,000 per year.  Teleradiology cost NKr108 per patient, in comparison with 
NKr178 per patient for the visiting radiologist.  For teleradiology to be the cheaper 
option, the workload had to exceed 1,576 patients per year. 
 
A cost analysis of the use of teleradiology at a military training area in Hawaii or 
sending patients to a hospital which was 400km away for radiological diagnosis (direct 
referral to hospital – ground evacuation) was conducted by Brumage and colleagues 
(2001).  They hypothesised that a teleradiology system would reduce the number of 
patient transfers to the hospital, thereby leading to savings.  In total, 323 patients were 
seen by teleradiology, and 33 patients were transferred to hospital during the 2 months 
training exercise.  Teleradiology costs included the cost of the teleradiology system, 
operating costs, and personnel costs.  Direct referral costs included the cost of 
transportation and fuel, driver, a medical attendant, costs of emergency room and 
tests.  Direct referral to hospital cost was US$1,261.  When teleradiology was provided, 
in total 29 evacuations were avoided and the savings amounted to US$36,569.  Over 
the course of the year, the teleradiology system would cost US$167,203 and assuming 
a constant rate of evacuations over the year which would be 140, the expected cost 
would have been US$176,540, and hence the teleradiology system saved US$9,337.  
Over five years, the costs and savings were estimated to be US$349,940 and 
US$882,700, respectively.  The authors stated the benefits of teleradiology included: 
(1) a reduction in air and ground transportation costs; (2) a reduction in hospital costs; 
(3) man-hours saved during medical evacuations; (4) less use of materials (e.g. X-ray 
film); (5) better quality of care (determined by satisfaction questions of providers); and 
(6) better access to care (determined by time to diagnosis and treatment).  The authors 
concluded that not only did the teleradiology system prove to be cost-effective during 
the exercise, but there was also an improvement in the quality of care at the point of 
need. 
 
Crowe and colleagues (1996) wanted to find out whether a 3-month pilot teleradiology 
project at a children‟s hospital in Australia was cost-saving compared to patient 
transfers to a hospital.  In total, 575 images were transmitted and the mean 
transmission time per image was 3.26 minutes.  Costs were calculated in terms of 
transmission, equipment, maintenance, ISDN lines and staff components.  The cost 
analysis found that the cost per image transmitted would vary from A$80.14 for 2,500 
images to A$34.00 for 10,000 images per year.  The study estimated that 20 
emergency transfers between A$7,000 to A$10,000 would be needed to break-even 
each year.  The authors found that the adoption of teleradiology would have potential 
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improvements in patient management due to quicker diagnosis and earlier intervention, 
and also potential savings through avoiding transfer of some emergency cases. 
 
A cost-minimisation analysis from the healthcare perspective of a wide-area 
teleradiology network in a French region was undertaken by Daucourt and colleagues 
(2006).  They compared the teleradiology service with direct transfers over the course 
of a year for all patients for whom a remote consultation in radiology was required.  
Teleradiology costs included equipment costs per workstation, maintenance costs and 
staff costs.  Direct referral costs included costs related to transfers and hospitalisations, 
consultations and staff costs.  In total, 664 teleconsultations took place during the year 
and 309 transfers were avoided.  Hospitalisations were avoided for 27 patients.  
Therefore, the savings due to proportions of transfers, hospitalisation and consultations 
avoided were estimated to be €102,779.  The authors concluded that the teleradiology 
network enabled savings despite the large capital outlay. 
 
Davis (1997) conducted a cost analysis of teleradiology in a rural imaging centre in the 
USA compared with a courier service for radiological transfers over the course of two 
years.  Just over 8,000 teleradiology examinations were performed and the average 
transmission time for a typical case of 50 images was between 6 and 8 minutes.  For 
the teleradiology service the costs included: the cost of the capital, maintenance, floor-
space rental, line rental charges, call charges, ISDN transmission and personnel costs.  
For the off-site radiology, the cost of the courier was also included.  So for 2,000 cases, 
a mid-field magnetic resonance imaging unit was predicted to cost US$470 per case 
using teleradiology (total costs US$940,515) and US$544 per case using film and a 
courier service (total costs US$1,087,975).  The author found that teleradiology 
reduced travelling time for both patients and physicians, and had an overall positive 
effect on patient care.  The results of the survey indicated that the teleradiology system 
was cheaper than the more traditional courier service.  
 
A cost-minimisation analysis from a societal perspective of teleradiology services for 
remote communities in Norway was conducted by Halvorsen and Kristiansen (1996).  
The teleradiology system (most examinations at site and more advanced examinations 
at the host site) was compared to the existing system (a small x-ray unit at the remote 
site and all other examinations at the nearest radiology dept (the host site)) and to all 
examinations at the host site.  Of the 1,793 identified referrals for radiological 
examinations in 1993, one third (n = 597) were randomly selected.  For the three 
options, the annual direct medical costs were the equipment costs and staff costs; the 
direct non-medical costs were the travel costs; and indirect costs were the lost 
  277 
production (number of hours absent from work).  During the 12-month study, the direct 
medical, direct non-medical, and indirect costs of the three options were: £9,000, 
£51,000, and £31,500 (total £91,500) for the existing system; £108,000, £2,000, and 
£13,500 (total £123,500) for the teleradiology option; and £0, £75,000, and £42,000 
(£117,000 in total) for the "all at host" option, respectively.  The teleradiology option did 
not seem to be cost-saving and an increase in the annual number of teleradiology 
referrals to 590, would make the teleradiology system cost-saving. 
 
A cost analysis of an emergency computerized tomography teleradiology system 
compared to transporting films by taxi or transporting patients to nearest central 
hospital for scanning in Austria was undertaken by Stoeger and colleagues (1997).  
During the 13-month study period, 121 emergency examinations of 116 patients took 
place and the average transmission time per examination was 15 minutes.  The costs 
of teleradiology included the ISDN connection and rental, whereas for the alternative 
options this included the transportation (courier service only) and staff costs.  The 
capital cost of the scanners were excluded as they were installed in both hospitals.  
The fixed cost of teleradiology was DM926 and average cost of one emergency 
computerized tomography examination by teleradiology was DM372.  Transporting the 
films by taxi was cheaper, estimated cost DM156.  Transporting the patient to the 
nearest hospital was more expensive: DM524 by road or DM4,667 by helicopter 
ambulance.  Overall, teleradiology was cheaper than transporting the patient to the 
nearest central hospital for scanning; however, more expensive than transporting the 
films by taxi, but taxi option would have been much slower.  
 
Vuletic (2001) wanted to determine the costs of teleradiology versus patient referral in 
Croatia.  A teleradiology system connecting 35 workstations in 27 hospitals was 
established and the teleconsultations which took place were transmitted in real-time 
and store-and-forward.  Eighty patients were transported urgently, a further 181 were 
transported non-urgently and an additional 181 patients remained in their local hospital.  
Over two years, 2,071 consultations took place which represented an average rate of 
four neurosurgical teleconsultations per day.  By avoiding unnecessary patient 
transfers, over 3.5 million kunas per year was saved.  The author felt the benefits of 
teleradiology included: decreased travelling time and expenses for both patients and 
specialists; decreased hospital expenses; shorter waiting times; increased efficiency; 
and better medical education.  The author concluded that the avoidance of 
unnecessary patient transfers led to significant cost savings. 
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So in the eight articles mentioned above in radiology, two studies were conducted in 
USA and further two studies were from Norway.  Six studies conducted cost analyses 
and the other two articles conducted cost-minimisation analyses.  All studies that 
reported a time frame were conducted within 2 years.  Five studies did not state their 
viewpoint, two were from the healthcare perspective and one from a societal 
perspective.  Four studies undertook some sort of sensitivity analyses and none 
undertook discounting.  Teleradiology was cheaper than conventional care in four 
studies; only one study indicated that teleradiology was more expensive than 
conventional care; in another study teleradiology was either more expensive or 
cheaper depending on the alternative; and two studies stated that telemedicine can 
enable savings as long as the patient throughput is above a certain number. 
 
c) Psychiatry. Doze and colleagues (1999) conducted a cost analysis of a 
telepsychiatry pilot project in which a psychiatric hospital was linked with five general 
hospitals mental health clinics in Canada and this was compared to the costs of a 
travelling psychiatrist.  Ninety psychiatric patients were seen during the 9 months and 
109 telepsychiatry consultations took place.  The telepsychiatry costs included a 
videoconferencing unit, dual monitors, document camera, video recorder, the 
installation of ISDN lines, call charges and staff costs.  For the travelling psychiatrist, 
staff costs and travel costs were included.  The cost analysis indicated that at 396 
consultations per year, the service cost the same as providing a travelling psychiatrist 
(C$610 per consultation); with more consultations, telepsychiatry was cheaper.  In the 
sensitivity analysis, the authors found that a reduction of 10% in equipment cost 
reduced the break-even point from 396 to 368 telepsychiatry consultations a year.  For 
patients, the authors emphasised that telepsychiatry had greater benefits in terms of 
reduced travel time, less stress, less absence from work, less delays in accessing a 
psychiatrist, more patient choice and improvement in quality of life.  The authors 
concluded that telepsychiatry was a more expensive option than in-person psychiatry 
at a low volume of service, but less expensive at a higher volume. 
 
A cost analysis of a 3-month pilot telepsychiatry service for children in Canada was 
undertaken by Elford and colleagues (2001).  Thirty patients accompanied by a parent, 
completed a psychiatric assessment using the videoconferencing system compared to 
conventional consultation at a referral centre.  The costs of telepsychiatry included the 
videoconferencing unit, installation of ISDN lines, line rental, call charges and 
personnel costs.  The conventional care costs included the cost of travel, 
accommodation, food expenses and staff costs.  Excluded costs included the loss of 
income for parents, babysitting costs and other incidental costs.  The cost analysis 
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estimated the total travel cost for the 30 patients was C$12,849, an average of 
C$428.30 per patient, whereas the total cost of the telepsychiatry service was 
C$12,575, or C$419.17 per patient, this was based on a patient volume of 10 patients 
per month.  The authors indicated that telepsychiatry advantages included decreased 
travel costs, decreased travel time, greater convenience, improved access to 
psychiatrist and children felt more comfortable.  The authors stated that the pilot project 
was a success and with more patients the costs for telepsychiatry would decrease. 
 
Harley (2006) conducted a cost analysis of a telepsychiatry service compared with 
direct travel to a specialist psychiatric hospital in London.  During the course of the six 
months pilot study, 11 videoconferences took place between Jersey in the Channel 
Islands to London, England.  The costs for videoconferencing included the cost of the 
equipment, installation of ISDN lines, annual line rental, ISDN call charges, 
maintenance cost and personnel costs.  For direct referral the costs included travel 
costs and personnel costs.  Family travel costs and subsistence costs were excluded.  
The total cost of videoconferencing was £3,483 and the traditional service was 
£12,975.  The study suggested that telemedicine is cost-saving in providing tertiary 
mental health services. 
 
A cost analysis of psychiatric inpatient care-planning consultations to remote areas 
using videoconferencing, instead of the conventional face-to-face consultations at a 
hospital in Finland from a societal perspective was conducted [Mielonen et al, 2000].  
The study duration was 11 months and during this time 14 videoconferences and 20 
conventional consultations took place.  The videoconferencing costs included the 
equipment costs which consisted of the video and monitor, adjustable camera, an 
audio unit; installation and monthly line rental of the ISDN lines and personnel costs.  
For conventional care the costs included personnel and travel costs.  The results from 
the costs analysis found at a workload of 20 patients per year, the cost of the 
videoconferences was FM2,510 per patient and the cost of the conventional alternative 
was FM4,750 per patient.  At 50 consultations per year, a remote area would save 
about FM117,000.  The authors concluded that consultations via videoconferencing in 
the long run are cost-saving compared with conventional practice. 
 
Modai et al (2006) looked at the cost-effectiveness of video telepsychiatry versus face-
to-face care for psychiatric treatment for mental health patients who lived in remote 
communities in Israel.  Data was collected for 1 year, 39 patients formed the 
telepsychiatry group and 42 patients formed the comparison group.  Costs included the 
costs of the salaries, psychiatrist travel expenses, equipment and running costs, phone 
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expenses, and patient travel expenses.  During the study, satisfaction was measured at 
the 3-, 6-, 9-, and 12-month visits using the Patient Satisfaction Questionnaire.  For the 
telepsychiatry group, total operating costs were US$94.40 compared with the 
comparison group, were total operating costs were US$84.70.  One hour of 
telepsychiatry treatment was more expensive than face-to-face care and the authors 
found patients were generally satisfied.  The authors also commented on the limited 
sample size which meant it was harder to draw definitive conclusions and further 
studies are needed involving a larger population and a longer study duration. 
 
Ruskin et al (2004) in a cost-consequences analysis alongside a randomised trial, 
examined treatment outcomes of patients with depressive disorders who were treated 
remotely by means of telepsychiatry compared to in-person treatment from the 
healthcare perspective in the USA.  Fifty-nine veterans were randomised to the 
telepsychiatry group and 60 veterans were seen conventionally.  Psychiatric treatment 
lasted 6 months (8 sessions over a 6 month period, with each session lasting 20 
minutes) and consisted of psychotropic medication, psychoeducation, and brief 
supportive counselling.  Telepsychiatry costs included the computer based 
videoconferencing equipment, cameras, ISDN lines, line charges, maintenance fees 
and staff costs.  For the conventional consultation, staff costs and travel costs were 
included.  Telepsychiatry was more expensive per treatment session than onsite care 
(US$86.16 vs. US$63.25) and the cost was lower if the psychiatrists had to travel more 
than 22 miles.  The authors concluded that telepsychiatry and in-person treatment for 
depression have comparable outcomes and equivalent levels of patient adherence, 
patient satisfaction, and healthcare cost.   
 
An evaluation of a telepsychiatry service compared to a visiting psychiatrist following 
the completion of a pilot project in rural areas of a Canadian province was undertaken 
by Simpson and colleagues (2001b).  During the 24 months of routine operation, a total 
of 546 consultations for 379 patients were completed at the five participating general 
hospitals, at an average rate of 23 consultations per month.  The telemedicine 
equipment was also used for administrative and clinical meetings.  The telemedicine 
costs included the cost of the equipment, installation, annual line charges, call charges 
and staff costs.  For the visiting psychiatrist costs included the cost of the travel and 
time for the psychiatrist.  The total fixed costs for telepsychiatry were C$169,800 per 
year, the total variable costs for telepsychiatry were C$140 per consultation and for a 
travelling psychiatrist (for time, travel and subsistence) were C$630 per consultation.  
The cost analysis found that the break-even point was at 348 consultations.  If the cost 
of the other meetings were included, the break-even point would be 224 consultations 
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per year.  From the health service perspective, telepsychiatry proved to be an 
appropriate use of resources and was a useful addition to existing mental health 
services. 
 
Simpson and colleagues (2001a) evaluated the telepsychiatry service versus patient 
travel to a referral centre in Canada.  Information on patient‟s time and travel costs 
were gathered through self-reported questionnaires and telephone interviews.  Patient 
satisfaction with the service was also obtained from the questionnaires.  The authors 
found that the availability of telepsychiatry led to an estimated cost-saving of C$210 per 
consultation for patient who would otherwise have had to travel and thus, lose time at 
work and pay for child care expenses.  Patients overall were very satisfied with the 
service.  The main advantages for the patient were reduction in waiting times for 
consultation and the avoidance of the expense and inconvenience in travel.  From the 
patient‟s perspective, telepsychiatry was an acceptable technique that increased 
access to services and produced cost savings. 
 
A cost analysis of delivering a mental health service either by telepsychiatry or 
conventional methods (patient transfer to the specialist centre) in Australia was 
undertaken by Trott and Blignault (1998).  Telemedicine costs included: 
videoconferencing equipment, camera, ISDN connection and line rental, call charges 
and staff costs.  Conventional costs included travel costs, accommodation, meals, and 
staff costs.  Fifty patients including both adults and children were seen during the 12 
months.  Total telemedicine costs would be A$82,340 in the first year and A$54,960 in 
subsequent years and for the conventional service the cost was A$167,750.  The 
savings were estimated to be A$85,380 in the first year and A$112,790 in subsequent 
years, not allowing for maintenance and equipment upgrading.  The authors estimated 
there was a 40% reduction in transfers due to the introduction of telemedicine.  Based 
on the previous year of 27 transfers at A$8,920 each, this would produce an annual 
saving of A$96,336 for the Royal Flying Doctor Service.  The results of the study 
showed considerable savings from reduced travel by patients and health care workers. 
 
In the nine articles mentioned above on psychiatry: four of these studies were from 
Canada; all nine studies compared telemedicine to one method of conventional 
referral; all studies except one were cost analyses; and eight of the nine studies which 
stated a timeframe were conducted within a year, apart from one study which lasted 
two years.  Only four studies stated a viewpoint: one was a societal perspective, two 
were from the healthcare perspective and the final study was from the patient‟s 
perspective.  Only three studies undertook some sort of sensitivity analyses and no 
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studies undertook discounting.  In three studies, benefits were measured in terms of 
patient satisfaction.  In conclusion, telepsychiatry was cheaper than conventional care 
in five studies (one was from the viewpoint of the patient), two studies found 
telepsychiatry to be more expensive than conventional care, and the final two studies 
stated that telepsychiatry had the potential to be cost-saving. 
 
d) Cardiology.  The experience of real-time telemedicine to transmit paediatric 
echocardiographic images in Canada was reported by Finley and colleagues (1997).  
During the 24 months, telemedicine was used for 135 paediatric patients: 69 (51%) 
were urgent examinations of newborns; 30 (22%) were urgent examinations of older 
children; and 36 (27%) of the examinations were for repeat or post-operative checks.  
The cost analysis found that the cost of the telemedicine network (equipment leasing 
costs and telecommunications costs including connection costs) was C$90,000 for the 
two years (annual cost of C$45,000).  Use of the telemedicine network saved 
unnecessary patient transfers in 31 cases, at an average of C$8,500 per flight and 
C$1,200 per ambulance trip for transportation avoided.  The cost of the transportations 
avoided was between C$100,000 and C$118,000.  The authors found telemedicine to 
be cost-saving and provides a service comparable in availability and accuracy to that 
provided in their paediatric cardiology division. 
 
To determine the costs over a year of using a store-and-forward telemedicine system 
for cardiotocographic recording of fetal heart rate, Ippolito and colleagues (2003) 
compared the telemedicine system to conventional referral in Italy.  The cohort of 
patients included women with both high and low risk pregnancies: 162 patients were 
seen by telemedicine and a control group consisted of 2,710 deliveries.  Equipment 
costs and operating costs of each of the five centres included equipment, maintenance, 
electricity charges, staff costs, telephone charges and modem.  Hospital costs were 
calculated according to length of hospitalisation and the resources used.  The cost 
analysis found that the total cost of telemedicine was €344,796.  In the intervention 
group, 11 of the 87 high-risk patients were admitted to hospital and in the control 
group, 203 of the 813 women in the high-risk group were admitted to hospital and 
stayed on average of 20 days.  If the women in the control group had been seen by 
telemedicine there would have been a saving, through avoided bed days, amounting to 
€358,280, which was similar to the cost of the telemedicine system.  The study 
suggested that the use of telemedicine in cardiotocographic monitoring improves the 
quality of prenatal care. 
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Kildemoes and Kristiansen (2004) used decision analysis to estimate costs and health 
benefits of a public awareness campaign compared to a campaign combined with 
telemedicine which was aimed at shortening the delay for thrombolytic therapy in 
patients with acute myocardial infarction in Denmark.  The authors adopted a 
healthcare perspective.  Costs of the public awareness campaign, the cost of the 
telemedicine equipment, the cost of running the telemedicine diagnostics in 
ambulances and the cost of hospital stays were included.  The results found that the 
campaign only will translate into five fewer fatal acute myocardial infarctions (62 life 
years gained) and a cost per life year of DKK283,300.  When combining the public 
campaign with prehospital telemedicine diagnostics, the incremental cost per life year 
gained was DKK854,700.  The authors concluded that whether such programs can be 
considered cost-effective will depend on how life year gains are valued by society. 
 
McCue and colleagues (2000) evaluated the cost savings of 3 years of telecardiology 
use in a prison in the USA.  The study compared the cost per visit of providing 
cardiology services by telemedicine to patients in prison versus the cost of providing 
traditional cardiology services at the cardiology clinic.  Telemedicine costs included the 
cost of the equipment, maintenance costs, transmission lines, telephone charges and 
personnel costs and the non-telemedicine costs included staff costs and travel costs.  
The number of telemedicine consultations for the 3 years were: 24 (1996), 78 (1997) 
and 86 (1998).  The authors found that the lower use of telecardiology services in 1996 
resulted in higher cost per visit of US$189.  This was US$45 more than the cost of 
traditional cardiology in the clinic (US$144).  In 1997 and 1998, however, the higher 
utilization of telecardiology services decreased the cost per visit to US$135 and 
US$132, respectively.  This resulted in a cost saving with telecardiology of US$15 per 
visit in 1997 (clinic cost = US$150) and US$46 per visit in 1998 (clinic cost = US$178).  
The authors found that because the vast proportion of telemedicine operating costs are 
fixed, increased utilization reduces the cost per visit and results in cost savings. 
 
Rendina et al (1998) looked the effect of the use of telemedicine to transmit 
echocardiograms digitally for immediate interpretation versus sending videotapes via 
an overnight courier in the USA.  The study was conducted from a healthcare 
perspective.  In total, 48 infants were in the telemedicine group and 39 infants were in 
the control group.  The telemedicine costs included desktop videoconferencing unit, 
video recorder, lines and installation, maintenance and communication charges.  The 
control costs included the averted costs of shipping videotapes by overnight courier, 
materials and sonographer‟s time.  The cost analysis found that the total telemedicine 
costs were US$6,405 and the total control costs were US$2,750.  The cost per 
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echocardiogram transmitted was calculated at US$33 (difference between two 
methods (US$3,955) divided by the number of echocardiograms transmitted during the 
intervention period (110)), compared to the previous method of sending videotapes via 
an overnight courier (US$25).  In terms of benefits the authors looked at the mortality 
rates, length of stay in the neonatal intensive care unit and the rate of transfer.  Even 
though telemedicine was more expensive, over a longer time period and given a bigger 
patient throughput, telemedicine has the potential to be cost-saving.  The authors found 
that while the sample size was inadequate to demonstrate improvements in health 
outcomes, the magnitude of change and the low costs of the system suggest that this 
intervention is practical for obtaining rapid diagnostic and treatment support. 
 
To investigate the effect of immediate echocardiogram interpretation via telemedicine 
on rates of neonatal transfer to academic medical centres, Rendina and colleagues 
(2001) developed a logit model to predict the probability of transfer from two regional 
level three neonatal intensive care units to academic medical centres in the USA.  One 
unit implemented a telecardiology program and the other acted as a comparison site.  
Telecardiology intervention began 18 months into the 36-month study period.  The 
authors estimated that there would be a 58% reduction in transfers and approximately 
30 transfers (1 transfer = US$5,000) were eliminated during the study period, resulting 
in the elimination of approximately US$150,000 in hospital charges.  Introduction of 
telecardiology can lead to elimination of transfers and ultimately to cost savings. 
 
Sicotte and colleagues (2004) conducted a cost-effectiveness analysis of interactive 
paediatric telecardiology to see whether the service was a worthwhile alternative to 
conventional referral (patient travel and 6 monthly outreach cardiology clinics) in 
Canada.  The study was conducted from a societal perspective and during the 4 year 
study period, 78 children suffering from cardiac pathologies were seen in 129 
consultations, at an average of 32 consultations per year.  Telemedicine costs included 
the cost of the equipment and system installation, equipment maintenance, ISDN 
telecommunication fees and staff costs.  The conventional care costs included patient 
travel expenses and consultant fees.  The outcome measure was avoidance of patient 
journeys and with telemedicine the number of patient journeys was reduced by 42%.  
The total cost of telecardiology was C$272,327 and the total cost of conventional care 
would have been C$157,212.  Telemedicine represented a supplementary cost of 
C$1,500 per patient.  The incremental cost-effectiveness ratio of teleconsultation was 
estimated to C$3,488 per patient journey avoided.  The authors felt that telemedicine 
can be reliable method of reducing patient journeys and the delay in consulting 
specialists.   
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Vincent et al (1997) wanted to examine the costs of a routine monthly and anytime 
emergency telemedicine monitoring in children and young adults compared to routine 
outpatient clinic visits or comparable emergency room treatment in the USA.  Ninety-six 
patients were followed for 3 years after pacemaker implant.  Costs included the cost of 
telemedicine equipment, outpatient clinic charges, emergency room charges and 
pacemaker analysis charges.  Monthly charges for use of telemedicine including 
emergency transmission was US$70 and total charges for 75 emergency telemedicine 
transmissions were US$5,250.  Outpatient clinic charges including pacemaker analysis 
were approximately US$200, whereas the standard emergency room charge without 
pacemaker analysis was US$260.  For conventional care, the total charges for either 
alternative were US$19,500.  Charges for use of telemedicine were significantly less (p 
< 0.01) than comparable outpatient visits. 
 
So in summarising the impact of telemedicine in cardiology, four of the eight articles 
were from USA and a further two studies were conducted in Canada.  Five studies 
conducted simple cost analyses and three were cost-effectiveness analyses.  All 
studies except one were conducted for the duration of a year or more.  One study was 
conducted from a societal viewpoint, two studies were from a healthcare perspective, 
and the other five studies did not state their viewpoint.  Three studies had some 
outcome measure in their analyses; only two studies undertook sensitivity analyses; 
and only one study undertook discounting, even though the majority of the studies were 
equal to or greater than a year in length.  Telecardiology was cheaper than 
conventional care in two studies, three studies indicated that telecardiology was more 
expensive than conventional care, one study found that the costs of telecardiology 
were similar to conventional care, and finally, two studies stated that telemedicine had 
the potential to be cost-saving. 
  286 
APPENDIX 5: SUMMARY OF SYSTEMATIC REVIEWS OF TELEMEDICINE 
 
Whitten and colleagues (2002) as mentioned in Chapter 3, section 3.2.1 undertook a 
systematic review of the cost-effectiveness of telemedicine studies which were 
published until June 2000.  The authors separated the articles into those without (n = 
557) and with (n = 55) cost data and established a checklist of criteria for assessing the 
quality of economic evaluations in healthcare.  Of the 55 cost studies, only 24 articles 
met their selection criteria and were subject to a full review.  For those 24 articles which 
reported cost data they presented quantitative and qualitative analyses.  Twenty of 
these 24 studies were limited to simple cost comparisons; no study used cost-utility 
analysis; 11 studies stated the viewpoint of the cost analyses and only four of these 
were from a societal perspective; and most of the studies provided no details of 
sensitivity analyses.  They found that studies assessing the cost-effectiveness of 
telemedicine are generally small, of a short-term duration and of poor quality.  They 
concluded that “there was no good evidence that telemedicine is a cost-effective 
means of delivering healthcare compared to standard healthcare delivery”.   
 
Roine and colleagues (2001) as mentioned earlier examined the evidence for the 
effectiveness or cost-effectiveness of telemedicine in order to clarify the current status 
of the technology.  They identified telemedicine studies that reported information on 
patient outcomes, administrative changes or economic assessments.  From more than 
1,100 abstracts which were surveyed, they reviewed 133 full text articles for further 
inspection and of these 133 articles, only 50 met their inclusion criteria for their review.  
Thirty-four of these articles assessed at least some clinical outcomes, and the 
remaining 16 articles were economic analyses.  They found that most of the available 
literature referred only to pilot studies, short-term outcomes and most studies were of 
low quality.  They felt that a systematic comparison of the costs and more work on the 
effects should be done in the future.  They concluded that the “evidence regarding the 
effectiveness or cost-effectiveness of telemedicine is still limited.  Based on the current 
scientific evidence, only a few telemedicine applications can be recommended for 
broader use”.    
 
Hailey and colleagues (2002) in their systematic review of the evidence for the benefits 
of telemedicine identified 66 studies that included a comparison with a non-
telemedicine alternative (mentioned earlier in section 3.2.1).  The main problems they 
encountered were that: most of the available literature referred only to pilot projects 
and to short-term outcomes, poor measurement of effectiveness, identification and 
timing of costs (and consequences), the absence of incremental analysis and only a 
few papers considered the long-term or routine use of telemedicine.  They found that 
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the most convincing evidence on the efficacy and effectiveness of telemedicine was in 
the area of radiology, where savings were through avoidance of travel and associated 
delays.  Over half the studies (56.1%, 37 articles) suggested that telemedicine had 
advantages over the alternative approach, 24 studies (36.4%) were unclear whether 
telemedicine had advantages; and the final five studies (7.6%) found the alternative 
approach had advantages over telemedicine.  The authors concluded that “although 
useful clinical and economic outcomes data have been obtained for some telemedicine 
applications, good quality studies are still scarce and the generalisability of most 
assessment findings is rather limited”.  
 
In a follow-up to this review, Hailey and colleagues (2004) developed a simple 
approach to the measurement of quality for telemedicine studies that takes into 
account both study design and study performance.  For example, for study design a 
large RCT was given a higher score than a retrospective comparative study; and for 
study performance such as patient selection and description of the interventions, if no 
information was missing this was given a higher score than if relevant information was 
missing or was given in little detail.  They also assessed the quality of the economic 
evaluation by using a checklist, for each study a score of 1 was given to each of the 
criterion that was fulfilled (score range: 0 to 10).  From the literature review, 48 papers 
met the selection criteria and were included in the review.  Twenty-five papers (52.1%) 
included some kind of economic analysis and only two of these papers included health 
related quality-of-life measures.  Thirteen of the 25 papers met five or more of the 
economic criteria and were rated as good, or good to fair, although the authors 
mentioned that the scope of the economic analysis was limited.  The authors felt the 
results confirmed previous findings and that good quality studies are still scarce. 
 
Mair and Whitten (2000) provided a systematic review of 32 studies on patient 
satisfaction with telemedicine, involving real-time videoconferencing.  The main 
outcome measures examined included patients‟ satisfaction and patients‟ willingness to 
use telemedicine in the future.  The studies used videoconferencing for a variety of 
purposes ranging from specialist consultations to home nursing.  Most of the studies 
included in the review were pilot and feasibility studies with small sample sizes.   
Twenty-six studies used simple survey instruments, five did not specify any methods 
and one study used qualitative methods.  All studies reported good levels of patient 
satisfaction with telemedicine and the main advantages from teleconsultations were 
noted as: increased accessibility of specialist expertise, less travel required, and 
reduced waiting times.  The authors concluded that “methodological deficiencies (low 
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sample sizes, context, and study designs) of the published research limit the 
generalisability of the findings”.   
 
Williams et al (2001) provided a systematic review of 93 studies on patient satisfaction 
with telemedicine and this review differed to the one by Mair and Whitten (2000) as it 
had more emphasis on patient satisfaction measures and included all forms of 
telemedicine rather than just videoconferencing.  Telepsychiatry and telepsychology 
studies represented the largest proportion of studies which used patient satisfaction 
measures (24.7%) and real-time videoconferencing alone was used in 71.0% of the 
studies.  Ninety-four percent of studies on patient satisfaction in telemedicine used 
uniquely designed questionnaires and the most of them (86.0%) did not report on the 
validity or reliability of the questionnaires.  Almost a quarter of studies did not provide 
enough detail to determine the type of questions patients were asked.  Sixty-four 
studies used Likert-type questions in which the patient responds to statements about 
telemedicine using a scale of agreement to disagreement.  Aspects of patient 
satisfaction which were assessed included: professional-patient interaction, patient‟s 
feeling about the consultation such as comfort and convenience, overall satisfaction, 
technical aspects and physical environment.  Preferences between telemedicine and 
face-to-face consultation were assessed in 28 studies.  Consistent with the earlier 
review, more than 80.0% of patients were satisfied with the service they received.  One 
of the main criticisms the authors stated was that “patient satisfaction data may be 
biased due to self-selection, as those who are “less satisfied” are more likely to opt out 
of satisfaction studies”.  Overall, the authors concluded that “the current evidence 
concerning patient satisfaction with telemedicine is rather limited.” 
 
Other systematic reviews of telemedicine also found no conclusive evidence that their 
findings could be generalised to other telemedicine applications.  Hersh and colleagues 
(2002) conducted a systematic review of the literature to evaluate the efficacy of 
telemedicine for making diagnostic and management decisions for three different types 
of telemedicine applications: office/hospital based, store-and-forward and home-based.  
The authors wanted to determine whether telemedicine can provide at least equally 
good diagnostic and management decisions as face-to-face care.  A total of 58 studies 
were included in the review and the articles were summarised and graded for quality 
and direction of the evidence.  The authors stated that the overall methodological 
quality of most studies was low.  Typical problems they encountered with studies 
included: small sample sizes, the use of the same clinician for both telemedicine and 
face-to-face care, and lack of inter-observer agreement within modalities.  The 
strongest evidence for the efficacy of telemedicine for diagnostic and management 
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decisions came from the areas of psychiatry and dermatology.  There was also good 
evidence that general medical history and physical examinations performed via 
telemedicine had relatively good sensitivity and specificity.  The authors concluded 
“despite the widespread use of telemedicine in most major medical specialties, there is 
strong evidence in only a few of them that diagnostic and management decisions 
provided by telemedicine are comparable to face-to-face care”.  Hersh et al (2006) 
provided an update to the systematic review published in 2002 [Hersh et al, 2002]; 106 
studies were included in the review.  However, the methodology of many studies was 
still weak such as small sample sizes and most studies lacked statistical power to 
detect significant differences between the two groups.  The authors concluded that 
“there are still significant gaps in the evidence base between where telemedicine is 
used and where its use is supported by high-quality evidence”.  
 
Whitten et al (2007) conducted a systematic review of 15 relevant databases for 
articles about telemedicine and telehealth relating to research methodology and after 
the exclusion criteria was applied, 1,615 articles remained for analysis.  Only 85 
studies (5%) of the telemedicine articles mentioned any theory or paradigmatic 
approach.  Most studies reported the overall study aim (96%), however only a few 
papers (11%) provided hypotheses or a research question.  Randomised selection of 
the subjects was reported in 11% of patient studies and the majority of studies were 
based on small sample sizes (100 patients or less).  Only 26% of the studies reported a 
time frame i.e. start and end points of a study.  The authors concluded that “until the 
telemedicine field adheres to agreed standards of reporting methodological details it 
will be difficult to draw firm conclusions from review studies”.   
 
Finally, the results produced in Chapter 3 are consistent with a recently published and 
up to date review by Bergmo (2009) who found that “the majority of the economic 
evaluations were not in accordance with standard evaluation techniques”.  The author 
referred to telemedicine as “technologies used in direct patient care such as real-time 
videoconferencing and store-and-forward applications”.  Only articles published in 
journals and written in English from the period 1990 to 2007 were analysed.  In total, 
the literature search identified 779 abstracts, and after review only 33 of them were full 
economic evaluations where both costs and outcomes were measured.  Studies which 
only looked at costs were excluded and studies which looked at outcome measures, for 
example, in terms of travel avoided or hospitalisations avoided were also excluded 
(these have been included in the literature review).  All 33 studies were also identified 
during this literature search, of which only 15 were included.  Seventeen of these 
studies evaluated telemedicine in a home setting and were excluded from the literature 
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review (see definition for „telecare‟ in Chapter 1, section 1.2) and the other excluded 
study was Dowie et al study (2007), which forms part of the case study for the thesis.  
The author said that only eight studies had addressed all the key issues: a clear study 
objective, adequate comparison(s), reporting of study perspective and design, 
transparent measurements and valuation of costs and outcomes, reporting of data 
sources, addressing of uncertainty and clear presentation of the results.  Most studies 
used multiple outcome measures and a cost-consequences approach was adopted for 
most economic evaluations.  Overall, the objectives, study design and choice of 
comparator were mostly well reported.  However, most studies lacked information on 
the study perspective; the cost methods were not reported in detail; and very few 
studies provided information on statistical and sensitivity analysis to assess the validity 
and robustness of the results.   
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APPENDIX 6: SELECTION BIAS 
 
A6.1 Literature search to identify methods to reduce selection bias in healthcare 
The aim of the literature search was to identify all methods which have been used to 
reduce selection bias in non-randomised studies.  The following electronic databases 
outlined below were searched from their inception date to 30th January 2009: 
MEDLINE, CINAHL, EconLit, Bids IBSS and Scopus.  Search terms were entered as 
free text and/or as MESH terms and they included: 
“selection bias OR bias selection OR susceptibility bias OR selectivity bias” 
AND 
“non-random* OR observational OR quasi-experiment* OR cohort OR case-control OR 
cross-sectional OR case series OR case report OR before and after” 
 
Once all abstracts were retrieved they were exported into the citation software 
package, Endnote [Endnote, 2002]; and any duplicates identified from the different 
databases and non-English language articles were deleted within Endnote.  The search 
retrieved 2,442 abstracts.  All titles, bibliographic data and abstracts of the results from 
these searches were then read and scanned.  Of these 2,442 abstracts, 246 of these 
abstracts indicated that they used some method to reduce selection bias.  If the 
method was explicitly stated in the abstract, a note was made of the method used; if 
the method was not explicitly stated in the abstract, then the full-text paper was 
obtained to find out the method which was used to reduce selection bias.  Some 
abstracts (or papers) identified more than one method.  Both, theoretical and practical 
abstracts (papers) were identified, which were not just related to healthcare, but were 
also related to the labour market.  Table A6.1 below lists the type and frequency of 
each method identified within the 246 abstracts.  
 
Table A6.1: Methods identified in the literature search to reduce selection bias 
and/or endogeneity 
Method Frequency 
Matching 13 
Stratification 5 
Regression analysis i.e. logistic or linear or multivariate or advanced  46 
Propensity analysis  29 
Propensity score matching 41 
Propensity scores used in stratified analysis (stratification method) 9 
Propensity scores used as a covariate in regression models (regression adjustment) 10 
Inverse probability weighting 8 
Instrumental variables analysis 26 
Sample selection models i.e. Heckman; Lee; Greene  65 
Two-part models 21 
Regression discontinuity 2 
Decomposition technique 1 
Difference-in-differences method 5 
Total 281 
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A6.2 Brief overview of the other methods identified in the literature review 
A6.2.1 Matching 
Matching is a method to remove bias in observational studies.  For example, in case-
control studies, individuals who have the disease under investigation (cases) are 
matched to individuals who do not have the disease (controls), but who are thought to 
be comparable in other respects.  Matching takes place to ensure that each case is 
matched to a control that has the same (or similar) values of the matching variables.  
Matching variables include risk factors such as age and gender; and sometimes there 
are two or more such controls for each case.  Matching ensures that any difference 
between cases and controls cannot be a result of differences in the matching variables, 
and any difference between the two groups is the treatment effect plus a random 
element.   
 
The main advantage of matching is that it is simple and can balance confounders (risk 
factors).  The main disadvantage to matching is that the more variables that are 
matched on, the more difficult it may be to find such controls.  If this is the case, a large 
population of potential controls from which to draw is also required.  There is also a 
possibility of overmatching, which can reduce statistical power.  In a large study with 
many variables, it is easier to take an unmatched control group and use regression 
methods.   
 
A6.2.2 Stratification 
The concept of stratification is very similar to matching.  Confounding variables (risk 
factors) are identified and subgroups are created using these variables.  Stratification is 
the process of dividing members of the population (i.e. cases and controls) into 
different strata (or subgroups) before comparisons are made.  For example, patients 
with similar ages (i.e. 15-24 years) form one group, and another group is formed with 
patients with similar ages (i.e. 25-34 years) and so forth.  Even though each stratum 
must contain patients from both groups, they may appear in unequal numbers.  The 
strata should be mutually exclusive: that is, every element in the population must be 
assigned to only one stratum.  Once subgroups are defined, analysis is then performed 
on each subgroup separately.  The main advantage of stratification is that it is simple; 
however, the main disadvantage is that it can be difficult to interpret with many 
subgroups.  
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A6.2.3 Inverse probability weighting14 
When treatment is offered over multiple time points, marginal structural models are 
used [Robins et al, 2000].  That is, marginal structural models are useful when there 
are time dependent treatments and/or time dependent confounders (i.e. observed 
covariates that are affected by treatment and relevant to the outcome of interest).  
Marginal structural models are estimated using a method called the inverse probability 
of weighting.  Inverse probability weighting has also been used for non-randomised 
studies where treatment is offered at a single time point, where there are two or more 
groups [Imbens, 2000].  Inverse probability weighting can only control for observed 
variables.   
 
The inverse probability weighting approach uses observed variables to estimate a 
treatment selection probability i.e. that is to calculate the probability of an individual 
receiving the treatment they actually received, conditional on their observed covariates 
(this is similar to the propensity score method) and the inverses of these treatment 
selection probabilities are used as observation weights [Rosenbaum, 1987].  That is, 
an individual is assigned a weight, equal to the inverse of the conditional probability of 
receiving his or her own treatment.  Specifically, the weight is the inverse of the 
propensity score for treated subjects and it is the inverse of one minus the propensity 
score for control subjects.  The weights (these are usually not known) can be 
calculated using logistic regression and by obtaining the predicted values.   
 
For example, Hogan and Lancaster (2004) used data from women in the HIV 
Epidemiologic Research Study and they wanted to evaluate the difference in CD4 cell 
count for an individual who receives the new therapy, versus if that same individual did 
not receive therapy.  They used inverse probability weighting, whereby observed 
confounders were used to estimate treatment selection probabilities which 
corresponded to their observed treatment histories and the inverse of these treatment 
selection probabilities were used as observation weights.  The authors used ordinary 
least squares regression analyses, where each unit was weighted relative to the 
inverse of its probability of being sampled (e.g. in a random sample (size = n), the 
sampling probability is 1/n, so the relative weights are equal to 1).  The weights then 
can be interpreted to quantify the number of non-sampled members of the population 
that are being represented by the sample unit (e.g. if the weight for an observed unit is 
¼, then this represents information from four people).  They found that the inverse 
probability weighting provided estimates close to ordinary least squares estimates. 
                                                 
14
 Inverse probability weighting or marginal structural model is a variant of regression adjustment for 
propensity score. 
  294 
 
A6.2.4 Instrumental variables 
Instrumental variables analysis accounts for both observed and unobserved covariates.  
The idea is to find one or more variables (instruments) that have two properties.  First, 
they should be related to the choice of treatment; the higher the correlation between 
the instrument and treatment variable, the more reliable the instrument.  Second, the 
instrument should be uncorrelated (have no direct effect) with outcome.  If the 
instrument(s) satisfies both properties, then the instruments are said to be good and 
consistent [Newhouse and McClellan, 1998].     
 
An instrumental variable is a device that aims to achieve pseudo randomisation 
[Newhouse and McClellan, 1998].  That is, to mimic a randomisation process whereby 
the instrument(s) predicts treatment allocation and these values are then used as a 
covariate in the outcome model (instrumental variable regression). 
 
The instrumental variables analysis is conducted in two steps.  In the first stage a 
logistic regression model is conducted, using both the independent variables and the 
instrument(s) in order to obtain predicted probabilities.  In the second stage, the 
instrumental variables regression is conducted using the predicted probabilities 
obtained from the first equation instead of actual (observed) values.  By using these 
predicted probabilities rather than the actual values one should get unbiased estimates.  
As the groups differ in terms of likelihoods for treatment and not in the treatments they 
receive, this method estimates an incremental effect of treatment only over a range of 
variation in the treatment across the instrumental variable groups.  In other words, the 
coefficients from the instrumental variable model are interpreted in terms of “mean” 
differences between the two groups.   
 
If the instrument(s) are weakly correlated with treatment, then instrumental variables 
analysis has less statistical power than standard regression analysis; and even a weak 
correlation between instrument(s) and the outcome variable may result in the 
coefficients being biased or at least more biased than the ordinary least squares 
estimates and this can also lead to large standard errors (this can also happen if the 
sample size is not large enough) [Fortney et al, 1998; Newhouse and McClellan, 1998].   
 
In the example by McClellan and colleagues (1994), they used instrumental variables 
analysis to find out whether more intensive treatment of acute myocardial infarction in 
the elderly reduces mortality.  The instrument used here was differential distance, 
where differential distance is defined as the additional distance, if any, beyond the 
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distance to the nearest hospital to reach a specialist hospital (e.g. catheterisation 
hospital).  The method estimated the incremental effect of invasive management for all 
patients who are „marginal‟ (that is, who undergo invasive treatment in the „relatively 
near‟ group but not in the „relatively far‟ group) given that the groups are balanced in 
observable characteristics and that there are no other treatment differences between 
the groups.  The authors found that observable health characteristics after instrumental 
variables estimation between the two groups were more similar than with the standard 
statistical comparison.  They also concluded that there was a lower mortality rate 
among elderly patients who received catheterisation than among those treated more 
conservatively.  
 
A6.2.5 Two-part models 
A two-part model uses a two-stage approach to control for observed covariates.  In the 
first part either a probit or logistic regression is conducted, to find out the probability of 
treatment selection i.e. separating those treated from those who are not treated.  In the 
second part, another type of regression is conducted.   
 
Two-part models can take various forms.  For example, one type of two-part model is 
the censored Tobit regression model.  This model is applied when the dependent 
variable is censored at some upper or lower bound.  In the first stage, the selection 
equation is estimated by a Tobit regression.  In the second stage, an additional variable 
estimated by Tobit regression is included in the equation to correct for possible 
endogeneity. 
 
Sturm and colleagues (1995) wanted to compare mental health utilization in prepaid 
and fee-for-service plans.  They used two-part models because of the presence of both 
non-use and skewness of use.  In the first part of the model, a logit equation was used 
to estimate the probability of any outpatient mental healthcare, this separated out users 
from non-users and addressed the large number of zero use.  The second part of the 
model used a multivariate regression model whereby the natural logarithm of the 
number of mental health visits on explanatory variables where used to analyse the 
level of use for patients with one or more visits.  The logarithmic transformation of the 
number of visits for users in the second equation alleviates the skewness displayed by 
the data.  The authors concluded that depressed pre-paid patients obtained 
substantially fewer mental health services than similar patients in fee-for-service. 
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A6.2.6 Regression discontinuity design 
Regression discontinuity design method only controls for observed variables that affect 
whether a subject is assigned to a treatment or control group.  The idea is that 
members of the study group are compared with themselves; instead of to a control 
group.  That is, observations on the variable of interest are collected from the study 
group prior to the intervention and after the intervention.  The design is characterised 
by its method of assigning subjects i.e. a cut-off score on an assignment measure, 
rather than by random assignment.  All subjects who are on one side of the cut-off are 
assigned to the intervention group, while those scoring on the other side of the cut-off 
are assigned to a control group.  The difference or „„discontinuity‟‟ in the two regression 
lines (one for the control and the other for the intervention) at the cut-off provides an 
estimate of the intervention effect.   
 
Zuckerman et al (2006) used the regression discontinuity design to analyse data from a 
Mid-Atlantic state Medicaid drug utilization intervention with the aim of improving the 
pharmacologic management of paediatric asthma.  For the simple analysis, they used 
repeated measure ANOVA to compare the differences in monthly short-acting b2-
agonist inhalers (SAB) prescription fills for the 333 „„high-user‟‟ children (intervention 
group) for a period of five months pre-intervention and five months post-intervention.  
For the regression discontinuity analysis, the authors compared the pre–post 
experience of the intervention group (n=333) to that of 3,306 children with asthma who 
had at least one prescription for a SAB and were below the cut-off value of an average 
of one SAB canister per month during the matched pre-intervention period.  They used 
ordinary least squares regression for the regression discontinuity model.  Both 
analyses indicated that the intervention significantly reduced SAB use among the high 
users. 
 
A6.2.7 Decomposition technique 
The „decomposition technique‟ is where the observed outcome effects in the treatment 
and control groups are divided into two components: treatment and population effects.  
The treatment effect is the difference in relative risk applied to the treatment groups, 
whereas the population effect is an adjustment for differences in the two study 
populations.   
 
The decomposition technique considers the benefits of a policy in terms of „avoided 
costs‟.  After decomposition, the treatment effect answers the question, „how much 
money will the new treatment save (cost) compared with the existing treatment?‟  In 
contrast, the population effect addresses the question, „how much money would have 
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been spent by a „potential‟ treatment group receiving the existing treatment compared 
with the control groups?‟ [Shih and Kauf, 1999].  In other words, the treatment effect is 
the incremental cost (benefit) resulting from the treatment itself, and the population 
effect is the incremental cost (benefit) resulting from population differences. 
 
In the example by Shih and Kauf (1999), individuals who were diagnosed with end-
stage renal disease, either had to have a kidney transplant or be on maintenance 
dialysis in order to survive.  Treatment consists of blood transfusions and the new 
treatment includes erythropoietin which increases haematocrit levels and prevents the 
onset of anaemia symptoms, and this treatment is given at every dialysis session.  In 
the context of Medicare coverage of erythropoietin and to quantify the cost impact a 
decision model of anaemia treatment in end-stage renal disease patients was built.  
Outcome effects are decomposed into a treatment effect and a population effect.  
Logistic and multiple regression analysis were used to estimate branch probabilities 
and payoffs (outcomes), respectively, for the two treatment options within a decision 
model.  Under standard methods of decision analysis, the authors found that an 
increase of US$7,032 per patient following erythropoietin coverage is observed.  With 
the decomposition technique, the policy effect is estimated to be less, US$6,172, the 
difference coming from the population effect. 
 
A6.2.8 Difference-in-differences method 
The difference-in-differences approach seeks to measure a treatment effect while 
accounting for any pre-treatment differences between the treatment and control 
groups.  Before the intervention, the difference between the treatment and control 
groups measures any existing (intrinsic) difference between the two groups; and after 
the intervention, the difference between the treatment and control groups measures the 
treatment effect plus intrinsic difference.  So, to calculate the treatment effect alone, 
one must subtract the difference between the treatment and control groups before the 
intervention from the difference between the treatment and control groups following the 
intervention [Barnett et al, 2006].  Hence, the treatment effect is measured as the 
difference between two differences (i.e. the term difference-in-differences).  By 
obtaining the treatment effect alone and by eliminating any existing difference between 
the treatment and control groups, one can control for observed differences between the 
groups. 
 
Barnett et al (2006) assessed the health care use among veterans with diabetes 
mellitus who were enrolled in a care co-ordination telehealth program compared to 
veterans with diabetes mellitus who were not enrolled in a program over 24 months.  
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Health care utilization such as length of stay and outpatient visits were assessed at 
baseline and at 24 months after intervention for the treatment (n = 400) and control (n = 
400) groups.  The authors used a difference-in-differences approach and found that the 
program reduced avoidable healthcare services (such as hospitalizations) for patients 
with diabetes mellitus.  
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APPENDIX 7: DATA EXTRACTION FORM 
 
Section 1: Personal Details 
ID  
Postcode  
Date of birth  
Number of fetuses  
Parity Primaparous 
Multiparous 
 
 
Risk factors 
(tick all that apply) 
Diabetes 
Anti-epileptic therapy 
Lithium 
Down‟s risk 
Elevated serum 
Family history of CHD 
Previous pregnancy with abnormality 
High BMI 
Any other factor __________________________ 
No risk 
 
 
 
 
 
 
 
 
 
 
Was the patient high risk according to Medway criteria? Yes 
No 
 
 
Was the patient high risk according to TelePaed 
criteria? 
Yes 
No 
 
 
Was the patient low risk but an abnormality was 
suspected? 
Yes 
No 
 
 
Any other comment(s)? 
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Section 2: DGH Anomaly Scan at 20 weeks 
Type of scan 
 
Anomaly scan  
Other scan e.g. 
______________________   
  
 
Date of scan  
Gestation in weeks   
Visual heart satisfactory  Yes 
No  
  
 
Visual heart satisfactory Normal heart  
Abnormal heart  
Abnormal excluding heart  
Multi-organ abnormality including heart 
  
 
  
 
Cardiac abnormalities  
 
Was the scan videoed? Yes 
No 
  
 
 
Section 3: Referral to specialist via Telemedicine 
Date of TM consultation  
When did they decide the patient was a suitable 
candidate for TM? 
 
Type of consult 
Live transmission 
Store-and-forward 
 
 
 
Outcome of consult 
Normal heart  
Abnormal heart  
Abnormal excluding heart  
Multi-organ abnormality including heart 
 
 
 
 
 
Severity 
Mild 
Moderate 
 
 
 
 
Severe 
Unknown 
 
 
 
Provisional Diagnosis 
 
Any further TM consults (please provide the dates) 
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Section 4: Referral to specialist – direct referral to London 
Date seen by specialist in London  
 
Specialist scan done Yes 
No 
 
 
Outcome of scan 
Normal heart  
Abnormal heart  
Abnormal excluding heart  
Multi-organ abnormality including heart 
 
 
 
 
 
Counselling by specialist  
Yes 
No 
 
 
 
Severity 
Mild 
Moderate 
 
 
 
 
Severe 
Unknown 
 
 
 
Provisional Diagnosis 
 
 
 
 
Any further specialist scans (please provide the dates) 
 
 
 
 
Any further counselling by specialist (please provide the dates) 
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Section 5: Antenatal scans and clinic resource use at Medway Hospital from 20 
weeks 
Antenatal Scans from 20 weeks 
Date  Gestation in 
weeks  
Type of scan:  
1) anomaly;  
2) repeat 
anomaly;   
3) detailed; or 
4) other 
Outcome of scan: 
1) normal heart;  
2) abnormal heart;  
3) abnormal exc. heart; or  
4) multi-organ abnormality inc. 
heart 
 
 
 
 
 
 
 
 
 
 
 
 
   
Antenatal clinics from 20 weeks 
Date  Type of clinic:  
1) peripheral antenatal; 2) hospital antenatal; or 3) other 
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Section 6: Prenatal Admissions from 20 weeks 
Prenatal stays  
Admission date Discharge date Outcome:  
1) Discharge home 
2) Discharged to London 
3) Transferred to labour ward 
 
 
 
 
 
 
 
 
 
  
 
Section 7: Terminations (if applicable) 
Date admitted  
Date discharged  
Type of procedure 
Fetocide 
Induction/vaginal delivery 
Intercardiac KLC inject 
Medical TOP 
Surgical TOP 
Other 
 
 
 
 
 
 
 
Fetal outcome 
Normal heart  
Abnormal heart  
Abnormal excluding heart  
Multi-organ abnormality including heart 
 
 
 
 
 
Reason for termination – diagnosis 
for abnormal heart  
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Section 8: Labour information  
Labour admission date and time  
 
Labour discharge date and time  
 
Gestation in weeks at delivery  
 
Mode of delivery 
Normal 
Forceps 
Ventouse 
Caesarean – elective 
Caesarean - emergency 
Water 
 
 
 
 
 
 
 
Delivery place 
Medway Hospital 
London Hospital 
Home  
Other ------------------ 
-------------------------- 
 
 
 
 
 
 
Section 9: Birth outcome 
Number of births  
Birth outcome 
Live birth 
Still birth 
Miscarriage 
Unknown 
Baby 1 
 
 
 
 
Baby 2 
 
 
 
 
Baby 3 
 
 
 
 
Baby’s cardiac status 
Normal heart  
Abnormal heart  
Abnormal excluding heart  
Multi-organ abnormality including 
heart 
Baby 1 
 
 
 
 
Baby 2 
 
 
 
 
Baby 3 
 
 
 
 
Date of birth(s)  
Any other comment(s)? 
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Section 10: Postnatal admission 
Postnatal stays  
Admission date Discharge date Outcome:  
1) Discharge home 
2) Other 
 
 
 
 
 
  
 
Section 11: Any other information or comments 
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APPENDIX 8: REGRESSION RESULTS 
 
Table A8.1: Conditional costs adjusting for all risk factors  
 Unadjusted costs Adjusted costs for all 
risk factors  
Total costs of pregnancy 
2001/2002 period with telemedicine £4,242.15 £4,118.01 
2001/2002 period without telemedicine £4,229.04 £4,104.90 
2005/2006 period with telemedicine £3,583.24 £3,733.25 
2005/2006 period without telemedicine £3,567.07 £3,717.09 
  
 Table A8.1a: Unadjusted costs (observed) and adjusted costs for all risk factors from 
time of anomaly scan up until after delivery for all time periods 
Variable Unadjusted costs Adjusted costs for all risk 
factors  
N = 1492, R
2 
= 0.860 N = 1492, R
2 
= 0.884 
Coefficient SE) p-value Coefficient (SE) p-value 
1) 2001/2002 (with TM) 
2) 2001/2002 (without TM) 
3) 2005/2006 (with TM) 
4) 2005/2006 (without TM) 
4242.15 (86.79) 
4229.04 (86.76) 
3583.24 (75.76) 
3567.07 (75.51) 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
3473.84 (808.53) 
3460.73 (808.39) 
3089.08 (791.04) 
3072.92 (790.98) 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
Mother‟s age 
Number of fetuses 
Parity 
Gestation at anomaly scan 
  23.37 (9.57) 
1498.43 (220.50) 
-368.94 (114.65) 
-61.56 (34.25) 
0.015 
< 0.001 
0.001 
0.073 
Diabetes 
Downs 
Elevated serum 
Family history of CHD 
Previous pregnancy with anomaly 
  1807.06 (301.80) 
25.26 (288.22) 
-67.89 (138.65) 
267.16 (172.37) 
18.43 (265.30) 
< 0.001 
0.930 
0.624 
0.122 
0.945 
Tests: 
1 = 2 
3 = 4 
 
F1, 745  = 54.23, p < 0.001 
F1, 745  = 82.12, p < 0.001  
 
F1, 745  = 53.91, p < 0.001 
F1, 745  = 81.62, p < 0.001 
Note: Standard errors (SE) are robust standard errors 
 
Adjusting for all risk factors: 
Period 1: 3473.84+ (23.37*29.448)+(1498.43*1.135)+(-368.94*1.540)+(-61.56*21.038)+ 
(1807.06*0.054) +(25.26*0.063)+(-67.89*0.150)+(267.16*0.107)+(18.43*0.051) = £4,118.01 
Period 2: 3460.73+ (23.37*29.448)+(1498.43*1.135)+(-368.94*1.540)+(-61.56*21.038)+ 
(1807.06*0.054)+ (25.26*0.063)+(-67.89*0.150)+(267.16*0.107)+(18.43*0.051) = £4,104.90 
Period 3: 3089.08+ (23.37*29.448)+(1498.43*1.135)+(-368.94*1.540)+(-61.56*21.038)+ 
(1807.06*0.054)+ (25.26*0.063)+(-67.89*0.150)+(267.16*0.107)+(18.43*0.051) = £3,733.25 
Period 4: 3072.92+ (23.37*29.448)+(1498.43*1.135)+(-368.94*1.540)+(-61.56*21.038)+ 
(1807.06*0.054)+(25.26*0.063)+(-67.89*0.150)+(267.16*0.107)+(18.43*0.051) = £3,717.09 
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Table A8.2: Conditional cost results adjusting for all risk factors by risk group 
 Telemedicine 
group 
Direct referral 
group 
Medium risk 
women 
Low risk 
women 
Total costs of pregnancy 
2001/2002 period with TM £4,429.02 £3,937.85 £4,338.22 £3,945.55 
2001/2002 period without TM n/a £4,099.53 £4,375.21 £3,911.03 
2005/2006 period with TM £3,876.18 £3,535.66 £3,651.49 £3,423.49 
2005/2006 period without TM n/a £3,638.62 £3,709.99 £3,422.34 
 
Table A8.2a: Unadjusted costs (observed) and adjusted costs for all risk factors from 
time of anomaly scan up until after delivery (or for a few cases after termination of 
pregnancy) for period 2001/2002 with TM 
Variable Unadjusted costs Adjusted costs for all risk 
factors  
N = 408, R
2 
= 0.859 N = 408, R2 = 0.885 
Coefficient (SE) p-value Coefficient (SE) p-value 
Telemedicine (TM) 
Direct referral (DR) 
Medium risk (MR) 
Low risk (LR) 
4363.31 (240.02) 
3824.78 (353.29) 
4445.67 (110.58) 
3711.72 (185.56) 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
3122.79 (1480.26) 
2631.62 (1564.91) 
3031.99 (1523.83) 
2639.32 (1451.26) 
0.036 
0.093 
0.047 
0.070 
Parity 
Number of fetuses 
Mother‟s age 
Gestation at anomaly scan 
  -494.35 (170.25) 
1221.40 (309.01) 
46.88 (14.84) 
-35.60 (63.37) 
0.004 
< 0.001 
0.002 
0.575 
Diabetes 
Elevated serum 
Downs 
Family history of CHD 
Previous pregnancy with 
anomaly 
  1526.87 (364.58) 
-390.48 (310.58) 
184.00 (473.17) 
-39.79 (296.50) 
 
-571.10 (447.68) 
< 0.001 
0.209 
0.698 
0.893 
 
0.203 
Tests: 
TM = DR 
TM = MR 
TM = LR 
DR = MR 
DR = LR 
MR = LR 
 
F1, 404  = 1.59, p = 0.208 
F1, 404  = 0.10, p = 0.756 
F1, 404  = 4.61, p = 0.032 
F1, 404  = 2.81, p = 0.094 
F1, 404  = 0.08, p = 0.777 
F1, 404  = 11.55, p = 0.001 
 
F1, 395  = 1.50, p = 0.221 
F1, 395  = 0.10, p = 0.757 
F1, 395  = 2.33, p = 0.127 
F1, 395  = 1.22, p = 0.271 
F1, 395  = 0.00, p = 0.985 
F1, 395  = 1.54, p = 0.215 
 
Adjusted for all risk factors: 
TM = 3122.79 + (-494.35*1.600)+(1221.40*1.218)+(46.88*29.260)+(-35.60*20.973)+ 
(1526.87*0.064)+(-390.48*0.203)+(184.00*0.059)+(-39.79*0.137)+(-571.10*0.069) = £4429.02 
DR = 2631.62 + (-494.35*1.600)+(1221.40*1.218)+(46.88*29.260)+(-35.60*20.973)+ 
(1526.87*0.064)+(-390.48*0.203)+(184.00*0.059)+(-39.79*0.137)+(-571.10*0.069) = £3937.85 
MR = 3031.99 + (-494.35*1.600)+(1221.40*1.218)+(46.88*29.260)+(-35.60*20.973)+ 
(1526.87*0.064)+(-390.48*0.203)+(184.00*0.059)+(-39.79*0.137)+(-571.10*0.069) = £4338.22 
LR = 2639.32 + (-494.35*1.600)+(1221.40*1.218)+(46.88*29.260)+(-35.60*20.973)+ 
(1526.87*0.064)+(-390.48*0.203)+(184.00*0.059)+(-39.79*0.137)+(-571.10*0.069) = £3945.55 
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Table A8.2b: Unadjusted costs (observed) and adjusted costs for all risk factors from 
time of anomaly scan up until after delivery (or for a few cases after termination of 
pregnancy) for period 2001/2002 without TM  
Variable 
 
Unadjusted costs Adjusted costs for all risk 
factors  
N = 408, R
2 
= 0.858 N = 408, R
2 
= 0.884 
Coefficient (SE) p-value Coefficient (SE) p-value 
Direct referral (DR) 
Medium risk (MR) 
Low risk (LR) 
4054.91 (208.14) 
4455.31 (108.91) 
3711.72 (185.37) 
< 0.001 
< 0.001 
< 0.001 
3032.23 (1476.31) 
3307.91 (1483.29) 
2843.73 (1424.88) 
0.041 
0.026 
0.047 
Parity 
Number of fetuses 
Mother‟s age 
Gestation at anomaly scan 
  -482.86 (169.54) 
1147.53 (297.41) 
45.70 (14.83) 
-41.01 (62.63) 
0.005 
< 0.001 
0.002 
0.513 
Diabetes 
Elevated serum 
Downs 
Family history of CHD 
Previous pregnancy with 
anomaly 
  1547.67 (364.06) 
-464.92 (300.13) 
113.00 (475.86) 
-43.09 (294.01) 
 
-584.47 (440.59) 
< 0.001 
0.122 
0.812 
0.884 
 
0.185 
Tests: 
DR = MR 
DR = LR 
MR = LR 
 
F1, 405  = 2.91, p = 0.089 
F1, 405  = 1.52, p = 0.219 
F1, 405  = 11.96, p = 0.001 
 
F1, 396 = 1.12, p = 0.291 
F1, 396 = 0.39, p = 0.534 
F1, 396 = 2.32, p = 0.128 
 
Adjusted for all risk factors: 
DR = 3032.23 + (-482.86*1.600)+(1147.53*1.218)+(45.70*29.260)+(-41.01*20.973)+ 
(1547.67*0.064)+(-464.92*0.203)+(113.00*0.059)+(-43.09*0.137)+(-584.47*0.069) = £4099.53 
MR = 3307.91 + (-482.86*1.600)+(1147.53*1.218)+(45.70*29.260)+(-41.01*20.973)+ 
(1547.67*0.064)+(-464.92*0.203)+(113.00*0.059)+(-43.09*0.137)+(-584.47*0.069) = £4375.21 
LR = 2843.73 + (-482.86*1.600)+(1147.53*1.218)+(45.70*29.260)+(-41.01*20.973)+ 
(1547.67*0.064)+(-464.92*0.203)+(113.00*0.059)+(-43.09*0.137)+(-584.47*0.069) = £3911.03 
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Table A8.2c: Unadjusted costs (observed) and adjusted costs for all risk factors from 
time of anomaly scan up until after delivery (or for a few cases after termination of 
pregnancy) for period 2005/2006 with TM 
Variable Unadjusted costs Adjusted costs for all risk 
factors  
N = 338, R
2 
= 0.875 N = 338, R
2 
= 0.889 
Coefficient (SE) p-value Coefficient (SE) p-value 
Telemedicine (TM) 
Direct referral (DR) 
Medium risk (MR) 
Low risk (LR) 
4050.74 (160.88) 
3612.22 (253.49) 
3705.30 (143.89) 
3273.80 (112.59) 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
4441.89 (1406.90) 
4101.37 (1347.32) 
4217.20 (1420.37) 
3989.20 (1373.29) 
0.002 
0.003 
0.003 
0.004 
Parity 
Number of fetuses 
Mother‟s age 
Gestation at anomaly scan 
  -279.86 (148.59) 
1426.85 (369.99) 
4.45 (11.89) 
-87.41 (60.51) 
0.061 
< 0.001 
0.709 
0.150 
Diabetes 
Elevated serum 
Downs 
Family history of CHD 
Previous pregnancy with 
anomaly 
  1762.39 (383.26) 
-142.68 (297.32) 
-45.28 (308.19) 
173.51 (320.60) 
 
367.02 (450.09) 
< 0.001 
0.632 
0.883 
0.589 
 
0.415 
Tests: 
TM = DR 
TM = MR 
TM = LR 
DR = MR 
DR = LR 
MR = LR 
 
F1, 334  = 2.13, p = 0.145 
F1, 334  = 2.56, p = 0.111 
F1, 334  = 15.65, p < 0.001  
F1, 334  = 0.10, p = 0.750 
F1, 334  = 1.49, p = 0.223 
F1, 334  = 5.58, p = 0.019 
 
F1, 325 = 1.01, p = 0.317 
F1, 325 = 0.56, p = 0.454 
F1, 325 = 3.63, p = 0.058 
F1, 325 = 0.13, p = 0.718 
F1, 325 = 0.15, p = 0.701 
F1, 325 = 1.03, p = 0.311 
 
Adjusted for all risk factors: 
TM = 4441.89+(-279.86*1.467)+(1426.85*1.036)+(4.45*29.675)+(-87.41*21.115)+ 
(1762.39*0.041)+(-142.68*0.086)+(-45.28*0.068)+(173.51*0.071)+ (367.02*0.030) = £3876.18 
DR = 4101.37+(-279.86*1.467)+(1426.85*1.036)+(4.45*29.675)+(-87.41*21.115)+ 
(1762.39*0.041)+(-142.68*0.086)+(-45.28*0.068)+(173.51*0.071)+ (367.02*0.030) = £3535.66 
MR = 4217.20+(-279.86*1.467)+(1426.85*1.036)+(4.45*29.675)+(-87.41*21.115)+ 
(1762.39*0.041)+(-142.68*0.086)+(-45.28*0.068)+(173.51*0.071)+ (367.02*0.030) = £3651.49 
LR = 3989.20+(-279.86*1.467)+(1426.85*1.036)+(4.45*29.675)+(-87.41*21.115)+ 
(1762.39*0.041)+(-142.68*0.086)+(-45.28*0.068)+(173.51*0.071)+ (367.02*0.030) = £3423.49 
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Table A8.2d: Unadjusted costs (observed) and adjusted costs for all risk factors from 
time of anomaly scan up until after delivery (or for a few cases after termination of 
pregnancy) for period 2005/2006 without TM 
Variable Unadjusted costs Adjusted costs for all risk 
factors  
N = 338, R
2 
= 0.874 N = 338, R
2 
= 0.888 
Coefficient (SE) p-value Coefficient (SE) p-value 
Direct referral (DR) 
Medium risk (MR) 
Low risk (LR) 
3877.06 (150.02) 
3728.00 (131.52) 
3273.80 (112.73) 
< 0.001 
< 0.001 
< 0.001 
4036.65 (1342.30) 
4108.02 (1386.78) 
3820.37 (1341.27) 
0.003 
0.003 
0.005 
Parity 
Number of fetuses 
Mother‟s age 
Gestation at anomaly scan 
  -265.85 (147.96) 
1412.36 (370.75) 
2.48 (11.81) 
-77.12 (59.04) 
0.073 
< 0.001 
0.834 
0.192 
Diabetes 
Elevated serum 
Downs 
Family history of CHD 
Previous pregnancy with 
anomaly 
  1876.26 (387.93) 
-192.44 (290.62) 
-98.77 (304.00) 
248.01 (329.12) 
 
409.82 (449.64) 
< 0.001 
0.508 
0.745 
0.452 
 
0.363 
Tests: 
DR = MR 
DR = LR 
MR = LR 
 
F1, 335  = 0.56, p = 0.456 
F1, 335  = 10.33, p = 0.001 
F1, 335  = 6.88, p = 0.009 
 
F1, 326 = 0.08, p = 0.775 
F1, 326 = 0.97, p = 0.326 
F1, 326 = 1.91, p = 0.168 
 
Adjusted for all risk factors: 
DR = 4036.65+(-265.85*1.467)+(1412.36*1.036)+(2.48*29.675)+(-77.12*21.115)+ 
(1876.26*0.041)+(-192.44*0.086)+(-98.77*0.068)+(248.01*0.071)+ (409.82*0.030) = £3638.62 
MR = 4108.02+(-265.85*1.467)+(1412.36*1.036)+(2.48*29.675)+(-77.12*21.115)+ 
(1876.26*0.041)+(-192.44*0.086)+(-98.77*0.068)+(248.01*0.071)+ (409.82*0.030) = £3709.99 
LR = 3820.37+(-265.85*1.467)+(1412.36*1.036)+(2.48*29.675)+(-77.12*21.115)+ 
(1876.26*0.041)+(-192.44*0.086)+(-98.77*0.068)+(248.01*0.071)+ (409.82*0.030) = £3422.34 
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Appendix 9: Published paper – Dowie et al (2007) 
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Appendix 10: Published paper – Dowie et al (2008) 
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Appendix 11: Published paper – Mistry et al (2007) 
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